

January 2016

Volume 4 Number 0

Editor: Kaye Wilson

email: enquiry@pharmac.govt.nz

Telephone +64 4 460 4990

Facsimile +64 4 460 4995

Level 9, 40 Mercer Street

PO Box 10 254 Wellington 6143

Freephone Information Line**0800 66 00 50** (9am – 5pm weekdays)**Circulation**

Accessible in an electronic format at no cost from the Health Professionals section of the PHARMAC website www.pharmac.govt.nz

You can register to have an electronic version of the Pharmaceutical Schedule (link to PDF copy) emailed to your nominated email address each month. Alternatively there is a nominal charge for an annual subscription to the printed Schedule publications. To access either of these subscriptions visit our subscription website www.schedule.co.nz.

ProductionTypeset automatically from XML and T_EX.

XML version of the Schedule available from www.pharmac.govt.nz/pub/schedule/archive/

Programmers

Anrik Drenth & John Geering

email: texschedule@pharmac.govt.nz

©Pharmaceutical Management Agency



ISSN 1179-3708 pdf
ISSN 1172-9694 print

This work is licensed under the Creative Commons Attribution 3.0 New Zealand licence. In essence, you are free to copy, distribute and adapt it, as long as you attribute the work to PHARMAC and abide by the other licence terms. To view a copy of this licence, visit:

creativecommons.org/licenses/by/3.0/nz/.

Attribution to PHARMAC should be in written form and not by reproduction of the PHARMAC logo. While care has been taken in compiling this Schedule, PHARMAC takes no responsibility for any errors or omissions, and shall not be liable for any consequences arising there from.

Part I

General Rules 5

Part II

Alimentary Tract and Metabolism 13

Blood and Blood Forming Organs 27

Cardiovascular System 37

Dermatologicals 49

Genito-Urinary System 56

Hormone Preparations 60

Infections 70

Musculoskeletal System 93

Nervous System 103

Oncology Agents and Immunosuppressants 129

Respiratory System and Allergies 173

Sensory Organs 180

Various 186

Extemporaneous Compounds (ECPs) 194

Special Foods 197

Vaccines 211

Part III

Optional Pharmaceuticals 217

Index 219

Introducing PHARMAC

The Pharmaceutical Management Agency (PHARMAC) makes decisions that help control Government spending on pharmaceuticals. This includes community pharmaceuticals, hospital pharmaceuticals, vaccines and increasingly, hospital medical devices. PHARMAC negotiates prices, sets subsidy levels and conditions, and makes decisions on changes to the subsidised list. The funding for pharmaceuticals comes from District Health Boards.

PHARMAC's role:

"Secure for eligible people in need of pharmaceuticals, the best health outcomes that can reasonably be achieved, and from within the amount of funding provided."

New Zealand Public Health and Disability Act 2000

To ensure our decisions are as fair and robust as possible we use a decision-making process that incorporates clinical, economic and commercial issues. We also seek the views of users and the wider community through consultation. The processes we generally use are outlined in our Operating Policies and Procedures.

Further information about PHARMAC and the way we make funding decisions can be found on the PHARMAC website at <http://www.pharmac.health.nz/about>.

Named Patient Pharmaceutical Assessment policy

Named Patient Pharmaceutical Assessment (NPPA) provides a mechanism for individual patients to receive funding for medicines not listed in the Pharmaceutical Schedule (either at all or for their clinical circumstances). PHARMAC will assess applications that meet the prerequisites according to its Decision Criteria before deciding whether to approve applications for funding. The Decision Criteria will be used to assess both the individual clinical circumstances of each NPPA applicant, and the implications of each NPPA funding decision on PHARMAC's ability to carry out its legislative functions.

For more information on NPPA, or to apply, visit the PHARMAC website at <http://www.pharmac.health.nz/link/nppa> or call the Panel Coordinators at 0800 660 050 Option 2.

The Pharmaceutical Schedule

The purpose of the Schedule is to list:

- the Community Pharmaceuticals that are subsidised by the Government and to show the amount of the subsidy paid to contractors, as well as the manufacturer's price and any access conditions that may apply;
- the Hospital Pharmaceuticals that may be used in DHB Hospitals, as well as any access conditions that may apply; and
- the Pharmaceuticals, including Medical Devices, used in DHB Hospitals for which national prices have been negotiated by PHARMAC.

The Schedule does not show the final cost to Government of subsidising each community pharmaceutical, nor to DHB hospitals in purchasing each hospital pharmaceutical or other pharmaceuticals, including medical devices. The final cost will depend on any rebate and other arrangements PHARMAC has with the supplier or on any logistics arrangements put in place.

Finding Information in Section H

This book contains Section H of the Pharmaceutical Schedule and lists pharmaceuticals that can be used in DHB hospitals:

- Part I lists the rules in relation to use of Pharmaceuticals by DHB hospitals.
- Part II lists hospital pharmaceuticals that are funded for use in DHB hospitals. These are listed by therapeutic group, which is based on the WHO Anatomical Therapeutic Chemical (ATC) system. It also provides information on any national contracts that exist, and indicates which products have Hospital Supply Status (HSS).
- Part III lists optional pharmaceuticals for which national contracts exist, and DHB hospitals may choose to fund. In addition to the products listed in this book, a number of additional Optional Pharmaceuticals are listed in an addendum to Part III available at <http://www.pharmac.govt.nz>.

The listings are displayed alphabetically under each heading. The index lists both chemical entities and product brand names.

Glossary

Units of Measure

gram	g	microgram.....	mcg	millimole.....	mmol
kilogram	kg	milligram	mg	unit.....	u
international unit.....	iu	millilitre.....	ml		

Abbreviations

application	app	enteric coated.....	EC	solution	soln
capsule	cap	granules	grans	suppository.....	suppos
cream.....	crm	injection	inj	tablet.....	tab
dispersible	disp	liquid	liq	tincture.....	tinc
effervescent	eff	lotion	lotn		
emulsion	emul	ointment.....	oint		

HSS Hospital Supply Status (Refer to Rule 20)

Guide to Section H listings

Example

ANATOMICAL HEADING				
	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer	
THERAPEUTIC HEADING				
Generic name listed by therapeutic group and subgroup	CHEMICAL A - Restricted see terms below ⚠ Presentation A.....	10.00	100	Brand A
	↳ Restricted Only for use in children under 12 years of age			Brand or manufacturer's name
Indicates only presentation B1 is Restricted	CHEMICAL B - Some items restricted see terms below ⚠ Presentation B1..... Presentation B2	1,589.00	1	Brand B1 e.g. Brand B2
	↳ Restricted Oncologist or haematologist			
From 1 January 2012 to 30 June 2014, at least 99% of the total volume of this item purchased must be Brand C	CHEMICAL C Presentation C - -1% DV Limit Jan-12 to 2014	15.00	28	Brand C
	CHEMICAL D - Restricted see terms below ⚠ Presentation D - -1% DV Limit Mar-13 to 2014	38.65	500	Brand D
Standard national price excluding GST	↳ Restricted <i>Limited to five weeks' treatment</i> Either: 1 For the prophylaxis of venous thromboembolism following a total hip replacement; or 2 For the prophylaxis of venous thromboembolism following a total knee replacement.			Product with Hospital Supply Status (HSS) Quantity the Price applies to
Form and strength	CHEMICAL E Presentation E.....			e.g. Brand E Not a contracted product

⚠ Item restricted (see above); ⚠ Item restricted (see below)
Products with Hospital Supply Status (HSS) are in **bold**

INTRODUCTION

Section H contains general rules that apply, and other information relating, to Hospital Pharmaceuticals and Optional Pharmaceuticals.

Where relevant, Section H shows the Price at which a Pharmaceutical can be purchased directly from the Pharmaceutical supplier by DHBs, providers of logistics services, wholesalers or other such distributors, or Contract Manufacturers.

The Price is determined via contractual arrangements between PHARMAC and the relevant Pharmaceutical supplier. Where a Pharmaceutical is listed in Part II of Section H, but no Price and/or brand of Pharmaceutical is indicated, each DHB may purchase any brand and/or pay the price that the DHB negotiates with the relevant Pharmaceutical supplier.

As required by section 23(7) of the Act, in performing any of its functions in relation to the supply of Pharmaceuticals, a DHB must not act inconsistently with the Pharmaceutical Schedule.

INTERPRETATION AND DEFINITIONS

1 Interpretation and Definitions

1.1 In this Schedule, unless the context otherwise requires:

“**Act**”, means the New Zealand Public Health and Disability Act 2000.

“**Combined Pharmaceutical Budget**”, means the pharmaceutical budget set for PHARMAC by the Crown for the subsidised supply of Community Pharmaceuticals and Pharmaceutical Cancer Treatments including for named patients in exceptional circumstances.

“**Community**”, means any setting outside of a DHB Hospital.

“**Community Pharmaceutical**”, means a Pharmaceutical listed in Sections A to G or I of the Pharmaceutical Schedule that is subsidised by the Funder from the Combined Pharmaceutical Budget and, for the purposes of this Section H, includes Pharmaceutical Cancer Treatments (PCTs).

“**Contract Manufacturer**”, means a manufacturer or a supplier that is a party to a contract with the relevant DHB Hospital to compound Pharmaceuticals, on request from that DHB Hospital.

“**Designated Delivery Point**”, means at a DHB Hospital’s discretion:

- a) a delivery point agreed between a Pharmaceutical supplier and the relevant DHB Hospital, to which delivery point that Pharmaceutical supplier must supply a National Contract Pharmaceutical directly at the Price; and/or
- b) any delivery point designated by the relevant DHB Hospital or PHARMAC, such delivery point being within 30 km of the relevant Pharmaceutical supplier’s national distribution centre.

“**DHB**”, means an organisation established as a District Health Board by or under Section 19 of the Act.

“**DHB Hospital**”, means a hospital (including community trust hospitals) and/or an associated health service that is funded by a DHB including (but not limited to) district nursing services and child dental services.

“**DV Limit**”, means, for a particular National Contract Pharmaceutical with HSS, the National DV Limit or the Individual DV Limit.

“**DV Pharmaceutical**”, means a discretionary variance Pharmaceutical that does not have HSS but is used in place of one that does. Usually this means it is the same chemical entity, at the same strength, and in the same or a similar presentation or form, as the relevant National Contract Pharmaceutical with HSS. Where this is not the case, a note will be included with the listing of the relevant Hospital Pharmaceutical.

“**Extemporaneously Compounded Product**”, means a Pharmaceutical that is compounded from two or more Pharmaceuticals, for the purposes of reconstitution, dilution or otherwise.

“**First Transition Period**”, means the period of time after notification that a Pharmaceutical has been awarded HSS and before HSS is implemented.

“**Funder**”, means the body or bodies responsible, pursuant to the Act, for the funding of Pharmaceuticals listed on the Schedule (which may be one or more DHBs and/or the Ministry of Health) and their successors.

“**Give**”, means to administer, provide or dispense (or, in the case of a Medical Device, use) a Pharmaceutical, or to arrange for the administration, provision or dispensing (or, in the case of a Medical Device, use) of a Pharmaceutical, and “**Given**” has a corresponding meaning.

“**Hospital Pharmaceuticals**”, means the list of Pharmaceuticals set out in Section H Part II of the Schedule which includes some National Contract Pharmaceuticals.

“**HSS**”, stands for hospital supply status, which means the status of being the brand of the relevant National Contract Pharmaceutical that DHBs are obliged to purchase, subject to any DV Limit, for the period of hospital supply,

as awarded under an agreement between PHARMAC and the relevant Pharmaceutical supplier. Pharmaceuticals with HSS are listed in Section H in bold text.

“**Indication Restriction**”, means a limitation placed by PHARMAC on the funding of a Hospital Pharmaceutical which restricts funding to treatment of particular clinical circumstances.

“**Individual DV Limit**”, means, for a particular National Contract Pharmaceutical with HSS and a particular DHB Hospital, the discretionary variance limit, being the specified percentage of that DHB Hospital’s Total Market Volume up to which that DHB Hospital may purchase DV Pharmaceuticals of that National Contract Pharmaceutical.

“**Local Restriction**”, means a restriction on the use of a Pharmaceutical in specific DHB Hospitals on the basis of prescriber type that is implemented by the relevant DHB in accordance with rule 7.

“**Medical Device**”, has the meaning set out in the Medicines Act 1981.

“**Named Patient Pharmaceutical Assessment Advisory Panel**”, means the panel of clinicians, appointed by the PHARMAC Board, that is responsible for advising PHARMAC, in accordance with its Terms of Reference, on Named Patient Pharmaceutical Assessment applications and any Exceptional Circumstances renewal applications submitted after 1 March 2012.

“**National Contract**”, means a contractual arrangement between PHARMAC and a Pharmaceutical supplier which sets out the basis on which any Pharmaceutical may be purchased for use in a DHB Hospital, including an agreement as to a national price.

“**National Contract Pharmaceutical**”, means a brand of Pharmaceutical listed in Section H, where PHARMAC has entered into contractual arrangements with the relevant Pharmaceutical supplier that specify the terms and conditions of listing, including the Price. Such Pharmaceuticals are recognisable in Section H because the relevant listing identifies the brand and Price.

“**National DV Limit**”, means, for a particular National Contract Pharmaceutical with HSS, the discretionary variance limit, being the specified percentage of the Total Market Volume up to which all DHB Hospitals may collectively purchase DV Pharmaceuticals of that National Contract Pharmaceutical.

“**Optional Pharmaceuticals**”, means the list of National Contract Pharmaceuticals set out in Section H Part III of the Schedule.

“**PHARMAC**”, means the Pharmaceutical Management Agency established by Section 46 of the Act.

“**Pharmacode**”, means the six or seven digit identifier assigned to a Pharmaceutical by the Pharmacy Guild following application from a Pharmaceutical supplier.

“**Pharmaceutical**”, means a medicine, therapeutic medical device, or related product or related thing listed in Sections B to I of the Schedule.

“**Pharmaceutical Cancer Treatment**”, means Pharmaceuticals for the treatment of cancer, listed in Sections A to G of the Schedule and identified therein as a “PCT” or “PCT only” Pharmaceutical that DHBs must fund for use in their DHB hospitals, and/or in association with outpatient services provided by their DHB Hospitals, in relation to the treatment of cancers.

“**Prescriber Restriction**”, means a restriction placed by PHARMAC on the funding of a Pharmaceutical on the basis of prescriber type (and where relevant in these rules, includes a Local Restriction).

“**Price**”, means the standard national price for a National Contract Pharmaceutical, and, unless agreed otherwise between PHARMAC and the Pharmaceutical supplier, includes any costs associated with the supply of the National Contract Pharmaceutical to, at a DHB Hospital’s discretion, any Designated Delivery Point, or to a Contract Manufacturer (expressly for the purpose of compounding), but does not include the effect of any rebates which may have been negotiated between PHARMAC and the Pharmaceutical supplier.

“**Restriction**”, means a limitation, put in place by PHARMAC or a DHB, restricting the funding of a Pharmaceutical and includes Indication Restrictions, Local Restrictions and Prescriber Restrictions (as defined in this Part I of Section H).

“**Schedule**”, means this Pharmaceutical Schedule and all its sections and appendices.

“**Special Authority Approval**”, means an approval for funding of a Community Pharmaceutical that is marked in Sections B-G of the Schedule as being subject to a Special Authority restriction.

“**Total Market Volume**”, means, for a particular Hospital Pharmaceutical with HSS in any given period, in accordance with the data available to PHARMAC, the sum of:

- a) the total number of Units of the relevant Hospital Pharmaceutical with HSS purchased by all DHB Hospitals, or by a particular DHB Hospital in the case of the Individual DV Limit; and
- b) the total number of Units of all the relevant DV Pharmaceuticals purchased by all DHB Hospitals, or by a particular DHB Hospital in the case of the Individual DV Limit.

“**Unapproved Indication**”, means, for a Pharmaceutical, an indication for which it is not approved under the Medicines Act 1981. Clinicians prescribing Pharmaceuticals for Unapproved Indications should be aware of, and comply with, their obligations under Section 25 and/or Section 29 of the Medicines Act 1981 and as set out in rule 23.

“**Unit**”, means an individual unit of a Pharmaceutical (e.g. a tablet, 1 ml of an oral liquid, an ampoule or a syringe).

“**Unlisted Pharmaceutical**”, means a Pharmaceutical that is within the scope of a Hospital Pharmaceutical, but is not listed in Section H Part II.

- 1.2 In addition to the above interpretations and definitions, unless the content requires otherwise, a reference in the Schedule to:
- a) the singular includes the plural; and
 - b) any legislation includes a modification and re-enactment of, legislation enacted in substitution for, and a regulation, Order in Council, and other instrument from time to time issued or made under, that legislation.

HOSPITAL SUPPLY OF PHARMACEUTICALS

2 Hospital Pharmaceuticals

- 2.1 Section H Part II contains the list of Hospital Pharmaceuticals that must be funded by DHB Hospitals. Section H Part II does not currently encompass the following categories of pharmaceuticals except for any items specifically listed in this Section H Part II:

- a) Medical Devices;
- b) whole or fractionated blood products;
- c) diagnostic products which have an ex vivo use, such as pregnancy tests and reagents;
- d) disinfectants and sterilising products, except those that are to be used in or on a patient;
- e) foods and probiotics;
- f) radioactive materials;
- g) medical gases; and
- h) parenteral nutrition.

Subject to rule 2.2, the funding of pharmaceuticals identified in a)–h) above is a decision for individual DHB Hospitals.

- 2.2 Section H Part III lists Optional Pharmaceuticals that PHARMAC and the relevant Pharmaceutical supplier have entered into contractual arrangements for the purchase of, including an agreement on a national price and other obligations such as HSS. DHB Hospitals may choose whether or not to fund the Optional Pharmaceuticals listed in Part III of Section H, but if they do, they must comply with any National Contract requirements.
- 2.3 Section H Part II does not encompass the provision of pharmaceutical treatments for DHB Hospital staff as part of an occupational health and safety programme. DHB Hospitals may choose whether or not to fund pharmaceutical treatments for such use, but if they do, they must comply with any National Contract requirements.

3 DHB Supply Obligations

- 3.1 In accordance with section 23(7) of the Act, in performing any of its functions in relation to the supply of pharmaceuticals, a DHB must not act inconsistently with the Pharmaceutical Schedule, which includes these General Rules.
- 3.2 DHB Hospitals are not required to hold stock of every Hospital Pharmaceutical listed in Section H Part II, but they must Give it within a reasonable time if it is prescribed.
- 3.3 DHB Hospitals are able to hold stock of an Unlisted Pharmaceutical if doing so is considered necessary for the DHB Hospital to be able to Give the Unlisted Pharmaceutical in a timely manner under rules 11–17 inclusive.
- 3.4 Except where permitted in accordance with rule 11, DHBs must not Give:
- a) an Unlisted Pharmaceutical; or
 - b) a Hospital Pharmaceutical outside of any relevant Restrictions.

4 Funding

- 4.1 The purchase costs of Hospital Pharmaceuticals or Optional Pharmaceuticals administered, provided or dispensed by DHB Hospitals must be funded by the relevant DHB Hospital from its own budget, with the exception of:
- a) Pharmaceutical Cancer Treatments;
 - b) Community Pharmaceuticals that have been brought to the DHB hospital by the patient who is being treated by outpatient Services or who is admitted as an inpatient;
 - c) Community Pharmaceuticals that have been dispensed to a mental health day clinic under a Practitioner's

- Supply Order; and
 - d) Unlisted Pharmaceutical that have been brought to the DHB Hospital by the patient who is admitted as an inpatient.
- 4.2 For the avoidance of doubt, Pharmaceutical Cancer Treatments and Community Pharmaceuticals are funded through the Combined Pharmaceutical Budget, and Unlisted Pharmaceuticals are funded by the patient.

LIMITS ON SUPPLY

5 Prescriber Restrictions

- 5.1 A DHB Hospital may only Give a Hospital Pharmaceutical that has a Prescriber Restriction if it is prescribed:
- a) by a clinician of the type specified in the restriction for that Pharmaceutical or, subject to rule 5.2, pursuant to a recommendation from such a clinician;
 - b) in accordance with a protocol or guideline that has been endorsed by the DHB Hospital; or
 - c) in an emergency situation, provided that the prescriber has made reasonable attempts to comply with rule 5.1(a) above. If on-going treatment is required (i.e. beyond 24 hours) subsequent prescribing must comply with rule 5.1(a).
- 5.2 Where a Hospital Pharmaceutical is prescribed pursuant to a recommendation from a clinician of the type specified in the restriction for that Pharmaceutical:
- a) the prescriber must consult with a clinician of the type specified in the restriction for that Pharmaceutical; and
 - b) the consultation must relate to the patient for whom the prescription is written; and
 - c) the consultation may be in person, by telephone, letter, facsimile or email; and
 - d) appropriate records are kept of the consultation, including recording the name of the advising clinician on the prescription/chart.
- 5.3 Where a clinician is working under supervision of a consultant who is of the type specified in the restriction for that Pharmaceutical, the requirements of rule 5.2 can be deemed to have been met.

6 Indication Restrictions

- 6.1 A DHB Hospital may only Give a Hospital Pharmaceutical that has an Indication Restriction, if it is prescribed for treatment of a patient with the particular clinical circumstances set out in the Indication Restriction.
- 6.2 If a patient has a current Special Authority Approval for the Hospital Pharmaceutical that the DHB Hospital wishes to Give, then the Indication Restriction is deemed to have been met.
- 6.3 If a Hospital Pharmaceutical has an Indication Restriction that is “for continuation only” then the DHB Hospital should only Give the Hospital Pharmaceutical where:
- a) the patient has been treated with the Pharmaceutical in the Community; or
 - b) the patient is unable to be treated with an alternative Hospital Pharmaceutical, and the prescriber has explained to the patient that the Pharmaceutical is not fully subsidised in the Community.

7 Local Restrictions

- 7.1 A DHB Hospital may implement a Local Restriction, provided that:
- a) in doing so, it ensures that the Local Restriction does not unreasonably limit funded access to the Hospital Pharmaceutical or undermine PHARMAC’s decision that the Hospital Pharmaceutical must be funded;
 - b) it provides PHARMAC with details of each Local Restriction that it implements; and
- 7.2 PHARMAC may, when it considers that a Local Restriction does not conform to rule 7.1 above, require a DHB to amend or remove that Local Restriction.

8 Community use of Hospital Pharmaceuticals

- 8.1 Except where otherwise specified in Section H, DHB Hospitals can Give any Hospital Pharmaceutical to a patient for use in the Community, provided that:
- a) the quantity does not exceed that sufficient for up to 30 days’ treatment, unless:
 - i) it would be inappropriate to provide less than the amount in an original pack; or
 - ii) the relevant DHB Hospital has a Dispensing for Discharge Policy and the quantity dispensed is in accordance with that policy; and
 - b) the Hospital Pharmaceutical is supplied consistent with any applicable Restrictions.

9 Community use of Medical Devices

- 9.1 Subject to rules 9.2 and 9.3, DHB Hospitals may Give a Medical Device for patients for use in the Community.
- 9.2 Where a Medical Device (or a similar Medical Device) is a Community Pharmaceutical, the DHB Hospital must supply:

- a) the brand of Medical Device that is listed in Sections A-G of the Schedule; and
 - b) only to patients who meet the funding eligibility criteria set out in Sections A-G of the Schedule.
- 9.3 Where a DHB Hospital has supplied a Medical Device to a patient; and
- a) that Medical Device (or a similar Medical Device) is subsequently listed in Sections A-G of the Schedule; and
 - b) the patient would not meet any funding eligibility criteria for the Medical Device set out in Sections A-G of the Schedule; and
 - c) the Medical Device has consumable components that need to be replaced throughout its usable life; then DHB Hospitals may continue to fund consumable products for that patient until the end of the usable life of the Medical Device. At the end of the usable life of the device, funding for a replacement device must be consistent with the Pharmaceutical Schedule and/or in accordance with the Named Patient Pharmaceutical Assessment policy.
- 9.4 DHB Hospitals may also continue to fund consumable products, as in rule 9.3 above, in situations where the DHB has been funding consumable products but where the Medical Device was funded by the patient.
- 10 Extemporaneous Compounding**
- 10.1 A DHB Hospital may Give any Extemporaneously Compounded Product for a patient in its care, provided that:
- a) all of the component Pharmaceuticals of the Extemporaneously Compounded Product are Hospital Pharmaceuticals; and
 - b) the Extemporaneously Compounded Product is supplied consistent with any applicable rules or Restrictions for its component Hospital Pharmaceuticals.
- 10.2 For the avoidance of doubt, this rule 10.1 applies to any Extemporaneously Compounded Product, whether it is manufactured by the DHB Hospital or by a Contract Manufacturer.

EXCEPTIONS

11 Named Patient Pharmaceutical Assessment

- 11.1 A DHB Hospitals may only Give:
- a) an Unlisted Pharmaceutical; or
 - b) a Hospital Pharmaceutical outside of any relevant Restrictions,
- in accordance with the Named Patient Pharmaceutical Assessment Policy or rules 12–17 inclusive.

12 Continuation

- 12.1 Where a patient's clinical circumstances have been stabilised via treatment in the Community with a pharmaceutical that has not been funded by the Funder, and that patient is admitted to hospital as an inpatient, a DHB Hospital may fund that pharmaceutical for the duration of the patient's stay, where:
- a) the patient has not brought (or cannot arrange to bring) the pharmaceuticals to the DHB Hospital, or pharmacy staff consider that the pharmaceuticals brought to the DHB Hospital by the patient cannot be used; and
 - b) interrupted or delayed treatment would have significant adverse clinical consequences; and
 - c) it is not considered appropriate to switch treatment to a Hospital Pharmaceutical.

13 Pre-Existing Use

- 13.1 Subject to 13.2, where a DHB Hospital has Given a pharmaceutical for a patient prior to 1 July 2013, and the pharmaceutical:
- a) is an Unlisted Pharmaceutical; or
 - b) treatment of the patient would not comply with any relevant Restrictions;
- the DHB Hospital may continue to Give that pharmaceutical if it is considered that there would be significant adverse clinical consequences from ceasing or switching treatment.
- 13.2 Each DHB Hospital must, by no later than 1 October 2013, provide PHARMAC with a report on pharmaceuticals it has Given in accordance with this rule 13 where treatment has continued beyond 1 August 2013.

14 Clinical Trials and Free Stock

- 14.1 DHB Hospitals may Give any pharmaceutical that is funded by a third party and is being used:
- 14.1.1 as part of a clinical trial that has Ethics Committee approval; or
 - 14.1.2 for on-going treatment of patients following the end of such a clinical trial.
- 14.2 DHB Hospitals may Give any pharmaceutical that is provided free of charge by a supplier, provided that the pharmaceutical is provided as part of a programme of which the DHB, or supplier, has notified PHARMAC.

15 Pharmaceutical Cancer Treatments in Paediatrics

DHB Hospitals may Give any pharmaceutical for use within a paediatric oncology/haematology service for the treatment of

cancer.

16 Other Government Funding

DHB Hospitals may Give any pharmaceutical where funding for that pharmaceutical has been specifically provided by a Government entity other than PHARMAC or a DHB.

17 Other Exceptions

- 17.1 PHARMAC may also approve the funding of a pharmaceutical within a single DHB Hospital for information gathering purposes or otherwise related to PHARMAC's decision-making process for considering additions to or amendments to the Pharmaceutical Schedule.
- 17.2 Funding approvals granted under rule 17.1 will be subject to specific limitations on use as determined appropriate by PHARMAC in each circumstance, in consultation with the relevant DHB Hospital and/or DHB.

NATIONAL CONTRACTING

18 Hospital Pharmaceutical Contracts

- 18.1 A DHB Hospital may enter into a contract for the purchase of any Pharmaceutical, including any Medical Device, that it is entitled to fund in accordance with this Schedule H and that is not a National Contract Pharmaceutical, provided that such a contract:
 - a) does not oblige the relevant DHB Hospital to purchase a volume of that Pharmaceutical, if that Pharmaceutical is a DV Pharmaceutical, that is greater than the relevant DV Limit;
 - b) enables PHARMAC to access and use future price and volume data in respect of that Pharmaceutical; and
 - c) enables the relevant DHB Hospital to terminate the contract or relevant parts of the contract in order to give full effect to the National Contract on no more than 3 months' written notice to the Pharmaceutical supplier.
- 18.2 From 1 July 2013, where a DHB Hospital has a pre-existing supply contract for a particular brand of chemical entity for which there is a National Contract Pharmaceutical, the DHB may continue purchasing the chemical entity in accordance with its pre-existing supply contract however:
 - a) from the day its pre-existing supply contract expires, that DHB Hospital is to purchase the relevant National Contract Pharmaceutical listed in Section H at the Price, and is to comply with any DV Limits for the National Contract Pharmaceutical where it has HSS;
 - b) if purchase of the relevant National Contract Pharmaceutical listed in Section H at the Price, where it has HSS, would not cause the relevant DHB Hospital to be in breach of its pre-existing supply contract for a particular brand of chemical entity; the DHB Hospital must purchase the National Contract Pharmaceutical.
- 18.3 Following written notification from PHARMAC that a Pharmaceutical is a National Contract Pharmaceutical, either through Section H updates or otherwise, DHB Hospitals must, unless PHARMAC expressly notifies otherwise:
 - a) take any steps available to them to terminate pre-existing contracts or relevant parts of such a contract, and
 - b) not enter any new contracts or extend the period of any current contracts, for the supply of that National Contract Pharmaceutical or the relevant chemical entity or Medical Device.

19 National Contract Pharmaceuticals

- 19.1 DHB Hospitals must take all necessary steps to enable any contracts between PHARMAC and a Pharmaceutical supplier in relation to National Contract Pharmaceuticals to be given full effect.
- 19.2 The contractual arrangement between PHARMAC and the relevant supplier of a National Contract Pharmaceutical requires it to be made available for purchase at the relevant Price by any or all of the following:
 - a) DHB Hospitals at Designated Delivery Points; and/or
 - b) Contract Manufacturers (expressly for the purpose of compounding).

In the case of Medical Devices, a National Contract may require the Medical Device to be purchased by, and/or supplied to, a third party logistics provider.

20 Hospital Supply Status (HSS)

- 20.1 The DV Limit for any National Contract Pharmaceutical which has HSS is set out in the listing of the relevant National Contract Pharmaceutical in Section H, and may be amended from time to time.
- 20.2 If a National Contract Pharmaceutical is listed in Section H as having HSS, DHB Hospitals:
 - a) are expected to use up any existing stocks of DV Pharmaceuticals during the First Transition Period;
 - b) must not purchase DV Pharmaceuticals in volumes exceeding their usual requirements, or in volumes exceeding those which they reasonably expect to use, within the First Transition Period;
 - c) must ensure that Contract Manufacturers, when manufacturing an Extemporaneously Compounded Product on their behalf, use the National Contract Pharmaceutical with HSS; and

- d) must purchase the National Contract Pharmaceutical with HSS except:
 - i) to the extent that the DHB Hospital may use its discretion to purchase a DV Pharmaceutical within the DV Limit, provided that (subject to rule 20.2(d)(iii) below) the DV Limit has not been exceeded nationally;
 - ii) if the Pharmaceutical supplier fails to supply that National Contract Pharmaceutical, in which case the relevant DHB Hospital does not have to comply with the DV Limit for that National Contract Pharmaceutical during that period of non-supply (and any such month(s) included in a period of non-supply will be excluded in any review of the DV Limit in accordance with rule 20.3 below);
 - iii) that where the DV Limit has been exceeded nationally, the DHB Hospital may negotiate with the Pharmaceutical supplier that supplies the National Contract Pharmaceutical with HSS for written permission to vary the application of that DHB Hospital's Individual DV Limit for any patient whose exceptional needs require a DV Pharmaceutical.

20.3 PHARMAC may, in its discretion, for any period or part period:

- a) review usage by DHB Hospitals of the National Contract Pharmaceutical and DV Pharmaceuticals to determine whether the DV Limit has been exceeded; and
- b) audit compliance by DHB Hospitals with the DV Limits and related requirements.

20.4 PHARMAC will address any issues of non-compliance by any individual DHB or DHB Hospital with a DV Limit by:

- a) obtaining the relevant DHB or DHB Hospital's assurance that it will comply with the DV Limit for that National Contract Pharmaceutical with HSS in the remainder of the applicable period and any subsequent periods; and
- b) informing the relevant supplier of the HSS Pharmaceutical of any individual DHB or DHB Hospital's non-compliance with the DV Limit for that HSS Pharmaceutical.

20.5 In addition to the steps taken by PHARMAC under rule 20.4 above to address any issues of non-compliance by any individual DHB or DHB Hospital with a DV Limit, the relevant Pharmaceutical supplier may require, in its discretion, financial compensation from the relevant DHB or DHB Hospital:

- a) an amount representing that DHB or DHB Hospital's contribution towards exceeding the DV Limit (where PHARMAC is able to quantify this based on the information available to it); or
- b) the sum of \$1,000 or \$5,000 (depending on the terms of the applicable national contract applying to the HSS Pharmaceutical),

whichever is the greater as between sub-paragraphs (a) and (b) within the number of business days specified in the notice from the Pharmaceutical supplier requiring such payment to be made.

21 Collection of rebates and payment of financial compensation

21.1 Following the receipt of any rebates from a Pharmaceutical supplier in respect of a particular National Contract Pharmaceutical, PHARMAC will notify each relevant DHB and DHB Hospital of the amount of the rebate owing to it, being a portion of the total rebate determined by PHARMAC on the basis of that DHB Hospital's usage of that National Contract Pharmaceutical, where this is able to be determined. Where data to determine individual DHB Hospitals' usage is not available, PHARMAC will apportion rebates on the basis of an alternative method agreed between the relevant DHBs and PHARMAC.

21.2 PHARMAC will pay each DHB Hospital the rebate amounts (if any) owing to it, no less frequently than once each calendar quarter in respect of rebates received quarterly (or more often).

22 Price and Volume Data

22.1 DHB Hospitals must provide to PHARMAC, on a monthly basis in accordance with PHARMAC's requirements, any volume data and, unless it would result in a breach of a pre-existing contract, price data held by those DHB Hospitals in respect of any Pharmaceutical (including any Medical Device) listed in Section H.

22.2 All price and volume data provided to PHARMAC under rule 22.1 above should identify the relevant Hospital Pharmaceutical by using a Pharmacode or some other unique numerical identifier, and the date (month and year) on which the DHB Hospital incurred a cost for the purchase of that Hospital Pharmaceutical. Volume is to be measured in units (that being the smallest possible whole Unit – e.g. a capsule, a vial, a millilitre etc).

MISCELLANEOUS PROVISIONS

23 Unapproved Pharmaceuticals

Prescribers should, where possible, prescribe Hospital Pharmaceuticals that are approved under the Medicines Act 1981. However, the funding criteria (including Restrictions) under which a Hospital Pharmaceutical is listed in Section H of the

Schedule may:

23.1 in some cases, explicitly permit a DHB to fund a Pharmaceutical that is not approved under the Medicines Act 1981 or for an Unapproved Indication; or

23.2 not explicitly prohibit a DHB from funding a Pharmaceutical for use for an Unapproved Indication;

Accordingly, if clinicians are planning on prescribing an unapproved Pharmaceutical or a Pharmaceutical for an Unapproved Indication, they should:

23.1 be aware of and comply with their obligations under sections 25 and/or 29 of the Medicines Act 1981, as applicable, and otherwise under that Act and the Medicines Regulations 1984;

23.2 be aware of and comply with their obligations under the Health and Disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that clinicians obtain written consent); and

23.3 exercise their own skill, judgment, expertise and discretion, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical or a Pharmaceutical for an Unapproved Indication.

Clinicians should be aware that simply by listing a Pharmaceutical on the Pharmaceutical Schedule, PHARMAC makes no representations about whether that Pharmaceutical has any form of approval or consent under, or whether the supply or use of the Pharmaceutical otherwise complies with, the Medicines Act 1981. Further, the Pharmaceutical Schedule does not constitute an advertisement, advertising material or a medical advertisement as defined in the Medicines Act or otherwise.

Price
(ex man. excl. GST)
\$ Per Brand or
Generic
Manufacturer

Antacids and Antiflatulents

Antacids and Reflux Barrier Agents

ALUMINIUM HYDROXIDE WITH MAGNESIUM HYDROXIDE AND SIMETHICONE

Tab 200 mg with magnesium hydroxide 200 mg and simethicone 20 mg

e.g. Mylanta

Oral liq 200 mg with magnesium hydroxide 200 mg and simethicone
20 mg per 5 ml

e.g. Mylanta

Oral liq 400 mg with magnesium hydroxide 400 mg and simethicone
30 mg per 5 ml

*e.g. Mylanta Double
Strength*

SIMETHICONE

Oral drops 100 mg per ml

SODIUM ALGINATE WITH MAGNESIUM ALGINATE

Powder for oral soln 225 mg with magnesium alginate 87.5 mg, sachet

e.g. Gaviscon Infant

SODIUM ALGINATE WITH SODIUM BICARBONATE AND CALCIUM CARBONATE

Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate
160 mg

*e.g. Gaviscon Double
Strength*

Oral liq 500 mg with sodium bicarbonate 267 mg and calcium carbon-
ate 160 mg per 10 ml

4.95 500 ml Acidex

SODIUM CITRATE

Oral liq 8.8% (300 mmol/l)

Phosphate Binding Agents

ALUMINIUM HYDROXIDE

Tab 600 mg

CALCIUM CARBONATE – **Restricted** see terms below

⚡ Oral liq 250 mg per ml (100 mg elemental per ml)39.00

500 ml Roxane

➡ **Restricted**

Only for use in children under 12 years of age for use as a phosphate binding agent

Antidiarrhoeals and Intestinal Anti-Inflammatory Agents

Antipropulsives

DIPHENOXYLATE HYDROCHLORIDE WITH ATROPINE SULPHATE

Tab 2.5 mg with atropine sulphate 25 mcg

LOPERAMIDE HYDROCHLORIDE

Tab 2 mg

Cap 2 mg – 1% DV Jul-14 to 20167.84

400 Diamide Relief

Rectal and Colonic Anti-Inflammatories

BUDESONIDE – **Restricted** see terms on the next page

⚡ Cap 3 mg

ALIMENTARY TRACT AND METABOLISM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
➔Restricted			
Crohn's disease			
Both:			
1	Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and		
2	Any of the following:		
2.1	Diabetes; or		
2.2	Cushingoid habitus; or		
2.3	Osteoporosis where there is significant risk of fracture; or		
2.4	Severe acne following treatment with conventional corticosteroid therapy; or		
2.5	History of severe psychiatric problems associated with corticosteroid treatment; or		
2.6	History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or		
2.7	Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated).		
Collagenous and lymphocytic colitis (microscopic colitis)			
Patient has a diagnosis of microscopic colitis (collagenous or lymphocytic colitis) by colonoscopy with biopsies			
Gut Graft versus Host disease			
Patient has a gut Graft versus Host disease following allogenic bone marrow transplantation			
HYDROCORTISONE ACETATE			
Rectal foam 10%, CFC free (14 applications) – 1% DV Oct-15 to 2018	26.55	21.1 g	Colifoam
MESALAZINE			
Tab EC 400 mg	49.50	100	Asacol
Tab EC 500 mg	49.50	100	Asamax
Tab long-acting 500 mg	59.05	100	Pentasa
Tab 800 mg	85.55	90	Asacol
Modified release granules 1 g	141.72	120 g	Pentasa
Suppos 500 mg	22.80	20	Asacol
Suppos 1 g – 1% DV Jun-15 to 2018	54.60	30	Pentasa
Enema 1 g per 100 ml – 1% DV Sep-15 to 2018	41.30	7	Pentasa
OLSALAZINE			
Tab 500 mg			
Cap 250 mg			
SODIUM CROMOGLYCATE			
Cap 100 mg			
SULPHASALAZINE			
Tab 500 mg – 1% DV Oct-13 to 2016	11.68	100	Salazopyrin
Tab EC 500 mg – 1% DV Oct-13 to 2016	12.89	100	Salazopyrin EN
Local Preparations for Anal and Rectal Disorders			
Antihaemorrhoidal Preparations			
CINCHOCAINE HYDROCHLORIDE WITH HYDROCORTISONE			
Oint 5 mg with hydrocortisone 5 mg per g	15.00	30 g	Proctosedyl
Suppos 5 mg with hydrocortisone 5 mg per g	9.90	12	Proctosedyl
FLUCORTOLONE CAPROATE WITH FLUCORTOLONE PIVALATE AND CINCHOCAINE			
Oint 950 mcg with flucortolone pivalate 920 mcg and cinchocaine hydrochloride 5 mg per g	6.35	30 g	Ultraproct
Suppos 630 mcg with flucortolone pivalate 610 mcg and cinchocaine hydrochloride 1 mg	2.66	12	Ultraproct

↑ Item restricted (see ➔ above); ↓ Item restricted (see ➔ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Management of Anal Fissures			
GLYCERYL TRINITRATE			
Oint 0.2%	22.00	30 g	Rectogesic
Rectal Sclerosants			
OILY PHENOL [PHENOL OILY]			
Inj 5%, 5 ml vial			
Antispasmodics and Other Agents Altering Gut Motility			
GLYCOPYRRONIUM BROMIDE			
Inj 200 mcg per ml, 1 ml ampoule – 1% DV Oct-13 to 2016	28.56	10	Max Health
HYOSCINE BUTYLBROMIDE			
Tab 10 mg	2.18	20	Gastrosoothe
Inj 20 mg, 1 ml ampoule	9.57	5	Buscopan
MEBEVERINE HYDROCHLORIDE			
Tab 135 mg – 1% DV Sep-14 to 2017	18.00	90	Colofac
Antiulcerants			
Antisecretory and Cytoprotective			
MISOPROSTOL			
Tab 200 mcg			
H2 Antagonists			
CIMETIDINE			
Tab 200 mg			
Tab 400 mg			
RANITIDINE			
Tab 150 mg – 1% DV Nov-14 to 2017	10.30	500	Ranitidine Relief
Tab 300 mg – 1% DV Nov-14 to 2017	14.73	500	Ranitidine Relief
Oral liq 150 mg per 10 ml – 1% DV Sep-14 to 2017	4.92	300 ml	Peptisoothe
Inj 25 mg per ml, 2 ml ampoule	8.75	5	Zantac
Proton Pump Inhibitors			
LANSOPRAZOLE			
Cap 15 mg – 1% DV Jan-16 to 2018	5.08	100	Lanzol Relief
Cap 30 mg – 1% DV Jan-16 to 2018	5.93	100	Lanzol Relief
OMEPRAZOLE			
⚡ Tab dispersible 20 mg			
➔ Restricted			
Only for use in tube-fed patients			
Cap 10 mg – 1% DV Jan-15 to 2017	2.23	90	Omezol Relief
Cap 20 mg – 1% DV Jan-15 to 2017	2.91	90	Omezol Relief
Cap 40 mg – 1% DV Jan-15 to 2017	4.42	90	Omezol Relief
Powder for oral liq	42.50	5 g	Midwest
Inj 40 mg ampoule	19.00	5	Dr Reddy's Omeprazole
Inj 40 mg ampoule with diluent	28.65	5	Dr Reddy's Omeprazole

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

ALIMENTARY TRACT AND METABOLISM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
PANTOPRAZOLE			
Tab EC 20 mg – 1% DV May-14 to 2016	2.68	100	Pantoprazole Actavis 20
Tab EC 40 mg – 1% DV May-14 to 2016	3.54	100	Pantoprazole Actavis 40
Inj 40 mg vial			

Site Protective Agents

BISMUTH TRIOXIDE			
Tab 120 mg	32.50	112	De-Nol
SUCRALFATE			
Tab 1 g			

Bile and Liver Therapy

L-ORNITHINE L-ASPARTATE – **Restricted** see terms below

‡ Grans for oral liquid 3 g

➔ **Restricted**

For patients with chronic hepatic encephalopathy who have not responded to treatment with, or are intolerant to lactulose, or where lactulose is contraindicated.

RIFAXIMIN – **Restricted** see terms below

‡ Tab 550 mg – 1% DV Oct-14 to 2017	625.00	56	Xifaxan
---	--------	----	----------------

➔ **Restricted**

For patients with hepatic encephalopathy despite an adequate trial of maximum tolerated doses of lactulose.

Diabetes

Alpha Glucosidase Inhibitors

ACARBOSE			
Tab 50 mg – 1% DV Oct-15 to 2018	4.28	90	Glucobay
Tab 100 mg – 1% DV Oct-15 to 2018	7.78	90	Glucobay

Hyperglycaemic Agents

DIAZOXIDE – **Restricted** see terms below

‡ Cap 25 mg	110.00	100	Proglicem
‡ Cap 100 mg	280.00	100	Proglicem
‡ Oral liq 50 mg per ml	620.00	30 ml	Proglicem

➔ **Restricted**

For patients with confirmed hypoglycaemia caused by hyperinsulinism.

GLUCAGON HYDROCHLORIDE

Inj 1 mg syringe kit	32.00	1	Glucagen Hypokit
----------------------------	-------	---	------------------

GLUCOSE [DEXTROSE]

Tab 1.5 g
Tab 3.1 g
Tab 4 g
Gel 40%

GLUCOSE WITH SUCROSE AND FRUCTOSE

Gel 19.7% with sucrose 35% and fructose 19.7%, 18 g sachet

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Insulin - Intermediate-Acting Preparations			
INSULIN ASPART WITH INSULIN ASPART PROTAMINE			
Inj insulin aspart 30% with insulin aspart protamine 70%, 100 u per ml, 3 ml prefilled pen	52.15	5	NovoMix 30 FlexPen
INSULIN ISOPHANE			
Inj insulin human 100 u per ml, 10 ml vial			
Inj insulin human 100 u per ml, 3 ml cartridge			
INSULIN LISPRO WITH INSULIN LISPRO PROTAMINE			
Inj insulin lispro 25% with insulin lispro protamine 75%, 100 u per ml, 3 ml cartridge	42.66	5	Humalog Mix 25
Inj insulin lispro 50% with insulin lispro protamine 50%, 100 u per ml, 3 ml cartridge	42.66	5	Humalog Mix 50
INSULIN NEUTRAL WITH INSULIN ISOPHANE			
Inj insulin neutral 30% with insulin isophane 70%, 100 u per ml, 10 ml vial			
Inj insulin neutral 30% with insulin isophane 70%, 100 u per ml, 3 ml cartridge			
Inj insulin neutral 40% with insulin isophane 60%, 100 u per ml, 3 ml cartridge			
Inj insulin neutral 50% with insulin isophane 50%, 100 u per ml, 3 ml cartridge			
Insulin - Long-Acting Preparations			
INSULIN GLARGINE			
Inj 100 u per ml, 3 ml disposable pen	94.50	5	Lantus SoloStar
Inj 100 u per ml, 3 ml cartridge	94.50	5	Lantus
Inj 100 u per ml, 10 ml vial	63.00	1	Lantus
Insulin - Rapid-Acting Preparations			
INSULIN ASPART			
Inj 100 u per ml, 10 ml vial			
Inj 100 u per ml, 3 ml cartridge			
Inj 100 u per ml, 3 ml syringe	51.19	5	NovoRapid FlexPen
INSULIN GLULISINE			
Inj 100 u per ml, 10 ml vial	27.03	1	Apidra
Inj 100 u per ml, 3 ml cartridge	46.07	5	Apidra
Inj 100 u per ml, 3 ml disposable pen	46.07	5	Apidra Solostar
INSULIN LISPRO			
Inj 100 u per ml, 10 ml vial			
Inj 100 u per ml, 3 ml cartridge			
Insulin - Short-Acting Preparations			
INSULIN NEUTRAL			
Inj human 100 u per ml, 10 ml vial			
Inj human 100 u per ml, 3 ml cartridge			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Oral Hypoglycaemic Agents			
GLIBENCLAMIDE			
Tab 5 mg			
GLICLAZIDE			
Tab 80 mg – 1% DV Nov-14 to 2017	11.50	500	Glizide
GLIPIZIDE			
Tab 5 mg – 1% DV Sep-15 to 2018	2.85	100	Minidiab
METFORMIN HYDROCHLORIDE			
Tab immediate-release 500 mg – 1% DV Nov-15 to 2018	9.59	1,000	Metckek
Tab immediate-release 850 mg – 1% DV Dec-15 to 2018	7.82	500	Metformin Mylan
PIOGLITAZONE			
Tab 15 mg – 1% DV Dec-15 to 2018	3.47	90	Vexazone
Tab 30 mg – 1% DV Dec-15 to 2018	5.06	90	Vexazone
Tab 45 mg – 1% DV Dec-15 to 2018	7.10	90	Vexazone

Digestives Including Enzymes
PANCREATIC ENZYME

Cap EC 10,000 BP u lipase, 9,000 BP u amylase and 210 BP u protease – 1% DV Oct-15 to 2018	34.93	100	Creon 10000
Cap EC 25,000 BP u lipase, 18,000 BP u amylase and 1,000 BP u protease – 1% DV Oct-15 to 2018	94.38	100	Creon 25000
Cap EC 25,000 BP u lipase, 22,500 BP u amylase and 1,250 BP u protease			
Powder 25,000 u lipase with 30,000 u amylase and 1,400 u protease per g			

URSODEOXYCHOLIC ACID – Restricted see terms below

⚡ Cap 250 mg – 1% DV Sep-14 to 2017	53.40	100	Ursosan
---	-------	-----	----------------

➡ Restricted
Alagille syndrome or progressive familial intrahepatic cholestasis

Either:

- 1 Patient has been diagnosed with Alagille syndrome; or
- 2 Patient has progressive familial intrahepatic cholestasis.

Chronic severe drug induced cholestatic liver injury

All of the following:

- 1 Patient has chronic severe drug induced cholestatic liver injury; and
- 2 Cholestatic liver injury not due to Total Parenteral Nutrition (TPN) use in adults; and
- 3 Treatment with ursodeoxycholic acid may prevent hospital admission or reduce duration of stay.

Cirrhosis

Both:

- 1 Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative by liver biopsy; and
- 2 Patient not requiring a liver transplant (bilirubin > 100 µmol/l; decompensated cirrhosis).

Pregnancy

Patient diagnosed with cholestasis of pregnancy.

Haematological transplant

Both:

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 1 Patient at risk of veno-occlusive disease or has hepatic impairment and is undergoing conditioning treatment prior to allogenic stem cell or bone marrow transplantation; and
- 2 Treatment for up to 13 weeks.

Total parenteral nutrition induced cholestasis

Both:

- 1 Paediatric patient has developed abnormal liver function as indicated on testing which is likely to be induced by TPN; and
- 2 Liver function has not improved with modifying the TPN composition.

Laxatives

Bowel-Cleansing Preparations

CITRIC ACID WITH MAGNESIUM OXIDE AND SODIUM PICOSULFATE

Powder for oral soln 12 g with magnesium oxide 3.5 g and sodium picosulfate 10 mg per sachet

e.g. PicoPrep

MACROGOL 3350 WITH ASCORBIC ACID, POTASSIUM CHLORIDE AND SODIUM CHLORIDE

Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 210 g sachet

e.g. Glycoprep-C

Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 70 g sachet

e.g. Glycoprep-C

MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE AND SODIUM SULPHATE

Powder for oral soln 59 g with potassium chloride 0.7425 g, sodium bicarbonate 1.685 g, sodium chloride 1.465 g and sodium sulphate 5.685 g per sachet

14.31 4 Klean Prep

Bulk-Forming Agents

ISPAGHULA (PSYLLIUM) HUSK

Powder for oral soln – 1% DV Sep-13 to 2016.....5.51

500 g **Konsyl-D**

STERCULIA WITH FRANGULA

For continuation only

➔ Powder for oral soln

Faecal Softeners

DOCUSATE SODIUM

Tab 50 mg – 1% DV Jan-15 to 2017.....2.31

100 **Coloxyl**

Tab 120 mg – 1% DV Jan-15 to 2017.....3.13

100 **Coloxyl**

DOCUSATE SODIUM WITH SENNOSIDES

Tab 50 mg with sennosides 8 mg4.40

200 **Laxsol**

PARAFFIN

Oral liquid 1 mg per ml

Enema 133 ml

POLOXAMER

Oral drops 10% – 1% DV Sep-14 to 20173.78

30 ml **Coloxyl**

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Osmotic Laxatives			
GLYCEROL			
Suppos 1.27 g			
Suppos 2.55 g			
Suppos 3.6 g – 1% DV Sep-15 to 2018	6.50	20	PSM
LACTULOSE			
Oral liq 10 g per 15 ml	3.84	500 ml	Laevolac
MACROGOL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE AND SODIUM CHLORIDE – Restricted see terms below			
⚡ Powder for oral soln 6.563 g with potassium chloride 23.3 mg, sodium bicarbonate 89.3 mg and sodium chloride 175.4 mg			
⚡ Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg – 1% DV Oct-14 to 2017	7.65	30	Lax-Sachets
➔ Restricted			
Either:			
1 Both:			
1.1 The patient has problematic constipation despite an adequate trial of other oral pharmacotherapies including lactulose where lactulose is not contraindicated; and			
1.2 The patient would otherwise require a per rectal preparation; or			
2 For short-term use for faecal disimpaction.			
SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE			
Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml – 1% DV Sep-13 to 2016	19.95	50	Micolette
SODIUM PHOSPHATE WITH PHOSPHORIC ACID			
Oral liq 16.4% with phosphoric acid 25.14%			
Enema 10% with phosphoric acid 6.58%	2.50	1	Fleet Phosphate Enema
Stimulant Laxatives			
BISACODYL			
Tab 5 mg – 1% DV Oct-15 to 2018	5.99	200	Lax-Tabs
Suppos 10 mg – 1% DV Jan-16 to 2018	3.78	10	Lax-Suppositories
SENNOSIDES			
Tab 7.5 mg			
Metabolic Disorder Agents			
ARGININE			
Powder			
Inj 600 mg per ml, 25 ml vial			
BETAINE – Restricted see terms below			
⚡ Powder			
➔ Restricted			
Metabolic disorders physician or metabolic disorders dietitian			
BIOTIN – Restricted see terms on the next page			
⚡ Cap 50 mg			
⚡ Cap 100 mg			
⚡ Inj 10 mg per ml, 5 ml vial			

↑ Item restricted (see ➔ above); ⚡ Item restricted (see ➔ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

➔Restricted

Metabolic disorders physician or metabolic disorders dietitian.

HAEM ARGINATE

Inj 25 mg per ml, 10 ml ampoule

IMIGLUCERASE – Restricted see terms below

⚡ Inj 40 iu per ml, 5 ml vial

⚡ Inj 40 iu per ml, 10 ml vial

➔Restricted

Only for use in patients with approval by the Gaucher's Treatment Panel

LEVOCARNITINE – Restricted see terms below

⚡ Cap 500 mg

⚡ Oral soln 1,100 mg per 15 ml

⚡ Inj 200 mg per ml, 5 ml vial

➔Restricted

Metabolic disorders physician, metabolic disorders dietitian or neurologist

PYRIDOXAL-5-PHOSPHATE – Restricted see terms below

⚡ Tab 50 mg

➔Restricted

Metabolic disorders physician, metabolic disorders dietitian or neurologist

SODIUM BENZOATE

Cap 500 mg

Powder

Soln 100 mg per ml

Inj 20%, 10 ml ampoule

SODIUM PHENYLBUTYRATE

Tab 500 mg

Oral liq 250 mg per ml

Inj 200 mg per ml, 10 ml ampoule

TRIENTINE DIHYDROCHLORIDE

Cap 300 mg

Minerals**Calcium****CALCIUM CARBONATE**Tab 1.25 g (500 mg elemental) – **1% DV Sep-14 to 2017**..... 5.38 250 **Arrow-Calcium**

Tab eff 1.75 g (1 g elemental) 6.21 30 Calsource

Fluoride**SODIUM FLUORIDE**

Tab 1.1 mg (0.5 mg elemental)

Iodine**POTASSIUM IODATE**Tab 253 mcg (150 mcg elemental iodine) – **1% DV Dec-14 to 2017** 3.65 90 **NeuroTabs****POTASSIUM IODATE WITH IODINE**

Oral liq 10% with iodine 5%

ALIMENTARY TRACT AND METABOLISM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Iron			
FERRIC CARBOXYMALTOSE – Restricted see terms below			
‡ Inj 50 mg per ml, 10 ml vial	150.00	1	Ferinject
➔ Restricted Treatment with oral iron has proven ineffective or is clinically inappropriate.			
FERROUS FUMARATE			
Tab 200 mg (65 mg elemental) – 1% DV Jun-15 to 2018	2.89	100	Ferro-tab
FERROUS FUMARATE WITH FOLIC ACID			
Tab 310 mg (100 mg elemental) with folic acid 350 mcg	4.75	60	Ferro-F-Tabs
FERROUS GLUCONATE WITH ASCORBIC ACID			
Tab 170 mg (20 mg elemental) with ascorbic acid 40 mg			
FERROUS SULPHATE			
Tab long-acting 325 mg (105 mg elemental)	2.06	30	Ferrograd
Oral liq 30 mg (6 mg elemental) per ml – 1% DV Apr-14 to 2016	10.28	500 ml	Ferodan
FERROUS SULPHATE WITH ASCORBIC ACID			
Tab long-acting 325 mg (105 mg elemental) with ascorbic acid 500 mg			
FERROUS SULPHATE WITH FOLIC ACID			
Tab long-acting 325 mg (105 mg elemental) with folic acid 350 mcg			
IRON POLYMALTOSE			
Inj 50 mg per ml, 2 ml ampoule – 1% DV Sep-14 to 2017	15.22	5	Ferrum H
IRON SUCROSE			
Inj 20 mg per ml, 5 ml ampoule	100.00	5	Venofer
Magnesium			
MAGNESIUM HYDROXIDE			
Tab 311 mg (130 mg elemental)			
MAGNESIUM OXIDE			
Cap 663 mg (400 mg elemental)			
MAGNESIUM SULPHATE			
Inj 0.4 mmol per ml, 250 ml bag			
Inj 2 mmol per ml, 5 ml ampoule – 1% DV Oct-14 to 2017	12.65	10	DBL
Zinc			
ZINC			
Oral liq 5 mg per 5 drops			
ZINC CHLORIDE			
Inj 5.3 mg per ml (5.1 mg per ml elemental), 2 ml ampoule			
ZINC SULPHATE			
Cap 137.4 mg (50 mg elemental) – 1% DV Mar-15 to 2017	11.00	100	Zincaps

‡ Item restricted (see ➔ above); † Item restricted (see ➔ below)
e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Mouth and Throat

Agents Used in Mouth Ulceration

BENZYDAMINE HYDROCHLORIDE

Soln 0.15%
Spray 0.15%
Spray 0.3%

BENZYDAMINE HYDROCHLORIDE WITH CETYLPYRIDINIUM CHLORIDE

Lozenge 3 mg with cetylpyridinium chloride

CARBOXYMETHYLCELLULOSE

Oral spray

CHLORHEXIDINE GLUCONATE

Mouthwash 0.2% – 1% DV Sep-15 to 2018 2.57 200 ml **healthE**

CHOLINE SALICYLATE WITH CETALKONIUM CHLORIDE

Adhesive gel 8.7% with cetalkonium chloride 0.01%

DICHLOROBENZYL ALCOHOL WITH AMYLMETACRESOL

Lozenge 1.2 mg with amylmetacresol 0.6 mg

SODIUM CARBOXYMETHYLCELLULOSE WITH PECTIN AND GELATINE

Paste
Powder

TRIAMCINOLONE ACETONIDE

Paste 0.1% – 1% DV Apr-15 to 2017 5.33 5 g **Kenalog in Orabase**

Oropharyngeal Anti-Infectives

AMPHOTERICIN B

Lozenge 10 mg 5.86 20 **Fungilin**

MICONAZOLE

Oral gel 20 mg per g – 1% DV Sep-15 to 2018 4.79 40 g **Decozol**

NYSTATIN

Oral liquid 100,000 u per ml – 1% DV Feb-16 to 2017 2.55 24 ml **m-Nystatin**
3.35 Nilstat

(Nilstat Oral liquid 100,000 u per ml to be delisted 1 February 2016)

Other Oral Agents

SODIUM HYALURONATE [HYALURONIC ACID] – **Restricted** see terms below

⚡ Inj 20 mg per ml, 1 ml syringe

➔ **Restricted**

Otolaryngologist

THYMOL GLYCERIN

Compound, BPC

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Vitamins

Multivitamin Preparations

MULTIVITAMIN AND MINERAL SUPPLEMENT – **Restricted** see terms below

⚡ Cap	23.35	180	Clinicians Multivit & Mineral Boost
-------------	-------	-----	-------------------------------------

➡ **Restricted**

Limited to 3 months' treatment

Both:

- 1 Patient was admitted to hospital with burns; and
- 2 Any of the following:
 - 2.1 Burn size is greater than 15% of total body surface area (BSA) for all types of burns; or
 - 2.2 Burn size is greater than 10% of BSA for mid-dermal or deep dermal burns; or
 - 2.3 Nutritional status prior to admission or dietary intake is poor.

MULTIVITAMIN RENAL – **Restricted** see terms below

⚡ Cap	8.39	30	Clinicians Renal Vit
-------------	------	----	----------------------

➡ **Restricted**

Either:

- 1 The patient has chronic kidney disease and is receiving either peritoneal dialysis or haemodialysis; or
- 2 The patient has chronic kidney disease grade 5, defined as patient with an estimated glomerular filtration rate of < 15 ml/min/1.73m² body surface area (BSA).

MULTIVITAMINS

Tab (BPC cap strength) e.g. *Mvite*

⚡ Cap vitamin A 2500 u, betacarotene 3 mg, cholecalciferol 11 mcg, alpha tocopherol 150 u, phytomenadione 150 mcg, folic acid 0.2 mg, ascorbic acid 100 mg, thiamine 1.5 mg, pantothenic acid 12 mg, riboflavin 1.7 mg, niacin 20 mg, pyridoxine hydrochloride 1.9 mg, cyanocobalamin 3 mcg, zinc 7.5 mg and biotin 100 mcg	e.g. <i>Vitabdeck</i>
---	-----------------------

➡ **Restricted**

Either:

- 1 Patient has cystic fibrosis with pancreatic insufficiency; or
- 2 Patient is an infant or child with liver disease or short gut syndrome.

⚡ Powder vitamin A 4200 mcg with vitamin D 155.5 mcg, vitamin E 21.4 mg, vitamin C 400 mg, vitamin K1 166 mcg thiamine 3.2 mg, riboflavin 4.4 mg, niacin 35 mg, vitamin B6 3.4 mg, folic acid 303 mcg, vitamin B12 8.6 mcg, biotin 214 mcg, pantothenic acid 17 mg, choline 350 mg and inositol 700 mg	e.g. <i>Paediatric Seravit</i>
--	--------------------------------

➡ **Restricted**

Patient has inborn errors of metabolism.

Inj thiamine hydrochloride 250 mg with riboflavin 4 mg and pyridoxine hydrochloride 50 mg, 5 ml ampoule (1) and inj ascorbic acid 500 mg with nicotinamide 160 mg and glucose 1000 mg, 5 ml ampoule (1) e.g. *Pabrinex IV*

Inj thiamine hydrochloride 250 mg with riboflavin 4 mg and pyridoxine hydrochloride 50 mg, 5 ml ampoule (1) and inj ascorbic acid 500 mg with nicotinamide 160 mg, 2 ml ampoule (1) e.g. *Pabrinex IM*

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Inj thiamine hydrochloride 500 mg with riboflavin 8 mg and pyridoxine hydrochloride 100 mg, 10 ml ampoule (1) and inj ascorbic acid 1000 mg with nicotinamide 320 mg and glucose 2000 mg, 10 ml ampoule (1)			<i>e.g. Pabrinex IV</i>
VITAMIN A WITH VITAMINS D AND C			
Soln 1,000 u with vitamin D 400 u and ascorbic acid 30 mg per 10 drops			<i>e.g. Vitadol C</i>
Vitamin A			
RETINOL			
Tab 10,000 iu			
Cap 25,000 iu			
Oral liq 150,000 iu per ml			
Vitamin B			
HYDROXOCOBALAMIN			
Inj 1 mg per ml, 1 ml ampoule – 1% DV Sep-15 to 2018	2.31	3	Neo-B12
PYRIDOXINE HYDROCHLORIDE			
Tab 25 mg – 1% DV Apr-15 to 2017	2.15	90	Vitamin B6 25
Tab 50 mg – 1% DV Oct-14 to 2017	11.55	500	Apo-Pyridoxine
Inj 100 mg per ml, 1 ml ampoule			
THIAMINE HYDROCHLORIDE			
Tab 50 mg			
Tab 100 mg			
Inj 100 mg per ml, 1 ml vial			<i>e.g. Benerva</i>
Inj 100 mg per ml, 2 ml vial			
VITAMIN B COMPLEX			
Tab strong, BPC			
Vitamin C			
ASCORBIC ACID			
Tab 100 mg – 1% DV Nov-13 to 2016	7.00	500	Cvite
Tab chewable 250 mg			
Vitamin D			
ALFACALCIDOL			
Cap 0.25 mcg	26.32	100	One-Alpha
Cap 1 mcg	87.98	100	One-Alpha
Oral drops 2 mcg per ml			
CALCITRIOL			
Cap 0.25 mcg	3.03	30	Airflow
	10.10	100	Calcitriol-AFT
Cap 0.5 mcg	5.62	30	Airflow
	18.73	100	Calcitriol-AFT
Oral liq 1 mcg per ml			
Inj 1 mcg per ml, 1 ml ampoule			
CHOLECALCIFEROL			
Tab 1.25 mg (50,000 iu)	7.76	12	Cal-d-Forte

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Vitamin E

ALPHA TOCOPHERYL ACETATE – **Restricted** see terms below

- ⚡ Cap 100 u
- ⚡ Cap 500 u
- ⚡ Oral liq 156 u per ml

↪ **Restricted**

Cystic fibrosis

Both:

- 1 Cystic fibrosis patient; and
- 2 Either:
 - 2.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck); or
 - 2.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for the patient.

Osteoradionecrosis

For the treatment of osteoradionecrosis

Other indications

All of the following:

- 1 Infant or child with liver disease or short gut syndrome; and
- 2 Requires vitamin supplementation; and
- 3 Either:
 - 3.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplements (Vitabdeck); or
 - 3.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for patient.

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Antianaemics

Hypoplastic and Haemolytic

EPOETIN ALFA [ERYTHROPOIETIN ALFA] – **Restricted** see terms below

⚡ Inj 1,000 iu in 0.5 ml syringe – 5% DV Mar-15 to 28 Feb 2018	48.68	6	Eprex
⚡ Inj 2,000 iu in 0.5 ml syringe – 5% DV Mar-15 to 28 Feb 2018	120.18	6	Eprex
⚡ Inj 3,000 iu in 0.3 ml syringe – 5% DV Mar-15 to 28 Feb 2018	166.87	6	Eprex
⚡ Inj 4,000 iu in 0.4 ml syringe – 5% DV Mar-15 to 28 Feb 2018	193.13	6	Eprex
⚡ Inj 5,000 iu in 0.5 ml syringe – 5% DV Mar-15 to 28 Feb 2018	243.26	6	Eprex
⚡ Inj 6,000 iu in 0.6 ml syringe – 5% DV Mar-15 to 28 Feb 2018	291.92	6	Eprex
⚡ Inj 8,000 iu in 0.8 ml syringe – 5% DV May-15 to 28 Feb 2018	352.69	6	Eprex
⚡ Inj 10,000 iu in 1 ml syringe – 5% DV Mar-15 to 28 Feb 2018	395.18	6	Eprex
⚡ Inj 40,000 iu in 1 ml syringe – 5% DV May-15 to 28 Feb 2018	263.45	1	Eprex

→ **Restricted**

Initiation - chronic renal failure

All of the following:

- 1 Patient in chronic renal failure; and
- 2 Haemoglobin ≤ 100g/L; and
- 3 Any of the following:
 - 3.1 Both:
 - 3.1.1 Patient does not have diabetes mellitus; and
 - 3.1.2 Glomerular filtration rate ≤ 30ml/min; or
 - 3.2 Both:
 - 3.2.1 Patient has diabetes mellitus; and
 - 3.2.2 Glomerular filtration rate ≤ 45ml/min; or
- 4 Patient is on haemodialysis or peritoneal dialysis.

Initiation - myelodysplasia*

Re-assessment required after 2 months

All of the following:

- 1 Patient has a confirmed diagnosis of myelodysplasia (MDS); and
- 2 Has had symptomatic anaemia with haemoglobin < 100g/L and is red cell transfusion-dependent; and
- 3 Patient has very low, low or intermediate risk MDS based on the WHO classification-based prognostic scoring system for myelodysplastic syndrome (WPSS); and
- 4 Other causes of anaemia such as B12 and folate deficiency have been excluded; and
- 5 Patient has a serum erythropoietin level of < 500 IU/L; and
- 6 The minimum necessary dose of erythropoietin would be used and will not exceed 80,000 iu per week.

Continuation - myelodysplasia*

Re-assessment required after 12 months

All of the following:

- 1 The patient's transfusion requirement continues to be reduced with erythropoietin treatment; and
- 2 Transformation to acute myeloid leukaemia has not occurred; and
- 3 The minimum necessary dose of erythropoietin would be used and will not exceed 80,000 iu per week.

Initiation - all other indications

Haematologist

For use in patients where blood transfusion is not a viable treatment alternative.

*Note: Indications marked with * are Unapproved Indications.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Megaloblastic			
FOLIC ACID			
Tab 0.8 mg – 1% DV Oct-15 to 2018	20.60	1,000	Apo-Folic Acid
Tab 5 mg – 1% DV Oct-15 to 2018	10.92	500	Apo-Folic Acid
Oral liq 50 mcg per ml	24.00	25 ml	Biomed
Inj 5 mg per ml, 10 ml vial			

Antifibrinolytics, Haemostatics and Local Sclerosants

ALUMINIUM CHLORIDE – **Restricted** see terms below

☒ Topical soln 20% w/v

e.g. Driclor

☛ **Restricted**

For use as a haemostatis agent.

APROTININ – **Restricted** see terms below

☒ Inj 10,000 kIU per ml (equivalent to 200 mg per ml), 50 ml vial

☛ **Restricted**

Cardiac anaesthetist

Either:

- 1 Paediatric patient undergoing cardiopulmonary bypass procedure; or
- 2 Adult patient undergoing cardiac surgical procedure where the significant risk of massive bleeding outweighs the potential adverse effects of the drug.

ELTROMBOPAG – **Restricted** see terms below

☒ Tab 25 mg 1,771.00

28

Revolade

☒ Tab 50 mg 3,542.00

28

Revolade

☛ **Restricted**

Haematologist

Initiation (idiopathic thrombocytopenic purpura - post-splenectomy)

Re-assessment required after 6 weeks

All of the following:

- 1 Patient has had a splenectomy; and
- 2 Two immunosuppressive therapies have been trialled and failed after therapy of 3 months each (or 1 month for rituximab); and
- 3 Any of the following:
 - 3.1 Patient has a platelet count of 20,000 to 30,000 platelets per microlitre and has evidence of significant mucocutaneous bleeding; or
 - 3.2 Patient has a platelet count of \leq 20,000 platelets per microlitre and has evidence of active bleeding; or
 - 3.3 Patient has a platelet count of \leq 10,000 platelets per microlitre.

Initiation - (idiopathic thrombocytopenic purpura - preparation for splenectomy)

Re-assessment required after 6 weeks

The patient requires eltrombopag treatment as preparation for splenectomy.

Continuation - (idiopathic thrombocytopenic purpura - post-splenectomy)

Re-assessment required after 12 months

The patient has obtained a response (see Note) from treatment during the initial approval or subsequent renewal periods and further treatment is required.

Note: Response to treatment is defined as a platelet count of $>$ 30,000 platelets per microlitre.

FERRIC SUBSULFATE

Gel 25.9%

Soln 500 ml

POLIDOCANOL

Inj 0.5%, 30 ml vial

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
SODIUM TETRADECYL SULPHATE			
Inj 3%, 2 ml ampoule			
THROMBIN			
Powder			
TRANEXAMIC ACID			
Tab 500 mg – 1% DV Oct-14 to 2016	23.00	100	Cyklokapron
Inj 100 mg per ml, 5 ml ampoule – 1% DV Sep-15 to 2018	55.00	10	Cyklokapron

Blood Factors

EPTACOG ALFA [RECOMBINANT FACTOR VIIA] – **Restricted** see terms below

⚡ Inj 1 mg syringe	1,163.75	1	NovoSeven RT
⚡ Inj 2 mg syringe	2,327.50	1	NovoSeven RT
⚡ Inj 5 mg syringe	5,818.75	1	NovoSeven RT
⚡ Inj 8 mg syringe	9,310.00	1	NovoSeven RT

➔**Restricted**

When used in the treatment of haemophilia, access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

FACTOR EIGHT INHIBITOR BYPASSING FRACTION – **Restricted** see terms below

⚡ Inj 500 U	1,450.00	1	FEIBA NF
⚡ Inj 1,000 U	2,900.00	1	FEIBA NF
⚡ Inj 2,500 U	7,250.00	1	FEIBA NF

➔**Restricted**

When used in the treatment of haemophilia, access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

MOROCTOCOG ALFA [RECOMBINANT FACTOR VIII] – **Restricted** see terms below

⚡ Inj 250 iu prefilled syringe	210.00	1	Xyntha
⚡ Inj 500 iu prefilled syringe	420.00	1	Xyntha
⚡ Inj 1,000 iu prefilled syringe	840.00	1	Xyntha
⚡ Inj 2,000 iu prefilled syringe	1,680.00	1	Xyntha
⚡ Inj 3,000 iu prefilled syringe	2,520.00	1	Xyntha

➔**Restricted**

When used in the treatment of haemophilia, treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

NONACOG ALFA [RECOMBINANT FACTOR IX] – **Restricted** see terms below

⚡ Inj 250 iu vial	310.00	1	BeneFIX
⚡ Inj 500 iu vial	620.00	1	BeneFIX
⚡ Inj 1,000 iu vial	1,240.00	1	BeneFIX
⚡ Inj 2,000 iu vial	2,480.00	1	BeneFIX
⚡ Inj 3,000 iu vial	3,720.00	1	BeneFIX

➔**Restricted**

When used in the treatment of haemophilia, access to funded treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

BLOOD AND BLOOD FORMING ORGANS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
OCTOCOG ALFA [RECOMBINANT FACTOR VIII] – Restricted see terms below			
☞ Inj 250 iu vial	237.50	1	Kogenate FS
	287.50		Advate
☞ Inj 500 iu vial	475.00	1	Kogenate FS
	575.00		Advate
☞ Inj 1,000 iu vial	950.00	1	Kogenate FS
	1,150.00		Advate
☞ Inj 1,500 iu vial	1,725.00	1	Advate
☞ Inj 2,000 iu vial	1,900.00	1	Kogenate FS
	2,300.00		Advate
☞ Inj 3,000 iu vial	2,850.00	1	Kogenate FS
	3,450.00		Advate

☞Restricted

When used in the treatment of haemophilia, treatment is managed by the Haemophilia Treaters Group in conjunction with the National Haemophilia Management Group.

Vitamin K

PHYTOMENADIONE			
Inj 2 mg in 0.2 ml ampoule	8.00	5	Konaktion MM
Inj 10 mg per ml, 1 ml ampoule	9.21	5	Konaktion MM

Antithrombotics

Anticoagulants

BIVALIRUDIN – Restricted see terms below

☞ Inj 250 mg vial

☞Restricted

Either:

- 1 For use in heparin-induced thrombocytopenia, heparin resistance or heparin intolerance; or
- 2 For use in patients undergoing endovascular procedures.

DABIGATRAN

Cap 75 mg	148.00	60	Pradaxa
Cap 110 mg	148.00	60	Pradaxa
Cap 150 mg	148.00	60	Pradaxa

DALTEPARIN

Inj 2,500 iu in 0.2 ml syringe	19.97	10	Fragmin
Inj 5,000 iu in 0.2 ml syringe	39.94	10	Fragmin
Inj 7,500 iu in 0.75 ml syringe	60.03	10	Fragmin
Inj 10,000 iu in 1 ml syringe	77.55	10	Fragmin
Inj 12,500 iu in 0.5 ml syringe	99.96	10	Fragmin
Inj 15,000 iu in 0.6 ml syringe	120.05	10	Fragmin
Inj 18,000 iu in 0.72 ml syringe	158.47	10	Fragmin

DANAPAROID – Restricted see terms below

☞ Inj 750 u in 0.6 ml ampoule

☞Restricted

For use in heparin-induced thrombocytopenia, heparin resistance or heparin intolerance

DEFIBROTIDE – Restricted see terms on the next page

☞ Inj 80 mg per ml, 2.5 ml ampoule

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
➔Restricted			
Haematologist			
Patient has moderate or severe sinusoidal obstruction syndrome as a result of chemotherapy or regimen-related toxicities			
DEXTROSE WITH SODIUM CITRATE AND CITRIC ACID [ACID CITRATE DEXTROSE A]			
Inj 24.5 mg with sodium citrate 22 mg and citric acid 7.3 mg per ml, 100 ml bag			
ENOXAPARIN			
Inj 20 mg in 0.2 ml syringe	37.24	10	Clexane
Inj 40 mg in 0.4 ml ampoule			
Inj 40 mg in 0.4 ml syringe	49.69	10	Clexane
Inj 60 mg in 0.6 ml syringe	74.91	10	Clexane
Inj 80 mg in 0.8 ml syringe	99.86	10	Clexane
Inj 100 mg in 1 ml syringe	125.06	10	Clexane
Inj 120 mg in 0.8 ml syringe	155.40	10	Clexane
Inj 150 mg in 1 ml syringe	177.60	10	Clexane
FONDAPARINUX SODIUM – Restricted see terms below			
⚡ Inj 2.5 mg in 0.5 ml syringe			
⚡ Inj 7.5 mg in 0.6 ml syringe			
➔Restricted			
For use in heparin-induced thrombocytopenia, heparin resistance or heparin intolerance			
HEPARIN SODIUM			
Inj 100 iu per ml, 250 ml bag			
Inj 1,000 iu per ml, 1 ml ampoule	66.80	50	Hospira
Inj 1,000 iu per ml, 35 ml vial			
Inj 1,000 iu per ml, 5 ml ampoule	61.04	50	Pfizer
Inj 5,000 iu in 0.2 ml ampoule			
Inj 5,000 iu per ml, 1 ml ampoule	14.20	5	Hospira
Inj 5,000 iu per ml, 5 ml ampoule	236.60	50	Pfizer
HEPARINISED SALINE			
Inj 10 iu per ml, 5 ml ampoule	39.00	50	Pfizer
Inj 100 iu per ml, 2 ml ampoule			
Inj 100 iu per ml, 5 ml ampoule			
PHENINDIONE			
Tab 10 mg			
Tab 25 mg			
Tab 50 mg			
PROTAMINE SULPHATE			
Inj 10 mg per ml, 5 ml ampoule			
RIVAROXABAN – Restricted see terms below			
⚡ Tab 10 mg	153.00	15	Xarelto
➔Restricted			
Either:			
1 Limited to five weeks' treatment for the prophylaxis of venous thromboembolism following a total hip replacement; or			
2 Limited to two weeks' treatment for the prophylaxis of venous thromboembolism following a total knee replacement.			
SODIUM CITRATE WITH SODIUM CHLORIDE AND POTASSIUM CHLORIDE			
Inj 4.2 mg with sodium chloride 5.7 mg and potassium chloride 74.6 mcg per ml, 5,000 ml bag			

BLOOD AND BLOOD FORMING ORGANS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
TRISODIUM CITRATE			
Inj 4%, 5 ml ampoule			
Inj 46.7%, 3 ml syringe			
Inj 46.7%, 5 ml ampoule			
WARFARIN SODIUM			
Tab 1 mg	6.86	100	Marevan
Tab 2 mg			
Tab 3 mg	9.70	100	Marevan
Tab 5 mg	11.75	100	Marevan
Antiplatelets			
ASPIRIN			
Tab 100 mg – 1% DV Mar-14 to 2016	1.60	90	Ethics Aspirin EC
	10.50	990	Ethics Aspirin EC
Suppos 300 mg			
CLOPIDOGREL			
Tab 75 mg – 1% DV Dec-13 to 2016	5.48	84	Arrow - Clopid
DIPYRIDAMOLE			
Tab 25 mg			
Tab long-acting 150 mg	11.52	60	Pytazen SR
Inj 5 mg per ml, 2 ml ampoule			
EPTIFIBATIDE – Restricted see terms below			
⚡ Inj 2 mg per ml, 10 ml vial	111.00	1	Integrilin
⚡ Inj 750 mcg per ml, 100 ml vial	324.00	1	Integrilin
↪ Restricted			
Either:			
1 For use in patients with acute coronary syndromes undergoing percutaneous coronary intervention; or			
2 For use in patients with definite or strongly suspected intra-coronary thrombus on coronary angiography.			
PRASUGREL – Restricted see terms below			
⚡ Tab 5 mg	108.00	28	Effient
⚡ Tab 10 mg	120.00	28	Effient
↪ Restricted			
Bare metal stents			
Limited to 6 months' treatment			
Patient has undergone coronary angioplasty in the previous 4 weeks and is clopidogrel-allergic.			
Drug-eluting stents			
Limited to 12 months' treatment			
Patient has had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic.			
Stent thrombosis			
Patient has experienced cardiac stent thrombosis whilst on clopidogrel.			
Myocardial infarction			
Limited to 7 days' treatment			
For short term use while in hospital following ST-elevated myocardial infarction.			
Note: Clopidogrel allergy is defined as a history of anaphylaxis, urticaria, generalised rash or asthma (in non-asthmatic patients) developing soon after clopidogrel is started and is considered unlikely to be caused by any other treatment.			
TICAGRELOR – Restricted see terms on the next page			
⚡ Tab 90 mg	90.00	56	Brillinta

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➔ **Restricted**

Restricted to treatment of acute coronary syndromes specifically for patients who have recently (within the last 60 days) been diagnosed with an ST-elevation or a non-ST-elevation acute coronary syndrome, and in whom fibrinolytic therapy has not been given in the last 24 hours and is not planned.

TICLOPIDINE

Tab 250 mg

Fibrinolytic Agents

ALTEPLASE

Inj 2 mg vial

Inj 10 mg vial

Inj 50 mg vial

TENECTEPLASE

Inj 50 mg vial

UROKINASE

Inj 10,000 iu vial

Inj 50,000 iu vial

Inj 100,000 iu vial

Inj 500,000 iu vial

Colony-Stimulating Factors

Granulocyte Colony-Stimulating Factors

FILGRASTIM – **Restricted** see terms below

⚡ Inj 300 mcg in 0.5 ml syringe	540.00	5	Zarzio
⚡ Inj 300 mcg in 1 ml vial	650.00	5	Neupogen
⚡ Inj 480 mcg in 0.5 ml syringe	864.00	5	Zarzio

➔ **Restricted**

Oncologist or haematologist

PEGFILGRASTIM – **Restricted** see terms below

⚡ Inj 6 mg per 0.6 ml syringe	1,080.00	1	Neulastim
-------------------------------------	----------	---	-----------

➔ **Restricted**

For prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk \geq 20%*).

*Febrile neutropenia risk \geq 20% after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines.

Fluids and Electrolytes

Intravenous Administration

CALCIUM CHLORIDE

Inj 100 mg per ml, 10 ml vial

CALCIUM GLUCONATE

Inj 10%, 10 ml ampoule	34.24	10	Hospira
------------------------------	-------	----	---------

COMPOUND ELECTROLYTES

Inj sodium 140 mmol/l with potassium 5 mmol/l, magnesium 1.5 mmol/l, chloride 98 mmol/l, acetate 27 mmol/l and gluconate 23 mmol/l, bag	5.00	500 ml	Baxter
	3.10	1,000 ml	Baxter

BLOOD AND BLOOD FORMING ORGANS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
COMPOUND ELECTROLYTES WITH GLUCOSE			
Inj glucose 50 g with 140 mmol/l sodium, 5 mmol/l potassium, 1.5 mmol/l magnesium, 98 mmol/l chloride, 27 mmol/l acetate and 23 mmol/l gluconate, bag	7.00	1,000 ml	Baxter
COMPOUND SODIUM LACTATE [HARTMANN'S SOLUTION]			
Inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l, bi-carbonate 29 mmol/l, chloride 111 mmol/l, bag	1.77	500 ml	Baxter
	1.80	1,000 ml	Baxter
COMPOUND SODIUM LACTATE WITH GLUCOSE			
Inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l, bi-carbonate 29 mmol/l, chloride 111 mmol/l and glucose 5%, bag	5.38	1,000 ml	Baxter
GLUCOSE [DEXTROSE]			
Inj 5%, bag	2.87	50 ml	Baxter
	2.84	100 ml	Baxter
	3.87	250 ml	Baxter
	1.77	500 ml	Baxter
	1.80	1,000 ml	Baxter
Inj 10%, bag	3.70	500 ml	Baxter
	5.29	1,000 ml	Baxter
Inj 50%, bag	6.84	500 ml	Baxter
Inj 50%, 10 ml ampoule – 1% DV Oct-14 to 2017	27.50	5	Biomed
Inj 50%, 90 ml bottle – 1% DV Oct-14 to 2017	14.50	1	Biomed
Inj 70%, 1,000 ml bag			
Inj 70%, 500 ml bag			
GLUCOSE WITH POTASSIUM CHLORIDE			
Inj 5% glucose with 20 mmol/l potassium chloride, bag	7.36	1,000 ml	Baxter
Inj 5% glucose with 30 mmol/l potassium chloride, 1,000 ml bag			
Inj 10% glucose with 10 mmol/l potassium chloride, 500 ml bag			
GLUCOSE WITH POTASSIUM CHLORIDE AND SODIUM CHLORIDE			
Inj 4% glucose with potassium chloride 20 mmol/l and sodium chloride 0.18%, bag	3.45	500 ml	Baxter
	4.30	1,000 ml	Baxter
Inj 4% glucose with potassium chloride 30 mmol/l and sodium chloride 0.18%, bag	3.62	1,000 ml	Baxter
Inj 2.5% glucose with potassium chloride 20 mmol/l and sodium chloride 0.45%, 3,000 ml bag			
Inj 10% glucose with potassium chloride 10 mmol/l and sodium chloride 15 mmol/l, 500 ml bag			
GLUCOSE WITH SODIUM CHLORIDE			
Inj glucose 2.5% with sodium chloride 0.45%, bag	4.95	500 ml	Baxter
Inj glucose 5% with sodium chloride 0.45%, bag	9.87	500 ml	Baxter
	5.80	1,000 ml	Baxter
Inj glucose 5% with sodium chloride 0.9%, bag	4.54	1,000 ml	Baxter
Inj glucose 5% with sodium chloride 0.2%, 500 ml bag			
POTASSIUM CHLORIDE			
Inj 75 mg (1 mmol) per ml, 10 ml ampoule			
Inj 225 mg (3 mmol) per ml, 20 ml ampoule			

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

BLOOD AND BLOOD FORMING ORGANS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
POTASSIUM CHLORIDE WITH SODIUM CHLORIDE			
Inj 20 mmol/l potassium chloride with 0.9% sodium chloride, bag	3.85	1,000 ml	Baxter
Inj 30 mmol/l potassium chloride with 0.9% sodium chloride, bag	2.59	1,000 ml	Baxter
Inj 40 mmol/l potassium chloride with 0.9% sodium chloride, bag	6.62	1,000 ml	Baxter
Inj 10 mmol potassium chloride with 0.29% sodium chloride, 100 ml bag			
Inj 40 mmol potassium chloride with 0.9% sodium chloride, 100 ml bag			
POTASSIUM DIHYDROGEN PHOSPHATE			
Inj 1 mmol per ml, 10 ml ampoule – 1% DV Oct-15 to 2018.....	151.80	10	Hospira
RINGER'S SOLUTION			
Inj sodium 147 mmol/l with potassium 4 mmol/l, calcium 2.2 mmol/l, chloride 156 mmol/l, bag	5.13	1,000 ml	Baxter
SODIUM ACETATE			
Inj 4 mmol per ml, 20 ml ampoule			
SODIUM BICARBONATE			
Inj 8.4%, 10 ml vial			
Inj 8.4%, 50 ml vial	19.95	1	Biomed
Inj 8.4%, 100 ml vial	20.50	1	Biomed
SODIUM CHLORIDE			
Inj 0.45%, bag	5.50	500 ml	Baxter
Inj 0.9%, bag	1.70	500 ml	Freeflex
	1.71	1,000 ml	Freeflex
	3.01	50 ml	Baxter
	2.28	100 ml	Baxter
	3.60	250 ml	Baxter
	1.77	500 ml	Baxter
	1.80	1,000 ml	Baxter
Inj 3%, bag	5.69	1,000 ml	Baxter
Inj 0.9%, 5 ml ampoule	10.85	50	Multichem
	15.50		Pfizer
Inj 0.9%, 10 ml ampoule	11.50	50	Multichem
	15.50		Pfizer
⚡ Inj 0.9%, 3 ml syringe, non-sterile pack – 1% DV Jun-15 to 2018.....	10.65	30	BD PosiFlush
➔ Restricted			
For use in flushing of in-situ vascular access devices only.			
⚡ Inj 0.9%, 5 ml syringe, non-sterile pack – 1% DV Jun-15 to 2018.....	10.80	30	BD PosiFlush
➔ Restricted			
For use in flushing of in-situ vascular access devices only.			
⚡ Inj 0.9%, 10 ml syringe, non-sterile pack – 1% DV Jun-15 to 2018.....	11.25	30	BD PosiFlush
➔ Restricted			
For use in flushing of in-situ vascular access devices only.			
Inj 0.9%, 20 ml ampoule	8.41	20	Multichem
Inj 23.4% (4 mmol/ml), 20 ml – 1% DV Sep-13 to 2016	31.25	5	Biomed
Inj 1.8%, 500 ml bottle			
SODIUM DIHYDROGEN PHOSPHATE [SODIUM ACID PHOSPHATE]			
Inj 1 mmol per ml, 20 ml ampoule – 1% DV Oct-15 to 2018.....	47.50	5	Biomed

BLOOD AND BLOOD FORMING ORGANS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
WATER			
Inj, bag	2.75	1,000 ml	Baxter
Inj 5 ml ampoule	10.25	50	Multichem
Inj 10 ml ampoule	11.25	50	Multichem
Inj 20 ml ampoule	6.50	20	Multichem
Inj 250 ml bag			
Inj 500 ml bag			
Oral Administration			
CALCIUM POLYSTYRENE SULPHONATE			
Powder	169.85	300 g	Calcium Resonium
COMPOUND ELECTROLYTES			
Powder for oral soln			
COMPOUND ELECTROLYTES WITH GLUCOSE			
Soln with electrolytes			
PHOSPHORUS			
Tab eff 500 mg (16 mmol)			
POTASSIUM CHLORIDE			
Tab eff 548 mg (14 mmol) with chloride 285 mg (8 mmol)			
Tab long-acting 600 mg (8 mmol) – 1% DV Sep-15 to 2018	7.42	200	Span-K
Oral liq 2 mmol per ml			
SODIUM BICARBONATE			
Cap 840 mg	8.52	100	Sodibic
SODIUM CHLORIDE			
Tab 600 mg			
Oral liq 2 mmol/ml			
SODIUM POLYSTYRENE SULPHONATE			
Powder – 1% DV Sep-15 to 2018	84.65	454 g	Resonium A
Plasma Volume Expanders			
GELATINE, SUCCINYLATED			
Inj 4%, 500 ml bag	108.00	10	Gelofusine
HYDROXYETHYL STARCH 130/0.4 WITH MAGNESIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ACETATE AND SODIUM CHLORIDE			
Inj 6% with magnesium chloride 0.03%, potassium chloride 0.03%, sodium acetate 0.463% and sodium chloride 0.6%, 500 ml bag	198.00	20	Volulyte 6%
HYDROXYETHYL STARCH 130/0.4 WITH SODIUM CHLORIDE			
Inj 6% with sodium chloride 0.9%, 500 ml bag	198.00	20	Voluven

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Agents Affecting the Renin-Angiotensin System

ACE Inhibitors

CAPTOPRIL

☒ Oral liq 5 mg per ml94.99 95 ml Capoten

➔ Restricted

Any of the following:

- 1 For use in children under 12 years of age; or
- 2 For use in tube-fed patients; or
- 3 For management of rebound transient hypertension following cardiac surgery.

CILAZAPRIL

Tab 0.5 mg – 1% DV Sep-13 to 20162.00 90 **Zapril**
 Tab 2.5 mg – 1% DV Sep-13 to 20164.31 90 **Zapril**
 Tab 5 mg – 1% DV Sep-13 to 20166.98 90 **Zapril**

ENALAPRIL MALEATE

Tab 5 mg – 1% DV Sep-15 to 20180.96 100 **Ethics Enalapril**
 Tab 10 mg – 1% DV Sep-15 to 20181.24 100 **Ethics Enalapril**
 Tab 20 mg – 1% DV Sep-15 to 20181.78 100 **Ethics Enalapril**

LISINOPRIL

Tab 5 mg – 1% DV Jan-16 to 20181.80 90 **Ethics Lisinopril**
 Tab 10 mg – 1% DV Jan-16 to 20182.05 90 **Ethics Lisinopril**
 Tab 20 mg – 1% DV Jan-16 to 20182.76 90 **Ethics Lisinopril**

PERINDOPRIL

Tab 2 mg – 1% DV Oct-14 to 20173.75 30 **Apo-Perindopril**
 Tab 4 mg – 1% DV Oct-14 to 20174.80 30 **Apo-Perindopril**

QUINAPRIL

Tab 5 mg – 1% DV Sep-15 to 20184.31 90 **Arrow-Quinapril 5**
 Tab 10 mg – 1% DV Sep-15 to 20183.15 90 **Arrow-Quinapril 10**
 Tab 20 mg – 1% DV Sep-15 to 20185.97 90 **Arrow-Quinapril 20**

TRANDOLAPRIL

For continuation only

- ➔ Cap 1 mg
- ➔ Cap 2 mg

ACE Inhibitors with Diuretics

CILAZAPRIL WITH HYDROCHLOROTHIAZIDE

Tab 5 mg with hydrochlorothiazide 12.5 mg – 1% DV Mar-14 to 201610.72 100 **Apo-Cilazapril/
Hydrochlorothiazide**

ENALAPRIL MALEATE WITH HYDROCHLOROTHIAZIDE

For continuation only

- ➔ Tab 20 mg with hydrochlorothiazide 12.5 mg

QUINAPRIL WITH HYDROCHLOROTHIAZIDE

Tab 10 mg with hydrochlorothiazide 12.5 mg – 1% DV Oct-15 to 20183.65 30 **Accuretic 10**
 Tab 20 mg with hydrochlorothiazide 12.5 mg – 1% DV Oct-15 to 20184.78 30 **Accuretic 20**

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Angiotensin II Antagonists			
CANDESARTAN CILEXETIL – Restricted see terms below			
⚡ Tab 4 mg – 1% DV Sep-15 to 2018	2.50	90	Candestar
⚡ Tab 8 mg – 1% DV Sep-15 to 2018	3.68	90	Candestar
⚡ Tab 16 mg – 1% DV Sep-15 to 2018	6.12	90	Candestar
⚡ Tab 32 mg – 1% DV Sep-15 to 2018	10.66	90	Candestar

➡Restricted
ACE inhibitor intolerance

Either:

- 1 Patient has persistent ACE inhibitor induced cough that is not resolved by ACE inhibitor retrial (same or new ACE inhibitor);
or
- 2 Patient has a history of angioedema.

Unsatisfactory response to ACE inhibitor

Patient is not adequately controlled on maximum tolerated dose of an ACE inhibitor.

LOSARTAN POTASSIUM

Tab 12.5 mg – 1% DV Jan-15 to 2017	1.55	84	Losartan Actavis
Tab 25 mg – 1% DV Jan-15 to 2017	1.90	84	Losartan Actavis
Tab 50 mg – 1% DV Jan-15 to 2017	2.25	84	Losartan Actavis
Tab 100 mg – 1% DV Jan-15 to 2017	2.60	84	Losartan Actavis

Angiotensin II Antagonists with Diuretics
LOSARTAN POTASSIUM WITH HYDROCHLOROTHIAZIDE

Tab 50 mg with hydrochlorothiazide 12.5 mg – 1% DV Oct-14 to 2017	2.18	30	Arrow-Losartan & Hydrochlorothiazide
---	------	----	---

Alpha-Adrenoceptor Blockers
DOXAZOSIN

Tab 2 mg – 1% DV Sep-14 to 2017	6.75	500	Apo-Doxazosin
Tab 4 mg – 1% DV Sep-14 to 2017	9.67	500	Apo-Doxazosin

PHENOXYBENZAMINE HYDROCHLORIDE

 Cap 10 mg
 Inj 50 mg per ml, 2 ml ampoule

PHEHTOLAMINE MESYLATE

Inj 10 mg per ml, 1 ml ampoule

PRAZOSIN

Tab 1 mg	5.53	100	Apo-Prazosin
Tab 2 mg	7.00	100	Apo-Prazosin
Tab 5 mg	11.70	100	Apo-Prazosin

TERAZOSIN

Tab 1 mg – 1% DV Sep-13 to 2016	0.50	28	Arrow
Tab 2 mg – 1% DV Sep-13 to 2016	0.45	28	Arrow
Tab 5 mg – 1% DV Sep-13 to 2016	0.68	28	Arrow

Antiarrhythmics
ADENOSINE

 Inj 3 mg per ml, 2 ml vial
 ⚡ Inj 3 mg per ml, 10 ml vial

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
➔Restricted			
For use in cardiac catheterisation, electrophysiology and MRI.			
AJMALINE – Restricted see terms below			
⚡ Inj 5 mg per ml, 10 ml ampoule			
➔Restricted			
Cardiologist			
AMIODARONE HYDROCHLORIDE			
Tab 100 mg			
Tab 200 mg			
Inj 50 mg per ml, 3 ml ampoule – 1% DV Aug-13 to 2016	22.80	6	Cordarone-X
ATROPINE SULPHATE			
Inj 600 mcg per ml, 1 ml ampoule	71.00	50	AstraZeneca
DIGOXIN			
Tab 62.5 mcg			
Tab 250 mcg			
Oral liq 50 mcg per ml			
Inj 250 mcg per ml, 2 ml vial			
DISOPYRAMIDE PHOSPHATE			
Cap 100 mg			
Cap 150 mg			
FLECAINIDE ACETATE			
Tab 50 mg	38.95	60	Tambocor
Cap long-acting 100 mg	38.95	30	Tambocor CR
Cap long-acting 200 mg	68.78	30	Tambocor CR
Inj 10 mg per ml, 15 ml ampoule	52.45	5	Tambocor
MEXILETINE HYDROCHLORIDE			
Cap 150 mg	162.00	100	Mexiletine Hydrochloride USP
Cap 250 mg	202.00	100	Mexiletine Hydrochloride USP
PROPAFENONE HYDROCHLORIDE			
Tab 150 mg			

Antihypotensives

MIDODRINE – **Restricted** see terms below

⚡ Tab 2.5 mg

⚡ Tab 5 mg

➔Restricted

Patient has disabling orthostatic hypotension not due to drugs.

Beta-Adrenoceptor Blockers

ATENOLOL

Tab 50 mg – 1% DV Sep-15 to 2018	4.61	500	Mylan Atenolol
Tab 100 mg – 1% DV Sep-15 to 2018	7.67	500	Mylan Atenolol
Oral liq 5 mg per ml	21.25	300 ml	Atenolol-AFT

CARDIOVASCULAR SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
BISOPROLOL FUMARATE			
Tab 2.5 mg – 1% DV Mar-15 to 2017	2.40	30	Bosvate
Tab 5 mg – 1% DV Mar-15 to 2017	3.50	30	Bosvate
Tab 10 mg – 1% DV Mar-15 to 2017	6.40	30	Bosvate
CARVEDILOL			
Tab 6.25 mg – 1% DV Jun-15 to 2017	3.90	60	Dicarz
Tab 12.5 mg – 1% DV Jun-15 to 2017	5.10	60	Dicarz
Tab 25 mg – 1% DV Jun-15 to 2017	6.30	60	Dicarz
CELIPROLOL			
Tab 200 mg	21.40	180	Celol
ESMOLOL HYDROCHLORIDE			
Inj 10 mg per ml, 10 ml vial			
LABETALOL			
Tab 50 mg	8.23	100	Hybloc
Tab 100 mg	10.06	100	Hybloc
Tab 200 mg	17.55	100	Hybloc
Tab 400 mg			
Inj 5 mg per ml, 20 ml ampoule			
METOPROLOL SUCCINATE			
Tab long-acting 23.75 mg	0.96	30	Metoprolol - AFT CR
Tab long-acting 47.5 mg	1.41	30	Metoprolol - AFT CR
Tab long-acting 95 mg	2.42	30	Metoprolol - AFT CR
Tab long-acting 190 mg	4.66	30	Metoprolol - AFT CR
METOPROLOL TARTRATE			
Tab 50 mg	16.00	100	Lopresor
Tab 100 mg	21.00	60	Lopresor
Tab long-acting 200 mg	18.00	28	Slow-Lopresor
Inj 1 mg per ml, 5 ml vial	24.00	5	Lopresor
NADOLOL			
Tab 40 mg – 1% DV Oct-15 to 2018	16.05	100	Apo-Nadolol
Tab 80 mg – 1% DV Oct-15 to 2018	24.70	100	Apo-Nadolol
PINDOLOL			
Tab 5 mg – 1% DV Nov-13 to 2016	9.72	100	Apo-Pindolol
Tab 10 mg – 1% DV Nov-13 to 2016	15.62	100	Apo-Pindolol
Tab 15 mg – 1% DV Nov-13 to 2016	23.46	100	Apo-Pindolol
PROPRANOLOL			
Tab 10 mg	3.65	100	Apo-Propranolol
Tab 40 mg	4.65	100	Apo-Propranolol
Cap long-acting 160 mg	18.17	100	Cardinol LA
Oral liq 4 mg per ml			
Inj 1 mg per ml, 1 ml ampoule			
SOTALOL			
Tab 80 mg	27.50	500	Mylan
Tab 160 mg	10.50	100	Mylan
Inj 10 mg per ml, 4 ml ampoule	65.39	5	Sotacor
TIMOLOL MALEATE			
Tab 10 mg			

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

40 e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Calcium Channel Blockers

Dihydropyridine Calcium Channel Blockers

AMLODIPINE

Tab 2.5 mg – 1% DV Feb-15 to 2017	2.21	100	Apo-Amlodipine
Tab 5 mg – 1% DV May-15 to 2017	5.04	250	Apo-Amlodipine
Tab 10 mg – 1% DV May-15 to 2017	7.21	250	Apo-Amlodipine

FELODIPINE

Tab long-acting 2.5 mg – 1% DV Sep-15 to 2018	1.45	30	Plendil ER
Tab long-acting 5 mg – 1% DV Sep-15 to 2018	1.55	30	Plendil ER
Tab long-acting 10 mg – 1% DV Sep-15 to 2018	2.30	30	Plendil ER

ISRADIPINE

Tab 2.5 mg			
Cap 2.5 mg			
Cap long-acting 2.5 mg			
Cap long-acting 5 mg			

NICARDIPINE HYDROCHLORIDE – **Restricted** see terms below

☿ Inj 2.5 mg per ml, 10 ml vial

☛ **Restricted**

Anaesthetist, intensivist or paediatric cardiologist

Both:

- 1 Patient is a paediatric patient; and
- 2 Any of the following:
 - 2.1 Patient has hypertension requiring urgent treatment with an intravenous agent; or
 - 2.2 Patient has excessive ventricular afterload; or
 - 2.3 Patient is awaiting or undergoing cardiac surgery using cardiopulmonary bypass.

NIFEDIPINE

Tab long-acting 10 mg			
Tab long-acting 20 mg	9.59	100	Nyefax Retard
Tab long-acting 30 mg – 1% DV Sep-14 to 2017	3.75	30	Adefin XL
Tab long-acting 60 mg – 1% DV Sep-14 to 2017	5.75	30	Adefin XL
Cap 5 mg			

NIMODIPINE

Tab 30 mg			
Inj 200 mcg per ml, 50 ml vial			

Other Calcium Channel Blockers

DILTIAZEM HYDROCHLORIDE

Tab 30 mg	4.60	100	Dilzem
Tab 60 mg	8.50	100	Dilzem
Cap long-acting 120 mg	1.91	30	Cardizem CD
	31.83	500	Apo-Diltiazem CD
Cap long-acting 180 mg	7.56	30	Cardizem CD
	47.67	500	Apo-Diltiazem CD
Cap long-acting 240 mg	10.22	30	Cardizem CD
	63.58	500	Apo-Diltiazem CD
Inj 5 mg per ml, 5 ml vial			

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

CARDIOVASCULAR SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
PERHEXILINE MALEATE			
Tab 100 mg	62.90	100	Pexsig
VERAPAMIL HYDROCHLORIDE			
Tab 40 mg	7.01	100	Isoptin
Tab 80 mg – 1% DV Sep-14 to 2017	11.74	100	Isoptin
Tab long-acting 120 mg	15.20	250	Verpamil SR
Tab long-acting 240 mg	25.00	250	Verpamil SR
Inj 2.5 mg per ml, 2 ml ampoule	7.54	5	Isoptin

Centrally-Acting Agents

CLONIDINE			
Patch 2.5 mg, 100 mcg per day – 1% DV Jul-14 to 2017	12.80	4	Catapres-TTS-1
Patch 5 mg, 200 mcg per day – 1% DV Jul-14 to 2017	18.04	4	Catapres-TTS-2
Patch 7.5 mg, 300 mcg per day – 1% DV Jul-14 to 2017	22.68	4	Catapres-TTS-3
CLONIDINE HYDROCHLORIDE			
Tab 25 mcg – 1% DV Sep-15 to 2018	10.53	112	Clonidine BNM
Tab 150 mcg	34.32	100	Catapres
Inj 150 mcg per ml, 1 ml ampoule	16.07	5	Catapres
METHYLDOPA			
Tab 125 mg	14.25	100	Prodopa
Tab 250 mg	15.10	100	Prodopa
Tab 500 mg	23.15	100	Prodopa

Diuretics

Loop Diuretics

BUMETANIDE			
Tab 1 mg	16.36	100	Burinex
Inj 500 mcg per ml, 4 ml vial			
FUROSEMIDE (FRUSEMIDE)			
Tab 40 mg – 1% DV Sep-15 to 2018	8.00	1,000	Diurin 40
Tab 500 mg – 1% DV Sep-15 to 2018	25.00	50	Urex Forte
Oral liq 10 mg per ml			
Inj 10 mg per ml, 2 ml ampoule	1.30	5	Frusemide-Clarix
Inj 10 mg per ml, 25 ml ampoule			

Osmotic Diuretics

MANNITOL			
Inj 10%, 1,000 ml bag	14.21	1,000 ml	Baxter
Inj 15%, 500 ml bag	9.84	500 ml	Baxter
Inj 20%, 500 ml bag	10.80	500 ml	Baxter

Potassium Sparing Combination Diuretics

AMILORIDE HYDROCHLORIDE WITH FUROSEMIDE			
Tab 5 mg with furosemide 40 mg			
AMILORIDE HYDROCHLORIDE WITH HYDROCHLOROTHIAZIDE			
Tab 5 mg with hydrochlorothiazide 50 mg			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Potassium Sparing Diuretics			
AMILORIDE HYDROCHLORIDE			
Tab 5 mg	17.50	100	Apo-Amiloride
Oral liq 1 mg per ml	30.00	25 ml	Biomed
SPIRONOLACTONE			
Tab 25 mg – 1% DV Sep-13 to 2016	3.65	100	Spiractin
Tab 100 mg – 1% DV Sep-13 to 2016	11.80	100	Spiractin
Oral liq 5 mg per ml	30.00	25 ml	Biomed
Thiazide and Related Diuretics			
BENDROFLUMETHIAZIDE [BENDROFLUAZIDE]			
Tab 2.5 mg – 1% DV Sep-14 to 2017	5.48	500	Arrow-Bendrofluazide
Tab 5 mg – 1% DV Sep-14 to 2017	8.95	500	Arrow-Bendrofluazide
CHLOROTHIAZIDE			
Oral liq 50 mg per ml	26.00	25 ml	Biomed
CHLORTALIDONE [CHLORTHALIDONE]			
Tab 25 mg	8.00	50	Hygroton
INDAPAMIDE			
Tab 2.5 mg – 1% DV Oct-13 to 2016	2.25	90	Dapa-Tabs
METOLAZONE – Restricted see terms below			
⬇ Tab 5 mg			
➡ Restricted			
Either:			
1 Patient has refractory heart failure and is intolerant or has not responded to loop diuretics and/or loop-thiazide combination therapy; or			
2 Patient has severe refractory nephrotic oedema unresponsive to high dose loop diuretics and concentrated albumin infusions			
Lipid-Modifying Agents			
Fibrates			
BEZAFIBRATE			
Tab 200 mg – 1% DV Oct-15 to 2018	9.05	90	Bezalip
Tab long-acting 400 mg – 1% DV Oct-15 to 2018	6.78	30	Bezalip Retard
GEMFIBROZIL			
Tab 600 mg – 1% DV Nov-13 to 2016	17.60	60	Lipazil
HMG CoA Reductase Inhibitors (Statins)			
ATORVASTATIN			
Tab 10 mg	2.52	90	Zarator
Tab 20 mg	4.17	90	Zarator
Tab 40 mg	7.32	90	Zarator
Tab 80 mg	16.23	90	Zarator
PRAVASTATIN			
Tab 10 mg			
Tab 20 mg – 1% DV Oct-14 to 2017	3.45	30	Cholvastin
Tab 40 mg – 1% DV Oct-14 to 2017	6.36	30	Cholvastin

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
SIMVASTATIN			
Tab 10 mg – 1% DV Sep-14 to 2017	0.95	90	Arrow-Simva
Tab 20 mg – 1% DV Sep-14 to 2017	1.61	90	Arrow-Simva
Tab 40 mg – 1% DV Sep-14 to 2017	2.83	90	Arrow-Simva
Tab 80 mg – 1% DV Sep-14 to 2017	7.91	90	Arrow-Simva

Resins

CHOLESTYRAMINE			
Powder for oral liq 4 g			
COLESTIPOL HYDROCHLORIDE			
Grans for oral liq 5 g			

Selective Cholesterol Absorption Inhibitors

EZETIMIBE – Restricted see terms below

⚡ Tab 10 mg – 1% DV Aug-15 to 2017	3.35	30	Ezemibe
--	------	----	----------------

➡Restricted

All of the following:

- 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and
- 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
- 3 Any of the following:
 - 3.1 The patient has rhabdomyolysis (defined as muscle aches and creatine kinase more than 10 × normal) when treated with one statin; or
 - 3.2 The patient is intolerant to both simvastatin and atorvastatin; or
 - 3.3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

EZETIMIBE WITH SIMVASTATIN – Restricted see terms below

⚡ Tab 10 mg with simvastatin 10 mg – 1% DV Aug-15 to 2017	5.15	30	Zimybe
⚡ Tab 10 mg with simvastatin 20 mg – 1% DV Aug-15 to 2017	6.15	30	Zimybe
⚡ Tab 10 mg with simvastatin 40 mg – 1% DV Aug-15 to 2017	7.15	30	Zimybe
⚡ Tab 10 mg with simvastatin 80 mg – 1% DV Aug-15 to 2017	8.15	30	Zimybe

➡Restricted

All of the following:

- 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and
- 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
- 3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

Other Lipid-Modifying Agents

ACIPIMOX			
Cap 250 mg			
NICOTINIC ACID			
Tab 50 mg – 1% DV Oct-14 to 2017	3.96	100	Apo-Nicotinic Acid
Tab 500 mg – 1% DV Oct-14 to 2017	17.37	100	Apo-Nicotinic Acid

⚡ Item restricted (see ➡ above); ⚡ Item restricted (see ➡ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Nitrates			
GLYCERYL TRINITRATE			
Tab 600 mcg	8.00	100	Lycinate
Inj 1 mg per ml, 5 ml ampoule	22.70	10	Nitronal
Inj 1 mg per ml, 50 ml vial	86.60	10	Nitronal
Inj 5 mg per ml, 10 ml ampoule	100.00	5	Hospira
Oral pump spray, 400 mcg per dose	4.45	250 dose	Nitrolingual Pump Spray
Oral spray, 400 mcg per dose	4.45	250 dose	Glytrin
Patch 25 mg, 5 mg per day – 1% DV Sep-14 to 2017	15.73	30	Nitroderm TTS 5
Patch 50 mg, 10 mg per day – 1% DV Sep-14 to 2017	18.62	30	Nitroderm TTS 10
ISOSORBIDE MONONITRATE			
Tab 20 mg – 1% DV Sep-14 to 2017	17.10	100	Ismo-20
Tab long-acting 40 mg	7.50	30	Ismo 40 Retard
Tab long-acting 60 mg	3.94	90	Duride
Other Cardiac Agents			
LEVOSIMENDAN – Restricted see terms below			
⚡ Inj 2.5 mg per ml, 5 ml vial			
⚡ Inj 2.5 mg per ml, 10 ml vial			
➔ Restricted			
Heart transplant			
Either:			
1 For use as a bridge to heart transplant, in patients who have been accepted for transplant; or			
2 For the treatment of heart failure following heart transplant.			
Heart failure			
cardiologist or intensivist			
For the treatment of severe acute decompensated heart failure that is non-responsive to dobutamine.			
Sympathomimetics			
ADRENALINE			
Inj 1 in 1,000, 1 ml ampoule	4.98	5	Aspen Adrenaline
	5.25		Hospira
Inj 1 in 1,000, 30 ml vial			
Inj 1 in 10,000, 10 ml ampoule	27.00	5	Hospira
	49.00	10	Aspen Adrenaline
Inj 1 in 10,000, 10 ml syringe			
DOBUTAMINE HYDROCHLORIDE			
Inj 12.5 mg per ml, 20 ml ampoule – 1% DV Jan-16 to 2018	24.45	5	Dobutamine-Claris
DOPAMINE HYDROCHLORIDE			
Inj 40 mg per ml, 5 ml ampoule – 1% DV Sep-15 to 2018	16.89	5	DBL Sterile Dopamine Concentrate
EPHEDRINE			
Inj 3 mg per ml, 10 ml syringe			
Inj 30 mg per ml, 1 ml ampoule – 1% DV Mar-15 to 2017	51.48	10	Max Health
ISOPRENALINE			
Inj 200 mcg per ml, 1 ml ampoule			
Inj 200 mcg per ml, 5 ml ampoule			

CARDIOVASCULAR SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
METARAMINOL			
Inj 0.5 mg per ml, 20 ml syringe			
Inj 1 mg per ml, 1 ml ampoule			
Inj 1 mg per ml, 10 ml syringe			
Inj 10 mg per ml, 1 ml ampoule			
NORADRENALINE			
Inj 0.06 mg per ml, 100 ml bag			
Inj 0.06 mg per ml, 50 ml syringe			
Inj 0.1 mg per ml, 100 ml bag			
Inj 0.12 mg per ml, 100 ml bag			
Inj 0.12 mg per ml, 50 ml syringe			
Inj 0.16 mg per ml, 50 ml syringe			
Inj 1 mg per ml, 100 ml bag			
Inj 1 mg per ml, 4 ml ampoule			
PHENYLEPHRINE HYDROCHLORIDE			
Inj 10 mg per ml, 1 ml vial	115.50	25	Neosynephrine HCL

Vasodilators

ALPROSTADIL HYDROCHLORIDE			
Inj 500 mcg per ml, 1 ml ampoule – 1% DV Oct-15 to 2018.....	1,650.00	5	Prostin VR
AMYL NITRITE			
Liq 98% in 3 ml capsule			
DIAZOXIDE			
Inj 15 mg per ml, 20 ml ampoule			
HYDRALAZINE HYDROCHLORIDE			
⚡ Tab 25 mg			
➡ Restricted			
Either:			
1 For the treatment of refractory hypertension; or			
2 For the treatment of heart failure, in combination with a nitrate, in patients who are intolerant or have not responded to ACE inhibitors and/or angiotensin receptor blockers.			
Inj 20 mg ampoule	25.90	5	Apresoline
MILRINONE			
Inj 1 mg per ml, 10 ml ampoule			
MINOXIDIL – Restricted see terms below			
⚡ Tab 25 mg	70.00	100	Loniten
➡ Restricted			
For patients with severe refractory hypertension who have failed to respond to extensive multiple therapies.			
NICORANDIL			
Tab 10 mg	27.95	60	Ikorel
Tab 20 mg	33.28	60	Ikorel
PAPAVERINE HYDROCHLORIDE			
Inj 30 mg per ml, 1 ml vial			
Inj 12 mg per ml, 10 ml ampoule	217.90	5	Hospira
PENTOXIFYLLINE [OXPENTIFYLLINE]			
Tab 400 mg			

⚡ Item restricted (see ➡ above); ⚡ Item restricted (see ➡ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
SODIUM NITROPRUSSIDE			
Inj 50 mg vial			

Endothelin Receptor Antagonists

AMBRISENTAN – **Restricted** see terms below

⚡ Tab 5 mg	4,585.00	30	Volibris
⚡ Tab 10 mg	4,585.00	30	Volibris

➔ **Restricted**

- 1 For use in patients with approval by the Pulmonary Arterial Hypertension Panel; or
- 2 In hospital stabilisations in emergency situations.

BOSENTAN – **Restricted** see terms below

⚡ Tab 62.5 mg – 1% DV Jan-16 to 2018	375.00	56	Mylan-Bosentan
⚡ Tab 125 mg – 1% DV Jan-16 to 2018	375.00	56	Mylan-Bosentan

➔ **Restricted**

- 1 For use in patients with approval by the Pulmonary Arterial Hypertension Panel; or
- 2 In hospital stabilisation in emergency situations.

Phosphodiesterase Type 5 Inhibitors

SILDENAFIL – **Restricted** see terms below

⚡ Tab 25 mg – 1% DV Sep-15 to 2018	0.75	4	Vedafil
⚡ Tab 50 mg – 1% DV Sep-15 to 2018	0.75	4	Vedafil
⚡ Tab 100 mg – 1% DV Sep-15 to 2018	2.75	4	Vedafil

➔ **Restricted**

Any of the following:

- 1 For use in patients with approval by the Pulmonary Arterial Hypertension Panel; or
- 2 For use in neonatal units for persistent pulmonary hypertension of the newborn (PPHN); or
- 3 For use in weaning patients from inhaled nitric oxide; or
- 4 For perioperative use in cardiac surgery patients; or
- 5 For use in intensive care as an alternative to nitric oxide; or
- 6 In-hospital stabilisation in emergency situations; or
- 7 All of the following:
 - 7.1 Patient has Raynaud's phenomenon; and
 - 7.2 Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene); and
 - 7.3 Patient is following lifestyle management (proper body insulation, avoidance of cold exposure, smoking cessation support, avoidance of sympathomimetic drugs); and
 - 7.4 Patient has persisting severe symptoms despite treatment with calcium channel blockers and nitrates (unless contraindicated or not tolerated).

Prostacyclin Analogues

EPOPROSTENOL – **Restricted** see terms below

⚡ Inj 0.5 mg vial	36.61	1	Veletri
⚡ Inj 1.5 mg vial	73.21	1	Veletri

➔ **Restricted**

For use as a bridge to transplant for patients with Pulmonary Arterial Hypertension who are on the active waiting list for lung transplantation.

CARDIOVASCULAR SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
ILOPROST			
Inj 50 mcg in 0.5 ml ampoule – 1% DV Sep-15 to 2016	89.50	1	Arrow-Iloprost
¶ Nebuliser soln 10 mcg per ml, 2 ml	1,185.00	30	Ventavis

➡ Restricted

Any of the following:

- 1 For use in patients with approval by the Pulmonary Arterial Hypertension Panel; or
- 2 For diagnostic use in catheter laboratories; or
- 3 For use following mitral or tricuspid valve surgery; or
- 4 In hospital stabilisation in emergency situations.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Anti-Infective Preparations			
Antibacterials			
FUSIDIC ACID			
Crn 2% – 1% DV Jan-15 to 2016.....	2.52	15 g	DP Fusidic Acid Cream
Oint 2% – 1% DV Sep-13 to 2016	3.45	15 g	Foban
HYDROGEN PEROXIDE			
Crn 1%	8.56	15 g	Crystaderm
Soln 3% (10 vol) – 1% DV Nov-15 to 2018.....	1.40	100 ml	Pharmacy Health
MAFENIDE ACETATE – Restricted see terms below			
↓ Powder 50 g sachet			
➔ Restricted			
For the treatment of burns patients.			
MUPIROCIN			
Oint 2%			
SULPHADIAZINE SILVER			
Crn 1%	12.30	50 g	Flamazine
Antifungals			
AMOROLFINE			
Nail soln 5% – 1% DV Jan-15 to 2017.....	19.95	5 ml	MycosNail
CICLOPIROX OLAMINE			
Nail soln 8% – 1% DV Sep-15 to 2018	6.50	7 ml	Apo-Ciclopirox
➔ Soln 1%			
For continuation only			
CLOTRIMAZOLE			
Crn 1% – 1% DV Sep-14 to 2017	0.52	20 g	Clomazol
➔ Soln 1%			
For continuation only			
ECONAZOLE NITRATE			
➔ Crm 1%			
For continuation only			
Foaming soln 1%			
KETOCONAZOLE			
Shampoo 2% – 1% DV Dec-14 to 2017.....	2.99	100 ml	Sebizole
METRONIDAZOLE			
Gel 0.75%			
MICONAZOLE NITRATE			
Crn 2% – 1% DV Mar-15 to 2017	0.55	15 g	Multichem
➔ Lotn 2%			
For continuation only			
Tinc 2%			
NYSTATIN			
Crn 100,000 u per g			

DERMATOLOGICALS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Antiparasitics

MALATHION [MALDISON]

- Lotn 0.5%
- Shampoo 1%

MALATHION WITH PERMETHRIN AND PIPERONYL BUTOXIDE

Spray 0.25% with permethrin 0.5% and piperonyl butoxide 2%

Note: Temporary listing to cover out-of-stock.

PERMETHRIN

Crm 5% – 1% DV Apr-15 to 2017	4.20	30 g	Lyderm
Lotn 5% – 1% DV Sep-14 to 2017	3.19	30 ml	A-Scabies

Antiacne Preparations

ADAPALENE

- Crm 0.1%
- Gel 0.1%

BENZOYL PEROXIDE

- Soln 5%

ISOTRETINOIN

Cap 10 mg	12.47	100	Isotane 10
	14.96	120	Oratane
Cap 20 mg	19.27	100	Isotane 20
	23.12	120	Oratane

TRETINOIN

- Crm 0.05%

Antipruritic Preparations

CALAMINE

Crm, aqueous, BP – 1% DV Dec-15 to 2018	1.49	100 g	Pharmacy Health
Lotn, BP – 1% DV Dec-15 to 2018	12.94	2,000 ml	PSM

CROTAMITON

Crm 10% – 1% DV Sep-15 to 2018	3.37	20 g	Itch-Soothe
--------------------------------------	------	------	--------------------

Barrier Creams and Emollients

Barrier Creams

DIMETHICONE

Crm 5% tube – 1% DV Apr-14 to 2016	1.65	100 g	healthE Dimethicone 5%
Crm 5% pump bottle – 1% DV Apr-14 to 2016	4.73	500 ml	healthE Dimethicone 5%
Crm 10% pump bottle – 1% DV Nov-15 to 2018	4.90	500 ml	healthE Dimethicone 10%

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
ZINC			
Crm			<i>e.g. Zinc Cream (Orion); Zinc Cream (PSM)</i>
Oint Paste			<i>e.g. Zinc oxide (PSM)</i>
ZINC AND CASTOR OIL			
Crm	1.63	20 g	Orion
Oint, BP – 1% DV Jul-15 to 2017	1.39	20 g	healthE
ZINC WITH WOOL FAT			
Crm zinc 15.25% with wool fat 4%			<i>e.g. Sudocrem</i>
Emollients			
AQUEOUS CREAM			
Crm 100 g – 1% DV Jan-16 to 2018	1.00	100 g	Pharmacy Health SLS-free
Note: DV limit applies to the pack sizes of 100 g or less.			
Crm 500 g – 1% DV Mar-16 to 2018	1.96	500 g	AFT
	1.99		AFT SLS-free
Note: DV limit applies to the pack sizes of greater than 100 g. (AFT Crm 500 g to be delisted 1 March 2016)			
CETOMACROGOL			
Crm BP, 500 g – 1% DV Nov-15 to 2018	2.74	500 g	healthE
Crm BP, 100 g – 1% DV Jan-16 to 2018	1.47	1	healthE
CETOMACROGOL WITH GLYCEROL			
Crm 90% with glycerol 10%,	2.10	100 g	Pharmacy Health
	2.00		Pharmacy Health
	3.20		healthE
Crm 90% with glycerol 10%	4.50	500 ml	Pharmacy Health
			Sorbolene with Glycerin
	6.50	1,000 ml	Pharmacy Health
			Sorbolene with Glycerin
Crm 90% with glycerol 10%, 500 ml, 1 bottle	5.46	1	healthE
EMULSIFYING OINTMENT			
Oint BP – 1% DV Apr-15 to 2017	1.84	100 g	Jaychem
Note: DV limit applies to pack sizes of less than 200 g.			
Oint BP, 500 g – 1% DV Jul-15 to 2017	2.73	500 g	AFT
Note: DV limit applies to pack sizes of greater than 200 g.			
GLYCEROL WITH PARAFFIN			
Crm glycerol 10% with white soft paraffin 5% and liquid paraffin 10%			<i>e.g. QV cream</i>
OIL IN WATER EMULSION			
Crm	2.63	500 g	healthE Fatty Cream
Crm, 100 g	1.60	1	healthE Fatty Cream

DERMATOLOGICALS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
PARAFFIN			
Oint liquid paraffin 50% with white soft paraffin 50%	3.10	100 g	healthE
White soft – 1% DV Sep-15 to 2018	0.85	10 g	healthE
Note: DV limit applies to pack sizes of 30 g or less, and to both white soft paraffin and yellow soft paraffin.			
Yellow soft			
PARAFFIN WITH WOOL FAT			
Lotn liquid paraffin 15.9% with wool fat 0.6%			<i>e.g. AlphaKeri;BK ;DP; Hydroderm Lotn</i>
Lotn liquid paraffin 91.7% with wool fat 3%			<i>e.g. Alpha Keri Bath Oil</i>
UREA			
Crm 10%			
WOOL FAT			
Crm			
Corticosteroids			
BETAMETHASONE DIPROPIONATE			
Crm 0.05%			
Oint 0.05%			
BETAMETHASONE VALERATE			
Crm 0.1% – 1% DV Jun-15 to 2018	3.15	50 g	Beta Cream
Oint 0.1% – 1% DV Jun-15 to 2018	3.15	50 g	Beta Ointment
Lotn 0.1%			
CLOBETASOL PROPIONATE			
Crm 0.05% – 1% DV Jul-15 to 2016	3.20	30 g	Clobetasol BNM
Oint 0.05% – 1% DV Jul-15 to 2016	3.20	30 g	Clobetasol BNM
CLOBETASONE BUTYRATE			
Crm 0.05%			
DIFLUCORTOLONE VALERATE			
For continuation only			
➔ Crm 0.1%			
➔ Fatty oint 0.1%			
HYDROCORTISONE			
Crm 1%, 100 g	3.75	100 g	Pharmacy Health
Crm 1%, 500 g	14.00	500 g	Pharmacy Health
HYDROCORTISONE ACETATE			
Crm 1%	2.48	14.2 g	AFT
HYDROCORTISONE AND PARAFFIN LIQUID AND LANOLIN			
Lotn 1% with paraffin liquid 15.9% and lanolin 0.6% – 1% DV Dec-14 to 2017	10.57	250 ml	DP Lotn HC
HYDROCORTISONE BUTYRATE			
Crm 0.1%	2.30	30 g	Locoid Lipocream
	6.85	100 g	Locoid Lipocream
Oint 0.1%	6.85	100 g	Locoid
Milky emul 0.1%	6.85	100 ml	Locoid Crelo
HYDROCORTISONE WITH PARAFFIN AND WOOL FAT			
Lotn 1% with paraffin liquid 15.9% and wool fat 0.6%			

↑ Item restricted (see ➔ above); ↓ Item restricted (see ➔ below)

e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
METHYLPREDNISOLONE ACEPONATE			
Crn 0.1%	4.95	15 g	Advantan
Oint 0.1%	4.95	15 g	Advantan
MOMETASONE FUROATE			
Crn 0.1% – 1% DV Nov-15 to 2018	1.51	15 g	Elocon Alcohol Free
	2.90	50 g	Elocon Alcohol Free
Oint 0.1% – 1% DV Nov-15 to 2018	1.51	15 g	Elocon
	2.90	50 g	Elocon
Lotn 0.1% – 1% DV Sep-15 to 2018	7.35	30 ml	Elocon
TRIAMCINOLONE ACETONIDE			
Crn 0.02% – 1% DV Apr-15 to 2017	6.30	100 g	Aristocort
Oint 0.02% – 1% DV Apr-15 to 2017	6.35	100 g	Aristocort

Corticosteroids with Anti-Infective Agents

BETAMETHASONE VALERATE WITH CLIOQUINOL – **Restricted** see terms below

☞ Crn 0.1% with clioquinol 3%

☞ **Restricted**

Either:

- 1 For the treatment of intertrigo; or
- 2 For continuation use

BETAMETHASONE VALERATE WITH FUSIDIC ACID

Crn 0.1% with fusidic acid 2%

HYDROCORTISONE WITH MICONAZOLE

Crn 1% with miconazole nitrate 2% – 1% DV Sep-15 to 2018 2.00 15 g **Micreme H**

HYDROCORTISONE WITH NATAMYCIN AND NEOMYCIN

Crn 1% with natamycin 1% and neomycin sulphate 0.5% 2.79 15 g Pimafucort

Oint 1% with natamycin 1% and neomycin sulphate 0.5% 2.79 15 g Pimafucort

TRIAMCINOLONE ACETONIDE WITH NEOMYCIN SULPHATE, GRAMICIDIN AND NYSTATIN

Crn 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and
gramicidin 250 mcg per g

Psoriasis and Eczema Preparations

ACITRETIN

Cap 10 mg – 1% DV Nov-14 to 2017 17.86 60 **Novatretin**

Cap 25 mg – 1% DV Nov-14 to 2017 41.36 60 **Novatretin**

BETAMETHASONE DIPROPIONATE WITH CALCIPOTRIOL

Gel 500 mcg with calcipotriol 50 mcg per g – 1% DV Sep-15 to 2018 26.12 30 g **Daivobet**

Oint 500 mcg with calcipotriol 50 mcg per g – 1% DV Sep-15 to 2018 26.12 30 g **Daivobet**

CALCIPOTRIOL

Crn 50 mcg per g 45.00 100 g Daivonex

Oint 50 mcg per g 45.00 100 g Daivonex

Soln 50 mcg per ml 16.00 30 ml Daivonex

COAL TAR WITH SALICYLIC ACID AND SULPHUR

Oint 12% with salicylic acid 2% and sulphur 4%

DERMATOLOGICALS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
COAL TAR WITH TRIETHANOLAMINE LAURYL SULPHATE AND FLUORESCEIN			
Soln 2.3% with triethanolamine lauryl sulphate and fluorescein sodium	3.36	500 ml	Pinetarsol
	5.82	1,000 ml	Pinetarsol
METHOXSALEN [8-METHOXYPSORALEN]			
Tab 10 mg			
Lotn 1.2%			
POTASSIUM PERMANGANATE			
Tab 400 mg			
Crystals			

Scalp Preparations

BETAMETHASONE VALERATE			
Scalp app 0.1%	7.75	100 ml	Beta Scalp
CLOBETASOL PROPIONATE			
Scalp app 0.05%	6.96	30 ml	Dermol
HYDROCORTISONE BUTYRATE			
Scalp lotn 0.1%	3.65	100 ml	Locoid

Wart Preparations

IMIQUIMOD			
Crn 5%, 250 mg sachet – 1% DV Feb-15 to 2017	17.98	12	Apo-Imiquimod Cream 5%
PODOPHYLLOTOXIN			
Soln 0.5%	33.60	3.5 ml	Condyline
SILVER NITRATE			
Sticks with applicator			

Other Skin Preparations

DIPHEMANIL METILSULFATE			
Powder 2%			
SUNSCREEN, PROPRIETARY			
Crn			
Lotn	3.30	100 g	Marine Blue Lotion SPF 50+
	5.10	200 g	Marine Blue Lotion SPF 50+

Antineoplastics

FLUOROURACIL SODIUM			
Crn 5% – 1% DV Sep-15 to 2018	8.95	20 g	Efudix
METHYL AMINOLEVULINATE HYDROCHLORIDE – Restricted see terms below			
☒ Crn 16%			
☛ Restricted			
Dermatologist or plastic surgeon			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Wound Management Products			
CALCIUM GLUCONATE			
Gel 2.5%	21.00	1	healthE

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Anti-Infective Agents			
ACETIC ACID			
Soln 3%			
Soln 5%			
ACETIC ACID WITH HYDROXYQUINOLINE, GLYCEROL AND RICINOLEIC ACID			
Jelly 0.94% with hydroxyquinoline sulphate 0.025%, glycerol 5% and ricinoleic acid 0.75% with applicator			
CHLORHEXIDINE GLUCONATE			
Crn 1% – 1% DV Sep-15 to 2018	1.21	50 g	healthE
Lotn 1%, 200 ml – 1% DV Sep-15 to 2018	2.98	1	healthE
CLOTRIMAZOLE			
Vaginal crm 1% with applicator – 1% DV Dec-13 to 2016	1.45	35 g	Clomazol
Vaginal crm 2% with applicator – 1% DV Dec-13 to 2016	2.20	20 g	Clomazol
MICONAZOLE NITRATE			
Vaginal crm 2% with applicator – 1% DV Oct-14 to 2017	3.95	40 g	Micreme
NYSTATIN			
Vaginal crm 100,000 u per 5 g with applicator(s)			
Contraceptives			
Antiandrogen Oral Contraceptives			
CYPROTERONE ACETATE WITH ETHINYLOESTRADIOL			
Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tablets – 1% DV Dec-14 to 2017	5.36	168	Ginet
Combined Oral Contraceptives			
ETHINYLOESTRADIOL WITH DESOGESTREL			
Tab 20 mcg with desogestrel 150 mcg			
Tab 30 mcg with desogestrel 150 mcg			
ETHINYLOESTRADIOL WITH LEVONORGESTREL			
Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tablets	2.65	84	Ava 20 ED
Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets	2.30	84	Ava 30 ED
Tab 20 mcg with levonorgestrel 100 mcg			
Tab 30 mcg with levonorgestrel 150 mcg			
Tab 50 mcg with levonorgestrel 125 mcg	9.45	84	Microgynon 50 ED
ETHINYLOESTRADIOL WITH NORETHISTERONE			
Tab 35 mcg with norethisterone 1 mg			
Tab 35 mcg with norethisterone 500 mcg			
NORETHISTERONE WITH MESTRANOL			
Tab 1 mg with mestranol 50 mcg			
Contraceptive Devices			
INTRA-UTERINE DEVICE			
IUD 29.1 mm length × 23.2 mm width	31.60	1	Choice TT380 Short
IUD 33.6 mm length × 29.9 mm width	31.60	1	Choice TT380 Standard

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Emergency Contraception

LEVONORGESTREL Tab 1.5 mg – 1% DV Jul-13 to 2016	3.50	1	Postinor-1
---	------	---	-------------------

Progestogen-Only Contraceptives

LEVONORGESTREL Tab 30 mcg Subdermal implant (2 x 75 mg rods) – 5% DV Oct-14 to 31 Dec 2017	133.65	1	Jadelle <i>e.g. Mirena</i>
⚡ Intra-uterine system, 20 mcg per day			

↪ Restricted

Obstetrician or gynaecologist

Initiation – heavy menstrual bleeding

All of the following:

- 1 The patient has a clinical diagnosis of heavy menstrual bleeding; and
- 2 The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and
- 3 Any of the following:
 - 3.1 Serum ferritin level < 16 mcg/l (within the last 12 months); or
 - 3.2 Haemoglobin level < 120 g/l; or
 - 3.3 The patient has had a uterine ultrasound and either a hysteroscopy or endometrial biopsy.

Continuation – heavy menstrual bleeding

Either:

- 1 Patient demonstrated clinical improvement of heavy menstrual bleeding; or
- 2 Previous insertion was removed or expelled within 3 months of insertion.

Initiation – endometriosis

The patient has a clinical diagnosis of endometriosis confirmed by laparoscopy.

Continuation – endometriosis

Either:

- 1 Patient demonstrated satisfactory management of endometriosis; or
- 2 Previous insertion was removed or expelled within 3 months of insertion.

Note: endometriosis is an unregistered indication.

MEDROXYPROGESTERONE ACETATE Inj 150 mg per ml, 1 ml syringe – 1% DV Sep-13 to 2016	7.00	1	Depo-Provera
NORETHISTERONE Tab 350 mcg – 1% DV Oct-15 to 2018	6.25	84	Noriday 28

Obstetric Preparations

Antiprogestogens

MIFEPRISTONE Tab 200 mg

Oxytocics

CARBOPROST TROMETAMOL Inj 250 mcg per ml, 1 ml ampoule

GENITO-URINARY SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
DINOPROSTONE			
Pessaries 10 mg			
Gel 1 mg in 2.5 ml	52.65	1	Prostin E2
Gel 2 mg in 2.5 ml	64.60	1	Prostin E2
ERGOMETRINE MALEATE			
Inj 500 mcg per ml, 1 ml ampoule – 1% DV Oct-14 to 2017	94.70	5	DBL Ergometrine
OXYTOCIN			
Inj 5 iu per ml, 1 ml ampoule – 1% DV Nov-15 to 2018	4.03	5	Oxytocin BNM
Inj 10 iu per ml, 1 ml ampoule – 1% DV Nov-15 to 2018	5.03	5	Oxytocin BNM
OXYTOCIN WITH ERGOMETRINE MALEATE			
Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml ampoule – 1% DV Sep-15 to 2018	11.13	5	Syntometrine

Tocolytics

PROGESTERONE – Restricted see terms below

⚡ Cap 100 mg 16.50 30 Utrogestan

➡ **Restricted**

Obstetrician or gynaecologist

Both:

- 1 For the prevention of pre-term labour*; and
- 2 Either:
 - 2.1 The patient has a short cervix on ultrasound (defined as < 25mm at 16 to 28 weeks) or
 - 2.2 The patient has a history of pre-term birth at less than 28 weeks.

Note: Indications marked with * are Unapproved Indications (refer to Section A: General Rules, Part I (Interpretations and Definitions) and Part IV (Miscellaneous Provisions) rule 23.1).

TERBUTALINE – Restricted see terms below

⚡ Inj 500 mcg ampoule

➡ **Restricted**

Obstetrician

Oestrogens

OESTRIOL

Crn 1 mg per g with applicator

Pessaries 500 mcg

Urologicals

5-Alpha Reductase Inhibitors

FINASTERIDE – Restricted see terms below

⚡ Tab 5 mg – 1% DV Dec-14 to 2017 2.08 30 **Finpro**

➡ **Restricted**

Both:

- 1 Patient has symptomatic benign prostatic hyperplasia; and
- 2 Either:
 - 2.1 The patient is intolerant of non-selective alpha blockers or these are contraindicated; or
 - 2.2 Symptoms are not adequately controlled with non-selective alpha blockers.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Alpha-1A Adrenoceptor Blockers

TAMSULOSIN – **Restricted** see terms below

⚡ Cap 400 mcg – 1% DV Dec-13 to 2016	13.51	100	Tamsulosin-Rex
---	-------	-----	-----------------------

➔**Restricted**

Both:

- 1 Patient has symptomatic benign prostatic hyperplasia; and
- 2 The patient is intolerant of non-selective alpha blockers or these are contraindicated.

Urinary Alkalisers

POTASSIUM CITRATE – **Restricted** see terms below

⚡ Oral liq 3 mmol per ml	30.00	200 ml	Biomed
--------------------------------	-------	--------	--------

➔**Restricted**

Both:

- 1 The patient has recurrent calcium oxalate urolithiasis; and
- 2 The patient has had more than two renal calculi in the two years prior to the application.

SODIUM CITRO-TARTRATE

Grans eff 4 g sachets – 1% DV Feb-15 to 2017	2.93	28	Ural
---	------	----	-------------

Urinary Antispasmodics

OXYBUTYNIN

Tab 5 mg – 1% DV Jun-13 to 2016	11.20	500	Apo-Oxybutynin
Oral liq 5 mg per 5 ml – 1% DV Jun-13 to 2016	56.45	473 ml	Apo-Oxybutynin

SOLIFENACIN SUCCINATE – **Restricted** see terms below

⚡ Tab 5 mg	37.50	30	Vesicare
⚡ Tab 10 mg	37.50	30	Vesicare

➔**Restricted**

Patient has overactive bladder and a documented intolerance of, or is non-responsive to, oxybutynin.

TOLTERODINE TARTRATE – **Restricted** see terms below

⚡ Tab 1 mg	14.56	56	Arrow-Tolterodine
⚡ Tab 2 mg	14.56	56	Arrow-Tolterodine

➔**Restricted**

Patient has overactive bladder and a documented intolerance of, or is non-responsive to, oxybutynin.

Price
(ex man. excl. GST)
\$ Per Brand or
Generic
Manufacturer

Anabolic Agents

OXANDROLONE

⚡ Tab 2.5 mg

➔ **Restricted**

For the treatment of burns patients.

Androgen Agonists and Antagonists

CYPROTERONE ACETATE

Tab 50 mg – 1% DV Oct-15 to 2018 15.87 50 **Procur**

Tab 100 mg – 1% DV Oct-15 to 2018 30.40 50 **Procur**

TESTOSTERONE

Patch 2.5 mg per day 80.00 60 **Androderm**

TESTOSTERONE CYPIONATE

Inj 100 mg per ml, 10 ml vial – 1% DV Sep-14 to 2017 76.50 1 **Depo-Testosterone**

TESTOSTERONE ESTERS

Inj testosterone decanoate 100 mg, testosterone isocarproate 60 mg,
testosterone phenylpropionate 60 mg and testosterone propionate
30 mg per ml, 1 ml ampoule

TESTOSTERONE UNDECANOATE

Cap 40 mg – 1% DV Sep-15 to 2018 16.80 60 **Andriol Testocaps**

Inj 250 mg per ml, 4 ml vial 86.00 1 **Reandron 1000**

Calcium Homeostasis

CALCITONIN

Inj 100 iu per ml, 1 ml ampoule – 1% DV Oct-14 to 2017 121.00 5 **Miacalcic**

ZOLEDRONIC ACID

⚡ Inj 4 mg per 5 ml, vial 550.00 1 **Zometa**

➔ **Restricted**

Oncologist, haematologist or palliative care specialist

Any of the following:

- 1 Patient has hypercalcaemia of malignancy; or
- 2 Both:
 - 2.1 Patient has bone metastases or involvement; and
 - 2.2 Patient has severe bone pain resistant to standard first-line treatments; or
- 3 Both:
 - 3.1 Patient has bone metastases or involvement; and
 - 3.2 Patient is at risk of skeletal-related events (pathological fracture, spinal cord compression, radiation to bone or surgery to bone).

Corticosteroids

BETAMETHASONE

Tab 500 mcg

Inj 4 mg per ml, 1 ml ampoule

BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHASONE ACETATE

Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml ampoule

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
DEXAMETHASONE			
Tab 0.5 mg – 1% DV Jan-16 to 2018	0.88	30	Dexamethsone
Tab 4 mg – 1% DV Jan-16 to 2018	1.84	30	Dexamethsone
Oral liq 1 mg per ml	45.00	25 ml	Biomed
DEXAMETHASONE PHOSPHATE			
Inj 4 mg per ml, 1 ml ampoule – 1% DV Apr-14 to 2016	25.80	10	Dexamethasone-hameln
Inj 4 mg per ml, 2 ml ampoule – 1% DV Apr-14 to 2016	17.98	5	Dexamethasone-hameln
FLUDROCORTISONE ACETATE			
Tab 100 mcg	14.32	100	Florinef
HYDROCORTISONE			
Tab 5 mg – 1% DV Sep-15 to 2018	8.10	100	Douglas
Tab 20 mg – 1% DV Sep-15 to 2018	20.32	100	Douglas
Inj 100 mg vial – 1% DV Oct-13 to 2016	4.99	1	Solu-Cortef
METHYLPREDNISOLONE (AS SODIUM SUCCINATE)			
Tab 4 mg – 1% DV Oct-15 to 2018	80.00	100	Medrol
Tab 100 mg – 1% DV Oct-15 to 2018	180.00	20	Medrol
Inj 40 mg vial – 1% DV Oct-15 to 2018	10.50	1	Solu-Medrol
Inj 125 mg vial – 1% DV Oct-15 to 2018	22.25	1	Solu-Medrol
Inj 500 mg vial – 1% DV Oct-15 to 2018	9.00	1	Solu-Medrol
Inj 1 g vial – 1% DV Oct-15 to 2018	16.00	1	Solu-Medrol
METHYLPREDNISOLONE ACETATE			
Inj 40 mg per ml, 1 ml vial – 1% DV Oct-15 to 2018	40.00	5	Depo-Medrol
METHYLPREDNISOLONE ACETATE WITH LIDOCAINE [LIGNOCAINE]			
Inj 40 mg with lidocaine [lignocaine], 1 ml vial – 1% DV Oct-15 to 2018	9.25	1	Depo-Medrol with Lidocaine
PREDNISOLONE			
Oral liq 5 mg per ml	7.50	30 ml	Redipred
Enema 200 mcg per ml, 100 ml			
PREDNISONE			
Tab 1 mg	2.13	100	Apo-Prednisone S29
	10.68	500	Apo-Prednisone
Tab 2.5 mg	12.09	500	Apo-Prednisone
Tab 5 mg	11.09	500	Apo-Prednisone
Tab 20 mg	29.03	500	Apo-Prednisone
TRIAMCINOLONE ACETONIDE			
Inj 10 mg per ml, 1 ml ampoule – 1% DV Apr-15 to 2017	20.80	5	Kenacort-A 10
Inj 40 mg per ml, 1 ml ampoule – 1% DV Apr-15 to 2017	51.70	5	Kenacort-A 40
TRIAMCINOLONE HEXACETONIDE			
Inj 20 mg per ml, 1 ml vial			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Hormone Replacement Therapy			
Oestrogens			
OESTRADIOL			
Tab 1 mg			
Tab 2 mg			
Patch 25 mcg per day			
Patch 50 mcg per day			
Patch 100 mcg per day			
OESTRADIOL VALERATE			
Tab 1 mg – 1% DV Jun-15 to 2018	12.36	84	Progynova
Tab 2 mg – 1% DV Jun-15 to 2018	12.36	84	Progynova
OESTROGENS (CONJUGATED EQUINE)			
Tab 300 mcg			
Tab 625 mcg			
Progestogen and Oestrogen Combined Preparations			
OESTRADIOL WITH NORETHISTERONE ACETATE			
Tab 1 mg with 0.5 mg norethisterone acetate			
Tab 2 mg with 1 mg norethisterone acetate			
Tab 2 mg with 1 mg norethisterone acetate (10), and tab 2 mg oestra- diol (12) and tab 1 mg oestradiol (6)			
OESTROGENS WITH MEDROXYPROGESTERONE ACETATE			
Tab 625 mcg conjugated equine with 2.5 mg medroxyprogesterone acetate			
Tab 625 mcg conjugated equine with 5 mg medroxyprogesterone ac- etate			
Progestogens			
MEDROXYPROGESTERONE ACETATE			
Tab 2.5 mg – 1% DV Sep-13 to 2016	3.09	30	Provera
Tab 5 mg – 1% DV Sep-13 to 2016	13.06	100	Provera
Tab 10 mg – 1% DV Sep-13 to 2016	6.85	30	Provera
Other Endocrine Agents			
CABERGOLINE – Restricted see terms below			
⚡ Tab 0.5 mg – 1% DV Sep-15 to 2018	4.75	2	Dostinex
	19.00	8	Dostinex
↪ Restricted			
Any of the following:			
1	Inhibition of lactation; or		
2	Patient has pathological hyperprolactinemia; or		
3	Patient has acromegaly.		
CLOMIPHENE CITRATE			
Tab 50 mg – 1% DV Sep-13 to 2016	29.84	10	Serophene

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
DANAZOL			
Cap 100 mg	68.33	100	Azol
Cap 200 mg	97.83	100	Azol
GESTRINONE			
Cap 2.5 mg			
METYRAPONE			
Cap 250 mg			
PENTAGASTRIN			
Inj 250 mcg per ml, 2 ml ampoule			

Other Oestrogen Preparations

ETHINYLOESTRADIOL			
Tab 10 mcg – 1% DV Sep-15 to 2018	17.60	100	NZ Medical & Scientific
OESTRADIOL			
Implant 50 mg			
OESTRIOL			
Tab 2 mg			

Other Progestogen Preparations

MEDROXYPROGESTERONE			
Tab 100 mg – 1% DV Sep-13 to 2016	96.50	100	Provera
NORETHISTERONE			
Tab 5 mg – 1% DV Jun-15 to 2018	18.29	100	Primolut N

Pituitary and Hypothalamic Hormones and Analogues

CORTICOTRORELIN (OVINE)			
Inj 100 mcg vial			
THYROTROPIN ALFA			
Inj 900 mcg vial			

Adrenocorticotrophic Hormones

TETRACOSACTIDE [TETRACOSACTRIN]			
Inj 250 mcg per ml, 1 ml ampoule	177.18	10	Synacthen
Inj 1 mg per ml, 1 ml ampoule	29.56	1	Synacthen Depot

GnRH Agonists and Antagonists

BUSERELIN			
Inj 1 mg per ml, 5.5 ml vial			
GONADORELIN			
Inj 100 mcg vial			
GOSERELIN			
Implant 3.6 mg	166.20	1	Zoladex
Implant 10.8 mg	443.76	1	Zoladex

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
LEUPRORELIN ACETATE			
Inj 3.75 mg syringe	221.60	1	Lucrin Depot PDS
Inj 7.5 mg syringe	166.20	1	Eligard
Inj 11.25 mg syringe	591.68	1	Lucrin Depot PDS
Inj 22.5 mg syringe	443.76	1	Eligard
Inj 30 mg syringe	1,109.40	1	Lucrin Depot PDS
Inj 30 mg vial	591.68	1	Eligard
Inj 45 mg syringe	832.05	1	Eligard

Gonadotrophins

CHORIOGONADOTROPIN ALFA

Inj 250 mcg in 0.5 ml syringe

Growth Hormone

SOMATROPIN – **Restricted** see terms below

‡ Inj 5 mg cartridge – 1% DV Jan-15 to 31 Dec 2017	109.50	1	Omnitrope
‡ Inj 10 mg cartridge – 1% DV Jan-15 to 31 Dec 2017	219.00	1	Omnitrope
‡ Inj 15 mg cartridge – 1% DV Jan-15 to 31 Dec 2017	328.50	1	Omnitrope

↪ **Restricted**

Initiation - growth hormone deficiency in children

Endocrinologist

Paediatric Endocrinologist

Either:

- Growth hormone deficiency causing symptomatic hypoglycaemia, or with other significant growth hormone deficient sequelae (e.g. cardiomyopathy, hepatic dysfunction) and diagnosed with GH < 5 mcg/l on at least two random blood samples in the first 2 weeks of life, or from samples during established hypoglycaemia (whole blood glucose < 2 mmol/l using a laboratory device); or
- All of the following:
 - Height velocity < 25th percentile for age; and adjusted for bone age/pubertal status if appropriate over 6 or 12 months using the standards of Tanner and Davies (1985); and
 - A current bone age is < 14 years (female patients) or < 16 years (male patients); and
 - Peak growth hormone value of < 5.0 mcg per litre in response to two different growth hormone stimulation tests. In children who are 5 years or older, GH testing with sex steroid priming is required; and
 - If the patient has been treated for a malignancy, they should be disease free for at least one year based upon follow-up laboratory and radiological imaging appropriate for the malignancy, unless there are strong medical reasons why this is either not necessary or appropriate; and
 - Appropriate imaging of the pituitary gland has been obtained.

Continuation - growth hormone deficiency in children

Endocrinologist

Paediatric Endocrinologist

Re-assessment required after 12 months

All of the following:

- A current bone age is ≤ 14 years (female patients) or ≤ 16 years (male patients); and
- Height velocity is ≥ 25th percentile for age (adjusted for bone age/pubertal status if appropriate) while on growth hormone treatment, as calculated over six months using the standards of Tanner and Davis (1985); and
- Height velocity is ≥ 2.0 cm per year, as calculated over 6 months; and
- No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- No malignancy has developed since starting growth hormone.

continued...

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
	Per

continued...

Initiation - Turner syndrome

Endocrinologist

Paediatric Endocrinologist

All of the following:

- 1 The patient has a post-natal genotype confirming Turner Syndrome; and
- 2 Height velocity is < 25th percentile over 6-12 months using the standards of Tanner and Davies (1985); and
- 3 A current bone age is < 14 years.

Continuation - Turner syndrome

Endocrinologist

Paediatric Endocrinologist

Re-assessment required after 12 months

All of the following:

- 1 Height velocity \geq 50th percentile for age (while on growth hormone calculated over 6 to 12 months using the Ranke's Turner Syndrome growth velocity charts); and
- 2 Height velocity is \geq 2 cm per year, calculated over six months; and
- 3 A current bone age is \leq 14 years; and
- 4 No serious adverse effect that the specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed since starting growth hormone.

Initiation - short stature without growth hormone deficiency

Endocrinologist

Paediatric Endocrinologist

All of the following:

- 1 The patient's height is more than 3 standard deviations below the mean for age or for bone age if there is marked growth acceleration or delay; and
- 2 Height velocity is < 25th percentile for age (adjusted for bone age/pubertal status if appropriate), as calculated over 6 to 12 months using the standards of Tanner and Davies(1985); and
- 3 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
- 4 The patient does not have severe chronic disease (including malignancy or recognized severe skeletal dysplasia) and is not receiving medications known to impair height velocity.

Continuation - short stature without growth hormone deficiency

Endocrinologist

Paediatric Endocrinologist

Re-assessment required after 12 months

All of the following:

- 1 Height velocity is \geq 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is \geq 2 cm per year as calculated over six months; and
- 3 Current bone age is \leq 14 years (female patients) or \leq 16 years (male patients); and
- 4 No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone treatment has occurred.

Initiation - short stature due to chronic renal insufficiency

Endocrinologist

Paediatric Endocrinologist

Renal Physician on the recommendation of a Paediatric Endocrinologist or Endocrinologist

All of the following:

- 1 The patient's height is more than 2 standard deviations below the mean; and

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 2 Height velocity is < 25th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 3 A current bone age is ≤ 14 years (female patients) or ≤ 16 years (male patients); and
- 4 The patient is metabolically stable, has no evidence of metabolic bone disease and absence of any other severe chronic disease; and
- 5 The patient is under the supervision of a specialist with expertise in renal medicine; and
- 6 Either:
 - 6.1 The patient has a GFR ≤ 30 ml/min/1.73 m² as measured by the Schwartz method (Height(cm)/plasma creatinine (umol/l × 40 = corrected GFR (ml/min/1.73 m²)) in a child who may or may not be receiving dialysis; or
 - 6.2 The patient has received a renal transplant and has received < 5mg/ m² /day of prednisone or equivalent for at least 6 months.

Continuation - short stature due to chronic renal insufficiency

Endocrinologist

Paediatric Endocrinologist

Renal Physician on the recommendation of a Paediatric Endocrinologist or Endocrinologist

Re-assessment required after 12 months

All of the following:

- 1 Height velocity is ≥ 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is ≥ 2 cm per year as calculated over six months; and
- 3 A current bone age is ≤ 14 years (female patients) or ≤ 16 years (male patients); and
- 4 No serious adverse effect that the patients specialist considers is likely to be attributable to growth hormone has occurred; and
- 5 No malignancy has developed after growth hormone therapy was commenced; and
- 6 The patient has not experienced significant biochemical or metabolic deterioration confirmed by diagnostic results; and
- 7 The patient has not received renal transplantation since starting growth hormone treatment; and
- 8 If the patient requires transplantation, growth hormone prescription should cease before transplantation and a new application should be made after transplantation based on the above criteria.

Initiation - Prader-Willi syndrome

Endocrinologist

Paediatric Endocrinologist

All of the following:

- 1 The patient has a diagnosis of Prader-Willi syndrome that has been confirmed by genetic testing or clinical scoring criteria; and
- 2 The patient's height velocity is < 25th percentile for bone age adjusted for bone age/pubertal status if appropriate as calculated over 6 to 12 months using the standards of Tanner and Davies (1985) or pubertal status over 6 to 12 months; and
- 3 Either:
 - 3.1 The patient is under two years of age and height velocity has been assessed over a minimum six month period from the age of 12 months, with at least three supine length measurements over this period demonstrating clear and consistent evidence of linear growth failure (with height velocity < 25th percentile); or
 - 3.2 The patient is aged two years or older; and
- 4 A current bone age is < 14 years (female patients) or < 16 years (male patients); and
- 5 Sleep studies or overnight oximetry have been performed and there is no obstructive sleep disorder requiring treatment, or if an obstructive sleep disorder is found, it has been adequately treated under the care of a paediatric respiratory physician and/or ENT surgeon; and
- 6 There is no evidence of type II diabetes or uncontrolled obesity defined by BMI that has increased by ≥ 0.5 standard deviations in the preceding 12 months.

continued...

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
	Per

continued...

Continuation - Prader-Willi syndrome

Endocrinologist

Paediatric Endocrinologist

Re-assessment required after 12 months

All of the following:

- 1 Height velocity is \geq 50th percentile (adjusted for bone age/pubertal status if appropriate) as calculated over 6 to 12 months using the standards of Tanner and Davies (1985); and
- 2 Height velocity is \geq 2 cm per year as calculated over six months; and
- 3 A current bone age is \leq 14 years (female patients) or \leq 16 years (male patients); and
- 4 No serious adverse effect that the patient's specialist considers is likely to be attributable to growth hormone treatment has occurred; and
- 5 No malignancy has developed after growth hormone therapy was commenced; and
- 6 The patient has not developed type II diabetes or uncontrolled obesity as defined by BMI that has increased by \geq 0.5 standard deviations in the preceding 12 months.

Initiation - adults and adolescents

Endocrinologist

Paediatric Endocrinologist

All of the following:

- 1 The patient has a medical condition that is known to cause growth hormone deficiency (e.g. surgical removal of the pituitary for treatment of a pituitary tumour); and
- 2 The patient has undergone appropriate treatment of other hormonal deficiencies and psychological illnesses; and
- 3 The patient has severe growth hormone deficiency (see notes); and
- 4 The patient's serum IGF-I is more than 1 standard deviation below the mean for age and sex; and
- 5 The patient has poor quality of life, as defined by a score of 16 or more using the disease-specific quality of life questionnaire for adult growth hormone deficiency (QoL-AGHDA[®]).

Notes:

For the purposes of adults and adolescents, severe growth hormone deficiency is defined as a peak serum growth hormone level of \leq 3 mcg per litre during an adequately performed insulin tolerance test (ITT) or glucagon stimulation test.

Patients with one or more additional anterior pituitary hormone deficiencies and a known structural pituitary lesion only require one test. Patients with isolated growth hormone deficiency require two growth hormone stimulation tests, of which, one should be ITT unless otherwise contraindicated. Where an additional test is required, an arginine provocation test can be used with a peak serum growth hormone level of \leq 0.4 mcg per litre.

The dose of somatropin should be started at 0.2 mg daily and be titrated by 0.1 mg monthly until it is within 1 standard deviation of the mean normal value for age and sex; and

The dose of somatropin not to exceed 0.7 mg per day for male patients, or 1 mg per day for female patients.

At the commencement of treatment for hypopituitarism, patients must be monitored for any required adjustment in replacement doses of corticosteroid and levothyroxine.

Continuation - adults and adolescents

Endocrinologist

Paediatric Endocrinologist

Re-assessment required after 12 months

Either:

- 1 All of the following:
 - 1.1 The patient has been treated with somatropin for $<$ 12 months; and
 - 1.2 There has been an improvement in the Quality of Life Assessment defined as a reduction of at least 8 points on the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA[®]) score from baseline; and
 - 1.3 Serum IGF-I levels have increased to within \pm 1SD of the mean of the normal range for age and sex; and
 - 1.4 The dose of somatropin does not exceed 0.7 mg per day for male patients, or 1 mg per day for female patients; and

continued...

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

HORMONE PREPARATIONS

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

2 All of the following:

- 2.1 The patient has been treated with somatropin for more than 12 months; and
- 2.2 The patient has not had a deterioration in Quality of Life defined as a 6 point or greater increase from their lowest QoL-AGHDA[®] score on treatment (other than due to obvious external factors such as external stressors); and
- 2.3 Serum IGF-I levels have continued to be maintained within $\pm 1SD$ of the mean of the normal range for age and sex (other than for obvious external factors); and
- 2.4 The dose of somatropin has not exceeded 0.7 mg per day for male patients or 1 mg per day for female patients.

Thyroid and Antithyroid Preparations

CARBIMAZOLE

Tab 5 mg

IODINE

Soln BP 50 mg per ml

LEVOTHYROXINE

Tab 25 mcg

Tab 50 mcg

Tab 100 mcg

LIOTHYRONINE SODIUM

⚡ Tab 20 mcg

➡ **Restricted**

For a maximum of 14 days' treatment in patients with thyroid cancer who are due to receive radioiodine therapy

Inj 20 mcg vial

POTASSIUM IODATE

Tab 170 mg

POTASSIUM PERCHLORATE

Cap 200 mg

PROPYLTHIOURACIL – **Restricted** see terms below

⚡ Tab 50 mg	35.00	100	PTU
-------------------	-------	-----	-----

➡ **Restricted**

Both:

- 1 The patient has hyperthyroidism; and
- 2 The patient is intolerant of carbimazole or carbimazole is contraindicated.

Note: Propylthiouracil is not recommended for patients under the age of 18 years unless the patient is pregnant and other treatments are contraindicated.

PROTIRELIN

Inj 100 mcg per ml, 2 ml ampoule

Vasopressin Agents

ARGIPRESSIN [VASOPRESSIN]

Inj 20 u per ml, 1 ml ampoule

DESMOPRESSIN ACETATE – **Some items restricted** see terms on the next page

⚡ Tab 100 mcg	36.40	30	Minirin
⚡ Tab 200 mcg	93.60	30	Minirin
Nasal spray 10 mcg per dose – 1% DV Sep-14 to 2017.....	22.95	6 ml	Desmopressin-PH&T
Inj 4 mcg per ml, 1 ml ampoule			
Inj 15 mcg per ml, 1 ml ampoule			
Nasal drops 100 mcg per ml			

⚡ Item restricted (see ➡ above); ⚡ Item restricted (see ➡ below)

e.g. Brand indicates brand example only. It is not a contracted product.

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

➔ **Restricted**

Nocturnal enuresis

Either:

- 1 The nasal forms of desmopressin are contraindicated; or
- 2 An enuresis alarm is contraindicated.

Cranial diabetes insipidus and the nasal forms of desmopressin are contraindicated

TERLIPRESSIN

Inj 0.1 mg per ml, 8.5 ml ampoule	450.00	5	Glypressin
Inj 1 mg per 8.5 ml ampoule – 1% DV Jun-15 to 2018	215.00	5	Glypressin

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Antibacterials			
Aminoglycosides			
AMIKACIN – Restricted see terms below			
‡ Inj 5 mg per ml, 10 ml syringe			
‡ Inj 5 mg per ml, 5 ml syringe	176.00	10	Biomed
‡ Inj 15 mg per ml, 5 ml syringe			
‡ Inj 250 mg per ml, 2 ml vial – 1% DV Oct-14 to 2017	431.20	5	DBL Amikacin
➔ Restricted			
Infectious disease physician, clinical microbiologist or respiratory physician			
GENTAMICIN SULPHATE			
Inj 10 mg per ml, 1 ml ampoule	8.56	5	Hospira
Inj 10 mg per ml, 2 ml ampoule	175.10	25	APP Pharmaceuticals
Inj 40 mg per ml, 2 ml ampoule – 1% DV Sep-15 to 2018	6.00	10	Pfizer
PAROMOMYCIN – Restricted see terms below			
‡ Cap 250 mg	126.00	16	Humatin
➔ Restricted			
Infectious disease physician or clinical microbiologist			
STREPTOMYCIN SULPHATE – Restricted see terms below			
‡ Inj 400 mg per ml, 2.5 ml ampoule			
➔ Restricted			
Infectious disease physician, clinical microbiologist or respiratory physician			
TOBRAMYCIN			
‡ Powder			
➔ Restricted			
For addition to orthopaedic bone cement.			
‡ Inj 40 mg per ml, 2 ml vial	38.00	5	DBL Tobramycin
➔ Restricted			
Infectious disease physician, clinical microbiologist or respiratory physician			
‡ Inj 100 mg per ml, 5 ml vial			
➔ Restricted			
Infectious disease physician, clinical microbiologist or respiratory physician			
‡ Solution for inhalation 60 mg per ml, 5 ml	2,200.00	56 dose	TOBI
➔ Restricted			
Patient has cystic fibrosis			
Carbapenems			
ERTAPENEM – Restricted see terms below			
‡ Inj 1 g vial	73.50	1	Invanz
➔ Restricted			
Infectious disease physician or clinical microbiologist			
IMIPENEM WITH CILASTATIN – Restricted see terms below			
‡ Inj 500 mg with 500 mg cilastatin vial – 1% DV Jun-15 to 2017	13.79	1	Imipenem+Cilastatin RBX
➔ Restricted			
Infectious disease physician or clinical microbiologist			
MEROPENEM – Restricted see terms on the next page			
‡ Inj 500 mg vial – 1% DV Oct-14 to 2017	35.22	10	DBL Meropenem
‡ Inj 1 g vial – 1% DV Oct-14 to 2017	65.21	10	DBL Meropenem

‡ Item restricted (see ➔ above); ‡ Item restricted (see ➔ below)
e.g. *Brand* indicates brand example only. It is not a contracted product.

Price
(ex man. excl. GST)
\$ Per Brand or
Generic
Manufacturer

➔ **Restricted**

Infectious disease physician or clinical microbiologist

Cephalosporins and Cephamycins - 1st Generation

CEFALEXIN

Cap 500 mg – 1% DV Oct-13 to 2016	5.70	20	Cephalexin ABM
Grans for oral liq 25 mg per ml – 1% DV Sep-15 to 2018	8.00	100 ml	Cefalexin Sandoz
Grans for oral liq 50 mg per ml – 1% DV Sep-15 to 2018	11.00	100 ml	Cefalexin Sandoz

CEFAZOLIN

Inj 500 mg vial – 1% DV Sep-14 to 2017	3.99	5	AFT
Inj 1 g vial – 1% DV Sep-14 to 2017	3.38	5	AFT

Cephalosporins and Cephamycins - 2nd Generation

CEFACLOR

Cap 250 mg – 1% DV Dec-13 to 2016	26.00	100	Ranbaxy-Cefaclor
Grans for oral liq 25 mg per ml – 1% DV Dec-13 to 2016	3.53	100 ml	Ranbaxy-Cefaclor

CEFOXITIN

Inj 1 g vial – 1% DV Jan-16 to 2018	58.00	10	Cefoxitin Actavis
---	-------	----	--------------------------

CEFUROXIME

Tab 250 mg	29.40	50	Zinnat
Inj 750 mg vial	3.70	5	Zinacef
Inj 1.5 g vial	1.30	1	Zinacef

Cephalosporins and Cephamycins - 3rd Generation

CEFOTAXIME

Inj 500 mg vial	1.90	1	Cefotaxime Sandoz
Inj 1 g vial – 1% DV Oct-14 to 2017	17.10	10	DBL Cefotaxime

CEFTAZIDIME – **Restricted** see terms below

⚡ Inj 500 mg vial – 1% DV Jan-15 to 2017	5.30	1	Fortum
⚡ Inj 1 g vial – 1% DV Jan-15 to 2017	1.55	1	Fortum
⚡ Inj 2 g vial – 1% DV Jan-15 to 2017	3.34	1	Fortum

➔ **Restricted**

Infectious disease physician, clinical microbiologist or respiratory physician

CEFTRIAZONE

Inj 500 mg vial – 1% DV Mar-14 to 2016	1.50	1	Ceftriaxone-AFT
Inj 1 g vial – 1% DV Mar-14 to 2016	5.22	5	Ceftriaxone-AFT
Inj 2 g vial – 1% DV Mar-14 to 2016	2.75	1	Ceftriaxone-AFT

Cephalosporins and Cephamycins - 4th Generation

CEFEPIME – **Restricted** see terms below

⚡ Inj 1 g vial – 1% DV Oct-15 to 2018	3.95	1	Cefepime-AFT
⚡ Inj 2 g vial – 1% DV Oct-15 to 2018	6.92	1	Cefepime-AFT

➔ **Restricted**

Infectious disease physician or clinical microbiologist

Cephalosporins and Cephamycins - 5th Generation

CEFTAROLINE FOSAMIL – **Restricted** see terms on the next page

⚡ Inj 600 mg vial	1,450.00	10	Zinforo
-------------------------	----------	----	---------

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
➔Restricted			
Infectious disease physician or clinical microbiologist			
Multi-resistant organism salvage therapy			
Either:			
1 for patients where alternative therapies have failed; or			
2 for patients who have a contraindication or hypersensitivity to standard current therapies.			
Macrolides			
AZITHROMYCIN – Restricted see terms below			
⚡ Tab 250 mg – 1% DV Sep-15 to 2018	9.00	30	Apo-Azithromycin
⚡ Tab 500 mg – 1% DV Sep-15 to 2018	1.05	2	Apo-Azithromycin
⚡ Grans for oral liq 200 mg per 5 ml (40 mg per ml) – 1% DV Oct-15 to 2018	12.50	15 ml	Zithromax
➔Restricted			
Any of the following:			
1 Patient has received a lung transplant and requires treatment or prophylaxis for bronchiolitis obliterans syndrome; or			
2 Patient has cystic fibrosis and has chronic infection with <i>Pseudomonas aeruginosa</i> or <i>Pseudomonas</i> related gram negative organisms; or			
3 For any other condition for five days' treatment, with review after five days.			
CLARITHROMYCIN – Restricted see terms below			
⚡ Tab 250 mg – 1% DV Sep-14 to 2017	3.98	14	Apo-Clarithromycin
⚡ Tab 500 mg – 1% DV Sep-14 to 2017	10.40	14	Apo-Clarithromycin
⚡ Grans for oral liq 25 mg per ml	23.12	70 ml	Klacid
⚡ Inj 500 mg vial – 1% DV Mar-15 to 2017	20.40	1	Martindale
➔Restricted			
Tab 250 mg and oral liquid			
Tab 250 mg and oral liquid			
1 Atypical mycobacterial infection; or			
2 Mycobacterium tuberculosis infection where there is drug resistance or intolerance to standard pharmaceutical agents.			
Tab 500 mg			
Helicobacter pylori eradication.			
Infusion			
Infusion			
1 Atypical mycobacterial infection; or			
2 Mycobacterium tuberculosis infection where there is drug resistance or intolerance to standard pharmaceutical agents; or			
3 Community-acquired pneumonia.			
ERYTHROMYCIN (AS ETHYLSUCCINATE)			
Tab 400 mg	16.95	100	E-Mycin
Grans for oral liq 200 mg per 5 ml	5.00	100 ml	E-Mycin
Grans for oral liq 400 mg per 5 ml	6.77	100 ml	E-Mycin
ERYTHROMYCIN (AS LACTOBIONATE)			
Inj 1 g vial	16.00	1	Erythrocin IV
ERYTHROMYCIN (AS STEARATE)			
For continuation only			
➔ Tab 250 mg			
➔ Tab 500 mg			
ROXITHROMYCIN			
Tab 150 mg	7.48	50	Arrow-Roxithromycin
Tab 300 mg	14.40	50	Arrow-Roxithromycin

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Penicillins			
AMOXICILLIN			
Cap 250 mg – 1% DV Mar-14 to 2016	16.18	500	Apo-Amoxi
Cap 500 mg – 1% DV Jul-14 to 2016	20.94	500	Apo-Amoxi
Grans for oral liq 125 mg per 5 ml	0.88	100 ml	Amoxicillin Actavis
	2.00		Ospamox
Grans for oral liq 250 mg per 5 ml	0.97	100 ml	Amoxicillin Actavis
	2.00		Ospamox
Inj 250 mg vial – 1% DV Oct-14 to 2017	10.67	10	Ibiamox
Inj 500 mg vial – 1% DV Oct-14 to 2017	12.41	10	Ibiamox
Inj 1 g vial – 1% DV Oct-14 to 2017	17.29	10	Ibiamox
AMOXICILLIN WITH CLAVULANIC ACID			
Tab 500 mg with clavulanic acid 125 mg	1.95	20	Augmentin
	9.75	100	Curam Duo
Grans for oral liq 25 mg with clavulanic acid 6.25 mg per ml	1.61	100 ml	Augmentin
Grans for oral liq 50 mg with clavulanic acid 12.5 mg per ml	2.19	100 ml	Augmentin
Inj 500 mg with clavulanic acid 100 mg vial – 1% DV Sep-15 to 2018	10.14	10	m-Amoxiclav
Inj 1,000 mg with clavulanic acid 200 mg vial – 1% DV Sep-15 to 2018	12.80	10	m-Amoxiclav
BENZATHINE BENZYL PENICILLIN			
Inj 900 mg (1.2 million units) in 2.3 ml syringe – 1% DV Sep-15 to 2018	315.00	10	Bicillin LA
BENZYL PENICILLIN SODIUM [PENICILLIN G]			
Inj 600 mg (1 million units) vial – 1% DV Sep-14 to 2017	10.35	10	Sandoz
FLUCLOXACILLIN			
Cap 250 mg – 1% DV Sep-15 to 2018	18.70	250	Staphlex
Cap 500 mg – 1% DV Sep-15 to 2018	62.90	500	Staphlex
Grans for oral liq 25 mg per ml – 1% DV Sep-15 to 2018	2.29	100 ml	AFT
Grans for oral liq 50 mg per ml – 1% DV Sep-15 to 2018	3.08	100 ml	AFT
Inj 250 mg vial – 1% DV Sep-14 to 2017	8.80	10	Flucloxin
Inj 500 mg vial – 1% DV Sep-14 to 2017	9.20	10	Flucloxin
Inj 1 g vial – 1% DV Jan-16 to 2017	11.60	10	Flucloxin
PHENOXYMETHYL PENICILLIN [PENICILLIN V]			
Cap 250 mg – 1% DV Jun-15 to 2018	2.88	50	Cilicaine VK
Cap 500 mg – 1% DV Jun-15 to 2018	4.73	50	Cilicaine VK
Grans for oral liq 125 mg per 5 ml – 1% DV Apr-14 to 2016	1.64	100 ml	AFT
Grans for oral liq 250 mg per 5 ml – 1% DV Apr-14 to 2016	1.74	100 ml	AFT
PIPERACILLIN WITH TAZOBACTAM – Restricted see terms below			
⚡ Inj 4 g with tazobactam 0.5 g vial	5.84	1	Hospira
➔Restricted			
Infectious disease physician, clinical microbiologist or respiratory physician			
PROCAINE PENICILLIN			
Inj 1.5 g in 3.4 ml syringe – 1% DV Sep-14 to 2017	123.50	5	Cilicaine
TICARCILLIN WITH CLAVULANIC ACID – Restricted see terms below			
⚡ Inj 3 g with clavulanic acid 0.1 mg vial			
➔Restricted			
Infectious disease physician, clinical microbiologist or respiratory physician			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Quinolones

CIPROFLOXACIN – **Restricted** see terms below

⚡ Tab 250 mg – 1% DV Sep-14 to 2017	1.75	28	Cipflox
⚡ Tab 500 mg – 1% DV Sep-14 to 2017	2.00	28	Cipflox
⚡ Tab 750 mg – 1% DV Sep-14 to 2017	3.75	28	Cipflox
⚡ Oral liq 50 mg per ml			
⚡ Oral liq 100 mg per ml			
⚡ Inj 2 mg per ml, 100 ml bag – 1% DV Mar-16 to 2018	30.58	10	Cipflox
	41.00		Aspen Ciprofloxacin

(Aspen Ciprofloxacin Inj 2 mg per ml, 100 ml bag to be delisted 1 March 2016)

➡ **Restricted**

Infectious disease physician or clinical microbiologist

MOXIFLOXACIN – **Restricted** see terms below

⚡ Tab 400 mg	52.00	5	Avelox
⚡ Inj 1.6 mg per ml, 250 ml bag	70.00	1	Avelox IV 400

➡ **Restricted**

Mycobacterium infection

Infectious disease physician, clinical microbiologist or respiratory physician

Either:

- 1 Active tuberculosis, with any of the following:
 - 1.1 Documented resistance to one or more first-line medications; or
 - 1.2 Suspected resistance to one or more first-line medications (tuberculosis assumed to be contracted in an area with known resistance), as part of regimen containing other second-line agents; or
 - 1.3 Impaired visual acuity (considered to preclude ethambutol use); or
 - 1.4 Significant pre-existing liver disease or hepatotoxicity from tuberculosis medications; or
 - 1.5 Significant documented intolerance and/or side effects following a reasonable trial of first-line medications; or
- 2 Mycobacterium avium-intracellulare complex not responding to other therapy or where such therapy is contraindicated

Pneumonia

Infectious disease physician or clinical microbiologist

- 1 Immunocompromised patient with pneumonia that is unresponsive to first-line treatment; or
- 2 Pneumococcal pneumonia or other invasive pneumococcal disease highly resistant to other antibiotics.

Penetrating eye injury

Ophthalmologist

Five days treatment for patients requiring prophylaxis following a penetrating eye injury

Mycoplasma genitalium

All of the following:

- 1 Has nucleic acid amplification test (NAAT) confirmed Mycoplasma genitalium; and
- 2 Has tried and failed to clear infection using azithromycin; and
- 3 Treatment is only for 7 days.

NORFLOXACIN

Tab 400 mg – 1% DV Sep-14 to 2017	13.50	100	Arrow-Norfloxacin
---	-------	-----	--------------------------

Tetracyclines

DEMECLOCYCLINE HYDROCHLORIDE

- Tab 150 mg
- Cap 150 mg
- Cap 300 mg

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
DOXYCYCLINE			
➔ Tab 50 mg			
For continuation only			
Tab 100 mg – 1% DV Sep-14 to 2017	6.75	250	Doxine
Inj 5 mg per ml, 20 ml vial			
MINOCYCLINE			
Tab 50 mg			
➔ Cap 100 mg			
For continuation only			
TETRACYCLINE			
Tab 250 mg			
Cap 500 mg	46.00	30	Tetracyclin Wolff
TIGECYCLINE – Restricted see terms below			
⚡ Inj 50 mg vial			
➔ Restricted			
Infectious disease physician or clinical microbiologist			
Other Antibacterials			
AZTREONAM – Restricted see terms below			
⚡ Inj 1 g vial	131.00	5	Azactam
➔ Restricted			
Infectious disease physician or clinical microbiologist			
CHLORAMPHENICOL – Restricted see terms below			
⚡ Inj 1 g vial			
➔ Restricted			
Infectious disease physician or clinical microbiologist			
CLINDAMYCIN – Restricted see terms below			
⚡ Cap 150 mg – 1% DV Oct-13 to 2016	5.80	16	Clindamycin ABM
⚡ Oral liq 15 mg per ml			
⚡ Inj 150 mg per ml, 4 ml ampoule – 1% DV Sep-13 to 2016	100.00	10	Dalacin C
➔ Restricted			
Infectious disease physician or clinical microbiologist			
COLISTIN SULPHOMETHATE [COLESTIMETHATE] – Restricted see terms below			
⚡ Inj 150 mg per ml, 1 ml vial	65.00	1	Colistin-Link
➔ Restricted			
Infectious disease physician, clinical microbiologist or respiratory physician			
DAPTOMYCIN – Restricted see terms below			
⚡ Inj 350 mg vial – 1% DV Sep-15 to 2018	175.16	1	Cubicin
⚡ Inj 500 mg vial – 1% DV Sep-15 to 2018	243.52	1	Cubicin
➔ Restricted			
Infectious disease physician or clinical microbiologist			
FOSFOMYCIN – Restricted see terms below			
⚡ Powder for oral solution, 3 g sachet			
➔ Restricted			
Infectious disease physician or clinical microbiologist			
FUSIDIC ACID – Restricted see terms below			
⚡ Tab 250 mg	34.50	12	Fucidin
➔ Restricted			
Infectious disease physician or clinical microbiologist			

INFECTIONS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
HEXAMINE HIPPURATE			
Tab 1 g			
LINCOMYCIN – Restricted see terms below			
⚡ Inj 300 mg per ml, 2 ml vial			
➡ Restricted			
Infectious disease physician or clinical microbiologist			
LINEZOLID – Restricted see terms below			
⚡ Tab 600 mg – 1% DV Sep-15 to 2018	800.00	10	Zyvox
⚡ Oral liq 20 mg per ml – 1% DV Sep-15 to 2018	775.00	150 ml	Zyvox
⚡ Inj 2 mg per ml, 300 ml bag – 1% DV Sep-15 to 2018	1,650.00	10	Zyvox
➡ Restricted			
Infectious disease physician or clinical microbiologist			
NITROFURANTOIN			
Tab 50 mg			
Tab 100 mg			
PIVMECILLINAM – Restricted see terms below			
⚡ Tab 200 mg			
➡ Restricted			
Infectious disease physician or clinical microbiologist			
SULPHADIAZINE – Restricted see terms below			
⚡ Tab 500 mg			
➡ Restricted			
Infectious disease physician, clinical microbiologist or maternal-foetal medicine specialist			
TEICOPLANIN – Restricted see terms below			
⚡ Inj 400 mg vial			
➡ Restricted			
Infectious disease physician or clinical microbiologist			
TRIMETHOPRIM			
Tab 100 mg			
Tab 300 mg – 1% DV Oct-15 to 2018	15.00	50	TMP
TRIMETHOPRIM WITH SULPHAMETHOXAZOLE [CO-TRIMOXAZOLE]			
Tab 80 mg with sulphamethoxazole 400 mg			
Oral liq 8 mg with sulphamethoxazole 40 mg per ml	2.15	100 ml	Deprim
Inj 16 mg with sulphamethoxazole 80 mg per ml, 5 ml ampoule			
VANCOMYCIN – Restricted see terms below			
⚡ Inj 500 mg vial – 1% DV Oct-14 to 2017	2.64	1	Mylan
➡ Restricted			
Infectious disease physician or clinical microbiologist			

Antifungals

Imidazoles

KETOCONAZOLE

⚡ Tab 200 mg

➡ **Restricted**

Oncologist

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Polyene Antimycotics

AMPHOTERICIN B

⚡ Inj (liposomal) 50 mg vial – 1% DV Sep-15 to 2018	3,450.00	10	AmBisome
---	----------	----	-----------------

➔ **Restricted**

Infectious disease physician, clinical microbiologist, haematologist, oncologist, transplant specialist or respiratory physician

Either:

- 1 Proven or probable invasive fungal infection, to be prescribed under an established protocol; or
- 2 Both:
 - 2.1 Possible invasive fungal infection; and
 - 2.2 A multidisciplinary team (including an infectious disease physician or a clinical microbiologist) considers the treatment to be appropriate.

⚡ Inj 50 mg vial			
------------------	--	--	--

➔ **Restricted**

Infectious disease physician, clinical microbiologist, haematologist, oncologist, transplant specialist or respiratory physician

NYSTATIN

Tab 500,000 u	17.09	50	Nilstat
Cap 500,000 u	15.47	50	Nilstat

Triazoles

FLUCONAZOLE – **Restricted** see terms below

⚡ Cap 50 mg – 1% DV Nov-14 to 2017	3.49	28	Ozole
⚡ Cap 150 mg – 1% DV Nov-14 to 2017	0.71	1	Ozole
⚡ Cap 200 mg – 1% DV Nov-14 to 2017	9.69	28	Ozole
⚡ Oral liquid 50 mg per 5 ml	98.50	35 ml	Diffucan
⚡ Inj 2 mg per ml, 50 ml vial – 1% DV Oct-13 to 2016	4.95	1	Fluconazole-Claris
⚡ Inj 2 mg per ml, 100 ml vial – 1% DV Oct-13 to 2016	6.47	1	Fluconazole-Claris

➔ **Restricted**

Consultant

ITRACONAZOLE – **Restricted** see terms below

⚡ Cap 100 mg – 1% DV Oct-13 to 2016	2.99	15	Itrazole
⚡ Oral liquid 10 mg per ml			

➔ **Restricted**

Infectious disease physician, clinical microbiologist, clinical immunologist or dermatologist

POSACONAZOLE – **Restricted** see terms below

⚡ Oral liq 40 mg per ml	761.13	105 ml	Noxafil
-------------------------------	--------	--------	---------

➔ **Restricted**

Infectious disease physician or haematologist

Initiation

Re-assessment required after 6 weeks

Both:

- 1 Either:
 - 1.1 Patient has acute myeloid leukaemia; or
 - 1.2 Patient is planned to receive a stem cell transplant and is at high risk for aspergillus infection; and
- 2 Patient is to be treated with high dose remission induction therapy or re-induction therapy

Continuation

Re-assessment required after 6 weeks

Both:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 1 Patient has previously received posaconazole prophylaxis during remission induction therapy; and
- 2 Any of the following:
 - 2.1 Patient is to be treated with high dose remission re-induction therapy; or
 - 2.2 Patient is to be treated with high dose consolidation therapy; or
 - 2.3 Patient is receiving a high risk stem cell transplant.

VORICONAZOLE – Restricted see terms below

☒ Tab 50 mg – 1% DV Jan-16 to 2018	130.00	56	Vttack
☒ Tab 200 mg – 1% DV Jan-16 to 2018	500.00	56	Vttack
☒ Oral liq 40 mg per ml	730.00	70 ml	Vfend
☒ Inj 200 mg vial	185.00	1	Vfend

☛ **Restricted**

Infectious disease physician, clinical microbiologist or haematologist

Proven or probable aspergillus infection

Both:

- 1 Patient is immunocompromised; and
- 2 Patient has proven or probable invasive aspergillus infection.

Possible aspergillus infection

All of the following:

- 1 Patient is immunocompromised; and
- 2 Patient has possible invasive aspergillus infection; and
- 3 A multidisciplinary team (including an infectious disease physician) considers the treatment to be appropriate.

Resistant candidiasis infections and other moulds

All of the following:

- 1 Patient is immunocompromised, and
- 2 Either:
 - 2.1 Patient has fluconazole resistant candidiasis; or
 - 2.2 Patient has mould strain such as *Fusarium* spp. and *Scedosporium* spp; and
- 3 A multidisciplinary team (including an infectious disease physician or clinical microbiologist) considers the treatment to be appropriate.

Other Antifungals

CASPOFUNGIN – Restricted see terms below

☒ Inj 50 mg vial	667.50	1	Cancidas
☒ Inj 70 mg vial	862.50	1	Cancidas

☛ **Restricted**

Infectious disease physician, clinical microbiologist, haematologist, oncologist, transplant specialist or respiratory physician

Either:

- 1 Proven or probable invasive fungal infection, to be prescribed under an established protocol; or
- 2 Both:
 - 2.1 Possible invasive fungal infection; and
 - 2.2 A multidisciplinary team (including an infectious disease physician or a clinical microbiologist) considers the treatment to be appropriate.

FLUCYTOSINE – Restricted see terms below

☒ Cap 500 mg

☛ **Restricted**

Infectious disease physician or clinical microbiologist.

TERBINAFINE

Tab 250 mg – 1% DV Sep-14 to 2017	1.50	14	Dr Reddy's Terbinafine
-----------------------------------	------	----	------------------------

Price
(ex man. excl. GST)
\$ Per Brand or
Generic
Manufacturer

Antimycobacterials

Antileprotics

CLOFAZIMINE – **Restricted** see terms below

⚡ Cap 50 mg

➔ **Restricted**

Infectious disease physician, clinical microbiologist or dermatologist

DAPSONE – **Restricted** see terms below

⚡ Tab 25 mg – 1% DV Sep-14 to 201795.00 100 **Dapsone**

⚡ Tab 100 mg – 1% DV Sep-14 to 2017110.00 100 **Dapsone**

➔ **Restricted**

Infectious disease physician, clinical microbiologist or dermatologist

Antituberculotics

CYCLOSERINE – **Restricted** see terms below

⚡ Cap 250 mg

➔ **Restricted**

Infectious disease physician, clinical microbiologist or respiratory physician

ETHAMBUTOL HYDROCHLORIDE – **Restricted** see terms below

⚡ Tab 100 mg48.01 56 Myambutol

⚡ Tab 400 mg49.34 56 Myambutol

➔ **Restricted**

Infectious disease physician, clinical microbiologist or respiratory physician

ISONIAZID – **Restricted** see terms below

⚡ Tab 100 mg – 1% DV Sep-15 to 201820.00 100 **PSM**

➔ **Restricted**

Internal medicine physician, paediatrician, clinical microbiologist, dermatologist or public health physician

ISONIAZID WITH RIFAMPICIN – **Restricted** see terms below

⚡ Tab 100 mg with rifampicin 150 mg – 1% DV Sep-15 to 201885.54 100 **Rifinah**

⚡ Tab 150 mg with rifampicin 300 mg – 1% DV Sep-15 to 2018170.60 100 **Rifinah**

➔ **Restricted**

Internal medicine physician, paediatrician, clinical microbiologist, dermatologist or public health physician

PARA-AMINOSALICYLIC ACID – **Restricted** see terms below

⚡ Grans for oral liq 4 g280.00 30 Paser

➔ **Restricted**

Infectious disease physician, clinical microbiologist or respiratory physician

PROTIONAMIDE – **Restricted** see terms below

⚡ Tab 250 mg305.00 100 Peteha

➔ **Restricted**

Infectious disease physician, clinical microbiologist or respiratory physician

PYRAZINAMIDE – **Restricted** see terms below

⚡ Tab 500 mg

➔ **Restricted**

Infectious disease physician, clinical microbiologist or respiratory physician

RIFABUTIN – **Restricted** see terms on the next page

⚡ Cap 150 mg – 1% DV Sep-13 to 2016213.19 30 **Mycobutin**

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
➔Restricted			
Infectious disease physician, clinical microbiologist, respiratory physician or gastroenterologist			
RIFAMPICIN – Restricted see terms below			
⚡ Tab 600 mg – 1% DV Nov-14 to 2017	108.70	30	Rifadin
⚡ Cap 150 mg – 1% DV Nov-14 to 2017	55.75	100	Rifadin
⚡ Cap 300 mg – 1% DV Nov-14 to 2017	116.25	100	Rifadin
⚡ Oral liq 100 mg per 5 ml – 1% DV Nov-14 to 2017	12.00	60 ml	Rifadin
⚡ Inj 600 mg vial – 1% DV Nov-14 to 2017	128.85	1	Rifadin

(Rifadin Tab 600 mg to be delisted 1 March 2016)

➔Restricted

Internal medicine physician, clinical microbiologist, dermatologist, paediatrician or public health physician

Antiparasitics

Anthelmintics

ALBENDAZOLE – **Restricted** see terms below

⚡ Tab 200 mg

⚡ Tab 400 mg

➔Restricted

Infectious disease physician or clinical microbiologist

IVERMECTIN – **Restricted** see terms below

⚡ Tab 3 mg

4

Stromectol

➔Restricted

Infectious disease physician, clinical microbiologist or dermatologist.

MEBENDAZOLE

Tab 100 mg

24

De-Worm

Oral liq 100 mg per 5 ml

PRAZIQUANTEL

Tab 600 mg

Antiprotozoals

ARTEMETHER WITH LUMEFANTRINE – **Restricted** see terms below

⚡ Tab 20 mg with lumefantrine 120 mg

➔Restricted

Infectious disease physician or clinical microbiologist

ARTESUNATE – **Restricted** see terms below

⚡ Inj 60 mg vial

➔Restricted

Infectious disease physician or clinical microbiologist

ATOVAQUONE WITH PROGUANIL HYDROCHLORIDE – **Restricted** see terms below

⚡ Tab 62.5 mg with proguanil hydrochloride 25 mg – 1% DV Nov-14 to 2017

12

Malarone Junior

⚡ Tab 250 mg with proguanil hydrochloride 100 mg – 1% DV Nov-14 to 2017

12

Malarone

➔Restricted

Infectious disease physician or clinical microbiologist

CHLOROQUINE PHOSPHATE – **Restricted** see terms on the next page

⚡ Tab 250 mg

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
➔Restricted			
Infectious disease physician, clinical microbiologist, dermatologist or rheumatologist			
MEFLOQUINE – Restricted see terms below			
⚡ Tab 250 mg – 1% DV Dec-14 to 2017	33.48	8	Lariam
➔Restricted			
Infectious disease physician, clinical microbiologist, dermatologist or rheumatologist			
METRONIDAZOLE			
Tab 200 mg	10.45	100	Trichozole
Tab 400 mg	18.15	100	Trichozole
Oral liq benzoate 200 mg per 5 ml	25.00	100 ml	Flagyl-S
Inj 5 mg per ml, 100 ml bag – 1% DV Apr-15 to 2017	6.94	5	AFT
Suppos 500 mg	24.48	10	Flagyl
NITAZOXANIDE – Restricted see terms below			
⚡ Tab 500 mg	1,680.00	30	Alinia
⚡ Oral liq 100 mg per 5 ml			
➔Restricted			
Infectious disease physician or clinical microbiologist			
ORNIDAZOLE			
Tab 500 mg	16.50	10	Arrow-Ornidazole
PENTAMIDINE ISETHIONATE – Restricted see terms below			
⚡ Inj 300 mg vial – 1% DV Mar-15 to 2017	180.00	5	Pentacarinat
➔Restricted			
Infectious disease physician or clinical microbiologist			
PRIMAQUINE PHOSPHATE – Restricted see terms below			
⚡ Tab 7.5 mg			
➔Restricted			
Infectious disease physician or clinical microbiologist			
PYRIMETHAMINE – Restricted see terms below			
⚡ Tab 25 mg			
➔Restricted			
Infectious disease physician, clinical microbiologist or maternal-foetal medicine specialist			
QUININE DIHYDROCHLORIDE – Restricted see terms below			
⚡ Inj 60 mg per ml, 10 ml ampoule			
⚡ Inj 300 mg per ml, 2 ml vial			
➔Restricted			
Infectious disease physician or clinical microbiologist			
QUININE SULPHATE			
Tab 300 mg	54.06	500	Q 300
SODIUM STIBOGLUCONATE – Restricted see terms below			
⚡ Inj 100 mg per ml, 1 ml vial			
➔Restricted			
Infectious disease physician or clinical microbiologist			
SPIRAMYCIN – Restricted see terms below			
⚡ Tab 500 mg			
➔Restricted			
Maternal-foetal medicine specialist			

Price (ex man. excl. GST)		Brand or Generic
\$	Per	Manufacturer

Antiretrovirals

HIV Fusion Inhibitors

ENFUVRTIDE – **Restricted** see terms below

‡ Inj 108 mg vial × 60	2,380.00	1	Fuzeon
------------------------------	----------	---	--------

↔ **Restricted**

Initiation

Re-assessment required after 12 months

All of the following:

- 1 Confirmed HIV infection; and
- 2 Enfuvirtide to be given in combination with optimized background therapy (including at least 1 other antiretroviral drug that the patient has never previously been exposed to) for treatment failure; and
- 3 Either:
 - 3.1 Patient has evidence of HIV replication, despite ongoing therapy; or
 - 3.2 Patient has treatment-limiting toxicity to previous antiretroviral agents; and
- 4 Previous treatment with 3 different antiretroviral regimens has failed; and
- 5 All of the following:
 - 5.1 Previous treatment with a non-nucleoside reverse transcriptase inhibitor has failed; and
 - 5.2 Previous treatment with a nucleoside reverse transcriptase inhibitor has failed; and
 - 5.3 Previous treatment with a protease inhibitor has failed.

Continuation

Patient has had at least a 10-fold reduction in viral load at 12 months

Non-Nucleoside Reverse Transcriptase Inhibitors

↔ **Restricted**

Confirmed HIV

Both:

- 1 Confirmed HIV infection; and
- 2 Any of the following:
 - 2.1 Symptomatic patient; or
 - 2.2 Patient aged 12 months and under; or
 - 2.3 Both:
 - 2.3.1 Patient aged 1 to 5 years; and
 - 2.3.2 Any of the following:
 - 2.3.2.1 CD4 counts < 1000 cells/mm³; or
 - 2.3.2.2 CD4 counts < 0.25 × total lymphocyte count; or
 - 2.3.2.3 Viral load counts > 100000 copies per ml; or
 - 2.4 Both:
 - 2.4.1 Patient aged 6 years and over; and
 - 2.4.2 CD4 counts < 500 cells/mm³

Prevention of maternal transmission

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

Post-exposure prophylaxis following non-occupational exposure to HIV

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
- 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
- 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Percutaneous exposure

Patient has percutaneous exposure to blood known to be HIV positive.

EFAVIRENZ – **Restricted** see terms on the preceding page

⬆ Tab 50 mg – 1% DV Sep-15 to 2018	63.38	30	Stocrin
⬆ Tab 200 mg – 1% DV Sep-15 to 2018	190.15	90	Stocrin
⬆ Tab 600 mg – 1% DV Sep-15 to 2018	63.38	30	Stocrin
⬆ Oral liq 30 mg per ml			

ETRAVIRINE – **Restricted** see terms on the preceding page

⬆ Tab 200 mg	770.00	60	Intelce
--------------	--------	----	---------

NEVIRAPINE – **Restricted** see terms on the preceding page

⬆ Tab 200 mg – 1% DV Nov-15 to 2018	65.00	60	Nevirapine Alphapharm
⬆ Oral suspension 10 mg per ml	134.55	240 ml	Viramune Suspension

Nucleoside Reverse Transcriptase Inhibitors

➔ **Restricted**

Confirmed HIV

Both:

- 1 Confirmed HIV infection; and
- 2 Any of the following:
 - 2.1 Symptomatic patient; or
 - 2.2 Patient aged 12 months and under; or
 - 2.3 Both:
 - 2.3.1 Patient aged 1 to 5 years; and
 - 2.3.2 Any of the following:
 - 2.3.2.1 CD4 counts < 1000 cells/mm³; or
 - 2.3.2.2 CD4 counts < 0.25 × total lymphocyte count; or
 - 2.3.2.3 Viral load counts > 100000 copies per ml; or
 - 2.4 Both:
 - 2.4.1 Patient aged 6 years and over; and
 - 2.4.2 CD4 counts < 500 cells/mm³

Prevention of maternal transmission

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

Post-exposure prophylaxis following non-occupational exposure to HIV

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
 - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Percutaneous exposure

Patient has percutaneous exposure to blood known to be HIV positive.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
ABACAVIR SULPHATE – Restricted see terms on the preceding page			
⚡ Tab 300 mg – 1% DV Oct-14 to 2017	229.00	60	Ziagen
⚡ Oral liq 20 mg per ml – 1% DV Oct-14 to 2017.....	256.31	240 ml	Ziagen
ABACAVIR SULPHATE WITH LAMIVUDINE – Restricted see terms on the preceding page			
⚡ Tab 600 mg with lamivudine 300 mg	630.00	30	Kivexa
DIDANOSINE [DDI] – Restricted see terms on the preceding page			
⚡ Cap 125 mg			
⚡ Cap 200 mg			
⚡ Cap 250 mg			
⚡ Cap 400 mg			
EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE – Restricted see terms on the preceding page			
⚡ Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg	1,313.19	30	Atripla
EMTRICITABINE – Restricted see terms on the preceding page			
⚡ Cap 200 mg	307.20	30	Emtriva
EMTRICITABINE WITH TENOFOVIR DISOPROXIL FUMARATE – Restricted see terms on the preceding page			
⚡ Tab 200 mg with tenofovir disoproxil fumarate 300 mg	838.20	30	Truvada
LAMIVUDINE – Restricted see terms on the preceding page			
⚡ Oral liq 10 mg per ml			
STAVUDINE – Restricted see terms on the preceding page			
⚡ Cap 30 mg			
⚡ Cap 40 mg			
⚡ Powder for oral soln 1 mg per ml			
ZIDOVUDINE [AZT] – Restricted see terms on the preceding page			
⚡ Cap 100 mg – 1% DV Oct-13 to 2016	152.25	100	Retrovir
⚡ Oral liq 10 mg per ml – 1% DV Oct-13 to 2016.....	30.45	200 ml	Retrovir
⚡ Inj 10 mg per ml, 20 ml vial – 1% DV Oct-14 to 2017.....	750.00	5	Retrovir IV
ZIDOVUDINE [AZT] WITH LAMIVUDINE – Restricted see terms on the preceding page			
⚡ Tab 300 mg with lamivudine 150 mg – 1% DV Sep-14 to 2017	44.00	60	Alphapharm

Protease Inhibitors

➡ Restricted

Confirmed HIV

Both:

- 1 Confirmed HIV infection; and
- 2 Any of the following:
 - 2.1 Symptomatic patient; or
 - 2.2 Patient aged 12 months and under; or
 - 2.3 Both:
 - 2.3.1 Patient aged 1 to 5 years; and
 - 2.3.2 Any of the following:
 - 2.3.2.1 CD4 counts < 1000 cells/mm³; or
 - 2.3.2.2 CD4 counts < 0.25 × total lymphocyte count; or
 - 2.3.2.3 Viral load counts > 100000 copies per ml; or
 - 2.4 Both:
 - 2.4.1 Patient aged 6 years and over; and

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

2.4.2 CD4 counts < 500 cells/mm³

Prevention of maternal transmission

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

Post-exposure prophylaxis following non-occupational exposure to HIV

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
 - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Percutaneous exposure

Patient has percutaneous exposure to blood known to be HIV positive.

ATAZANAVIR SULPHATE – **Restricted** see terms on the preceding page

⬆ Cap 150 mg	568.34	60	Reyataz
⬆ Cap 200 mg	757.79	60	Reyataz

DARUNAVIR – **Restricted** see terms on the preceding page

⬆ Tab 400 mg	837.50	60	Prezista
⬆ Tab 600 mg	1,190.00	60	Prezista

INDINAVIR – **Restricted** see terms on the preceding page

- ⬆ Cap 200 mg
- ⬆ Cap 400 mg

LOPINAVIR WITH RITONAVIR – **Restricted** see terms on the preceding page

⬆ Tab 100 mg with ritonavir 25 mg	183.75	60	Kaletra
⬆ Tab 200 mg with ritonavir 50 mg	735.00	120	Kaletra
⬆ Oral liq 80 mg with ritonavir 20 mg per ml	735.00	300 ml	Kaletra

RITONAVIR – **Restricted** see terms on the preceding page

⬆ Tab 100 mg	43.31	30	Norvir
⬆ Oral liq 80 mg per ml			

Strand Transfer Inhibitors

➔ Restricted

Confirmed HIV

Both:

- 1 Confirmed HIV infection; and
- 2 Any of the following:
 - 2.1 Symptomatic patient; or
 - 2.2 Patient aged 12 months and under; or
 - 2.3 Both:
 - 2.3.1 Patient aged 1 to 5 years; and
 - 2.3.2 Any of the following:
 - 2.3.2.1 CD4 counts < 1000 cells/mm³; or
 - 2.3.2.2 CD4 counts < 0.25 × total lymphocyte count; or
 - 2.3.2.3 Viral load counts > 100000 copies per ml; or
 - 2.4 Both:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 2.4.1 Patient aged 6 years and over; and
- 2.4.2 CD4 counts < 500 cells/mm³

Prevention of maternal transmission

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

Post-exposure prophylaxis following non-occupational exposure to HIV

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:
 - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Percutaneous exposure

Patient has percutaneous exposure to blood known to be HIV positive.

RALTEGRAVIR POTASSIUM – **Restricted** see terms on the preceding page

↑ Tab 400 mg	1,090.00	60	ISENTRESS
--------------------	----------	----	-----------

Antivirals

Hepatitis B

ADEFOVIR DIPIVOXIL – **Restricted** see terms below

⚡ Tab 10 mg	670.00	30	HEPSERA
-------------------	--------	----	---------

↪ **Restricted**

Gastroenterologist or infectious disease physician

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg+); and

Documented resistance to lamivudine, defined as:

- 1 Patient has raised serum ALT (> 1 × ULN); and
- 2 Patient has HBV DNA greater than 100,000 copies per mL, or viral load ≥ 10-fold over nadir; and
- 3 Detection of M204I or M204V mutation; and
- 4 Either:

4.1 Both:

- 4.1.1 Patient is cirrhotic; and
- 4.1.2 Adefovir dipivoxil to be used in combination with lamivudine; or

4.2 Both:

- 4.2.1 Patient is not cirrhotic; and
- 4.2.2 Adefovir dipivoxil to be used as monotherapy.

ENTECAVIR – **Restricted** see terms below

⚡ Tab 0.5 mg	400.00	30	BARACLUDE
--------------------	--------	----	-----------

↪ **Restricted**

Gastroenterologist or infectious disease physician

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
- 2 Patient is Hepatitis B nucleoside analogue treatment-naïve; and
- 3 Entecavir dose 0.5 mg/day; and
- 4 Either:

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 4.1 ALT greater than upper limit of normal; or
- 4.2 Bridging fibrosis or cirrhosis (Metavir stage 3 or greater or moderate fibrosis) on liver histology; and
- 5 Either:
 - 5.1 HBeAg positive; or
 - 5.2 Patient has \geq 2,000 IU HBV DNA units per ml and fibrosis (Metavir stage 2 or greater) on liver histology; and
- 6 No continuing alcohol abuse or intravenous drug use; and
- 7 Not co-infected with HCV, HIV or HDV; and
- 8 Neither ALT nor AST greater than 10 times upper limit of normal; and
- 9 No history of hypersensitivity to entecavir; and
- 10 No previous documented lamivudine resistance (either clinical or genotypic).

LAMIVUDINE – **Restricted** see terms below

⚡ Tab 100 mg – 1% DV Nov-14 to 2017	6.00	28	Zeffix
⚡ Oral liq 5 mg per ml – 1% DV Nov-14 to 2017	270.00	240 ml	Zeffix

➔**Restricted**

Gastroenterologist, infectious disease specialist, paediatrician or general physician

Initiation

Re-assessment required after 12 months

Any of the following:

- 1 HBV DNA positive cirrhosis prior to liver transplantation; or
- 2 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; or
- 3 Hepatitis B virus naive patient who has received a liver transplant from an anti-HBc (Hepatitis B core antibody) positive donor; or
- 4 Hepatitis B surface antigen positive (HbsAg) patient who is receiving chemotherapy for a malignancy, or who has received such treatment within the previous two months; and
- 5 Hepatitis B surface antigen positive patient who is receiving anti tumour necrosis factor treatment; or
- 6 Hepatitis B core antibody (anti-HBc) positive patient who is receiving rituximab plus high dose steroids (e.g. R-CHOP).

Continuation - patients who have maintained continuous treatment and response to lamivudine

Re-assessment required after 2 years

All of the following:

- 1 Have maintained continuous treatment with lamivudine; and
- 2 Most recent test result shows continuing biochemical response (normal ALT); and
- 3 HBV DNA <100,000 copies per ml by quantitative PCR at a reference laboratory; or

Continuation - when given in combination with adefovir dipivoxil for patients with cirrhosis and resistance to lamivudine

Re-assessment required after 2 years

All of the following:

- 1 Lamivudine to be used in combination with adefovir dipivoxil; and
- 2 Patient is cirrhotic; and

Documented resistance to lamivudine, defined as:

- 1 Patient has raised serum ALT ($> 1 \times$ ULN); and
- 2 Patient has HBV DNA greater than 100,000 copies per mL, or viral load \geq 10-fold over nadir; and
- 3 Detection of M204I or M204V mutation

Continuation - when given in combination with adefovir dipivoxil for patients with resistance to adefovir dipivoxil

Re-assessment required after 2 years

All of the following:

- 1 Lamivudine to be used in combination with adefovir dipivoxil; and

Documented resistance to adefovir, defined as:

- 1 Patient has raised serum ALT ($> 1 \times$ ULN); and
- 2 Patient has HBV DNA greater than 100,000 copies per mL, or viral load \geq 10-fold over nadir; and
- 3 Detection of N236T or A181T/V mutation.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
TENOFOVIR DISOPROXIL FUMARATE – Restricted see terms below			
☒ Tab 300 mg	531.00	30	Viread

☛ **Restricted**

Confirmed hepatitis B

Any of the following:

- 1 All of the following:
 - 1.1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
 - 1.2 Patient has had previous lamivudine, adefovir or entecavir therapy; and
 - 1.3 HBV DNA greater than 20,000 IU/mL or increased \leq 10-fold over nadir; and
 - 1.4 Any of the following:
 - 1.4.1 Lamivudine resistance - detection of M204I/V mutation; or
 - 1.4.2 Adefovir resistance - detection of A181T/V or N236T mutation; or
 - 1.4.3 Entecavir resistance - detection of relevant mutations including I169T, L180M T184S/A/I/L/G/C/M, S202C/G/I, M204V or M250I/V mutation; or
- 2 Patient is either listed or has undergone liver transplantation for HBV; or
- 3 Patient has a decompensated cirrhosis with a Mayo score > 20.

Pregnant or Breastfeeding, Active hepatitis B

Limited to twelve months' treatment

Both:

- 1 Patient is HBsAg positive and pregnant; and
- 2 HBV DNA > 20,000 IU/mL and ALT > ULN.

Pregnant, prevention of vertical transmission

Limited to six months' treatment

Both:

- 1 Patient is HBsAg positive and pregnant; and
- 2 HBV DNA > 20 million IU/mL and ALT normal.

Confirmed HIV

Both:

- 1 Confirmed HIV infection; and
- 2 Any of the following:
 - 2.1 Symptomatic patient; or
 - 2.2 Patient aged 12 months and under; or
 - 2.3 Both:
 - 2.3.1 Patient aged 1 to 5 years; and
 - 2.3.2 Any of the following:
 - 2.3.2.1 CD4 counts < 1000 cells/mm³; or
 - 2.3.2.2 CD4 counts < 0.25 \times total lymphocyte count; or
 - 2.3.2.3 Viral load counts > 100000 copies per ml; or
 - 2.4 Both:
 - 2.4.1 Patient aged 6 years and over; and
 - 2.4.2 CD4 counts < 500 cells/mm³

Prevention of maternal transmission

Either:

- 1 Prevention of maternal foetal transmission; or
- 2 Treatment of the newborn for up to eight weeks.

Post-exposure prophylaxis following non-occupational exposure to HIV

Both:

- 1 Treatment course to be initiated within 72 hours post exposure; and
- 2 Any of the following:

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
- 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or
- 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Percutaneous exposure

Patient has percutaneous exposure to blood known to be HIV positive.

Hepatitis C

BOCEPREVIR – **Restricted** see terms below

⚡ Cap 200 mg	5,015.00	336	Victrelis
--------------------	----------	-----	-----------

➡ **Restricted**

Chronic hepatitis C - genotype 1, first-line

Gastroenterologist, infectious disease physician or general physician

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has not received prior pegylated interferon treatment; and
- 3 Patient has IL-28B genotype CT or TT; and
- 4 Patient is to be treated in combination with pegylated interferon and ribavirin; and
- 5 Patient is hepatitis C protease inhibitor treatment-naive; and
- 6 Maximum of 44 weeks therapy.

Chronic hepatitis C - genotype 1, second-line

Gastroenterologist, infectious disease physician or general physician.

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has received pegylated interferon treatment; and
- 3 Any one of:
 - 3.1 Patient was a responder relapser; or
 - 3.2 Patient was a partial responder; or
 - 3.3 Patient received pegylated interferon prior to 2004; and
- 4 Patient is to be treated in combination with pegylated interferon and ribavirin; and
- 5 Maximum of 44 weeks therapy.

Note: Due to risk of severe sepsis boceprevir should not be initiated if either Platelet count <100 x10⁹ /l or Albumin <35 g/l.

Herpesviridae

ACICLOVIR

Tab dispersible 200 mg – 1% DV Sep-13 to 2016	1.78	25	Lovir
Tab dispersible 400 mg – 1% DV Sep-13 to 2016	5.98	56	Lovir
Tab dispersible 800 mg – 1% DV Sep-13 to 2016	6.64	35	Lovir
Inj 250 mg vial – 1% DV Jan-16 to 2018	10.10	5	Aciclovir-Claris

CIDOFVIR – **Restricted** see terms below

⚡ Inj 75 mg per ml, 5 ml vial

➡ **Restricted**

Infectious disease physician, clinical microbiologist, otolaryngologist or oral surgeon

FOSCARNET SODIUM – **Restricted** see terms below

⚡ Inj 24 mg per ml, 250 ml bottle

➡ **Restricted**

Infectious disease physician or clinical microbiologist

GANCICLOVIR – **Restricted** see terms on the next page

⚡ Inj 500 mg vial	380.00	5	Cymevene
-------------------------	--------	---	----------

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
➔Restricted			
Infectious disease physician or clinical microbiologist			
VALACICLOVIR – Restricted see terms below			
⚡ Tab 500 mg – 1% DV Mar-16 to 2018	6.42	30	Vaclovir
	102.72		Valtrex
⚡ Tab 1,000 mg – 1% DV Mar-16 to 2018	12.75	30	Vaclovir
<i>(Valtrex Tab 500 mg to be delisted 1 March 2016)</i>			

➔Restricted

Any of the following:

- 1 Patient has genital herpes with 2 or more breakthrough episodes in any 6 month period while treated with aciclovir 400 mg twice daily.
- 2 Patient has previous history of ophthalmic zoster and the patient is at risk of vision impairment.
- 3 Patient has undergone organ transplantation.

Immunocompromised patients

Limited to 7 days treatment

Both:

- 1 Patient is immunocompromised; and
- 2 Patient has herpes zoster.

VALGANCICLOVIR – **Restricted** see terms below

⚡ Tab 450 mg – 1% DV Jun-15 to 2018	1,050.00	60	Valcyte
---	----------	----	----------------

➔Restricted

Transplant cytomegalovirus prophylaxis

Limited to three months' treatment

Patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis.

Lung transplant cytomegalovirus prophylaxis

Limited to six months' treatment

Both:

- 1 Patient has undergone a lung transplant; and
- 2 Either:
 - 2.1 The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or
 - 2.2 The recipient is cytomegalovirus positive.

Cytomegalovirus in immunocompromised patients

Both:

- 1 Patient is immunocompromised; and
- 2 Any of the following:
 - 2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or
 - 2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or
 - 2.3 Patient has cytomegalovirus retinitis.

Influenza

OSELTAMIVIR – **Restricted** see terms below

⚡ Tab 75 mg

⚡ Powder for oral suspension 6 mg per ml

➔Restricted

Either:

- 1 Only for hospitalised patient with known or suspected influenza; or
- 2 For prophylaxis of influenza in hospitalised patients as part of a DHB hospital approved infections control plan.

ZANAMIVIR

⚡ Powder for inhalation 5 mg	37.38	20 dose	Relenza Rotadisk
------------------------------------	-------	---------	------------------

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

➔ **Restricted**

Either:

- 1 Only for hospitalised patient with known or suspected influenza; or
- 2 For prophylaxis of influenza in hospitalised patients as part of a DHB hospital approved infections control plan.

Immune Modulators

INTERFERON ALFA-2A

- Inj 3 m iu prefilled syringe
- Inj 6 m iu prefilled syringe
- Inj 9 m iu prefilled syringe

INTERFERON ALFA-2B

- Inj 18 m iu, 1.2 ml multidose pen
- Inj 30 m iu, 1.2 ml multidose pen
- Inj 60 m iu, 1.2 ml multidose pen

INTERFERON GAMMA – Restricted see terms below

- ⚡ Inj 100 mcg in 0.5 ml vial

➔ **Restricted**

Patient has chronic granulomatous disease and requires interferon gamma.

PEGYLATED INTERFERON ALFA-2A – Restricted see terms below

⚡ Inj 135 mcg prefilled syringe			
⚡ Inj 135 mcg prefilled syringe (4) with ribavirin tab 200 mg (112)			
⚡ Inj 135 mcg prefilled syringe (4) with ribavirin tab 200 mg (168)			
⚡ Inj 180 mcg prefilled syringe	900.00	4	PegasyS
⚡ Inj 180 mcg prefilled syringe (4) with ribavirin tab 200 mg (112)	1,159.84	1	PegasyS RBV Combination Pack
⚡ Inj 180 mcg prefilled syringe (4) with ribavirin tab 200 mg (168)	1,290.00	1	PegasyS RBV Combination Pack

➔ **Restricted**

Initiation – Chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV or genotype 2 or 3 post liver transplant

Both:

- 1 Any of the following:
 - 1.1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or
 - 1.2 Patient has chronic hepatitis C and is co-infected with HIV; or
 - 1.3 Patient has chronic hepatitis C genotype 2 or 3 and has received a liver transplant.
- 2 Maximum of 48 weeks therapy.

Notes:

Consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.

Consider reducing treatment to 24 weeks if serum HCV RNA level at Week 4 is undetectable by sensitive PCR assay (less than 50IU/ml) AND Baseline serum HCV RNA is less than 400,000IU/ml.

Continuation – (Chronic hepatitis C - genotype 1 infection)

Gastroenterologist, infectious disease physician or general physician

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has had previous treatment with pegylated interferon and ribavirin; and
- 3 Either:
 - 3.1 Patient has responder relapsed; or
 - 3.2 Patient was a partial responder; and

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 4 Patient is to be treated in combination with boceprevir; and
- 5 Maximum of 48 weeks therapy.

Initiation (Chronic Hepatitis C - genotype 1 infection treatment more than 4 years prior)

Gastroenterologist, infectious disease physician or general physician

All of the following:

- 1 Patient has chronic hepatitis C, genotype 1; and
- 2 Patient has had previous treatment with pegylated interferon and ribavirin; and
- 3 Any of the following:
 - 3.1 Patient has responder relapsed; or
 - 3.2 Patient was a partial responder; or
 - 3.3 Patient received interferon treatment prior to 2004; and
- 4 Patient is to be treated in combination with boceprevir; and
- 5 Maximum of 48 weeks therapy.

Initiation – Chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV

Both:

- 1 Patient has chronic hepatitis C, genotype 2 or 3 infection; and
- 2 Maximum of 6 months therapy.

Initiation – Hepatitis B

Gastroenterologist, infectious disease specialist or general physician

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
- 2 Patient is Hepatitis B treatment-naive; and
- 3 ALT > 2 times Upper Limit of Normal; and
- 4 HBV DNA < 10 log₁₀ IU/ml; and
- 5 Either:
 - 5.1 HBeAg positive; or
 - 5.2 Serum HBV DNA ≥ 2,000 units/ml and significant fibrosis (≥ Metavir Stage F2 or moderate fibrosis); and
- 6 Compensated liver disease; and
- 7 No continuing alcohol abuse or intravenous drug use; and
- 8 Not co-infected with HCV, HIV or HDV; and
- 9 Neither ALT nor AST > 10 times upper limit of normal; and
- 10 No history of hypersensitivity or contraindications to pegylated interferon; and
- 11 Maximum of 48 weeks therapy.

Notes:

Approved dose is 180 mcg once weekly.

The recommended dose of Pegylated Interferon alfa-2a is 180 mcg once weekly.

In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Pegylated Interferon alfa-2a dose should be reduced to 135 mcg once weekly.

In patients with neutropaenia and thrombocytopenia, dose should be reduced in accordance with the datasheet guidelines.

Pegylated Interferon alfa-2a is not approved for use in children.

Price
(ex man. excl. GST)
\$ Per Brand or
Generic
Manufacturer

Anticholinesterases

EDROPHONIUM CHLORIDE – **Restricted** see terms below

- ⚡ Inj 10 mg per ml, 15 ml vial
- ⚡ Inj 10 mg per ml, 1 ml ampoule

➔**Restricted**

For the diagnosis of myasthenia gravis

NEOSTIGMINE METILSULFATE

Inj 2.5 mg per ml, 1 ml ampoule – **1% DV Sep-14 to 2017** 98.00 50 **AstraZeneca**

NEOSTIGMINE METILSULFATE WITH GLYCOPYRRONIUM BROMIDE

Inj 2.5 mg with glycopyrronium bromide 0.5 mg per ml, 1 ml ampoule
– **1% DV Nov-13 to 2016** 27.86 10 **Max Health**

PYRIDOSTIGMINE BROMIDE

Tab 60 mg 38.90 100 Mestinon

Antirheumatoid Agents

AURANOFIN

Tab 3 mg

HYDROXYCHLOROQUINE

Tab 200 mg – **1% DV Sep-15 to 2018** 10.50 100 **Plaquenil**

LEFLUNOMIDE

Tab 10 mg 55.00 30 Arava
Tab 20 mg 76.00 30 Arava
Tab 100 mg 54.44 3 Arava

PENICILLAMINE

Tab 125 mg 61.93 100 D-Penaminate
Tab 250 mg 98.98 100 D-Penaminate

SODIUM AUROTHIOMALATE

- Inj 10 mg in 0.5 ml ampoule
- Inj 20 mg in 0.5 ml ampoule
- Inj 50 mg in 0.5 ml ampoule

Drugs Affecting Bone Metabolism

Bisphosphonates

ALENDRONATE SODIUM

⚡ Tab 40 mg 133.00 30 Fosamax

➔**Restricted**

Both:

- 1 Paget's disease; and
- 2 Any of the following:
 - 2.1 Bone or articular pain; or
 - 2.2 Bone deformity; or
 - 2.3 Bone, articular or neurological complications; or
 - 2.4 Asymptomatic disease, but risk of complications due to site (base of skull, spine, long bones of lower limbs); or
 - 2.5 Preparation for orthopaedic surgery.

⚡ Tab 70 mg 12.90 4 Fosamax

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

➔ **Restricted**

Osteoporosis

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5) (see Note); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score ≤ -3.0 (see Note); or
- 5 A 10-year risk of hip fracture $\geq 3\%$, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
- 6 Patient has had a Special Authority approval for zoledronic acid (osteoporosis) or raloxifene.

Initiation - glucocorticosteroid therapy

Re-assessment required after 12 months

Both:

- 1 The patient is receiving systemic glucocorticosteroid therapy (≥ 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and
- 2 Any of the following:
 - 2.1 The patient has documented BMD ≥ 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -1.5) (see Note); or
 - 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
 - 2.3 The patient has had a Special Authority approval for zoledronic acid (glucocorticosteroid therapy) or raloxifene.

Continuation - glucocorticosteroid therapy

Re-assessment required after 12 months

The patient is continuing systemic glucocorticosteroid therapy (≥ 5 mg per day prednisone equivalents)

Notes:

- 1 BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- 2 Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.
- 3 Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- 4 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

ALENDRONATE SODIUM WITH CHOLECALCIFEROL – **Restricted** see terms below

⚡ Tab 70 mg with cholecalciferol 5,600 iu	12.90	4	Fosamax Plus
---	-------	---	--------------

➔ **Restricted**

Osteoporosis

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5) (see Note); or

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued. . .

- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score \leq -3.0 (see Note); or
- 5 A 10-year risk of hip fracture \geq 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
- 6 Patient has had a Special Authority approval for zoledronic acid (osteoporosis) or raloxifene.

Initiation - glucocorticosteroid therapy

Re-assessment required after 12 months

- Both:
- 1 The patient is receiving systemic glucocorticosteroid therapy (\geq 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and
 - 2 Any of the following:
 - 2.1 The patient has documented BMD \geq 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -1.5) (see Note); or
 - 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
 - 2.3 The patient has had a Special Authority approval for zoledronic acid (glucocorticosteroid therapy) or raloxifene.

Continuation - glucocorticosteroid therapy

Re-assessment required after 12 months

The patient is continuing systemic glucocorticosteroid therapy (\geq 5 mg per day prednisone equivalents)

Notes:

- 1 BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- 2 Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score \geq -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.
- 3 Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- 4 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

ETIDRONATE DISODIUM

Tab 200 mg – 1% DV Sep-15 to 2018	13.50	100	Arrow-Etidronate
---	-------	-----	-------------------------

PAMIDRONATE DISODIUM

Inj 3 mg per ml, 10 ml vial	6.80	1	Pamisol
Inj 6 mg per ml, 10 ml vial	13.20	1	Pamisol
Inj 9 mg per ml, 10 ml vial	19.20	1	Pamisol

RISEDRONATE SODIUM

Tab 35 mg	4.00	4	Risedronate Sandoz
-----------------	------	---	--------------------

ZOLEDRONIC ACID

⚡ Inj 5 mg per 100 ml, vial	600.00	100 ml	Aclasta
-----------------------------------	--------	--------	---------

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

➔ **Restricted**

Inherited bone fragility disorders

Patient has been diagnosed with an inherited bone fragility disorder (e.g. osteogenesis imperfecta).

Osteoporosis

Both:

- 1 Any of the following:
 - 1.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) \geq 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -2.5) (see Note); or
 - 1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
 - 1.3 History of two significant osteoporotic fractures demonstrated radiologically; or
 - 1.4 Documented T-Score \geq -3.0 (see Note); or
 - 1.5 A 10-year risk of hip fracture \geq 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
 - 1.6 Patient has had a Special Authority approval for alendronate (Underlying cause - Osteoporosis) or raloxifene; and
- 2 The patient will not be prescribed more than 5 mg of zoledronic acid in a 12-month period.

Initiation - glucocorticosteroid therapy

Re-assessment required after 12 months

All of the following:

- 1 The patient is receiving systemic glucocorticosteroid therapy (\geq 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and
- 2 Any of the following:
 - 2.1 The patient has documented BMD \geq 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -1.5) (see Note); or
 - 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
 - 2.3 The patient has had a Special Authority approval for alendronate (Underlying cause - glucocorticosteroid therapy) or raloxifene; and
- 3 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Continuation - glucocorticosteroid therapy

Re-assessment required after 12 months

Both:

- 1 The patient is continuing systemic glucocorticosteroid therapy (\geq 5 mg per day prednisone equivalents); and
- 2 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Initiation - Paget's disease

Re-assessment required after 12 months

All of the following:

- 1 Paget's disease; and
- 2 Any of the following:
 - 2.1 Bone or articular pain; or
 - 2.2 Bone deformity; or
 - 2.3 Bone, articular or neurological complications; or
 - 2.4 Asymptomatic disease, but risk of complications; or
 - 2.5 Preparation for orthopaedic surgery; and
- 3 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Continuation - Paget's disease

Re-assessment required after 12 months

Both:

- 1 Any of the following:

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 1.1 The patient has relapsed (based on increases in serum alkaline phosphatase); or
- 1.2 The patient's serum alkaline phosphatase has not normalised following previous treatment with zoledronic acid; or
- 1.3 Symptomatic disease (prescriber determined); and
- 2 The patient will not be prescribed more than 5 mg of zoledronic acid in the 12-month approval period.

Notes:

- 1 BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- 2 Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.
- 3 Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- 4 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Other Drugs Affecting Bone Metabolism

RALOXIFENE – **Restricted** see terms below

⚡ Tab 60 mg	53.76	28	Evista
-------------------	-------	----	--------

→ **Restricted**

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) ≥ 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -2.5) (see Notes); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score ≥ -3.0 (see Notes); or
- 5 A 10-year risk of hip fracture $\geq 3\%$, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Notes); or
- 6 Patient has had a prior Special Authority approval for zoledronic acid (Underlying cause - Osteoporosis) or alendronate (Underlying cause - Osteoporosis).

Notes:

- 1 BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- 2 Evidence suggests that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5 and, therefore, do not require BMD measurement for raloxifene funding.
- 3 Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- 4 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

MUSCULOSKELETAL SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
TERIPARATIDE – Restricted see terms below			
☯ Inj 250 mcg per ml, 2.4 ml cartridge	490.00	1	Forteo

☛Restricted

Limited to 18 months' treatment

All of the following:

- 1 The patient has severe, established osteoporosis; and
- 2 The patient has a documented T-score less than or equal to -3.0 (see Notes); and
- 3 The patient has had two or more fractures due to minimal trauma; and
- 4 The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent at adequate doses (see Notes).

Notes:

- 1 The bone mineral density (BMD) measurement used to derive the T-score must be made using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable
- 2 Antiresorptive agents and their adequate doses for the purposes of this Special Authority are defined as: alendronate sodium tab 70 mg or tab 70 mg with cholecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily; zoledronic acid 5 mg per year. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialed so that the patient achieves the minimum requirement of 12 months' continuous therapy.
- 3 A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Enzymes

HYALURONIDASE

Inj 1,500 iu ampoule

Hyperuricaemia and Antigout

ALLOPURINOL

Tab 100 mg – 1% DV Mar-15 to 2017	15.11	1,000	Apo-Allopurinol
Tab 300 mg – 1% DV Mar-15 to 2017	15.91	500	Apo-Allopurinol

BENZBROMARONE – **Restricted** see terms below

☯ Tab 100 mg	45.00	100	Benzbromaron AL 100
--------------------	-------	-----	---------------------

☛Restricted

All of the following:

- 1 Patient has been diagnosed with gout; and
- 2 Any of the following:
 - 2.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
 - 2.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
 - 2.3 Both:
 - 2.3.1 The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note); and
 - 2.3.2 The patient has a rate of creatinine clearance greater than or equal to 20 ml/min; or
 - 2.4 All of the following:
 - 2.4.1 The patient is taking azathioprine and requires urate-lowering therapy; and
 - 2.4.2 Allopurinol is contraindicated; and

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

2.4.3 Appropriate doses of probenecid are ineffective or probenecid cannot be used due to reduced renal function; and

3 The patient is receiving monthly liver function tests.

Notes: Benzbromarone has been associated with potentially fatal hepatotoxicity. In chronic renal insufficiency, particularly when the glomerular filtration rate is 30 ml/minute or less, probenecid may not be effective. Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.

The New Zealand Rheumatology Association has developed information for prescribers which can be accessed from its website at www.rheumatology.org.nz/downloads/Benzbromarone-prescriber-information-NZRA-V2.pdf

COLCHICINE

Tab 500 mcg – 1% DV Oct-13 to 2016 10.08 100 **Colgout**

FEBUXOSTAT – Restricted see terms below

⚡ Tab 80 mg 39.50 28 Adenuric
 ⚡ Tab 120 mg 39.50 28 Adenuric

➡ **Restricted**

- Both:
- 1 Patient has been diagnosed with gout; and
 - 2 Any of the following:
 - 2.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
 - 2.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose; or
 - 2.3 The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note)

Note: In chronic renal insufficiency, particularly when the glomerular filtration rate is 30 ml/minute or less, probenecid may not be effective. The efficacy and safety of febuxostat have not been fully evaluated in patients with severe renal impairment (creatinine clearance less than 30 ml/minute). No dosage adjustment of febuxostat is necessary in patients with mild or moderate renal impairment. Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.

PROBENECID

Tab 500 mg

RASBURICASE – Restricted see terms below

⚡ Inj 1.5 mg vial

➡ **Restricted**

Haematologist

Muscle Relaxants and Related Agents

ATRACURIUM BESYLATE

Inj 10 mg per ml, 2.5 ml ampoule – 1% DV Jan-16 to 2018 10.00 5 **Tracrium**
 Inj 10 mg per ml, 5 ml ampoule – 1% DV Jan-16 to 2018 12.50 5 **Tracrium**

BACLOFEN

Tab 10 mg – 1% DV Jun-13 to 2016 3.85 100 **Pacifen**
 Oral liq 1 mg per ml
 Inj 0.05 mg per ml, 1 ml ampoule – 1% DV Sep-15 to 2018 11.55 1 **Lioresal Intrathecal**
 Inj 2 mg per ml, 5 ml ampoule 209.29 1 **Lioresal Intrathecal**

MUSCULOSKELETAL SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
CLOSTRIDIUM BOTULINUM TYPE A TOXIN			
Inj 100 u vial	467.50	1	Botox
Inj 500 u vial	1,295.00	2	Dysport
DANTROLENE			
Cap 25 mg	65.00	100	Dantrium
Cap 50 mg	77.00	100	Dantrium
Inj 20 mg vial	800.00	6	Dantrium IV
MIVACURIUM CHLORIDE			
Inj 2 mg per ml, 5 ml ampoule	33.92	5	Mivacron
Inj 2 mg per ml, 10 ml ampoule	67.17	5	Mivacron
ORPHENADRINE CITRATE			
Tab 100 mg			
PANCURONIUM BROMIDE			
Inj 2 mg per ml, 2 ml ampoule	260.00	50	AstraZeneca
ROCURONIUM BROMIDE			
Inj 10 mg per ml, 5 ml vial	38.25	10	DBL Rocuronium Bromide
SUXAMETHONIUM CHLORIDE			
Inj 50 mg per ml, 2 ml ampoule – 1% DV Jun-14 to 2017	78.00	50	AstraZeneca
VECURONIUM BROMIDE			
Inj 4 mg ampoule			
Inj 10 mg vial			

Reversers of Neuromuscular Blockade

SUGAMMADEX – Restricted see terms below

⚡ Inj 100 mg per ml, 2 ml vial	1,200.00	10	Bridion
⚡ Inj 100 mg per ml, 5 ml vial	3,000.00	10	Bridion

➡Restricted

Any of the following:

- 1 Patient requires reversal of profound neuromuscular blockade following rapid sequence induction that has been undertaken using rocuronium (i.e. suxamethonium is contraindicated or undesirable); or
- 2 Severe neuromuscular degenerative disease where the use of neuromuscular blockade is required; or
- 3 Patient has an unexpectedly difficult airway that cannot be intubated and requires a rapid reversal of anaesthesia and neuromuscular blockade; or
- 4 The duration of the patient's surgery is unexpectedly short; or
- 5 Neostigmine or a neostigmine/anticholinergic combination is contraindicated (for example the patient has ischaemic heart disease, morbid obesity or COPD); or
- 6 Patient has a partial residual block after conventional reversal.

Non-Steroidal Anti-Inflammatory Drugs

CELECOXIB – Restricted see terms below

⚡ Cap 100 mg			
⚡ Cap 200 mg			
⚡ Cap 400 mg			

➡Restricted

For preoperative and/or postoperative use for a total of up to 8 days' use.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
DICLOFENAC SODIUM			
Tab EC 25 mg – 1% DV Dec-15 to 2018	1.30	50	Diclofenac Sandoz
Tab 50 mg dispersible	1.50	20	Voltaren D
Tab EC 50 mg – 1% DV Dec-15 to 2018	1.00	50	Diclofenac Sandoz
Tab long-acting 75 mg – 1% DV Dec-15 to 2018.....	15.20	500	Apo-Diclo SR
Tab long-acting 100 mg – 1% DV Dec-15 to 2018.....	26.20	500	Apo-Diclo SR
Inj 25 mg per ml, 3 ml ampoule – 1% DV Oct-14 to 2017	13.20	5	Voltaren
Suppos 12.5 mg – 1% DV Oct-14 to 2017.....	2.04	10	Voltaren
Suppos 25 mg – 1% DV Oct-14 to 2017.....	2.44	10	Voltaren
Suppos 50 mg – 1% DV Oct-14 to 2017.....	4.22	10	Voltaren
Suppos 100 mg – 1% DV Oct-14 to 2017.....	7.00	10	Voltaren

ETORICOXIB – Restricted see terms below

- ⚡ Tab 30 mg
- ⚡ Tab 60 mg
- ⚡ Tab 90 mg
- ⚡ Tab 120 mg

➔ **Restricted**

For preoperative and/or postoperative use for a total of up to 8 days' use.

IBUPROFEN

Tab 200 mg			
➔ Tab 400 mg			
For continuation only			
➔ Tab 600 mg			
For continuation only			
Tab long-acting 800 mg – 1% DV Jul-15 to 2018	7.99	30	Brufen SR
Oral liq 20 mg per ml – 1% DV Mar-14 to 2016	1.89	200 ml	Fenpaed
Inj 5 mg per ml, 2 ml ampoule			
Inj 10 mg per ml, 2 ml vial			

INDOMETHACIN

- Cap 25 mg
- Cap 50 mg
- Cap long-acting 75 mg
- Inj 1 mg vial
- Suppos 100 mg

KETOPROFEN

Cap long-acting 200 mg	12.07	28	Oruvail SR
------------------------------	-------	----	-------------------

MEFENAMIC ACID

- For continuation only
- ➔ Cap 250 mg

MELOXICAM – Restricted see terms below

- ⚡ Tab 7.5 mg

➔ **Restricted**

Either:

- 1 Haemophilic arthropathy, with both of the following:
 - 1.1 The patient has moderate to severe haemophilia with less than or equal to 5% of normal circulating functional clotting factor; and
 - 1.2 Pain and inflammation associated with haemophilic arthropathy is inadequately controlled by alternative funded treatment options, or alternative funded treatment options are contraindicated; or
- 2 For preoperative and/or postoperative use for a total of up to 8 days' use.

MUSCULOSKELETAL SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
NAPROXEN			
Tab 250 mg – 1% DV Sep-15 to 2018	18.06	500	Noflam 250
Tab 500 mg – 1% DV Sep-15 to 2018	18.91	250	Noflam 500
Tab long-acting 750 mg – 1% DV Jun-15 to 2018	18.00	90	Naprosyn SR 750
Tab long-acting 1 g – 1% DV Jun-15 to 2018	21.00	90	Naprosyn SR 1000
PARECOXIB			
Inj 40 mg vial	100.00	10	Dynastat
SULINDAC			
Tab 100 mg			
Tab 200 mg			
TENOXCAM			
Tab 20 mg – 1% DV Jan-15 to 2016	3.05	20	Reutenox
Inj 20 mg vial	9.95	1	AFT

Topical Products for Joint and Muscular Pain

CAPSAICIN – **Restricted** see terms below

⚠ Crm 0.025%9.95 45 g Zostrix

➡ **Restricted**

Patient has osteoarthritis that is not responsive to paracetamol and oral non-steroidal anti-inflammatories are contraindicated.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Agents for Parkinsonism and Related Disorders

Agents for Essential Tremor, Chorea and Related Disorders

RILUZOLE – **Restricted** see terms below

⚡ Tab 50 mg	400.00	56	Rilutek
-------------------	--------	----	---------

➔ Restricted

Initiation

Neurologist or respiratory specialist

Re-assessment required after 6 months

All of the following:

- 1 The patient has amyotrophic lateral sclerosis with disease duration of 5 years or less; and
- 2 The patient has at least 60 percent of predicted forced vital capacity within 2 months prior to the initial application; and
- 3 The patient has not undergone a tracheostomy; and
- 4 The patient has not experienced respiratory failure; and
- 5 Any of the following:
 - 5.1 The patient is ambulatory; or
 - 5.2 The patient is able to use upper limbs; or
 - 5.3 The patient is able to swallow.

Continuation

Re-assessment required after 18 months

All of the following:

- 1 The patient has not undergone a tracheostomy; and
- 2 The patient has not experienced respiratory failure; and
- 3 Any of the following:
 - 3.1 The patient is ambulatory; or
 - 3.2 The patient is able to use upper limb; or
 - 3.3 The patient is able to swallow.

TETRABENAZINE

Tab 25 mg – 1% DV Sep-13 to 2016	118.00	112	Motetis
--	--------	-----	----------------

Anticholinergics

BENZTROPINE MESYLATE

Tab 2 mg	7.99	60	Benztrop
Inj 1 mg per ml, 2 ml ampoule	95.00	5	Cogentin

ORPHENADRINE HYDROCHLORIDE

Tab 50 mg

PROCYCLIDINE HYDROCHLORIDE

Tab 5 mg

Dopamine Agonists and Related Agents

AMANTADINE HYDROCHLORIDE

Cap 100 mg – 1% DV Oct-14 to 2017	38.24	60	Symmetrel
---	-------	----	------------------

APOMORPHINE HYDROCHLORIDE

Inj 10 mg per ml, 1 ml ampoule			
Inj 10 mg per ml, 2 ml ampoule	119.00	5	Apomine

BROMOCRIPTINE

Tab 2.5 mg

Cap 5 mg

NERVOUS SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
ENTACAPONE			
Tab 200 mg – 1% DV Sep-15 to 2018	28.00	100	Entapone
LEVODOPA WITH BENSERAZIDE			
Tab dispersible 50 mg with benserazide 12.5 mg	10.00	100	Madopar Rapid
Cap 50 mg with benserazide 12.5 mg	8.00	100	Madopar 62.5
Cap 100 mg with benserazide 25 mg	12.50	100	Madopar 125
Cap long-acting 100 mg with benserazide 25 mg	17.00	100	Madopar HBS
Cap 200 mg with benserazide 50 mg	25.00	100	Madopar 250
LEVODOPA WITH CARBIDOPA			
Tab 100 mg with carbidopa 25 mg	20.00	100	Sinemet <i>e.g. Kinson</i>
Tab long-acting 200 mg with carbidopa 50 mg	47.50	100	Sinemet CR
Tab 250 mg with carbidopa 25 mg	40.00	100	Sinemet <i>e.g. Sindopa</i>
LISURIDE HYDROGEN MALEATE			
Tab 200 mcg	25.00	30	Dopergin
PRAMIPEXOLE HYDROCHLORIDE			
Tab 0.25 mg – 1% DV Oct-14 to 2016	7.20	100	Ramipex
Tab 1 mg – 1% DV Oct-14 to 2016	24.39	100	Ramipex
ROPINIROLE HYDROCHLORIDE			
Tab 0.25 mg – 1% DV Mar-14 to 2016	2.36	100	Apo-Ropinirole
Tab 1 mg – 1% DV Mar-14 to 2016	5.32	100	Apo-Ropinirole
Tab 2 mg – 1% DV Mar-14 to 2016	7.72	100	Apo-Ropinirole
Tab 5 mg – 1% DV Mar-14 to 2016	14.48	100	Apo-Ropinirole
SELEGILINE HYDROCHLORIDE			
Tab 5 mg			
TOLCAPONE			
Tab 100 mg	126.20	100	Tasmar
Anaesthetics			
General Anaesthetics			
DESFLURANE			
Soln for inhalation 100%, 240 ml bottle	1,230.00	6	Suprane
DEXMEDETOMIDINE			
Inj 100 mcg per ml, 2 ml vial – 1% DV Oct-14 to 2017	479.85	5	Precedex
ETOMIDATE			
Inj 2 mg per ml, 10 ml ampoule			
ISOFLURANE			
Soln for inhalation 100%, 250 ml bottle	1,020.00	6	Aerrane
KETAMINE			
Inj 1 mg per ml, 100 ml bag – 1% DV Sep-14 to 2017	27.00	1	Biomed
Inj 4 mg per ml, 50 ml syringe – 1% DV Sep-14 to 2017	25.00	1	Biomed
Inj 10 mg per ml, 10 ml syringe – 1% DV Sep-14 to 2017	14.00	1	Biomed
Inj 100 mg per ml, 2 ml vial			
METHOHEXITAL SODIUM			
Inj 10 mg per ml, 50 ml vial			

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
PROPOFOL			
Inj 10 mg per ml, 20 ml ampoule	7.60	5	Fresofol 1%
Inj 10 mg per ml, 20 ml vial	7.60	5	Provive MCT-LCT 1%
	42.00		Diprivan
Inj 10 mg per ml, 50 ml syringe	47.00	1	Diprivan
Inj 10 mg per ml, 50 ml vial	4.00	1	Fresofol 1%
	25.00		Provive MCT-LCT 1%
			Diprivan
Inj 10 mg per ml, 100 ml vial	7.60	1	Fresofol 1%
			Provive MCT-LCT 1%
SEVOFLURANE			
Soln for inhalation 100%, 250 ml bottle	1,230.00	6	Baxter
THIOPENTAL [THIOPENTONE] SODIUM			
Inj 500 mg ampoule			
Local Anaesthetics			
ARTICAINE HYDROCHLORIDE			
Inj 1%			
ARTICAINE HYDROCHLORIDE WITH ADRENALINE			
Inj 4% with adrenaline 1:100,000, 1.7 ml dental cartridge			
Inj 4% with adrenaline 1:100,000, 2.2 ml dental cartridge			
Inj 4% with adrenaline 1:200,000, 1.7 ml dental cartridge			
Inj 4% with adrenaline 1:200,000, 2.2 ml dental cartridge			
BENZOCAINE			
Gel 20%			
BUPIVACAINE HYDROCHLORIDE			
Inj 5 mg per ml, 4 ml ampoule – 1% DV Jul-14 to 2017	50.00	5	Marcaïn Isobaric
Inj 2.5 mg per ml, 20 ml ampoule			
Inj 2.5 mg per ml, 20 ml ampoule sterile pack – 1% DV Sep-15 to 2018	29.20	5	Marcaïn
Inj 5 mg per ml, 10 ml ampoule sterile pack – 1% DV Sep-15 to 2018	20.25	5	Marcaïn
Inj 5 mg per ml, 20 ml ampoule			
Inj 5 mg per ml, 20 ml ampoule sterile pack – 1% DV Sep-15 to 2018	20.70	5	Marcaïn
Inj 1.25 mg per ml, 100 ml bag			
Inj 1.25 mg per ml, 200 ml bag			
Inj 2.5 mg per ml, 100 ml bag – 1% DV Jul-14 to 2017	150.00	5	Marcaïn
Inj 2.5 mg per ml, 200 ml bag			
Inj 1.25 mg per ml, 500 ml bag			
BUPIVACAINE HYDROCHLORIDE WITH ADRENALINE			
Inj 2.5 mg per ml with adrenaline 1:400,000, 20 ml vial – 1% DV Sep-14 to 2017	135.00	5	Marcaïn with Adrenaline
Inj 5 mg per ml with adrenaline 1:200,000, 20 ml vial – 1% DV Sep-14 to 2017	115.00	5	Marcaïn with Adrenaline

NERVOUS SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
BUPIVACAINE HYDROCHLORIDE WITH FENTANYL			
Inj 0.625 mg with fentanyl 2 mcg per ml, 100 ml bag			
Inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml syringe			
Inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml bag	210.00	10	Bupafen
Inj 1.25 mg with fentanyl 2 mcg per ml, 200 ml bag	210.00	10	Bupafen
Inj 1.25 mg with fentanyl 2 mcg per ml, 50 ml syringe			
Inj 1.25 mg with fentanyl 2 mcg per ml, 15 ml syringe	72.00	10	Biomed
Inj 1.25 mg with fentanyl 2 mcg per ml, 20 ml syringe	92.00	10	Biomed
BUPIVACAINE HYDROCHLORIDE WITH GLUCOSE			
Inj 0.5% with glucose 8%, 4 ml ampoule	38.00	5	Marcaïn Heavy
COCAINE HYDROCHLORIDE			
Paste 5%			
Soln 15%, 2 ml syringe			
Soln 4%, 2 ml syringe	25.46	1	Biomed
COCAINE HYDROCHLORIDE WITH ADRENALINE			
Paste 15% with adrenaline 0.06%			
Paste 25% with adrenaline 0.06%			
ETHYL CHLORIDE			
Spray 100%			
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE			
Gel 2% – 1% DV Sep-15 to 2018	3.40	20 ml	Orion
Soln 4%			
Spray 10% – 1% DV Sep-13 to 2016	75.00	50 ml	Xylocaine
Oral (viscous) soln 2% – 1% DV Sep-14 to 2017	55.00	200 ml	Xylocaine Viscous
Inj 1%, 20 ml ampoule, sterile pack			
Inj 2%, 20 ml ampoule, sterile pack			
Inj 1%, 5 ml ampoule	8.75	25	Lidocaine-Claris
Inj 1%, 20 ml ampoule	2.40	1	Lidocaine-Claris
Inj 2%, 5 ml ampoule	6.90	25	Lidocaine-Claris
Inj 2%, 20 ml ampoule	2.40	1	Lidocaine-Claris
Gel 2%, 10 ml urethral syringe	43.26	10	Pfizer
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE			
Inj 1% with adrenaline 1:100,000, 5 ml ampoule	27.00	10	Xylocaine
Inj 1% with adrenaline 1:200,000, 20 ml vial	50.00	5	Xylocaine
Inj 2% with adrenaline 1:80,000, 1.7 ml dental cartridge			
Inj 2% with adrenaline 1:80,000, 1.8 ml dental cartridge			
Inj 2% with adrenaline 1:80,000, 2.2 ml dental cartridge			
Inj 2% with adrenaline 1:200,000, 20 ml vial	60.00	5	Xylocaine
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE AND TETRACAINE HYDROCHLORIDE			
Soln 4% with adrenaline 0.1% and tetracaine hydrochloride 0.5%, 5 ml syringe – 1% DV Oct-14 to 2017	17.50	1	Topicaïne
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH CHLORHEXIDINE			
Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringe	43.26	10	Pfizer
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH PHENYLEPHRINE HYDROCHLORIDE			
Nasal spray 5% with phenylephrine hydrochloride 0.5%			

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
LIDOCAINE [LIGNOCAINE] WITH PRILOCAINE			
Crn 2.5% with prilocaine 2.5%	45.00	30 g	EMLA
Patch 25 mcg with prilocaine 25 mcg	115.00	20	EMLA
Crn 2.5% with prilocaine 2.5%, 5 g	45.00	5	EMLA
LIDOCAINE [LIGNOCAINE]			
Crn 4%	27.00	30 g	LMX4
Crn 4% (5 g tubes)	27.00	5	LMX4
MEPIVACAINE HYDROCHLORIDE			
Inj 3%, 1.8 ml dental cartridge – 1% DV Oct-14 to 2017	43.60	50	Scandonest 3%
Inj 3%, 2.2 ml dental cartridge – 1% DV Oct-14 to 2017	43.60	50	Scandonest 3%
PRILOCAINE HYDROCHLORIDE			
Inj 0.5%, 50 ml vial	100.00	5	Citanest
Inj 2%, 5 ml ampoule	55.00	10	Citanest
PRILOCAINE HYDROCHLORIDE WITH FELYPRESSIN			
Inj 3% with felypressin 0.03 iu per ml, 1.8 ml dental cartridge			
Inj 3% with felypressin 0.03 iu per ml, 2.2 ml dental cartridge			
ROPIVACAINE HYDROCHLORIDE			
Inj 2 mg per ml, 10 ml ampoule – 1% DV Aug-15 to 2017	9.05	5	Ropivacaine Kabi
Inj 2 mg per ml, 20 ml ampoule – 1% DV Aug-15 to 2017	9.50	5	Ropivacaine Kabi
Inj 2 mg per ml, 100 ml bag – 1% DV Jul-15 to 2017	60.00	5	Naropin
Inj 2 mg per ml, 200 ml bag – 1% DV Jul-15 to 2017	79.50	5	Naropin
Inj 7.5 mg per ml, 10 ml ampoule – 1% DV Aug-15 to 2017	10.20	5	Ropivacaine Kabi
Inj 7.5 mg per ml, 20 ml ampoule – 1% DV Aug-15 to 2017	12.50	5	Ropivacaine Kabi
Inj 10 mg per ml, 10 ml ampoule – 1% DV Aug-15 to 2017	10.90	5	Ropivacaine Kabi
Inj 10 mg per ml, 20 ml ampoule – 1% DV Aug-15 to 2017	16.30	5	Ropivacaine Kabi
ROPIVACAINE HYDROCHLORIDE WITH FENTANYL			
Inj 2 mg with fentanyl 2 mcg per ml, 100 ml bag	198.50	5	Naropin
Inj 2 mg with fentanyl 2 mcg per ml, 200 ml bag	270.00	5	Naropin
TETRACAINE [AMETHOCAINE] HYDROCHLORIDE			
Gel 4%			

Analgesics

Non-Opioid Analgesics

ASPIRIN

- Tab EC 300 mg
- Tab dispersible 300 mg

CAPSAICIN – Restricted see terms below

⚡ Crn 0.075% 12.50 45 g Zostrix HP

➔ **Restricted**

For post-herpetic neuralgia or diabetic peripheral neuropathy

METHOXYFLURANE – Restricted see terms below

⚡ Soln for inhalation 99.9%, 3 ml bottle

➔ **Restricted**

Both:

- 1 Patient is undergoing a painful procedure with an expected duration of less than one hour; and
- 2 Only to be used under supervision by a medical practitioner or nurse who is trained in the use of methoxyflurane.

NERVOUS SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
NEFOPAM HYDROCHLORIDE			
Tab 30 mg			
PARACETAMOL – Some items restricted see terms below			
Tab soluble 500 mg – 1% DV Oct-15 to 2017.....	1.60	20	Paragesic Soluble
Tab 500 mg			
Oral liq 120 mg per 5 ml – 20% DV Oct-14 to 2017.....	4.15	1,000 ml	Paracare
Oral liq 250 mg per 5 ml – 20% DV Sep-14 to 2017.....	4.35	1,000 ml	Paracare Double Strength
⚡ Inj 10 mg per ml, 50 ml vial – 1% DV Sep-14 to 2017.....	12.90	12	Perfalgan
⚡ Inj 10 mg per ml, 100 ml vial – 1% DV Sep-14 to 2017.....	12.90	12	Perfalgan
Suppos 25 mg.....	56.35	20	Biomed
Suppos 50 mg.....	56.35	20	Biomed
Suppos 125 mg – 1% DV Dec-15 to 2018.....	3.69	10	Gacet
Suppos 250 mg – 1% DV Dec-15 to 2018.....	3.79	10	Gacet
Suppos 500 mg – 1% DV Nov-15 to 2018.....	12.60	50	Paracare
➔ Restricted			
Intravenous paracetamol is only to be used where other routes are unavailable or impractical, or where there is reduced absorption. The need for IV paracetamol must be re-assessed every 24 hours.			
SUCROSE			
Oral liq 25%			
Opioid Analgesics			
ALFENTANIL			
Inj 0.5 mg per ml, 2 ml ampoule – 1% DV Jan-15 to 2017.....	39.07	10	Hamelin
CODEINE PHOSPHATE			
Tab 15 mg – 1% DV Jul-13 to 2016.....	4.75	100	PSM
Tab 30 mg – 1% DV Jul-13 to 2016.....	5.80	100	PSM
Tab 60 mg – 1% DV Jul-13 to 2016.....	12.50	100	PSM
DIHYDROCODEINE TARTRATE			
Tab long-acting 60 mg – 1% DV Sep-13 to 2016.....	13.64	60	DHC Continus
FENTANYL			
Inj 10 mcg per ml, 10 ml syringe			
Inj 50 mcg per ml, 2 ml ampoule – 1% DV Sep-15 to 2018.....	3.95	10	Boucher and Muir
Inj 10 mcg per ml, 50 ml bag.....	210.00	10	Biomed
Inj 10 mcg per ml, 50 ml syringe.....	165.00	10	Biomed
Inj 50 mcg per ml, 10 ml ampoule – 1% DV Sep-15 to 2018.....	10.45	10	Boucher and Muir
Inj 10 mcg per ml, 100 ml bag.....	210.00	10	Biomed
Inj 20 mcg per ml, 50 ml syringe.....	185.00	10	Biomed
Inj 20 mcg per ml, 100 ml bag.....			
Patch 12.5 mcg per hour – 1% DV Aug-15 to 2016.....	2.92	5	Fentanyl Sandoz
Patch 25 mcg per hour – 1% DV Aug-15 to 2016.....	3.66	5	Fentanyl Sandoz
Patch 50 mcg per hour – 1% DV Aug-15 to 2016.....	6.64	5	Fentanyl Sandoz
Patch 75 mcg per hour – 1% DV Aug-15 to 2016.....	9.18	5	Fentanyl Sandoz
Patch 100 mcg per hour – 1% DV Aug-15 to 2016.....	11.29	5	Fentanyl Sandoz

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
METHADONE HYDROCHLORIDE			
Tab 5 mg – 1% DV Sep-15 to 2018	1.85	10	Methatabs
Oral liq 2 mg per ml – 1% DV Sep-15 to 2018.....	5.55	200 ml	Biodone
Oral liq 5 mg per ml – 1% DV Sep-15 to 2018.....	5.00	200 ml	Biodone Forte
Oral liq 10 mg per ml – 1% DV Sep-15 to 2018.....	6.55	200 ml	Biodone Extra Forte
Inj 10 mg per ml, 1 ml vial	61.00	10	AFT
MORPHINE HYDROCHLORIDE			
Oral liq 1 mg per ml – 1% DV Oct-15 to 2018.....	8.84	200 ml	RA-Morph
Oral liq 2 mg per ml – 1% DV Oct-15 to 2018.....	14.00	200 ml	RA-Morph
Oral liq 5 mg per ml – 1% DV Oct-15 to 2018.....	18.00	200 ml	RA-Morph
Oral liq 10 mg per ml – 1% DV Oct-15 to 2018.....	26.00	200 ml	RA-Morph
MORPHINE SULPHATE			
Tab long-acting 10 mg – 1% DV Sep-13 to 2016.....	1.95	10	Arrow-Morphine LA
Tab immediate-release 10 mg – 1% DV Apr-15 to 2017	2.80	10	Sevredol
Tab immediate-release 20 mg – 1% DV Apr-15 to 2017	5.52	10	Sevredol
Tab long-acting 30 mg – 1% DV Sep-13 to 2016.....	2.98	10	Arrow-Morphine LA
Tab long-acting 60 mg – 1% DV Sep-13 to 2016.....	5.75	10	Arrow-Morphine LA
Tab long-acting 100 mg – 1% DV Sep-13 to 2016.....	6.45	10	Arrow-Morphine LA
Cap long-acting 10 mg – 1% DV Feb-14 to 2016	1.70	10	m-Eslon
Cap long-acting 30 mg – 1% DV Feb-14 to 2016	2.50	10	m-Eslon
Cap long-acting 60 mg – 1% DV Feb-14 to 2016	5.40	10	m-Eslon
Cap long-acting 100 mg – 1% DV Feb-14 to 2016	6.38	10	m-Eslon
Inj 1 mg per ml, 100 ml bag – 1% DV Oct-14 to 2017	185.00	10	Biomed
Inj 1 mg per ml, 10 ml syringe – 1% DV Oct-14 to 2017.....	45.00	10	Biomed
Inj 1 mg per ml, 50 ml syringe – 1% DV Oct-14 to 2017.....	87.50	10	Biomed
Inj 1 mg per ml, 2 ml syringe			
Inj 2 mg per ml, 30 ml syringe	135.00	10	Biomed
Inj 5 mg per ml, 1 ml ampoule – 1% DV Oct-14 to 2017	12.48	5	DBL Morphine Sulphate
Inj 10 mg per ml, 1 ml ampoule – 1% DV Oct-14 to 2017	9.09	5	DBL Morphine Sulphate
Inj 10 mg per ml, 100 mg cassette			
Inj 10 mg per ml, 100 ml bag			
Inj 15 mg per ml, 1 ml ampoule – 1% DV Oct-14 to 2017	9.77	5	DBL Morphine Sulphate
Inj 30 mg per ml, 1 ml ampoule – 1% DV Oct-14 to 2017	12.43	5	DBL Morphine Sulphate
Inj 200 mcg in 0.4 ml syringe			
Inj 300 mcg in 0.3 ml syringe			
MORPHINE TARTRATE			
Inj 80 mg per ml, 1.5 ml ampoule – 1% DV Sep-13 to 2016.....	35.60	5	Hospira
Inj 80 mg per ml, 5 ml ampoule – 1% DV Sep-13 to 2016.....	107.67	5	Hospira

NERVOUS SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
OXYCODONE HYDROCHLORIDE			
Tab controlled-release 5 mg	7.51	20	OxyContin
Tab controlled-release 10 mg	6.75	20	Oxycodone ControlledRelease Tablets(BNM)
Tab controlled-release 20 mg	11.50	20	Oxycodone ControlledRelease Tablets(BNM)
Tab controlled-release 40 mg	18.50	20	Oxycodone ControlledRelease Tablets(BNM)
Tab controlled-release 80 mg	34.00	20	Oxycodone ControlledRelease Tablets(BNM)
Cap immediate-release 5 mg – 1% DV Oct-15 to 2018	1.98	20	OxyNorm
Cap immediate-release 10 mg – 1% DV Oct-15 to 2018	3.91	20	OxyNorm
Cap immediate-release 20 mg – 1% DV Oct-15 to 2018	6.84	20	OxyNorm
Oral liq 5 mg per 5 ml	11.20	250 ml	OxyNorm
Inj 1 mg per ml, 100 ml bag			
Inj 10 mg per ml, 1 ml ampoule – 1% DV Feb-16 to 2018	8.57	5	OxyNorm
	10.08		Oxycodone Orion
Inj 10 mg per ml, 2 ml ampoule – 1% DV Feb-16 to 2018	16.89	5	OxyNorm
	19.87		Oxycodone Orion
Inj 50 mg per ml, 1 ml ampoule – 1% DV Dec-15 to 2018	51.00	5	OxyNorm
<i>(Oxycodone Orion Inj 10 mg per ml, 1 ml ampoule to be delisted 1 February 2016)</i>			
<i>(Oxycodone Orion Inj 10 mg per ml, 2 ml ampoule to be delisted 1 February 2016)</i>			
PARACETAMOL WITH CODEINE			
Tab paracetamol 500 mg with codeine phosphate 8 mg	2.11	100	Paracetamol + Codeine (Relieve)
PETHIDINE HYDROCHLORIDE			
Tab 50 mg – 1% DV Nov-15 to 2018	4.46	10	PSM
Tab 100 mg – 1% DV Nov-15 to 2018	6.25	10	PSM
Inj 5 mg per ml, 10 ml syringe			
Inj 5 mg per ml, 100 ml bag			
Inj 10 mg per ml, 100 ml bag			
Inj 10 mg per ml, 50 ml syringe			
Inj 50 mg per ml, 1 ml ampoule – 1% DV Sep-14 to 2017	5.51	5	DBL Pethidine Hydrochloride
Inj 50 mg per ml, 2 ml ampoule – 1% DV Sep-14 to 2017	5.83	5	DBL Pethidine Hydrochloride
REMIFENTANIL HYDROCHLORIDE			
Inj 1 mg vial – 1% DV Nov-14 to 2017	10.00	5	Ultiva
Inj 2 mg vial – 1% DV Nov-14 to 2017	18.00	5	Ultiva

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
TRAMADOL HYDROCHLORIDE			
Tab sustained-release 100 mg – 1% DV Oct-14 to 2017	2.00	20	Tramal SR 100
Tab sustained-release 150 mg – 1% DV Oct-14 to 2017	3.00	20	Tramal SR 150
Tab sustained-release 200 mg – 1% DV Oct-14 to 2017	4.00	20	Tramal SR 200
Cap 50 mg – 1% DV Oct-14 to 2017	2.50	100	Arrow-Tramadol
Oral drops 100 mg per ml			
Inj 10 mg per ml, 100 ml bag			
Inj 50 mg per ml, 1 ml ampoule – 1% DV Oct-14 to 2017	4.50	5	Tramal 50
Inj 50 mg per ml, 2 ml ampoule – 1% DV Oct-14 to 2017	4.50	5	Tramal 100

Antidepressants

Cyclic and Related Agents

AMITRIPTYLINE			
Tab 10 mg – 1% DV Sep-14 to 2017	1.68	100	Arrow-Amitriptyline
Tab 25 mg – 1% DV Jan-15 to 2017	1.68	100	Arrow-Amitriptyline
Tab 50 mg – 1% DV Jan-15 to 2017	2.82	100	Arrow-Amitriptyline

CLOMIPRAMINE HYDROCHLORIDE			
Tab 10 mg – 1% DV Sep-15 to 2018	12.60	100	Apo-Clomipramine
Tab 25 mg – 1% DV Sep-15 to 2018	8.68	100	Apo-Clomipramine

DOTHIPIIN HYDROCHLORIDE			
Tab 75 mg	10.50	100	Dopress
Cap 25 mg	6.17	100	Dopress

DOXEPIN HYDROCHLORIDE			
Cap 10 mg			
Cap 25 mg			
Cap 50 mg			

IMIPRAMINE HYDROCHLORIDE			
Tab 10 mg	5.48	50	Tofranil
	6.58	60	Tofranil
Tab 25 mg	8.80	50	Tofranil

MAPROTILINE HYDROCHLORIDE			
Tab 25 mg			
Tab 75 mg			

MIANSERIN HYDROCHLORIDE			
For continuation only			
➔ Tab 30 mg			

NORTRIPTYLINE HYDROCHLORIDE			
Tab 10 mg – 1% DV Jun-13 to 2016	4.00	100	Norpress
Tab 25 mg – 1% DV Jun-13 to 2016	9.00	180	Norpress

Monoamine-Oxidase Inhibitors - Non-Selective

PHENELZINE SULPHATE			
Tab 15 mg			

TRANLYCYPROMINE SULPHATE			
Tab 10 mg			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Monoamine-Oxidase Type A Inhibitors			
MOCLOBEMIDE			
Tab 150 mg – 1% DV Oct-15 to 2018	85.10	500	Apo-Moclobemide
Tab 300 mg – 1% DV Oct-15 to 2018	30.70	100	Apo-Moclobemide
Other Antidepressants			
MIRTAZAPINE			
Tab 30 mg – 1% DV Nov-15 to 2018	2.55	30	Apo-Mirtazapine
Tab 45 mg – 1% DV Nov-15 to 2018	3.25	30	Apo-Mirtazapine
VENLAFAXINE – Some items restricted see terms below			
Tab modified release 37.5 mg	5.06	28	Arrow-Venlafaxine XR
Tab modified release 75 mg	6.44	28	Arrow-Venlafaxine XR
Tab modified release 150 mg	8.86	28	Arrow-Venlafaxine XR
Tab modified release 225 mg	14.34	28	Arrow-Venlafaxine XR
⚡ Cap modified release 37.5 mg	5.69	28	Efexor XR
⚡ Cap modified release 75 mg	11.40	28	Efexor XR
⚡ Cap modified release 150 mg	13.98	28	Efexor XR
➔Restricted			
Initiation			
<i>Re-assessment required after two years</i>			
Both:			
1 The patient has 'treatment-resistant' depression; and			
2 Either:			
2.1 The patient must have had a trial of two different antidepressants and have had an inadequate response from an adequate dose over an adequate period of time (usually at least four weeks); or			
2.2 Both:			
2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and			
2.2.2 The patient must have had a trial of one other antidepressant and have had an inadequate response from an adequate dose over an adequate period of time.			
Continuation			
<i>Re-assessment required after two years</i>			
The patient has a high risk of relapse (prescriber determined)			
Selective Serotonin Reuptake Inhibitors			
CITALOPRAM HYDROBROMIDE			
Tab 20 mg – 1% DV Jan-16 to 2018	1.79	84	PSM Citalopram
ESCITALOPRAM			
Tab 10 mg – 1% DV Jul-15 to 2016	1.40	28	Air Flow Products
Tab 20 mg – 1% DV Jul-15 to 2016	2.40	28	Air Flow Products
FLUOXETINE HYDROCHLORIDE			
Tab dispersible 20 mg, scored – 1% DV Apr-14 to 2016	2.50	30	Arrow-Fluoxetine
Cap 20 mg – 1% DV Apr-14 to 2016	1.74	90	Arrow-Fluoxetine
PAROXETINE HYDROCHLORIDE			
Tab 20 mg	4.32	90	Loxamine
SERTRALINE			
Tab 50 mg	3.64	90	Arrow-Sertraline
Tab 100 mg – 1% DV Sep-13 to 2016	6.28	90	Arrow-Sertraline

↑ Item restricted (see ➔ above); ⚡ Item restricted (see ➔ below)

Price
(ex man. excl. GST)
\$ Per Brand or
Generic
Manufacturer

Antiepilepsy Drugs

Agents for the Control of Status Epilepticus

CLONAZEPAM		
Inj 1 mg per ml, 1 ml ampoule	19.00	5 Rivotril
DIAZEPAM		
Inj 5 mg per ml, 2 ml ampoule	11.83	5 Hospira
Rectal tubes 5 mg	25.05	5 Stesolid
Rectal tubes 10 mg	30.50	5 Stesolid
LORAZEPAM		
Inj 2 mg vial		
Inj 4 mg per ml, 1 ml vial		
PARALDEHYDE		
Inj 5 ml ampoule		
PHENYTOIN SODIUM		
Inj 50 mg per ml, 2 ml ampoule – 1% DV Oct-15 to 2018	88.63	5 Hospira
Inj 50 mg per ml, 5 ml ampoule – 1% DV Oct-15 to 2018	133.92	5 Hospira

Control of Epilepsy

CARBAMAZEPINE		
Tab 200 mg	14.53	100 Tegretol
Tab long-acting 200 mg	16.98	100 Tegretol CR
Tab 400 mg	34.58	100 Tegretol
Tab long-acting 400 mg	39.17	100 Tegretol CR
Oral liq 20 mg per ml	26.37	250 ml Tegretol
CLOBAZAM		
Tab 10 mg		
CLONAZEPAM		
Oral drops 2.5 mg per ml		
ETHOSUXIMIDE		
Cap 250 mg		
Oral liq 50 mg per ml		
GABAPENTIN – Restricted see terms on the next page		
⚡ Cap 100 mg	7.16	100 Arrow-Gabapentin Neurontin Nupentin
⚡ Cap 300 mg	11.00	100 Arrow-Gabapentin Neurontin Nupentin
⚡ Cap 400 mg	13.75	100 Arrow-Gabapentin Neurontin Nupentin

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

➔ **Restricted**

- 1 For preoperative and/or postoperative use for up to a total of 8 days' use; or
- 2 For the pain management of burns patients with monthly review.

Initiation - epilepsy

Re-assessment required after 15 months

Either:

- 1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
- 2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents.

Note: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Continuation - epilepsy

Patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life.

Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

Initiation - Neuropathic pain or Chronic Kidney Disease-associated pruritus

Re-assessment required after 3 months

Either:

- 1 The patient has been diagnosed with neuropathic pain; or
- 2 Both:
 - 2.1 The patient has Chronic Kidney Disease Stage 5-associated pruritus* where no other cause for pruritus can be identified (e.g. scabies, allergy); and
 - 2.2 The patient has persistent pruritus not relieved with a trial of emollient/moisturising creams alone.

Continuation - Neuropathic pain or Chronic Kidney Disease-associated pruritus

Either:

- 1 The patient has demonstrated a marked improvement in their control of pain or itch (prescriber determined); or
- 2 The patient has previously demonstrated clinical responsiveness to gabapentin and has now developed neuropathic pain in a new site.

Notes: Indications marked with * are Unapproved Indications. Dosage adjustment of gabapentin is recommended for patients with renal impairment.

LACOSAMIDE – **Restricted** see terms below

⚡ Tab 50 mg	25.04	14	Vimpat
⚡ Tab 100 mg	50.06	14	Vimpat
	200.24	56	Vimpat
⚡ Tab 150 mg	75.10	14	Vimpat
	300.40	56	Vimpat
⚡ Tab 200 mg	400.55	56	Vimpat
⚡ Inj 10 mg per ml, 20 ml vial			

➔ **Restricted**

Initiation

Re-assessment required after 15 months

Both:

- 1 Patient has partial-onset epilepsy; and
- 2 Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note).

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
continued. . .			
Note: "Optimal treatment" is defined as treatment which is indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Women of childbearing age are not required to have a trial of sodium valproate.			
Continuation			
Patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life compared with that prior to starting lamotrigine treatment (see Note).			
Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.			
LAMOTRIGINE			
Tab dispersible 2 mg	6.74	30	Lamictal
Tab dispersible 5 mg	9.64	30	Lamictal
	15.00	56	Arrow-Lamotrigine
Tab dispersible 25 mg	19.38	56	Logem
	20.40		Arrow-Lamotrigine
	29.09		Lamictal
Tab dispersible 50 mg	32.97	56	Logem
	34.70		Arrow-Lamotrigine
	47.89		Lamictal
Tab dispersible 100 mg	56.91	56	Logem
	59.90		Arrow-Lamotrigine
	79.16		Lamictal
LEVETIRACETAM			
Tab 250 mg	24.03	60	Levetiracetam-Rex
Tab 500 mg	28.71	60	Levetiracetam-Rex
Tab 750 mg	45.23	60	Levetiracetam-Rex
Inj 100 mg per ml, 5 ml vial			
PHENOBARBITONE			
Tab 15 mg – 1% DV Dec-15 to 2018	30.00	500	PSM
Tab 30 mg – 1% DV Dec-15 to 2018	31.00	500	PSM
PHENYTOIN			
Tab 50 mg			
PHENYTOIN SODIUM			
Cap 30 mg			
Cap 100 mg			
Oral liq 6 mg per ml			
PRIMIDONE			
Tab 250 mg			
SODIUM VALPROATE			
Tab 100 mg			
Tab EC 200 mg			
Tab EC 500 mg			
Oral liq 40 mg per ml			
Inj 100 mg per ml, 4 ml vial – 1% DV Sep-15 to 2018	16.60	1	Epilim IV
STIRIPENTOL – Restricted see terms on the next page			
⚡ Cap 250 mg	509.29	60	Diacomit
⚡ Powder for oral liq 250 mg sachet	509.29	60	Diacomit

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
➔Restricted			
Paediatric neurologist			
Initiation			
<i>Re-assessment required after 6 months</i>			
Both:			
1 Patient has confirmed diagnosis of Dravet syndrome; and			
2 Seizures have been inadequately controlled by appropriate courses of sodium valproate, clobazam and at least two of the following: topiramate, levetiracetam, ketogenic diet.			
Continuation			
Patient continues to benefit from treatment as measured by reduced seizure frequency from baseline.			
TOPIRAMATE			
Tab 25 mg	11.07	60	Arrow-Topiramate Topiramate Actavis
	26.04		Topamax
Tab 50 mg	18.81	60	Arrow-Topiramate Topiramate Actavis
	44.26		Topamax
Tab 100 mg	31.99	60	Arrow-Topiramate Topiramate Actavis
	75.25		Topamax
Tab 200 mg	55.19	60	Arrow-Topiramate Topiramate Actavis
	129.85		Topamax
Cap sprinkle 15 mg	20.84	60	Topamax
Cap sprinkle 25 mg	26.04	60	Topamax

VIGABATRIN – Restricted see terms below

⚡ Tab 500 mg

➔Restricted

Both:

- 1 Either:
 - 1.1 Patient has infantile spasms; or
 - 1.2 Both:
 - 1.2.1 Patient has epilepsy; and
 - 1.2.2 Either:
 - 1.2.2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
 - 1.2.2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; and
- 2 Either:
 - 2.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6-monthly basis thereafter); or
 - 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes:

"Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Antimigraine Preparations			
Acute Migraine Treatment			
DIHYDROERGOTAMINE MESYLATE Inj 1 mg per ml, 1 ml ampoule			
ERGOTAMINE TARTRATE WITH CAFFEINE Tab 1 mg with caffeine 100 mg			
METOCLOPRAMIDE HYDROCHLORIDE WITH PARACETAMOL Tab 5 mg with paracetamol 500 mg			
RIZATRIPTAN Tab orodispersible 10 mg – 1% DV Sep-14 to 2017 8.10 30 Rizamelt			
SUMATRIPTAN Tab 50 mg – 1% DV Sep-13 to 2016 29.80 100 Arrow-Sumatriptan Tab 100 mg – 1% DV Sep-13 to 2016 54.80 100 Arrow-Sumatriptan Inj 12 mg per ml, 0.5 ml cartridge 13.80 2 Arrow-Sumatriptan			
Prophylaxis of Migraine			
PIZOTIFEN Tab 500 mcg – 1% DV Sep-15 to 2018 23.21 100 Sandomigran			
Antinausea and Vertigo Agents			
APREPITANT – Restricted see terms below ⚡ Cap 2 × 80 mg and 1 × 125 mg – 1% DV Sep-14 to 2017 100.00 3 Emend Tri-Pack ➡ Restricted Patient is undergoing highly emetogenic chemotherapy and/or anthracycline-based chemotherapy for the treatment of malignancy.			
BETAHISTINE DIHYDROCHLORIDE Tab 16 mg – 1% DV Jun-14 to 2017 4.95 84 Vergo 16			
CYCLIZINE HYDROCHLORIDE Tab 50 mg – 1% DV Jan-16 to 2018 0.59 20 Nauzene			
CYCLIZINE LACTATE Inj 50 mg per ml, 1 ml ampoule 14.95 5 Nausicalm			
DOMPERIDONE Tab 10 mg – 1% DV Dec-15 to 2018 3.20 100 Prokinex			
DROPERIDOL Inj 2.5 mg per ml, 1 ml ampoule			
GRANISETRON Tab 1 mg – 1% DV Jan-15 to 2017 5.98 50 Granirex			
HYOSCINE HYDROBROMIDE Inj 400 mcg per ml, 1 ml ampoule 46.50 5 Hospira ⚡ Patch 1.5 mg – 1% DV Dec-13 to 2016 11.95 2 Scopoderm TTS			

NERVOUS SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
➔Restricted			
Any of the following:			
1 Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease where the patient cannot tolerate or does not adequately respond to oral anti-nausea agents; or			
2 Control of clozapine-induced hypersalivation where trials of at least two other alternative treatments have proven ineffective; or			
3 For treatment of post-operative nausea and vomiting where cyclizine, droperidol and a 5HT ₃ antagonist have proven ineffective, are not tolerated or are contraindicated.			
METOCLOPRAMIDE HYDROCHLORIDE			
Tab 10 mg – 1% DV Sep-14 to 2017	1.82	100	Metamide
Oral liq 5 mg per 5 ml			
Inj 5 mg per ml, 2 ml ampoule – 1% DV Sep-14 to 2017	4.50	10	Pfizer
ONDANSETRON			
Tab 4 mg – 1% DV Jan-14 to 2016	5.51	50	Onrex
Tab dispersible 4 mg – 1% DV Oct-14 to 2017	1.00	10	Dr Reddy's Ondansetron
Tab 8 mg – 1% DV Jan-14 to 2016	6.19	50	Onrex
Tab dispersible 8 mg – 1% DV Oct-14 to 2017	1.50	10	Ondansetron ODT-DRLA
Inj 2 mg per ml, 2 ml ampoule – 1% DV Sep-13 to 2016	1.82	5	Ondanaccord
Inj 2 mg per ml, 4 ml ampoule – 1% DV Sep-13 to 2016	2.18	5	Ondanaccord
PROCHLORPERAZINE			
Tab buccal 3 mg			
Tab 5 mg – 1% DV Jun-14 to 2017	9.75	500	Antinaus
Inj 12.5 mg per ml, 1 ml ampoule			
Suppos 25 mg			
PROMETHAZINE THEOCLATE			
For continuation only			
➔ Tab 25 mg			
TROPISETRON			
Inj 1 mg per ml, 2 ml ampoule – 1% DV Sep-15 to 2018	8.95	1	Tropisetron-AFT
Inj 1 mg per ml, 5 ml ampoule – 1% DV Sep-15 to 2018	13.95	1	Tropisetron-AFT

Antipsychotic Agents

General

AMISULPRIDE			
Tab 100 mg – 1% DV Jul-13 to 2016	6.22	30	Solian
Tab 200 mg – 1% DV Jul-13 to 2016	21.92	60	Solian
Tab 400 mg – 1% DV Jul-13 to 2016	44.52	60	Solian
Oral liq 100 mg per ml – 1% DV Jul-13 to 2016	52.50	60 ml	Solian
ARIPIPRAZOLE – Restricted see terms on the next page			
⚡ Tab 5 mg	123.54	30	Abilify
⚡ Tab 10 mg	123.54	30	Abilify
⚡ Tab 15 mg	175.28	30	Abilify
⚡ Tab 20 mg	213.42	30	Abilify
⚡ Tab 30 mg	260.07	30	Abilify

⚡ Item restricted (see ➔ above); ⚡ Item restricted (see ➔ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➔ **Restricted**

Initiation - schizophrenia or related psychoses

- Both:
- 1 Patient is suffering from schizophrenia or related psychoses; and
 - 2 Either:
 - 2.1 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of unacceptable side effects; or
 - 2.2 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of inadequate clinical response.

Initiation - Autism spectrum disorder*

Psychiatrist or paediatrician

All of the following:

- 1 The patient has been diagnosed with an autism spectrum disorder* and has symptoms of severe irritability; and
- 2 An effective dose of risperidone has been trialled and has been discontinued because of unacceptable side effects or inadequate response; and
- 3 The patient is aged less than 18 years.

Note: Indications marked with * are Unapproved Indications

CHLORPROMAZINE HYDROCHLORIDE

- Tab 10 mg
- Tab 25 mg
- Tab 100 mg
- Oral liq 10 mg per ml
- Inj 25 mg per ml, 2 ml ampoule

CLOZAPINE

Tab 25 mg	5.69	50	Clozaril
	11.36	100	Clozaril
	6.69	50	Clopine
	13.37	100	Clopine
Tab 50 mg	8.67	50	Clopine
	17.33	100	Clopine
Tab 100 mg	14.73	50	Clozaril
	29.45	100	Clozaril
	17.33	50	Clopine
	34.65	100	Clopine
Tab 200 mg	34.65	50	Clopine
	69.30	100	Clopine
Oral liq 50 mg per ml	17.33	100 ml	Clopine

HALOPERIDOL

Tab 500 mcg – 1% DV Oct-13 to 2016	6.23	100	Serenace
Tab 1.5 mg – 1% DV Oct-13 to 2016	9.43	100	Serenace
Tab 5 mg – 1% DV Oct-13 to 2016	29.72	100	Serenace
Oral liq 2 mg per ml – 1% DV Oct-13 to 2016	23.84	100 ml	Serenace
Inj 5 mg per ml, 1ml ampoule – 1% DV Oct-13 to 2016	21.55	10	Serenace

LEVOMEPRMAZINE

- Tab 25 mg
- Tab 100 mg
- Inj 25 mg per ml, 1 ml ampoule

NERVOUS SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
LITHIUM CARBONATE			
Tab long-acting 400 mg			
Tab 250 mg – 1% DV Sep-15 to 2018	34.30	500	Lithicarb FC
Tab 400 mg – 1% DV Sep-15 to 2018	12.83	100	Lithicarb FC
Cap 250 mg – 1% DV Sep-14 to 2017	9.42	100	Douglas
OLANZAPINE			
Tab 2.5 mg – 1% DV Sep-14 to 2017	0.75	28	Zypine
Tab 5 mg – 1% DV Sep-14 to 2017	1.65	28	Zypine
Tab orodispersible 5 mg – 1% DV Sep-14 to 2017	1.75	28	Zypine ODT
Tab 10 mg – 1% DV Sep-14 to 2017	2.55	28	Zypine
Tab orodispersible 10 mg – 1% DV Sep-14 to 2017	3.05	28	Zypine ODT
Inj 10 mg vial			
PERICYAZINE			
Tab 2.5 mg			
Tab 10 mg			
QUETIAPINE			
Tab 25 mg – 1% DV Sep-14 to 2017	2.10	90	Quetapel
Tab 100 mg – 1% DV Sep-14 to 2017	4.20	90	Quetapel
Tab 200 mg – 1% DV Sep-14 to 2017	7.20	90	Quetapel
Tab 300 mg – 1% DV Sep-14 to 2017	12.00	90	Quetapel
RISPERIDONE – Some items restricted see terms below			
Tab 0.5 mg – 1% DV Feb-15 to 2017	1.90	60	Actavis
⚡ Tab orodispersible 0.5 mg	21.42	28	Risperdal Quicklet
Tab 1 mg – 1% DV Feb-15 to 30 Sep 2017	2.10	60	Actavis
⚡ Tab orodispersible 1 mg	42.84	28	Risperdal Quicklet
Tab 2 mg – 1% DV Feb-15 to 2017	2.34	60	Actavis
⚡ Tab orodispersible 2 mg	85.71	28	Risperdal Quicklet
Tab 3 mg – 1% DV Feb-15 to 2017	2.55	60	Actavis
Tab 4 mg – 1% DV Feb-15 to 2017	3.50	60	Actavis
Oral liq 1 mg per ml – 1% DV Sep-14 to 2017	9.75	30 ml	Risperon
↪ Restricted			
Acute situations			
Both:			
1 For a non-adherent patient on oral therapy with standard risperidone tablets or risperidone oral liquid; and			
2 The patient is under direct supervision for administration of medicine.			
Chronic situations			
Both:			
1 The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid; and			
2 The patient is under direct supervision for administration of medicine.			
TRIFLUOPERAZINE HYDROCHLORIDE			
Tab 1 mg			
Tab 2 mg			
Tab 5 mg			

↑ Item restricted (see ↪ above); ⚡ Item restricted (see ↪ below)

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
ZIPRASIDONE			
⚡ Cap 20 mg – 1% DV Jan-16 to 2018	14.56	60	Zusdone
⚡ Cap 40 mg – 1% DV Jan-16 to 2018	24.75	60	Zusdone
⚡ Cap 60 mg – 1% DV Jan-16 to 2018	33.87	60	Zusdone
⚡ Cap 80 mg – 1% DV Jan-16 to 2018	39.74	60	Zusdone
Inj 20 mg			
Inj 100 mg			
<i>(Any Inj 20 mg to be delisted 1 March 2016)</i>			
<i>(Any Inj 100 mg to be delisted 1 March 2016)</i>			
ZUCLOPENTHIXOL ACETATE			
Inj 50 mg per ml, 1 ml ampoule			
Inj 50 mg per ml, 2 ml ampoule			
ZUCLOPENTHIXOL HYDROCHLORIDE			
Tab 10 mg	31.45	100	Clopixol

Depot Injections

FLUPENTHIXOL DECANOATE			
Inj 20 mg per ml, 1 ml ampoule	13.14	5	Fluanxol
Inj 20 mg per ml, 2 ml ampoule	20.90	5	Fluanxol
Inj 100 mg per ml, 1 ml ampoule	40.87	5	Fluanxol
FLUPHENAZINE DECANOATE			
Inj 12.5 mg per 0.5 ml ampoule	17.60	5	Modecate
Inj 25 mg per ml, 1 ml ampoule	27.90	5	Modecate
Inj 100 mg per ml, 1 ml ampoule	154.50	5	Modecate
HALOPERIDOL DECANOATE			
Inj 50 mg per ml, 1 ml ampoule	28.39	5	Haldol
Inj 100 mg per ml, 1 ml ampoule	55.90	5	Haldol Concentrate
OLANZAPINE – Restricted see terms below			
⚡ Inj 210 mg vial	280.00	1	Zyprexa Relprevv
⚡ Inj 300 mg vial	460.00	1	Zyprexa Relprevv
⚡ Inj 405 mg vial	560.00	1	Zyprexa Relprevv

➔ Restricted

Initiation

Re-assessment required after 12 months

Either:

- 1 The patient has had an initial Special Authority approval for risperidone depot injection or paliperidone depot injection; or
- 2 All of the following:
 - 2.1 The patient has schizophrenia; and
 - 2.2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
 - 2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

Continuation

Re-assessment required after 12 months

The initiation of olanzapine depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
PALIPERIDONE – Restricted see terms below			
‡ Inj 25 mg syringe	194.25	1	Invega Sustenna
‡ Inj 50 mg syringe	271.95	1	Invega Sustenna
‡ Inj 75 mg syringe	357.42	1	Invega Sustenna
‡ Inj 100 mg syringe	435.12	1	Invega Sustenna
‡ Inj 150 mg syringe	435.12	1	Invega Sustenna

➔ **Restricted**

Initiation

Re-assessment required after 12 months

Either:

- 1 The patient has had an initial Special Authority approval for risperidone depot injection or olanzapine depot injection; or
- 2 All of the following:
 - 2.1 The patient has schizophrenia or other psychotic disorder; and
 - 2.2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
 - 2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

Continuation

Re-assessment required after 12 months

The initiation of paliperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

PIPOTHIAZINE PALMITATE

For continuation only

- ➔ Inj 50 mg per ml, 1 ml ampoule
- ➔ Inj 50 mg per ml, 2 ml ampoule

RISPERIDONE – Restricted see terms below

‡ Inj 25 mg vial	135.98	1	Risperdal Consta
‡ Inj 37.5 mg vial	178.71	1	Risperdal Consta
‡ Inj 50 mg vial	217.56	1	Risperdal Consta

➔ **Restricted**

Initiation

Re-assessment required after 12 months

Either:

- 1 The patient has had an initial Special Authority approval for paliperidone depot injection or olanzapine depot injection; or
- 2 All of the following:
 - 2.1 The patient has schizophrenia or other psychotic disorder; and
 - 2.2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
 - 2.3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

Continuation

Re-assessment required after 12 months

The initiation of risperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of an atypical antipsychotic depot injection.

ZUCLOPENTHIXOL DECANOATE

Inj 200 mg per ml, 1 ml ampoule	19.80	5	Clopixol
Inj 500 mg per ml, 1 ml ampoule			<i>e.g. Clopixol Conc</i>

Price
(ex man. excl. GST)
\$ Per Brand or
Generic
Manufacturer

Anxiolytics

ALPRAZOLAM

- Tab 1 mg
- Tab 250 mcg
- Tab 500 mcg

BUSPIRONE HYDROCHLORIDE

- Tab 5 mg28.00 100 Pacific Buspirone
- Tab 10 mg17.00 100 Pacific Buspirone

CLONAZEPAM

- Tab 500 mcg7.53 100 Paxam
- Tab 2 mg14.37 100 Paxam

DIAZEPAM

- Tab 2 mg11.44 500 Arrow-Diazepam
- Tab 5 mg13.71 500 Arrow-Diazepam

LORAZEPAM

- Tab 1 mg – 1% DV Jun-15 to 201810.79 250 **Ativan**
- Tab 2.5 mg – 1% DV Jun-15 to 201813.88 100 **Ativan**

OXAZEPAM

- Tab 10 mg – 1% DV Dec-14 to 20176.17 100 **Ox-Pam**
- Tab 15 mg – 1% DV Dec-14 to 20178.53 100 **Ox-Pam**

Multiple Sclerosis Treatments

FINGOLIMOD – **Restricted** see terms below

- ⚡ Cap 0.5 mg2,650.00 28 Gilenya

➔ **Restricted**

Only for use in patients with approval by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (set out in Section B of the Pharmaceutical Schedule).

NATALIZUMAB – **Restricted** see terms below

- ⚡ Inj 20 mg per ml, 15 ml vial1,750.00 1 Tysabri

➔ **Restricted**

Only for use in patients with approval by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (set out in Section B of the Pharmaceutical Schedule).

Natalizumab can only be dispensed from a pharmacy registered in the Tysabri Australasian Prescribing Programme operated by the supplier.

Other Multiple Sclerosis Treatments

➔ **Restricted**

Only for use in patients with approval by the Multiple Sclerosis Treatment Assessment Committee (MSTAC). Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (set out in Section B of the Pharmaceutical Schedule).

GLATIRAMER ACETATE – **Restricted** see terms above

- ⚡ Inj 20 mg per ml, 1 ml syringe

INTERFERON BETA-1-ALPHA – **Restricted** see terms above

- ⚡ Inj 6 million iu in 0.5 ml pen injector1,170.00 4 Avonex Pen
- ⚡ Inj 6 million iu in 0.5 ml syringe1,170.00 4 Avonex
- ⚡ Inj 6 million iu vial1,170.00 4 Avonex

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

INTERFERON BETA-1-BETA – **Restricted** see terms on the preceding page

↑ Inj 8 million iu per ml, 1 ml vial

Sedatives and Hypnotics

CHLORAL HYDRATE

Oral liq 100 mg per ml

Oral liq 200 mg per ml

LORMETAZEPAM

For continuation only

➔ Tab 1 mg

MELATONIN – **Restricted** see terms below

⚡ Tab modified-release 2 mg

e.g. Circadin

⚡ Tab 1 mg

⚡ Tab 2 mg

⚡ Tab 3 mg

⚡ Cap 2 mg

⚡ Cap 3 mg

➔ **Restricted**

For in hospital use only. For the treatment of insomnia where benzodiazepines and zopiclone are contraindicated.

MIDAZOLAM

Tab 7.5 mg 40.00 100 Hypnovel

Oral liq 2 mg per ml

Inj 1 mg per ml, 5 ml ampoule 10.00 10 Pfizer

10.75

Inj 5 mg per ml, 3 ml ampoule 11.90 5 Hypnovel
Pfizer

NITRAZEPAM

Tab 5 mg – 1% DV Dec-14 to 2017 5.22 100 **Nitrados**

PHENOBARBITONE

Inj 200 mg per ml, 1 ml ampoule

TEMAZEPAM

Tab 10 mg – 1% DV Sep-14 to 2017 1.27 25 **Normison**

TRIAZOLAM

For continuation only

➔ Tab 125 mcg

➔ Tab 250 mcg

ZOPICLONE

Tab 7.5 mg – 1% DV Dec-15 to 2018 0.98 30 **Zopiclone Actavis**
8.99 500 **Zopiclone Actavis**

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Stimulants / ADHD Treatments

ATOMOXETINE – **Restricted** see terms below

⚡ Cap 10 mg	107.03	28	Strattera
⚡ Cap 18 mg	107.03	28	Strattera
⚡ Cap 25 mg	107.03	28	Strattera
⚡ Cap 40 mg	107.03	28	Strattera
⚡ Cap 60 mg	107.03	28	Strattera
⚡ Cap 80 mg	139.11	28	Strattera
⚡ Cap 100 mg	139.11	28	Strattera

➔ **Restricted**

All of the following:

- 1 Patient has ADHD (Attention Deficit and Hyperactivity Disorder) diagnosed according to DSM-IV or ICD 10 criteria; and
- 2 Once-daily dosing; and
- 3 Any of the following:
 - 3.1 Treatment with a subsidised formulation of a stimulant has resulted in the development or worsening of serious adverse reactions or where the combination of subsidised stimulant treatment with another agent would pose an unacceptable medical risk; or
 - 3.2 Treatment with a subsidised formulation of a stimulant has resulted in worsening of co-morbid substance abuse or there is a significant risk of diversion with subsidised stimulant therapy; or
 - 3.3 An effective dose of a subsidised formulation of a stimulant has been trialed and has been discontinued because of inadequate clinical response; or
 - 3.4 Treatment with a subsidised formulation of a stimulant is considered inappropriate because the patient has a history of psychoses or has a first-degree relative with schizophrenia; and
- 4 The patient will not be receiving treatment with atomoxetine in combination with a subsidised formulation of a stimulant, except for the purposes of transitioning from subsidised stimulant therapy to atomoxetine.

Note: A "subsidised formulation of a stimulant" refers to currently listed methylphenidate hydrochloride tablet formulations (immediate-release, sustained-release and extended-release) or dexamphetamine sulphate tablets.

CAFFEINE

Tab 100 mg

DEXAMFETAMINE SULFATE – **Restricted** see terms below

⚡ Tab 5 mg – 1% DV Dec-15 to 2018	17.00	100	PSM
---	-------	-----	------------

➔ **Restricted**

ADHD

Paediatrician or psychiatrist

Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed according to DSM-IV or ICD 10 criteria

Narcolepsy

Neurologist or respiratory specialist

Patient suffers from narcolepsy

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
METHYLPHENIDATE HYDROCHLORIDE – Restricted see terms below			
⚡ Tab extended-release 18 mg	58.96	30	Concerta
⚡ Tab extended-release 27 mg	65.44	30	Concerta
⚡ Tab extended-release 36 mg	71.93	30	Concerta
⚡ Tab extended-release 54 mg	86.24	30	Concerta
⚡ Tab immediate-release 5 mg	3.20	30	Rubifen
⚡ Tab immediate-release 10 mg	3.00	30	Ritalin
			Rubifen
⚡ Tab immediate-release 20 mg	7.85	30	Rubifen
⚡ Tab sustained-release 20 mg	10.95	30	Rubifen SR
	50.00	100	Ritalin SR
⚡ Cap modified-release 10 mg	15.60	30	Ritalin LA
⚡ Cap modified-release 20 mg	20.40	30	Ritalin LA
⚡ Cap modified-release 30 mg	25.52	30	Ritalin LA
⚡ Cap modified-release 40 mg	30.60	30	Ritalin LA

➡ Restricted

ADHD (immediate-release and sustained-release formulations)

Paediatrician or psychiatrist

Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed according to DSM-IV or ICD 10 criteria

Narcolepsy (immediate-release and sustained-release formulations)

Neurologist or respiratory specialist

Patient suffers from narcolepsy

Extended-release and modified-release formulations

Paediatrician or psychiatrist

Both:

- 1 Patient has ADHD (Attention Deficit and Hyperactivity Disorder), diagnosed according to DSM-IV or ICD 10 criteria; and
- 2 Either:
 - 2.1 Patient is taking a currently listed formulation of methylphenidate hydrochloride (immediate-release or sustained-release) which has not been effective due to significant administration and/or compliance difficulties; or
 - 2.2 There is significant concern regarding the risk of diversion or abuse of immediate-release methylphenidate hydrochloride.

MODAFINIL – Restricted

 see terms below

⚡ Tab 100 mg

➡ Restricted

Neurologist or respiratory specialist

All of the following:

- 1 The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more; and
- 2 Either:
 - 2.1 The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods; or
 - 2.2 The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations; and
- 3 Either:
 - 3.1 An effective dose of a listed formulation of methylphenidate or dexamphetamine has been trialled and discontinued because of intolerable side effects; or
 - 3.2 Methylphenidate and dexamphetamine are contraindicated.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Treatments for Dementia			
DONEPEZIL HYDROCHLORIDE			
Tab 5 mg – 1% DV Feb-15 to 2017	5.48	90	Donepezil-Rex
Tab 10 mg – 1% DV Feb-15 to 2017	10.51	90	Donepezil-Rex
RIVASTIGMINE – Restricted see terms below			
⚡ Patch 4.6 mg per 24 hour	90.00	30	Exelon
⚡ Patch 9.5 mg per 24 hour	90.00	30	Exelon
➔ Restricted			
Initiation			
<i>Re-assessment required after 6 months</i>			
Both:			
1 The patient has been diagnosed with dementia; and			
2 The patient has experienced intolerable nausea and/or vomiting from donepezil tablets.			
Continuation			
<i>Re-assessment required after 12 months</i>			
Both:			
1 The treatment remains appropriate; and			
2 The patient has demonstrated a significant and sustained benefit from treatment.			
Treatments for Substance Dependence			
BUPRENORPHINE WITH NALOXONE – Restricted see terms below			
⚡ Tab 2 mg with naloxone 0.5 mg	57.40	28	Suboxone
⚡ Tab 8 mg with naloxone 2 mg	166.00	28	Suboxone
➔ Restricted			
Detoxification			
All of the following:			
1 Patient is opioid dependent; and			
2 Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and			
3 Prescriber works in an opioid treatment service approved by the Ministry of Health.			
Maintenance treatment			
All of the following:			
1 Patient is opioid dependent; and			
2 Patient will not be receiving methadone; and			
3 Patient is currently enrolled in an opioid substitution treatment program in a service approved by the Ministry of Health; and			
4 Prescriber works in an opioid treatment service approved by the Ministry of Health.			
BUPROPION HYDROCHLORIDE			
Tab modified-release 150 mg – 1% DV Oct-13 to 2016	4.97	30	Zyban
DISULFIRAM			
Tab 200 mg	24.30	100	Antabuse
NALTREXONE HYDROCHLORIDE – Restricted see terms below			
⚡ Tab 50 mg – 1% DV Sep-13 to 2016	76.00	30	Naltraccord
➔ Restricted			
Alcohol dependence			
Both:			
1 Patient is currently enrolled, or is planned to be enrolled, in a recognised comprehensive treatment programme for alcohol dependence; and			
2 Naltrexone is to be prescribed by, or on the recommendation of, a physician working in an Alcohol and Drug Service.			
Constipation			
For the treatment of opioid-induced constipation			

NERVOUS SYSTEM

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
NICOTINE – Some items restricted see terms below			
Gum 2 mg – 1% DV Apr-14 to 2017	22.26	384	Habitrol (Classic) Habitrol (Fruit) Habitrol (Mint)
Gum 4 mg – 1% DV Apr-14 to 2017	25.67	384	Habitrol (Classic) Habitrol (Fruit) Habitrol (Mint)
Patch 7 mg per 24 hours – 1% DV Apr-14 to 2017	10.57	28	Habitrol
Patch 14 mg per 24 hours – 1% DV Apr-14 to 2017	11.31	28	Habitrol
Patch 21 mg per 24 hours – 1% DV Apr-14 to 2017	11.95	28	Habitrol
¶ Oral spray 1 mg per dose			<i>e.g. Nicorette QuickMist Mouth Spray</i>
Lozenge 1 mg – 1% DV Apr-14 to 2017	12.91	216	Habitrol
Lozenge 2 mg – 1% DV Apr-14 to 2017	14.14	216	Habitrol
¶ Soln for inhalation 15 mg cartridge			<i>e.g. Nicorette Inhalator</i>

➡ Restricted

Any of the following:

- 1 For perioperative use in patients who have a 'nil by mouth' instruction; or
- 2 For use within mental health inpatient units; or
- 3 For acute use in agitated patients who are unable to leave the hospital facilities.

VARENICLINE – Restricted see terms below

¶ Tab 0.5 mg × 11 and 1 mg × 14	60.48	25	Champix
¶ Tab 1 mg	67.74	28	Champix
	135.48	56	Champix

➡ Restricted

All of the following:

- 1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
- 2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
- 3 Either:
 - 3.1 The patient has tried but failed to quit smoking after at least two separate trials of nicotine replacement therapy, at least one of which included the patient receiving comprehensive advice on the optimal use of nicotine replacement therapy; or
 - 3.2 The patient has tried but failed to quit smoking using bupropion or nortriptyline; and
- 4 The patient has not used funded varenicline in the last 12 months; and
- 5 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
- 6 The patient is not pregnant; and
- 7 The patient will not be prescribed more than 3 months' funded varenicline in a 12 month period.

↑ Item restricted (see ➡ above); ¶ Item restricted (see ➡ below)

e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Chemotherapeutic Agents			
Alkylating Agents			
BUSULFAN			
Tab 2 mg	89.25	100	Myleran
Inj 6 mg per ml, 10 ml ampoule			
CARMUSTINE			
Inj 100 mg vial – 1% DV Sep-15 to 2018	532.00	1	BICNU
CHLORAMBUCIL			
Tab 2 mg			
CYCLOPHOSPHAMIDE			
Tab 50 mg	79.00	50	Endoxan
	158.00	100	Procytox
Inj 1 g vial – 1% DV Oct-15 to 2018	35.03	1	Endoxan
Inj 2 g vial – 1% DV Oct-15 to 2018	70.06	1	Endoxan
IFOSFAMIDE			
Inj 1 g vial	96.00	1	Holoxan
Inj 2 g vial	180.00	1	Holoxan
LOMUSTINE			
Cap 10 mg	132.59	20	Ceenu
Cap 40 mg	399.15	20	Ceenu
MELPHALAN			
Tab 2 mg			
Inj 50 mg vial			
THIOTEPA			
Inj 15 mg vial			
Inj 100 mg vial			
Anthracyclines and Other Cytotoxic Antibiotics			
BLEOMYCIN SULPHATE			
Inj 15,000 iu vial – 1% DV Oct-15 to 2018	150.48	1	DBL Bleomycin Sulfate
DACTINOMYCIN [ACTINOMYCIN D]			
Inj 0.5 mg vial	145.00	1	Cosmegen
DAUNORUBICIN			
Inj 2 mg per ml, 10 ml vial – 1% DV Aug-13 to 2016	118.72	1	Pfizer
DOXORUBICIN HYDROCHLORIDE			
Inj 2 mg per ml, 5 ml vial			
Inj 2 mg per ml, 25 ml vial – 1% DV Feb-16 to 2018	11.50	1	Doxorubicin Ebewe
	17.00		Arrow-Doxorubicin
Inj 50 mg vial			
Inj 2 mg per ml, 50 ml vial – 1% DV Feb-16 to 2018	23.00	1	Doxorubicin Ebewe
Inj 2 mg per ml, 100 ml vial – 1% DV Feb-16 to 2018	46.00	1	Doxorubicin Ebewe
	65.00		Arrow-Doxorubicin
<i>(Arrow-Doxorubicin Inj 2 mg per ml, 25 ml vial to be delisted 1 February 2016)</i>			
<i>(Any Inj 50 mg vial to be delisted 1 February 2016)</i>			
<i>(Arrow-Doxorubicin Inj 2 mg per ml, 100 ml vial to be delisted 1 February 2016)</i>			

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
EPIRUBICIN HYDROCHLORIDE			
Inj 2 mg per ml, 5 ml vial	25.00	1	Epirubicin Ebewe
Inj 2 mg per ml, 25 ml vial – 1% DV Nov-15 to 2018	30.00	1	Epirubicin Ebewe
Inj 2 mg per ml, 50 ml vial – 1% DV Nov-15 to 2018	32.50	1	Epirubicin Ebewe
Inj 2 mg per ml, 100 ml vial – 1% DV Nov-15 to 2018	65.00	1	Epirubicin Ebewe
IDARUBICIN HYDROCHLORIDE			
Inj 5 mg vial – 1% DV Nov-15 to 2018	125.00	1	Zavedos
Inj 10 mg vial – 1% DV Nov-15 to 2018	250.00	1	Zavedos
MITOMYCIN C			
Inj 5 mg vial – 1% DV Oct-13 to 2016	79.75	1	Arrow
MITOZANTRONE			
Inj 2 mg per ml, 10 ml vial – 1% DV Sep-15 to 2018	97.50	1	Mitozantrone Ebewe

Antimetabolites
AZACITIDINE – Restricted see terms below

⚡ Inj 100 mg vial 605.00 1 Vidaza

↔Restricted
Initiation

Haematologist

Re-assessment required after 12 months

All of the following:

1 Any of the following:

- 1.1 The patient has International Prognostic Scoring System (IPSS) intermediate-2 or high risk myelodysplastic syndrome; or
- 1.2 The patient has chronic myelomonocytic leukaemia (10%-29% marrow blasts without myeloproliferative disorder); or
- 1.3 The patient has acute myeloid leukaemia with 20-30% blasts and multi-lineage dysplasia, according to World Health Organisation Classification (WHO); and

2 The patient has performance status (WHO/ECOG) grade 0-2; and

3 The patient does not have secondary myelodysplastic syndrome resulting from chemical injury or prior treatment with chemotherapy and/or radiation for other diseases; and

4 The patient has an estimated life expectancy of at least 3 months.

Notes: Indication marked with a * is an Unapproved Indication. Studies of temozolomide show that its benefit is predominantly in those patients with a good performance status (WHO grade 0 or 1 or Karnofsky score >80), and in patients who have had at least a partial resection of the tumour.

Continuation

Haematologist

Re-assessment required after 12 months

Both:

- 1 No evidence of disease progression, and
- 2 The treatment remains appropriate and patient is benefitting from treatment.

CAPECITABINE

Tab 150 mg – 1% DV Sep-14 to 2016	30.00	60	Capecitabine Winthrop
Tab 500 mg – 1% DV Sep-14 to 2016	120.00	120	Capecitabine Winthrop

CLADRIBINE

Inj 2 mg per ml, 5 ml vial			
Inj 1 mg per ml, 10 ml vial	5,249.72	7	Leustatin

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
CYTARABINE			
Inj 20 mg per ml, 5 ml vial – 1% DV Nov-13 to 2016	55.00	5	Pfizer
Inj 20 mg per ml, 25 ml vial	18.15	1	Pfizer
Inj 100 mg per ml, 10 ml vial – 1% DV Nov-13 to 2016	8.83	1	Pfizer
Inj 100 mg per ml, 20 ml vial – 1% DV Nov-13 to 2016	17.65	1	Pfizer
FLUDARABINE PHOSPHATE			
Tab 10 mg – 1% DV Sep-15 to 2018	412.00	20	Fludara Oral
Inj 50 mg vial	525.00	5	Fludarabine Ebewe
FLUOROURACIL			
Inj 50 mg per ml, 20 ml vial – 1% DV Oct-15 to 2018	10.00	1	Fluorouracil Ebewe
Inj 50 mg per ml, 50 ml vial – 1% DV Oct-15 to 2018	17.00	1	Fluorouracil Ebewe
Inj 50 mg per ml, 100 ml vial – 1% DV Oct-15 to 2018	30.00	1	Fluorouracil Ebewe
GEMCITABINE			
Inj 10 mg per ml, 20 ml vial – 1% DV Oct-14 to 2017	8.36	1	Gemcitabine Ebewe
Inj 10 mg per ml, 100 ml vial – 1% DV Oct-14 to 2017	15.89	1	Gemcitabine Ebewe
MERCAPTOPYRINE			
Tab 50 mg – 1% DV Oct-13 to 2016	49.41	25	Puri-nethol
METHOTREXATE			
Tab 2.5 mg – 1% DV Sep-15 to 2018	3.18	30	Trexate
Tab 10 mg – 1% DV Sep-15 to 2018	21.00	50	Trexate
Inj 2.5 mg per ml, 2 ml vial			
Inj 7.5 mg prefilled syringe – 1% DV Jan-14 to 2016	17.19	1	Methotrexate Sandoz
Inj 10 mg prefilled syringe – 1% DV Jan-14 to 2016	17.25	1	Methotrexate Sandoz
Inj 15 mg prefilled syringe – 1% DV Jan-14 to 2016	17.38	1	Methotrexate Sandoz
Inj 20 mg prefilled syringe – 1% DV Jan-14 to 2016	17.50	1	Methotrexate Sandoz
Inj 25 mg prefilled syringe – 1% DV Jan-14 to 2016	17.63	1	Methotrexate Sandoz
Inj 30 mg prefilled syringe – 1% DV Jan-14 to 2016	17.75	1	Methotrexate Sandoz
Inj 25 mg per ml, 2 ml vial – 1% DV Sep-13 to 2016	20.20	5	Hospira
Inj 25 mg per ml, 20 ml vial – 1% DV Sep-13 to 2016	27.78	1	Hospira
Inj 100 mg per ml, 10 ml vial	25.00	1	Methotrexate Ebewe
Inj 100 mg per ml, 50 ml vial – 1% DV Oct-14 to 2017	99.99	1	Methotrexate Ebewe
THIOGUANINE			
Tab 40 mg			
Other Cytotoxic Agents			
AMSACRINE			
Inj 50 mg per ml, 1.5 ml ampoule			
Inj 75 mg			
ANAGRELIDE HYDROCHLORIDE			
Cap 0.5 mg			
ARSENIC TRIOXIDE			
Inj 1 mg per ml, 10 ml vial	4,817.00	10	AFT
BORTEZOMIB – Restricted see terms on the next page			
⚡ Inj 1 mg vial	540.70	1	Velcade
⚡ Inj 3.5 mg vial	1,892.50	1	Velcade

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
➔Restricted			
Initiation - treatment naive multiple myeloma/amyloidosis			
Both:			
1 Either:			
1.1 The patient has treatment-naive symptomatic multiple myeloma; or			
1.2 The patient has treatment-naive symptomatic systemic AL amyloidosis *; and			
2 Maximum of 9 treatment cycles.			
Note: Indications marked with * are Unapproved Indications.			
Initiation - relapsed/refractory multiple myeloma/amyloidosis			
All of the following:			
1 Either:			
1.1 The patient has relapsed or refractory multiple myeloma; or			
1.2 The patient has relapsed or refractory systemic AL amyloidosis *; and			
2 The patient has received only one prior front line chemotherapy for multiple myeloma or amyloidosis; and			
3 The patient has not had prior publicly funded treatment with bortezomib; and			
4 Maximum of 4 treatment cycles.			
Note: Indications marked with * are Unapproved Indications.			
Continuation - relapsed/refractory multiple myeloma/amyloidosis			
Both:			
1 The patient's disease obtained at least a partial response from treatment with bortezomib at the completion of cycle 4; and			
2 Maximum of 4 further treatment cycles (making a total maximum of 8 consecutive treatment cycles).			
Notes: Responding relapsed/refractory multiple myeloma patients should receive no more than 2 additional cycles of treatment beyond the cycle at which a confirmed complete response was first achieved. A line of therapy is considered to comprise either:			
1 A known therapeutic chemotherapy regimen and supportive treatments; or			
2 A transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments.			
Refer to datasheet for recommended dosage and number of doses of bortezomib per treatment cycle.			
COLASPASE [L-ASPARAGINASE]			
Inj 10,000 iu vial	102.32	1	Leunase
DACARBAZINE			
Inj 200 mg vial – 1% DV Oct-13 to 2016	51.84	1	Hospira
ETOPOSIDE			
Cap 50 mg	340.73	20	Vepesid
Cap 100 mg	340.73	10	Vepesid
Inj 20 mg per ml, 5 ml vial	25.00	1	Hospira
ETOPOSIDE (AS PHOSPHATE)			
Inj 100 mg vial	40.00	1	Etopophos
HYDROXYUREA			
Cap 500 mg	31.76	100	Hydrea
IRINOTECAN HYDROCHLORIDE			
Inj 20 mg per ml, 2 ml vial – 1% DV Sep-15 to 2018	11.50	1	Irinotecan Actavis 40
Inj 20 mg per ml, 5 ml vial – 1% DV Sep-15 to 2018	17.80	1	Irinotecan Actavis 100
LENALIDOMIDE – Restricted see terms on the next page			
⚡ Cap 10 mg	6,207.00	21	Revlimid
⚡ Cap 25 mg	7,627.00	21	Revlimid

⚡ Item restricted (see ➔ above); ⚡ Item restricted (see ➔ below)

e.g. Brand indicates brand example only. It is not a contracted product.

Price			Brand or
(ex man. excl. GST)			Generic
\$	Per		Manufacturer

➔ **Restricted**

Initiation

Haematologist

Re-assessment required after 6 months

All of the following:

- 1 Patient has relapsed or refractory multiple myeloma with progressive disease; and
- 2 Either:
 - 2.1 Lenalidomide to be used as third line* treatment for multiple myeloma; or
 - 2.2 Both:
 - 2.2.1 Lenalidomide to be used as second line treatment for multiple myeloma; and
 - 2.2.2 The patient has experienced severe (grade ≥ 3), dose limiting, peripheral neuropathy with either bortezomib or thalidomide that precludes further treatment with either of these treatments; and
- 3 Lenalidomide to be administered at a maximum dose of 25 mg/day in combination with dexamethasone.

Continuation

Haematologist

Re-assessment required after 6 months

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and patient is benefitting from treatment.

Notes: Indication marked with * is an Unapproved Indication (refer to Interpretations and Definitions). A line of treatment is considered to comprise either: a) a known therapeutic chemotherapy regimen and supportive treatments or b) a transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments. Prescriptions must be written by a registered prescriber in the lenalidomide risk management programme operated by the supplier.

PEGASPARGASE – **Restricted** see terms below

⚡ Inj 750 iu per ml, 5 ml vial	3,005.00	1	Oncaspar
--------------------------------------	----------	---	----------

➔ **Restricted**

Newly diagnosed ALL

Limited to 12 months' treatment

All of the following:

- 1 The patient has newly diagnosed acute lymphoblastic leukaemia; and
- 2 Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol; and
- 3 Treatment is with curative intent.

Relapsed ALL

Limited to 12 months' treatment

All of the following:

- 1 The patient has relapsed acute lymphoblastic leukaemia; and
- 2 Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol; and
- 3 Treatment is with curative intent.

PENTOSTATIN [DEOXYCOFORMYCIN]

Inj 10 mg vial

PROCARBAZINE HYDROCHLORIDE

Cap 50 mg	498.00	50	Natulan
-----------------	--------	----	---------

TEMOZOLOMIDE – **Restricted** see terms on the next page

⚡ Cap 5 mg – 1% DV Sep-13 to 2016.....	8.00	5	Temaccord
⚡ Cap 20 mg – 1% DV Sep-13 to 2016.....	36.00	5	Temaccord
⚡ Cap 100 mg – 1% DV Sep-13 to 2016.....	175.00	5	Temaccord
⚡ Cap 250 mg – 1% DV Sep-13 to 2016.....	410.00	5	Temaccord

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➔ **Restricted**

All of the following:

- 1 Either:
 - 1.1 Patient has newly diagnosed glioblastoma multiforme; or
 - 1.2 Patient has newly diagnosed anaplastic astrocytoma*; and
- 2 Temozolomide is to be (or has been) given concomitantly with radiotherapy; and
- 3 Following concomitant treatment temozolomide is to be used for a maximum of six cycles of 5 days treatment, at a maximum dose of 200 mg/m².

Notes: Indication marked with a * is an Unapproved Indication. Studies of temozolomide show that its benefit is predominantly in those patients with a good performance status (WHO grade 0 or 1 or Karnofsky score >80), and in patients who have had at least a partial resection of the tumour.

THALIDOMIDE – **Restricted** see terms below

⚡ Cap 50 mg	378.00	28	Thalomid
⚡ Cap 100 mg	756.00	28	Thalomid

➔ **Restricted**

Initiation

Any of the following:

- 1 The patient has multiple myeloma; or
- 2 The patient has systemic AL amyloidosis*; or
- 3 The patient has erythema nodosum leprosum.

Continuation

Patient has obtained a response from treatment during the initial approval period.

Notes: Prescription must be written by a registered prescriber in the thalidomide risk management programme operated by the supplier.

Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen.

Indication marked with * is an Unapproved Indication

TRETINOIN

Cap 10 mg	479.50	100	Vesanoid
-----------------	--------	-----	----------

Platinum Compounds

CARBOPLATIN

Inj 10 mg per ml, 5 ml vial – 1% DV Sep-15 to 2018	15.07	1	DBL Carboplatin
Inj 10 mg per ml, 15 ml vial – 1% DV Sep-15 to 2018	14.05	1	DBL Carboplatin
Inj 10 mg per ml, 45 ml vial – 1% DV Sep-15 to 2018	32.59	1	DBL Carboplatin

CISPLATIN

Inj 1 mg per ml, 50 ml vial – 1% DV Nov-15 to 2018	12.29	1	DBL Cisplatin
Inj 1 mg per ml, 100 ml vial – 1% DV Nov-15 to 2018	22.46	1	DBL Cisplatin

OXALIPLATIN

Inj 5 mg per ml, 10 ml vial – 1% DV Mar-16 to 2018	13.32	1	Oxaliccord
Inj 50 mg vial	15.32	1	Oxaliplatin Actavis 50
Inj 100 mg vial	25.01	1	Oxaliplatin Actavis 100
Inj 5 mg per ml, 20 ml vial – 1% DV Mar-16 to 2018	16.00	1	Oxaliccord

(Oxaliplatin Actavis 50 Inj 50 mg vial to be delisted 1 March 2016)

(Oxaliplatin Actavis 100 Inj 100 mg vial to be delisted 1 March 2016)

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Protein-Tyrosine Kinase Inhibitors

DASATINIB – **Restricted** see terms below

⚡ Tab 20 mg	3,774.06	60	Sprycel
⚡ Tab 50 mg	6,214.20	60	Sprycel
⚡ Tab 70 mg	7,692.58	60	Sprycel
⚡ Tab 100 mg	6,214.20	30	Sprycel

➔ **Restricted**

For use in patients with approval from the CML/GIST Co-ordinator

ERLOTINIB – **Restricted** see terms below

⚡ Tab 100 mg – 1% DV Jun-15 to 2018	1,000.00	30	Tarceva
⚡ Tab 150 mg – 1% DV Jun-15 to 2018	1,500.00	30	Tarceva

➔ **Restricted**

Initiation

Re-assessment required after 3 months

Either:

- 1 All of the following:
 - 1.1 Patient has locally advanced or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
 - 1.2 There is documentation confirming that the disease expresses activating mutations of EGFR tyrosine kinase; and
 - 1.3 Any of the following:
 - 1.3.1 Patient is treatment naive; or
 - 1.3.2 Both:
 - 1.3.2.1 Patient has documented disease progression following treatment with first line platinum based chemotherapy; and
 - 1.3.2.2 Patient has not received prior treatment with gefitinib; or
 - 1.3.3 Both:
 - 1.3.3.1 The patient has discontinued gefitinib within 6 weeks of starting treatment due to intolerance; and
 - 1.3.3.2 The cancer did not progress while on gefitinib; and
 - 1.4 Erlotinib is to be given for a maximum of 3 months, or
- 2 The patient received funded erlotinib prior to 31 December 2013 and radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

Continuation

Re-assessment required after 6 months

Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

GEFITINIB – **Restricted** see terms below

⚡ Tab 250 mg	1,700.00	30	Iressa
--------------------	----------	----	--------

➔ **Restricted**

Initiation

Re-assessment required after 3 months

All of the following:

- 1 Patient has locally advanced, or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
- 2 Either:
 - 2.1 Patient is treatment naive; or
 - 2.2 Both:
 - 2.2.1 The patient has discontinued erlotinib within 6 weeks of starting treatment due to intolerance; and
 - 2.2.2 The cancer did not progress whilst on erlotinib; and
- 3 There is documentation confirming that disease expresses activating mutations of EGFR tyrosine kinase.

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

Continuation

Re-assessment required after 6 months

Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

IMATINIB MESILATE

Note: Imatinib-AFT is not a registered for the treatment of Gastro Intestinal Stromal Tumours (GIST). The Glivec brand of imatinib mesilate (supplied by Novartis) remains fully subsidised under Special Authority for patients with unresectable and/or metastatic malignant GIST, see SA1460 in Section B of the Pharmaceutical Schedule.

⚡ Tab 100 mg	2,400.00	60	Glivec
--------------------	----------	----	--------

➡ **Restricted**

Initiation

Re-assessment required after 12 months

- Both:
- 1 Patient has diagnosis (confirmed by an oncologist) of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST); and
 - 2 Maximum dose of 400 mg/day.

Continuation

Re-assessment required after 12 months

Adequate clinical response to treatment with imatinib (prescriber determined).

Cap 100 mg – 1% DV Jul-14 to 2017	298.90	60	Imatinib-AFT
Cap 400 mg	597.80	30	Imatinib-AFT

LAPATINIB – Restricted see terms below

⚡ Tab 250 mg	1,899.00	70	Tykerb
--------------------	----------	----	--------

➡ **Restricted**

Initiation

Re-assessment required after 12 months

- Either:
- 1 All of the following:
 - 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 1.2 The patient has not previously received trastuzumab treatment for HER 2 positive metastatic breast cancer; and
 - 1.3 Lapatinib not to be given in combination with trastuzumab; and
 - 1.4 Lapatinib to be discontinued at disease progression; or
 - 2 All of the following:
 - 2.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 2.2 The patient started trastuzumab for metastatic breast cancer but discontinued trastuzumab within 3 months of starting treatment due to intolerance; and
 - 2.3 The cancer did not progress whilst on trastuzumab; and
 - 2.4 Lapatinib not to be given in combination with trastuzumab; and
 - 2.5 Lapatinib to be discontinued at disease progression.

Continuation

Re-assessment required after 12 months

- All of the following:
- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 2 The cancer has not progressed at any time point during the previous 12 months whilst on lapatinib; and
 - 3 Lapatinib not to be given in combination with trastuzumab; and
 - 4 Lapatinib to be discontinued at disease progression.

↑ Item restricted (see ➡ above); ⚡ Item restricted (see ➡ below)
e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
NILOTINIB – Restricted see terms below			
☒ Cap 150 mg	4,680.00	120	Tasigna
☒ Cap 200 mg	6,532.00	120	Tasigna

➔ **Restricted**

Initiation

Haematologist

Re-assessment required after 6 months

All of the following:

- 1 Patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis, accelerated phase, or in chronic phase; and
- 2 Either:
 - 2.1 Patient has documented CML treatment failure* with imatinib; or
 - 2.2 Patient has experienced treatment limiting toxicity with imatinib precluding further treatment with imatinib; and
- 3 Maximum nilotinib dose of 800 mg/day; and
- 4 Subsidised for use as monotherapy only.

Note: *treatment failure as defined by Leukaemia Net Guidelines.

Continuation

Haematologist

Re-assessment required after 6 months

All of the following:

- 1 Lack of treatment failure while on nilotinib as defined by Leukaemia Net Guidelines; and
- 2 Nilotinib treatment remains appropriate and the patient is benefiting from treatment; and
- 3 Maximum nilotinib dose of 800 mg/day; and
- 4 Subsidised for use as monotherapy only.

PAZOPANIB – Restricted see terms below

☒ Tab 200 mg	1,334.70	30	Votrient
☒ Tab 400 mg	2,669.40	30	Votrient

➔ **Restricted**

Initiation

Re-assessment required after 3 months

All of the following:

- 1 The patient has metastatic renal cell carcinoma; and
- 2 Any of the following:
 - 2.1 The patient is treatment naive; or
 - 2.2 The patient has only received prior cytokine treatment; or
 - 2.3 Both:
 - 2.3.1 The patient has discontinued sunitinib within 3 months of starting treatment due to intolerance; and
 - 2.3.2 The cancer did not progress whilst on sunitinib; and
- 3 The patient has good performance status (WHO/ECOG grade 0-2); and
- 4 The disease is of predominant clear cell histology; and
- 5 The patient has intermediate or poor prognosis defined as any of the following:
 - 5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or
 - 5.2 Haemoglobin level < lower limit of normal; or
 - 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or
 - 5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; or
 - 5.5 Karnofsky performance score of ≤ 70; or
 - 5.6 ≥ 2 sites of organ metastasis.

Continuation

Re-assessment required after 3 months

Both:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Notes: Pazopanib treatment should be stopped if disease progresses.

Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.

SUNITINIB – **Restricted** see terms below

⚡ Cap 12.5 mg	2,315.38	28	Sutent
⚡ Cap 25 mg	4,630.77	28	Sutent
⚡ Cap 50 mg	9,261.54	28	Sutent

↪ Restricted

Re-assessment required after 3 months

Initiation - RCC

- 1 The patient has metastatic renal cell carcinoma; and
- 2 Any of the following:
 - 2.1 The patient is treatment naive; or
 - 2.2 The patient has only received prior cytokine treatment; or
 - 2.3 The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial which has Ethics Committee approval; or
 - 2.4 Both:
 - 2.4.1 The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance; and
 - 2.4.2 The cancer did not progress whilst on pazopanib; and
- 3 The patient has good performance status (WHO/ECOG grade 0-2); and
- 4 The disease is of predominant clear cell histology; and
- 5 The patient has intermediate or poor prognosis defined as any of the following:
 - 5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or
 - 5.2 Haemoglobin level < lower limit of normal; or
 - 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or
 - 5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; or
 - 5.5 Karnofsky performance score of ≤ 70; or
 - 5.6 ≥ 2 sites of organ metastasis; and
- 6 Sunitinib to be used for a maximum of 2 cycles.

Continuation - RCC

Re-assessment required after 3 months

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Initiation - GIST

Re-assessment required after 3 months

Both:

- 1 The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST); and
- 2 Either:
 - 2.1 The patient's disease has progressed following treatment with imatinib; or
 - 2.2 The patient has documented treatment-limiting intolerance, or toxicity to, imatinib.

Continuation - GIST

Re-assessment required after 6 months

Both:

The patient has responded to treatment or has stable disease as determined by Choi's modified CT response evaluation criteria as follows:

continued...

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued..

- 1 Any of the following:
 - 1.1 The patient has had a complete response (disappearance of all lesions and no new lesions); or
 - 1.2 The patient has had a partial response (a decrease in size of $\geq 10\%$ or decrease in tumour density in Hounsfield Units (HU) of $\geq 15\%$ on CT and no new lesions and no obvious progression of non-measurable disease); or
 - 1.3 The patient has stable disease (does not meet criteria the two above) and does not have progressive disease and no symptomatic deterioration attributed to tumour progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Notes: RCC - Sunitinib treatment should be stopped if disease progresses.

Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6.

GIST - It is recommended that response to treatment be assessed using Choi's modified CT response evaluation criteria (J Clin Oncol, 2007, 25:1753-1759). Progressive disease is defined as either: an increase in tumour size of $\geq 10\%$ and not meeting criteria of partial response (PR) by tumour density (HU) on CT; or: new lesions, or new intratumoral nodules, or increase in the size of the existing intratumoral nodules.

Taxanes

DOCETAXEL

Inj 10 mg per ml, 2 ml vial – 1% DV Dec-14 to 2017	13.70	1	DBL Docetaxel
Inj 10 mg per ml, 8 ml vial – 1% DV Dec-14 to 2017	29.99	1	DBL Docetaxel

PACLITAXEL

Inj 6 mg per ml, 5 ml vial – 1% DV Sep-14 to 2017	45.00	5	Paclitaxel Ebewe
Inj 6 mg per ml, 16.7 ml vial – 1% DV Sep-14 to 2017	19.02	1	Paclitaxel Ebewe
Inj 6 mg per ml, 25 ml vial – 1% DV Sep-14 to 2017	26.69	1	Paclitaxel Ebewe
Inj 6 mg per ml, 50 ml vial – 1% DV Sep-14 to 2017	36.53	1	Paclitaxel Ebewe
Inj 6 mg per ml, 100 ml vial – 1% DV Sep-14 to 2017	73.06	1	Paclitaxel Ebewe

Treatment of Cytotoxic-Induced Side Effects

CALCIUM FOLINATE

Tab 15 mg	104.26	10	DBL Leucovorin Calcium
Inj 3 mg per ml, 1 ml ampoule			
Inj 10 mg per ml, 5 ml ampoule – 1% DV Oct-14 to 2017	18.25	5	Calcium Folate Ebewe
Inj 10 mg per ml, 10 ml vial – 1% DV Oct-14 to 2017	7.33	1	Calcium Folate Ebewe
Inj 10 mg per ml, 30 ml vial – 1% DV Oct-14 to 2017	22.51	1	Calcium Folate Ebewe
Inj 10 mg per ml, 100 ml vial – 1% DV Oct-14 to 2017	67.51	1	Calcium Folate Ebewe

MESNA

Tab 400 mg – 1% DV Oct-13 to 2016	227.50	50	Uromitexan
Tab 600 mg – 1% DV Oct-13 to 2016	339.50	50	Uromitexan
Inj 100 mg per ml, 4 ml ampoule – 1% DV Oct-13 to 2016	148.05	15	Uromitexan
Inj 100 mg per ml, 10 ml ampoule – 1% DV Oct-13 to 2016	339.90	15	Uromitexan

Vinca Alkaloids

VINBLASTINE SULPHATE

Inj 1 mg per ml, 10 ml vial	186.46	5	Hospira
-----------------------------------	--------	---	---------

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
VINCRIStINE SULPHATE			
Inj 1 mg per ml, 1 ml vial – 1% DV Sep-13 to 2016	64.80	5	Hospira
Inj 1 mg per ml, 2 ml vial – 1% DV Sep-13 to 2016	69.60	5	Hospira
VINORELBINE			
Inj 10 mg per ml, 1 ml vial – 1% DV Sep-15 to 2018	8.00	1	Navelbine
Inj 10 mg per ml, 5 ml vial – 1% DV Sep-15 to 2018	40.00	1	Navelbine
Endocrine Therapy			
ABIRATERONE ACETATE – Restricted see terms below			
⚡ Tab 250 mg	4,276.19	120	Zytiga
➔Restricted			
Initiation			
Medical oncologist, radiation oncologist or urologist			
<i>Re-assessment required after 5 months</i>			
All of the following:			
1 Patient has prostate cancer; and			
2 Patient has metastases; and			
3 Patient's disease is castration resistant; and			
4 Either:			
4.1 All of the following:			
4.1.1 Patient is symptomatic; and			
4.1.2 Patient has disease progression (rising serum PSA) after second line anti-androgen therapy; and			
4.1.3 Patient has ECOG performance score of 0-1; and			
4.1.4 Patient has not had prior treatment with taxane chemotherapy; or			
4.2 All of the following:			
4.2.1 Patient's disease has progressed following prior chemotherapy containing a taxane; and			
4.2.2 Patient has ECOG performance score of 0-2; and			
4.2.3 Patient has not had prior treatment with abiraterone.			
Continuation			
Medical oncologist, radiation oncologist or urologist			
<i>Re-assessment required after 5 months</i>			
All of the following:			
1 Significant decrease in serum PSA from baseline; and			
2 No evidence of clinical disease progression; and			
3 No initiation of taxane chemotherapy with abiraterone; and			
4 The treatment remains appropriate and the patient is benefiting from treatment.			
BICALUTAMIDE			
Tab 50 mg – 1% DV Sep-14 to 2017	4.90	28	Bicalaccord
FLUTAMIDE			
Tab 250 mg	55.00	100	Flutamin
MEGESTROL ACETATE			
Tab 160 mg – 1% DV Oct-15 to 2018	54.30	30	Apo-Megestrol
OCTREOTIDE – Some items restricted see terms on the next page			
Inj 50 mcg per ml, 1 ml ampoule – 1% DV Sep-14 to 2017	13.50	5	DBL
Inj 100 mcg per ml, 1 ml ampoule – 1% DV Sep-14 to 2017	22.40	5	DBL
Inj 500 mcg per ml, 1 ml ampoule – 1% DV Sep-14 to 2017	89.40	5	DBL
⚡ Inj 10 mg vial	1,772.50	1	Sandostatin LAR
⚡ Inj 20 mg vial	2,358.75	1	Sandostatin LAR
⚡ Inj 30 mg vial	2,951.25	1	Sandostatin LAR

⚡ Item restricted (see ➔ above); ⚡ Item restricted (see ➔ below)

e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➔ **Restricted**

Note: restriction applies only to the long-acting formulations of octreotide

Malignant bowel obstruction

All of the following:

- 1 The patient has nausea* and vomiting* due to malignant bowel obstruction*; and
- 2 Treatment with antiemetics, rehydration, antimuscarinic agents, corticosteroids and analgesics for at least 48 hours has failed; and
- 3 Octreotide to be given at a maximum dose 1500 mcg daily for up to 4 weeks.

Note: Indications marked with * are Unapproved Indications

Initiation - acromegaly

Re-assessment required after 3 months

Both:

- 1 The patient has acromegaly; and
- 2 Any of the following:
 - 2.1 Treatment with surgery, radiotherapy and a dopamine agonist has failed; or
 - 2.2 Treatment with octreotide is for an interim period while awaiting the effects of radiotherapy and a dopamine agonist has failed; or
 - 2.3 The patient is unwilling, or unable, to undergo surgery and/or radiotherapy.

Continuation - acromegaly

Both:

- 1 IGF1 levels have decreased since starting octreotide; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Note: In patients with acromegaly octreotide treatment should be discontinued if IGF1 levels have not decreased after 3 months treatment. In patients treated with radiotherapy octreotide treatment should be withdrawn every 2 years, for 1 month, for assessment of remission. Octreotide treatment should be stopped where there is biochemical evidence of remission (normal IGF1 levels) following octreotide treatment withdrawal for at least 4 weeks.

Other indications

Any of the following:

- 1 VIPomas and glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or
- 2 Both:
 - 2.1 Gastrinoma; and
 - 2.2 Either:
 - 2.2.1 Patient has failed surgery; or
 - 2.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or
- 3 Both:
 - 3.1 Insulinomas; and
 - 3.2 Surgery is contraindicated or has failed; or
- 4 For pre-operative control of hypoglycaemia and for maintenance therapy; or
- 5 Both:
 - 5.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and
 - 5.2 Disabling symptoms not controlled by maximal medical therapy.

TAMOXIFEN CITRATE

Tab 10 mg	17.50	100	Genox
Tab 20 mg	2.63	30	Genox
	8.75	100	Genox

Aromatase Inhibitors

ANASTROZOLE

Tab 1 mg	26.55	30	Aremed DP-Anastrozole
----------------	-------	----	--------------------------

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
EXEMESTANE			
Tab 25 mg – 1% DV Sep-14 to 2017	14.50	30	Aromasin
LETROZOLE			
Tab 2.5 mg – 1% DV Jan-16 to 2018	2.95	30	Letrole

Immunosuppressants

Calcineurin Inhibitors

CICLOSPORIN			
Cap 25 mg	44.63	50	Neoral
Cap 50 mg	88.91	50	Neoral
Cap 100 mg	177.81	50	Neoral
Oral liq 100 mg per ml	198.13	50 ml	Neoral
Inj 50 mg per ml, 5 ml ampoule – 1% DV Sep-15 to 2018	276.30	10	Sandimmun
TACROLIMUS – Restricted see terms below			
⚡ Cap 0.5 mg – 1% DV Nov-14 to 31 Oct 2018	85.60	100	Tacrolimus Sandoz
⚡ Cap 1 mg – 1% DV Nov-14 to 31 Oct 2018	171.20	100	Tacrolimus Sandoz
⚡ Cap 5 mg – 1% DV Nov-14 to 31 Oct 2018	428.00	50	Tacrolimus Sandoz
⚡ Inj 5 mg per ml, 1 ml ampoule			

↪ Restricted

Initiation - organ transplant recipients

For use in organ transplant recipients

Steroid-resistant nephrotic syndrome*

Either:

- 1 The patient is a child with steroid-resistant nephrotic syndrome* (SRNS) where ciclosporin has been trialled in combination with prednisone and discontinued because of unacceptable side effects or inadequate clinical response; or
- 2 All of the following:
 - 2.1 The patient is an adult with SRNS; and
 - 2.2 Ciclosporin has been trialled in combination with prednisone and discontinued because of unacceptable side effects or inadequate clinical response; and
 - 2.3 Cyclophosphamide or mycophenolate have been trialled and discontinued because of unacceptable side effects or inadequate clinical response, or these treatments are contraindicated.

Note: Indications marked with * are Unapproved Indications

Fusion Proteins

ETANERCEPT – Restricted see terms below			
⚡ Inj 25 mg vial	799.96	4	Enbrel
⚡ Inj 50 mg autoinjector	1,599.96	4	Enbrel
⚡ Inj 50 mg syringe	1,599.96	4	Enbrel

↪ Restricted

Initiation - juvenile idiopathic arthritis

Rheumatologist or named specialist

Re-assessment required after 4 months

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for juvenile idiopathic arthritis (JIA); and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for JIA; or

2 All of the following:

- 2.1 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and
- 2.2 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2.3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
- 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and
- 2.5 Both:
 - 2.5.1 Either:
 - 2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
 - 2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and
 - 2.5.2 Physician's global assessment indicating severe disease.

Continuation - juvenile idiopathic arthritis

Rheumatologist or named specialist

Re-assessment required after 6 months

- Both:
- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
 - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initiation - rheumatoid arthritis

Rheumatologist

Re-assessment required after 6 months

- Either:
- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for rheumatoid arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for rheumatoid arthritis; or
 - 2 All of the following:
 - 2.1 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
 - 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
 - 2.5 Any of the following:

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or
- 2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
- 2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
- 2.6 Either:
 - 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
 - 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2.7 Either:
 - 2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Continuation - rheumatoid arthritis

Rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation - ankylosing spondylitis

Rheumatologist

Re-assessment required after 6 months

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for ankylosing spondylitis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for ankylosing spondylitis; or
- 2 All of the following:
 - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
 - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
 - 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
 - 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of an exercise regime supervised by a physiotherapist; and
 - 2.5 Either:

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
- 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and
- 2.6 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of starting treatment.

Average normal chest expansion corrected for age and gender:

Age	Male	Female
18-24	7.0 cm	5.5 cm
25-34	7.5 cm	5.5 cm
35-44	6.5 cm	4.5 cm
45-54	6.0 cm	5.0 cm
55-64	5.5 cm	4.0 cm
65-74	4.0 cm	4.0 cm
75+	3.0 cm	2.5 cm

Continuation - ankylosing spondylitis

Rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Following 12 weeks of etanercept treatment, BASDAI has improved by 4 or more points from pre-treatment baseline on a 10 point scale, or by 50%, whichever is less; and
- 2 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation - psoriatic arthritis

Rheumatologist

Re-assessment required after 6 months

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for psoriatic arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for psoriatic arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
 - 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.3 Patient has tried and not responded to at least three months of sulphasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
 - 2.4 Either:
 - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
 - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.5 Any of the following:

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
- 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
- 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Continuation - psoriatic arthritis

Rheumatologist

Re-assessment required after 6 months

Both:

- 1 Either:
 - 1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician; and
- 2 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation - plaque psoriasis, prior TNF use

Dermatologist

Re-assessment required after 4 months

Both:

- 1 The patient has had an initial Special Authority approval for adalimumab for severe chronic plaque psoriasis; and
 - Either:
 - 1.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe chronic plaque psoriasis; and
- 2 Patient must be reassessed for continuation after 3 doses.

Initiation - plaque psoriasis, treatment-naive

Dermatologist

Re-assessment required after 4 months

All of the following:

- 1 Either:
 - 1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
- 2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
- 3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 4 The most recent PASI assessment is no more than 1 month old at the time of initiation.

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Continuation - plaque psoriasis

Dermatologist

Re-assessment required after 6 months

- Both:
- 1 Either:
 - 1.1 Both:
 - 1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
 - 1.1.2 Following each prior etanercept treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-etanercept treatment baseline value; or
 - 1.2 Both:
 - 1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 1.2.2 Either:
 - 1.2.2.1 Following each prior etanercept treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 1.2.2.2 Following each prior etanercept treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-etanercept treatment baseline value; and
 - 2 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Indication - pyoderma gangrenosum

Dermatologist

All of the following:

- 1 Patient has pyoderma gangrenosum*; and
- 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and
- 3 A maximum of 4 doses.

Note: Indications marked with * are Unapproved Indications (refer to Section A: General Rules, Part I (Interpretations and Definitions) and Part V (Miscellaneous Provisions) rule 5.5).

Renewal - pyoderma gangrenosum

Dermatologist

All of the following:

- 1 Patient has shown clinical improvement; and
- 2 Patient continues to require treatment; and
- 3 A maximum of 4 doses

Initiation - adult-onset Still's disease

Rheumatologist

Re-assessment required after 6 months

- Either:
- 1 Both:
 - 1.1 Either:
 - 1.1.1 The patient has had an initial Special Authority approval for etanercept for adult-onset Still's disease (AOSD); or

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the HML rules; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept and/or tocilizumab; or
 - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or
- 2 All of the following:
 - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
 - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and
 - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Continuation - adult-onset Still's disease

Paediatric rheumatologist

Re-assessment required after 6 months

The patient has a sustained improvement in inflammatory markers and functional status.

Monoclonal Antibodies

ABCIXIMAB – **Restricted** see terms below

⚡ Inj 2 mg per ml, 5 ml vial	579.53	1	ReoPro
------------------------------------	--------	---	--------

➡**Restricted**

Either:

- 1 For use in patients with acute coronary syndromes undergoing percutaneous coronary intervention; or
- 2 For use in patients undergoing intra-cranial intervention.

ADALIMUMAB – **Restricted** see terms below

⚡ Inj 10 mg per 0.2 ml prefilled syringe	1,599.96	2	Humira
⚡ Inj 20 mg per 0.4 ml syringe	1,599.96	2	Humira
⚡ Inj 40 mg per 0.8 ml pen	1,599.96	2	HumiraPen
⚡ Inj 40 mg per 0.8 ml syringe	1,599.96	2	Humira

➡**Restricted**

Initiation - juvenile idiopathic arthritis

Rheumatologist or named specialist

Re-assessment required after 4 months

Either:

- 1 Either:
 - 1.1 Both:
 - 1.1.1 The patient has had an initial Special Authority approval for etanercept for juvenile idiopathic arthritis (JIA); and
 - 1.1.2 Either:
 - 1.1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for JIA; or
 - 2 All of the following:
 - 2.1 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and
 - 2.2 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and

continued...

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
------------------------------------	-------------------------------------

continued...

2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and

2.5 Both:

2.5.1 Either:

2.5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or

2.5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and

2.5.2 Physician's global assessment indicating severe disease.

Continuation - juvenile idiopathic arthritis

Rheumatologist or named specialist

Re-assessment required after 6 months

Both:

1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2 Either:

2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or

2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initiation - fistulising Crohn's disease

Gastroenterologist

Re-assessment required after 4 months

All of the following

1 Patient has confirmed Crohn's disease; and

2 Either:

2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or

2.2 Patient has one or more rectovaginal fistula(e); and

3 A Baseline Fistula Assessment (a copy of which is available at www.pharmac.govt.nz/latest/BaselineFistulaAssessment.pdf) has been completed and is no more than 1 month old at the time of application.

Continuation - fistulising Crohn's disease

Gastroenterologist

Re-assessment required after 6 months

Either:

1 The number of open draining fistulae have decreased from baseline by at least 50%; or

2 There has been a marked reduction in drainage of all fistula(e) from baseline as demonstrated by a reduction in the Fistula Assessment score, together with less induration and patient-reported pain.

Initiation - Crohn's disease

Gastroenterologist

Re-assessment required after 3 months

All of the following:

1 Patient has severe active Crohn's disease; and

2 Any of the following:

2.1 Patient has a Crohn's Disease Activity Index (CDAI) score of greater than or equal to 300; or

2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or

2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate.

Continuation - Crohn's disease

Gastroenterologist

Re-assessment required after 3 months

Both:

- 1 Either:
 - 1.1 Either:
 - 1.1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on adalimumab; or
 - 1.1.2 CDAI score is 150 or less; or
 - 1.2 Both:
 - 1.2.1 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
 - 1.2.2 Applicant to indicate the reason that CDAI score cannot be assessed; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation - rheumatoid arthritis

Rheumatologist

Re-assessment required after 6 months

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for rheumatoid arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
 - 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
 - 2.5 Any of the following:
 - 2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or
 - 2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
 - 2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
 - 2.6 Either:
 - 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
 - 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.7 Either:

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
- 2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Continuation - rheumatoid arthritis

Rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 3 Adalimumab to be administered at doses no greater than 50 mg every 7 days.

Initiation - ankylosing spondylitis

Rheumatologist

Re-assessment required after 6 months

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for ankylosing spondylitis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for ankylosing spondylitis; or
- 2 All of the following:
 - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
 - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
 - 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
 - 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of an exercise regime supervised by a physiotherapist; and
 - 2.5 Either:
 - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
 - 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and
 - 2.6 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of starting treatment.

Average normal chest expansion corrected for age and gender:

Age	Male	Female
18-24	7.0 cm	5.5 cm
25-34	7.5 cm	5.5 cm
35-44	6.5 cm	4.5 cm
45-54	6.0 cm	5.0 cm
55-64	5.5 cm	4.0 cm
65-74	4.0 cm	4.0 cm
75+	3.0 cm	2.5 cm

Continuation - ankylosing spondylitis

Rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Following 12 weeks of adalimumab treatment, BASDAI has improved by 4 or more points from pre-treatment baseline on a 10 point scale, or by 50%, whichever is less; and
- 2 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation - psoriatic arthritis

Rheumatologist

Re-assessment required after 6 months

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for psoriatic arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for psoriatic arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
 - 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.3 Patient has tried and not responded to at least three months of sulphasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
 - 2.4 Either:
 - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
 - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.5 Any of the following:
 - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
 - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

Continuation - psoriatic arthritis

Rheumatologist

Re-assessment required after 6 months

Both:

- 1 Either:
 - 1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician; and
- 2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation - plaque psoriasis, prior TNF use

Dermatologist

Re-assessment required after 4 months

Both:

- 1 The patient has had an initial Special Authority approval for etanercept for severe chronic plaque psoriasis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from etanercept; or
 - 2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for severe chronic plaque psoriasis; and

Initiation - plaque psoriasis, treatment-naive

Dermatologist

Re-assessment required after 4 months

All of the following:

- 1 Either:
 - 1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
- 2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
- 3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
- 4 The most recent PASI assessment is no more than 1 month old at the time of initiation.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Continuation - plaque psoriasis

Dermatologist

Re-assessment required after 6 months

Both:

- 1 Either:
 - 1.1 Both:
 - 1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

1.1.2 Following each prior adalimumab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value; or

1.2 Both:

1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and

1.2.2 Either:

1.2.2.1 Following each prior adalimumab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or

1.2.2.2 Following each prior adalimumab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-etanercept treatment baseline value; and

2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Indication - pyoderma gangrenosum

Dermatologist

All of the following:

- 1 Patient has pyoderma gangrenosum*; and
- 2 Patient has received three months of conventional therapy including a minimum of three pharmaceuticals (e.g. prednisone, ciclosporin, azathioprine, or methotrexate) and not received an adequate response; and
- 3 A maximum of 4 doses.

Note: Indications marked with * are Unapproved Indications (refer to Section A: General Rules, Part I (Interpretations and Definitions) and Part V (Miscellaneous Provisions) rule 5.5).

Renewal - pyoderma gangrenosum

Dermatologist

All of the following:

- 1 Patient has shown clinical improvement; and
- 2 Patient continues to require treatment; and
- 3 A maximum of 4 doses

Initiation - adult-onset Still's disease

Rheumatologist

Re-assessment required after 6 months

Either:

- 1 Both:
 - 1.1 Either:
 - 1.1.1 The patient has had an initial Special Authority approval for etanercept for adult-onset Still's disease (AOSD); or
 - 1.1.2 The patient has been started on tocilizumab for AOSD in a DHB hospital in accordance with the HML rules; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept and/or tocilizumab; or
 - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of etanercept and/or tocilizumab such that they do not meet the renewal criteria for AOSD; or
- 2 All of the following:
 - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
 - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and
 - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Continuation - adult-onset Still's disease

Rheumatologist

Re-assessment required after 6 months

The patient has a sustained improvement in inflammatory markers and functional status.

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
BASILIXIMAB – Restricted see terms below			
⚡ Inj 20 mg vial	3,200.00	1	Simulect
➔ Restricted			
For use in solid organ transplants			
BEVACIZUMAB – Restricted see terms below			
⚡ Inj 25 mg per ml, 4 ml vial			
⚡ Inj 25 mg per ml, 16 ml vial			
➔ Restricted			
Either:			
1 Ocular neovascularisation; or			
2 Exudative ocular angiopathy.			
INFLIXIMAB – Restricted see terms below			
⚡ Inj 100 mg – 10% DV Mar-15 to 29 Feb 2020	806.00	1	Remicade

➔**Restricted**

Graft vs host disease

Patient has steroid-refractory acute graft vs. host disease of the gut

Initiation - rheumatoid arthritis

Rheumatologist

Re-assessment required after 3-4 months

All of the following:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
 - 2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept; and
- 3 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance

Continuation - rheumatoid arthritis

Rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 3 Infliximab to be administered at doses no greater than 3 mg/kg every 8 weeks.

Initiation - ankylosing spondylitis

Rheumatologist

Re-assessment required after 3 months

Both:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for ankylosing spondylitis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
 - 2.2 Following 12 weeks of adalimumab and/or etanercept treatment, the patient did not meet the renewal criteria for adalimumab and/or etanercept for ankylosing spondylitis.

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

Continuation - ankylosing spondylitis

Rheumatologist

Re-assessment required after 6 months

All of the following:

- 1 Following 12 weeks of infliximab treatment, BASDAI has improved by 4 or more points from pre-infliximab baseline on a 10 point scale, or by 50%, whichever is less; and
- 2 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 3 Infliximab to be administered at doses no greater than 5 mg/kg every 6-8 weeks.

Initiation - psoriatic arthritis

Rheumatologist

Re-assessment required after 3-4 months

Both:

- 1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for psoriatic arthritis; and
- 2 Either:
 - 2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
 - 2.2 Following 3-4 months' initial treatment with adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for psoriatic arthritis.

Continuation - psoriatic arthritis

Rheumatologist

Re-assessment required after 6 months

Both:

- 1 Either:
 - 1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior infliximab treatment in the opinion of the treating physician; and
- 2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

Initiation - severe ocular inflammation

Re-assessment required after 3 doses

Both:

- 1 Patient has severe, vision-threatening ocular inflammation requiring rapid control; and
- 2 Either:
 - 2.1 Patient has failed to achieve control of severe vision-threatening ocular inflammation following high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids; or
 - 2.2 Patient developed new inflammatory symptoms while receiving high dose steroids.

Initiation - chronic ocular inflammation

Re-assessment required after 3 doses

Both:

- 1 Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss; and
- 2 Patient has tried at least two other immunomodulatory agents.

Continuation - ocular inflammation

Both:

- 1 Patient had a good clinical response to initial treatment; and
- 2 Either:
 - 2.1 A withdrawal of infliximab has been trialled and patient has relapsed after trial withdrawal; or
 - 2.2 Patient has Behcet's disease.

Pulmonary sarcoidosis

Both:

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued. . .

- 1 Patient has life-threatening pulmonary sarcoidosis that is refractory to other treatments; and
- 2 Treatment is to be prescribed by, or has been recommended by, a physician with expertise in the treatment of pulmonary sarcoidosis.

Initiation - Crohn's disease (adults)

Gastroenterologist

Re-assessment required after 3 months

All of the following:

- 1 Patient has severe active Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has a Crohn's Disease Activity Index (CDAI) score of greater than or equal to 300; or
 - 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
 - 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
 - 2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate; and
- 5 Patient must be reassessed for continuation after 3 months of therapy.

Continuation - Crohn's disease (adults)

Gastroenterologist

Re-assessment required after 6 months

All of the following:

- 1 One of the following:
 - 1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on infliximab; or
 - 1.2 CDAI score is 150 or less; or
 - 1.3 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle; and
- 3 Patient must be reassessed for continuation after further 6 months.

Initiation - Crohn's disease (children)

Gastroenterologist

Re-assessment required after 3 months

All of the following:

- 1 Paediatric patient has severe active Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has a Paediatric Crohn's Disease Activity Index (PCDAI) score of greater than or equal to 30; or
 - 2.2 Patient has extensive small intestine disease; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate; and
- 5 Patient must be reassessed for continuation after 3 months of therapy.

Continuation - Crohn's disease (children)

Gastroenterologist

Re-assessment required after 6 months

All of the following:

- 1 One of the following:
 - 1.1 PCDAI score has reduced by 10 points from the PCDAI score when the patient was initiated on infliximab; or
 - 1.2 PCDAI score is 15 or less; or

continued. . .

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 1.3 The patient has demonstrated an adequate response to treatment but PCDAI score cannot be assessed; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle; and
- 3 Patient must be reassessed for continuation after further 6 months.

Initiation - fistulising Crohn's disease

Gastroenterologist

All of the following:

- 1 Patient has confirmed Crohn's disease; and
- 2 Either:
 - 2.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or
 - 2.2 Patient has one or more rectovaginal fistula(e); and
- 3 Patient must be reassessed for continuation after 4 months of therapy.

Continuation - fistulising Crohn's disease

Gastroenterologist

All of the following:

- 1 Either:
 - 1.1 The number of open draining fistulae have decreased from baseline by at least 50%; or
 - 1.2 There has been a marked reduction in drainage of all fistula(e) from baseline (in the case of adult patients, as demonstrated by a reduction in the Fistula Assessment score), together with less induration and patient reported pain; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle; and
- 3 Patient must be reassessed for continuation after further 6 months.

Initiation - acute severe fulminant ulcerative colitis

Gastroenterologist

All of the following:

- 1 Patient has acute, severe fulminant ulcerative colitis; and
- 2 Treatment with intravenous or high dose oral corticosteroids has not been successful; and
- 3 Patient must be reassessed for continuation after 6 weeks of therapy.

Continuation - severe fulminant ulcerative colitis

Gastroenterologist

All of the following:

- 1 Where maintenance treatment is considered appropriate, infliximab should be used in combination with immunomodulators and reassessed every 6 months; and
- 2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle; and
- 3 Patient must be reassessed for continuation after further 6 months.

Initiation - severe ulcerative colitis

Gastroenterologist

All of the following:

- 1 Patient has histologically confirmed ulcerative colitis; and
- 2 Either:
 - 2.1 Patient is 18 years or older and the Simple Clinical Colitis Activity Index (SCCAI) is ≥ 4 ; or
 - 2.2 Patient is under 18 years and the Paediatric Ulcerative Colitis Activity Index (PUCAI) score is ≥ 65 ; and

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses for an adequate duration (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate; and
- 5 Patient must be reassessed for continuation after 3 months of therapy.

Continuation - severe ulcerative colitis

Gastroenterologist

All of the following:

- 1 Patient is continuing to maintain remission and the benefit of continuing infliximab outweighs the risks; and
- 2 Either:
 - 2.1 Patient is 18 years or older and the SCCAI score has reduced by ≥ 2 points from the SCCAI score when the patient was initiated on infliximab; or
 - 2.2 Patient is under 18 years and the PUCAI score has reduced by ≥ 30 points from the PUCAI score when the patient was initiated on infliximab; and
- 3 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initiation - plaque psoriasis

Dermatologist

Re-assessment required after 3 doses

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab or etanercept for severe chronic plaque psoriasis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab or etanercept; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab or etanercept to meet the renewal criteria for adalimumab or etanercept for severe chronic plaque psoriasis.
- 2 All of the following:
 - 2.1 Either:
 - 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
 - 2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and
 - 2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
 - 2.4 The most recent PASI assessment is no more than 1 month old at the time of initiation.

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Continuation - plaque psoriasis

Dermatologist

Re-assessment required after 3 doses

Both:

- 1 Either:
 - 1.1 Both:
 - 1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
 - 1.1.2 Following each prior infliximab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-infliximab treatment baseline value; or
 - 1.2 Both:
 - 1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 1.2.2 Either:
 - 1.2.2.1 Following each prior infliximab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 1.2.2.2 Following each prior infliximab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-infliximab treatment baseline value; and
- 2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

OMALIZUMAB – **Restricted** see terms below

¶ Inj 150 mg vial	500.00	1	Xolair
-------------------------	--------	---	--------

➡Restricted

Initiation

Respiratory physician

Re-assessment required after 6 months

All of the following:

- 1 Patient is over the age of 6; and
- 2 Patient has a diagnosis of severe, life threatening asthma; and
- 3 Past or current evidence of atopy, documented by skin prick testing or RAST; and
- 4 Total serum human immunoglobulin E (IgE) between 76 IU/mL and 1300 IU/ml at baseline; and
- 5 Proven compliance with optimal inhaled therapy including high dose inhaled corticosteroid (budesonide 1600 micrograms per day or fluticasone propionate 1000 micrograms per day or equivalent), plus long-acting beta-2 agonist therapy (at least salmeterol 50 micrograms bd or eformoterol 12 micrograms bd) for at least 12 months, unless contraindicated or not tolerated; and
- 6 Patient has received courses of systemic corticosteroids equivalent to at least 28 days treatment in the past 12 months, unless contraindicated or not tolerated; and
- 7 At least four admissions to hospital for a severe asthma exacerbation over the previous 24 months with at least one of those being in the previous 12 months; and
- 8 An Asthma Control Questionnaire (ACQ-5) score of at least 3.0 as assessed in the previous month.

continued...

↑Item restricted (see ➡ above); ¶Item restricted (see ➡ below)

e.g. Brand indicates brand example only. It is not a contracted product.

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued. . .

Continuation

Respiratory physician

Re-assessment required after 6 months

All of the following:

- 1 Hospital admissions have been reduced as a result of treatment; and
- 2 A reduction in the Asthma Control Questionnaire (ACQ-5) score of at least 1.0 from baseline; and
- 3 A reduction in the maintenance oral corticosteroid dose of at least 50% from baseline.

RANIBIZUMAB – Restricted see terms below

⚡ Inj 10 mg per ml, 0.23 ml vial

⚡ Inj 10 mg per ml, 0.3 ml vial

➡ **Restricted**

Initiation

Re-assessment required after 3 doses

Both:

- 1 Either
 - 1.1 Age-related macular degeneration; or
 - 1.2 Choroidal neovascular membrane; and
- 2 Any of the following:
 - 2.1 The patient has had a severe ophthalmic inflammatory response following bevacizumab; or
 - 2.2 The patient has had a myocardial infarction or stroke within the last three months; or
 - 2.3 The patient has failed to respond to bevacizumab following three intraocular injections; or
 - 2.4 The patient is of child-bearing potential and has not completed a family.

Continuation

Both:

- 1 Documented benefit after three doses must be demonstrated to continue; and
- 2 In the case of but previous non-response to bevacizumab, a retreat of bevacizumab is required to confirm non-response before continuing with ranibizumab.

RITUXIMAB – Restricted see terms below

⚡ Inj 10 mg per ml, 10 ml vial	1,075.50	2	Mabthera
⚡ Inj 10 mg per ml, 50 ml vial	2,688.30	1	Mabthera

➡ **Restricted**

Initiation - haemophilia with inhibitors

Haematologist

Any of the following:

- 1 Patient has mild congenital haemophilia complicated by inhibitors; or
- 2 Patient has severe congenital haemophilia complicated by inhibitors and has failed immune tolerance therapy; or
- 3 Patient has acquired haemophilia.

Continuation - haemophilia with inhibitors

Haematologist

All of the following:

- 1 Patient was previously treated with rituximab for haemophilia with inhibitors; and
- 2 An initial response lasting at least 12 months was demonstrated; and
- 3 Patient now requires repeat treatment.

Initiation - post-transplant

Both:

- 1 The patient has B-cell post-transplant lymphoproliferative disorder*; and
- 2 To be used for a maximum of 8 treatment cycles.

continued. . .

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

Note: Indications marked with * are Unapproved Indications.

Continuation - post-transplant

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has B-cell post-transplant lymphoproliferative disorder*; and
- 3 To be used for no more than 6 treatment cycles.

Note: Indications marked with * are Unapproved Indications

Initiation - indolent, low-grade lymphomas

Either:

- 1 Both:
 - 1.1 The patient has indolent low grade NHL with relapsed disease following prior chemotherapy; and
 - 1.2 To be used for a maximum of 6 treatment cycles; or
- 2 Both:
 - 2.1 The patient has indolent, low grade lymphoma requiring first-line systemic chemotherapy; and
 - 2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia.

Continuation - indolent, low-grade lymphomas

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has indolent, low-grade NHL with relapsed disease following prior chemotherapy; and
- 3 To be used for no more than 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia.

Initiation - aggressive CD20 positive NHL

Either:

- 1 All of the following:
 - 1.1 The patient has treatment naive aggressive CD20 positive NHL; and
 - 1.2 To be used with a multi-agent chemotherapy regimen given with curative intent; and
 - 1.3 To be used for a maximum of 8 treatment cycles; or
- 2 Both:
 - 2.1 The patient has aggressive CD20 positive NHL with relapsed disease following prior chemotherapy; and
 - 2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.

Continuation - aggressive CD20 positive NHL

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has relapsed refractory/aggressive CD20 positive NHL; and
- 3 To be used with a multi-agent chemotherapy regimen given with curative intent; and
- 4 To be used for a maximum of 4 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.

Chronic lymphocytic leukaemia

All of the following:

- 1 The patient has progressive Binet stage A, B or C chronic lymphocytic leukaemia (CLL) requiring treatment; and
- 2 The patient is rituximab treatment naive; and
- 3 Either:
 - 3.1 The patient is chemotherapy treatment naive; or
 - 3.2 Both:
 - 3.2.1 The patient's disease has relapsed following no more than three prior lines of chemotherapy treatment; and

continued...

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

3.2.2 The patient has had a treatment-free interval of 12 months or more if previously treated with fludarabine and cyclophosphamide chemotherapy; and

- 4 The patient has good performance status; and
- 5 The patient has good renal function (creatinine clearance \geq 30 ml/min); and
- 6 The patient does not have chromosome 17p deletion CLL; and
- 7 Rituximab to be administered in combination with fludarabine and cyclophosphamide for a maximum of 6 treatment cycles; and
- 8 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration).

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with rituximab is expected to improve symptoms and improve ECOG score to <2.

Initiation - rheumatoid arthritis - prior TNF inhibitor use

Rheumatologist

Re-assessment required after 2 doses

All of the following:

- 1 Both:
 - 1.1 The patient has had an initial community Special Authority approval for at least one of etanercept and/or adalimumab for rheumatoid arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
 - 1.2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for rheumatoid arthritis; and
- 2 Either:
 - 2.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
 - 2.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 3 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Initiation - rheumatoid arthritis - TNF inhibitors contraindicated

Rheumatologist

Re-assessment required after 2 doses

All of the following:

- 1 Treatment with a Tumour Necrosis Factor alpha inhibitor is contraindicated; and
- 2 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
- 3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
- 4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
- 5 Any of the following:
 - 5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of ciclosporin; or
 - 5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
 - 5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
- 6 Either:
 - 6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 7 Either:
 - 7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months; and
- 8 Either:
 - 8.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
 - 8.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 9 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Continuation - rheumatoid arthritis - re-treatment in 'partial responders' to rituximab

Rheumatologist

Re-assessment required after 2 doses

All of the following:

- 1 Either:
 - 1.1 At 4 months following the initial course of rituximab infusions the patient had between a 30% and 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.2 At 4 months following the second course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.3 At 4 months following the third and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and
- 3 Either:
 - 3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
 - 3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Continuation - rheumatoid arthritis - re-treatment in 'responders' to rituximab

Rheumatologist

Re-assessment required after 2 doses

All of the following:

- 1 Either:
 - 1.1 At 4 months following the initial course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 1.2 At 4 months following the second and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and
- 3 Either:
 - 3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
 - 3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
- 4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Initiation – severe cold haemagglutinin disease (CHAD)

Haematologist

Limited to 4 weeks' treatment

Both:

- 1 Patient has cold haemagglutinin disease*; and

continued...

↑Item restricted (see ➡ above); ↓Item restricted (see ➡ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

Price (ex man. excl. GST) \$	Brand or Generic Manufacturer
------------------------------------	-------------------------------------

continued...

- 2 Patient has severe disease which is characterized by symptomatic anaemia, transfusion dependence or disabling circulatory symptoms.

Note: Indications marked with * are Unapproved Indications.

Continuation – severe cold haemagglutinin disease (CHAD)

Haematologist

Limited to 4 weeks' treatment

Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
- 2 All of the following:
 - 2.1 Patient was previously treated with rituximab for severe cold haemagglutinin disease*; and
 - 2.2 An initial response lasting at least 12 months was demonstrated; and
 - 2.3 Patient now requires repeat treatment.

Note: Indications marked with * are Unapproved Indications.

Initiation – warm autoimmune haemolytic anaemia (warm AIHA)

Haematologist

Limited to 4 weeks' treatment

Both:

- 1 Patient has warm autoimmune haemolytic anaemia*; and
- 2 One of the following treatments has been ineffective: steroids (including if patient requires ongoing steroids at doses equivalent to >5 mg prednisone daily), cytotoxic agents (e.g. cyclophosphamide monotherapy or in combination), intravenous immunoglobulin.

Note: Indications marked with * are Unapproved Indications.

Continuation – warm autoimmune haemolytic anaemia (warm AIHA)

Haematologist

Limited to 4 weeks' treatment

Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
- 2 All of the following:
 - 2.1 Patient was previously treated with rituximab for warm autoimmune haemolytic anaemia*; and
 - 2.2 An initial response lasting at least 12 months was demonstrated; and
 - 2.3 Patient now requires repeat treatment.

Note: Indications marked with * are Unapproved Indications.

Initiation – immune thrombocytopenic purpura (ITP)

Haematologist

Limited to 4 weeks' treatment

Both:

- 1 Either:
 - 1.1 Patient has immune thrombocytopenic purpura* with a platelet count of ≤ 20,000 platelets per microlitre; or
 - 1.2 Patient has immune thrombocytopenic purpura* with a platelet count of 20,000 to 30,000 platelets per microlitre and significant mucocutaneous bleeding; and
- 2 Any of the following:
 - 2.1 Treatment with steroids and splenectomy have been ineffective; or
 - 2.2 Treatment with steroids has been ineffective and splenectomy is an absolute contraindication; or
 - 2.3 Other treatments including steroids have been ineffective and patient is being prepared for elective surgery (e.g. splenectomy).

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

Note: Indications marked with * are Unapproved Indications.

Continuation – immune thrombocytopenic purpura (ITP)

Haematologist

Limited to 4 weeks' treatment

Either:

- 1 Previous treatment with lower doses of rituximab (100 mg weekly for 4 weeks) have proven ineffective and treatment with higher doses (375 mg/m² weekly for 4 weeks) is now planned; or
- 2 All of the following:
 - 2.1 Patient was previously treated with rituximab for immune thrombocytopenic purpura*; and
 - 2.2 An initial response lasting at least 12 months was demonstrated; and
 - 2.3 Patient now requires repeat treatment.

Note: Indications marked with * are Unapproved Indications.

Initiation – thrombotic thrombocytopenic purpura (TTP)

Haematologist

Limited to 4 weeks' treatment

Either:

- 1 Patient has thrombotic thrombocytopenic purpura* and has experienced progression of clinical symptoms or persistent thrombocytopenia despite plasma exchange; or
- 2 Patient has acute idiopathic thrombotic thrombocytopenic purpura* with neurological or cardiovascular pathology.

Note: Indications marked with * are Unapproved Indications.

Continuation – thrombotic thrombocytopenic purpura (TTP)

Haematologist

Limited to 4 weeks' treatment

All of the following:

- 1 Patient was previously treated with rituximab for thrombotic thrombocytopenic purpura*; and
- 2 An initial response lasting at least 12 months was demonstrated; and
- 3 Patient now requires repeat treatment.

Note: Indications marked with * are Unapproved Indications.

Initiation – pure red cell aplasia (PRCA)

Haematologist

Limited to 6 weeks' treatment

Patient has autoimmune pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder.

Note: Indications marked with * are Unapproved Indications.

Continuation – pure red cell aplasia (PRCA)

Haematologist

Limited to 6 weeks' treatment

Patient was previously treated with rituximab for pure red cell aplasia* associated with a demonstrable B-cell lymphoproliferative disorder and demonstrated an initial response lasting at least 12 months.

Note: Indications marked with * are Unapproved Indications.

Initiation – ANCA associated vasculitis

Limited to 4 weeks' treatment

All of the following:

- 1 Patient has been diagnosed with ANCA associated vasculitis*; and
- 2 Either:
 - 2.1 Patient does not have MPO-ANCA positive vasculitis*; or
 - 2.2 Mycophenolate mofetil has not been effective in those patients who have MPO-ANCA positive vasculitis*; and
- 3 The total rituximab dose would not exceed the equivalent of 375 mg/m² of body-surface area per week for a total of 4 weeks; and
- 4 Any of the following:

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- 4.1 Induction therapy with daily oral or pulse intravenous cyclophosphamide has failed to achieve complete absence of disease after at least 3 months; or
- 4.2 Patient has previously had a cumulative dose of cyclophosphamide >15 g or a further repeat 3 month induction course of cyclophosphamide would result in a cumulative dose >15 g; or
- 4.3 Cyclophosphamide and methotrexate are contraindicated; or
- 4.4 Patient is a female of child-bearing potential; or
- 4.5 Patient has a previous history of haemorrhagic cystitis, urological malignancy or haematological malignancy.

Note: Indications marked with * are Unapproved Indications.

Continuation – ANCA associated vasculitis

Limited to 4 weeks' treatment

All of the following:

- 1 Patient has been diagnosed with ANCA associated vasculitis*; and
- 2 Patient has previously responded to treatment with rituximab but is now experiencing an acute flare of vasculitis; and
- 3 The total rituximab dose would not exceed the equivalent of 375 mg/m² of body-surface area per week for a total of 4 weeks.

Note: Indications marked with * are Unapproved Indications.

Initiation – treatment refractory systemic lupus erythematosus (SLE)

Rheumatologist or nephrologist

All of the following:

- 1 The patient has severe, immediately life- or organ-threatening SLE*; and
- 2 The disease has proved refractory to treatment with steroids at a dose of at least 1 mg/kg; and
- 3 The disease has relapsed following prior treatment for at least 6 months with maximal tolerated doses of azathioprine, mycophenolate mofetil and high dose cyclophosphamide, or cyclophosphamide is contraindicated; and
- 4 Maximum of four 1000 mg infusions of rituximab.

Note: Indications marked with * are Unapproved Indications.

Continuation – treatment refractory systemic lupus erythematosus (SLE)

Rheumatologist or nephrologist

All of the following:

- 1 Patient's SLE* achieved at least a partial response to the previous round of prior rituximab treatment; and
- 2 The disease has subsequently relapsed; and
- 3 Maximum of two 1000 mg infusions of rituximab.

Note: Indications marked with * are Unapproved Indications.

Antibody-mediated renal transplant rejection

Nephrologist

Patient has been diagnosed with antibody-mediated renal transplant rejection*.

Note: Indications marked with * are Unapproved Indications.

ABO-incompatible renal transplant

Nephrologist

Patient is to undergo an ABO-incompatible renal transplant*.

Note: Indications marked with * are Unapproved Indications.

TOCILIZUMAB – **Restricted** see terms on the next page

⚡ Inj 20 mg per ml, 4 ml vial	220.00	1	Actemra
⚡ Inj 20 mg per ml, 10 ml vial	550.00	1	Actemra
⚡ Inj 20 mg per ml, 20 ml vial	1,100.00	1	Actemra

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

➔Restricted
Initiation -Rheumatoid Arthritis

Rheumatologist

Re-assessment required after 6 months

Either:

- 1 All of the following:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
 - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for rheumatoid arthritis; and
 - 1.3 The patient has been started on rituximab for rheumatoid arthritis in a DHB hospital in accordance with the HML rules; and
 - 1.4 Either:
 - 1.4.1 The patient has experienced intolerable side effects from rituximab; or
 - 1.4.2 At four months following the initial course of rituximab the patient has received insufficient benefit such that they do not meet the renewal criteria for rheumatoid arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
 - 2.2 Tocilizumab is to be used as monotherapy; and
 - 2.3 Either:
 - 2.3.1 Treatment with methotrexate is contraindicated; or
 - 2.3.2 Patient has tried and did not tolerate oral and/or parenteral methotrexate; and
 - 2.4 Either:
 - 2.4.1 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of ciclosporin alone or in combination with another agent; or
 - 2.4.2 Patient has tried and not responded to at least three months therapy at the maximum tolerated dose of leflunomide alone or in combination with another agent; and
 - 2.5 Either:
 - 2.5.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 active, swollen, tender joints; or
 - 2.5.2 Patient has persistent symptoms of poorly controlled and active disease in at least four active joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.6 Either:
 - 2.6.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.6.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Continuation - Rheumatoid Arthritis

Rheumatologist

Re-assessment required after 6 months

Either:

- 1 Following 6 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician.

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued. . .

Initiation - systemic juvenile idiopathic arthritis

Rheumatologist

Re-assessment required after 6 months

- Both:
- 1 Patient diagnosed with systemic juvenile idiopathic arthritis; and
 - 2 Patient has tried and not responded to a reasonable trial of all of the following, either alone or in combination: oral or parenteral methotrexate; non-steroidal anti-inflammatory drugs (NSAIDs); and systemic corticosteroids.

Continuation - systemic juvenile idiopathic arthritis

Rheumatologist

Re-assessment required after 6 months

- Either:
- 1 Following up to 6 months' initial treatment, the patient has achieved at least an American College of Rheumatology paediatric 30% improvement criteria (ACR Pedi 30) response from baseline; or
 - 2 On subsequent reapplications, the patient demonstrates at least a continuing ACR Pedi 30 response from baseline.

Initiation - adult-onset Still's disease

Rheumatologist

Re-assessment required after 6 months

- Either:
- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab or etanercept for adult-onset Still's disease (AOSD); and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab and/or etanercept; or
 - 1.2.2 The patient has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for AOSD; or
 - 2 All of the following:
 - 2.1 Patient diagnosed with AOSD according to the Yamaguchi criteria (J Rheumatol 1992;19:424-430); and
 - 2.2 Patient has tried and not responded to at least 6 months of glucocorticosteroids, non-steroidal antiinflammatory drugs (NSAIDs) and methotrexate; and
 - 2.3 Patient has persistent symptoms of disabling poorly controlled and active disease.

Continuation - adult-onset Still's disease

Rheumatologist

Re-assessment required after 6 months

The patient has a sustained improvement in inflammatory markers and functional status.

TRASTUZUMAB – **Restricted** see terms below

¶ Inj 150 mg vial	1,350.00	1	Herceptin
¶ Inj 440 mg vial	3,875.00	1	Herceptin

➔ **Restricted**

Early breast cancer

Limited to 12 months' treatment

- All of the following:
- 1 The patient has early breast cancer expressing HER 2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 2 Maximum cumulative dose of 106 mg/kg (12 months' treatment); and
 - 3 Any of the following:
 - 3.1 9 weeks' concurrent treatment with adjuvant chemotherapy is planned; or
 - 3.2 12 months' concurrent treatment with adjuvant chemotherapy is planned; or
 - 3.3 12 months' sequential treatment following adjuvant chemotherapy is planned; or
 - 3.4 12 months' treatment with neoadjuvant and adjuvant chemotherapy is planned, or

continued. . .

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

3.5 Other treatment regimen, in association with adjuvant chemotherapy, is planned.

Initiation - metastatic breast cancer (trastuzumab-naive patients)

Re-assessment required after 12 months

Either:

- 1 All of the following:
 - 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 1.2 The patient has not previously received lapatinib treatment for HER 2 positive metastatic breast cancer; and
 - 1.3 Trastuzumab not to be given in combination with lapatinib; and
 - 1.4 Trastuzumab to be discontinued at disease progression; or
- 2 All of the following:
 - 2.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 2.2 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
 - 2.3 The cancer did not progress whilst on lapatinib; and
 - 2.4 Trastuzumab not to be given in combination with lapatinib; and
 - 2.5 Trastuzumab to be discontinued at disease progression.

Initiation - metastatic breast cancer (patients previously treated with trastuzumab)

Re-assessment required after 12 months

All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The patient received prior adjuvant trastuzumab treatment for early breast cancer; and
- 3 Any of the following:
 - 3.1 All of the following:
 - 3.1.1 The patient has not previously received lapatinib treatment for metastatic breast cancer; and
 - 3.1.2 Trastuzumab not to be given in combination with lapatinib; and
 - 3.1.3 Trastuzumab to be discontinued at disease progression; or
 - 3.2 All of the following:
 - 3.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
 - 3.2.2 The cancer did not progress whilst on lapatinib; and
 - 3.2.3 Trastuzumab not to be given in combination with lapatinib; and
 - 3.2.4 Trastuzumab to be discontinued at disease progression; or
 - 3.3 All of the following:
 - 3.3.1 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
 - 3.3.2 Trastuzumab not to be given in combination with lapatinib; and
 - 3.3.3 Trastuzumab to be discontinued at disease progression.

Continuation - metastatic breast cancer

Re-assessment required after 12 months

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
- 3 Trastuzumab not to be given in combination with lapatinib; and
- 4 Trastuzumab to be discontinued at disease progression.

Other Immunosuppressants

ANTITHYMOCYTE GLOBULIN (EQUINE)

Inj 50 mg per ml, 5 ml ampoule	2,351.25	5	ATGAM
--------------------------------------	----------	---	-------

↑Item restricted (see ➡ above); ↓Item restricted (see ➡ below)

e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
ANTITHYMOCYTE GLOBULIN (RABBIT)			
Inj 25 mg vial			
AZATHIOPRINE			
Tab 25 mg	8.28	60	Azamun
Tab 50 mg – 1% DV Jun-14 to 2016	13.22	100	Azamun
Inj 50 mg vial	126.00	1	Imuran
BACILLUS CALMETTE-GUERIN (BCG) – Restricted see terms below			
⚡ Inj 2-8 × 10 ⁸ CFU vial – 1% DV Sep-13 to 2016	149.37	1	OncoTICE
⚡ Inj 40 mg per ml, vial	149.37	3	SII-Onco-BCG
➔ Restricted			
For use in bladder cancer			
EVEROLIMUS – Restricted see terms below			
⚡ Tab 5 mg	4,555.76	30	Afinitor
⚡ Tab 10 mg	6,512.29	30	Afinitor
➔ Restricted			
Initiation			
Neurologist or oncologist			
<i>Re-assessment required after 3 months</i>			
Both:			
1 Patient has tuberous sclerosis; and			
2 Patient has progressively enlarging sub-ependymal giant cell astrocytomas (SEGAs) that require treatment.			
Continuation			
Neurologist or oncologist			
<i>Re-assessment required after 12 months</i>			
All of the following:			
1 Documented evidence of SEGAs reduction or stabilisation by MRI within the last 3 months; and			
2 The treatment remains appropriate and the patient is benefiting from treatment; and			
3 Everolimus to be discontinued at progression of SEGAs.			
Note: MRI should be performed at minimum once every 12 months, more frequent scanning should be performed with new onset of symptoms such as headaches, visual complaints, nausea or vomiting, or increase in seizure activity.			
MYCOPHENOLATE MOFETIL			
Tab 500 mg – 1% DV Nov-13 to 2016	25.00	50	CellCept
Cap 250 mg – 1% DV Nov-13 to 2016	25.00	100	CellCept
Powder for oral liq 1 g per 5 ml – 1% DV Nov-13 to 2016	187.25	165 ml	CellCept
Inj 500 mg vial – 1% DV Nov-13 to 2016	133.33	4	CellCept
PICIBANIL			
Inj 100 mg vial			
SIROLIMUS – Restricted see terms below			
⚡ Tab 1 mg	813.00	100	Rapamune
⚡ Tab 2 mg	1,626.00	100	Rapamune
⚡ Oral liq 1 mg per ml	487.80	60 ml	Rapamune
➔ Restricted			
For rescue therapy for an organ transplant recipient			
Notes: Rescue therapy defined as unresponsive to calcineurin inhibitor treatment as defined by refractory rejection; or intolerant to calcineurin inhibitor treatment due to any of the following:			
<ul style="list-style-type: none"> ● GFR < 30 ml/min; or ● Rapidly progressive transplant vasculopathy; or ● Rapidly progressive obstructive bronchiolitis; or 			

continued...

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued...

- HUS or TTP; or
- Leukoencephalopathy; or
- Significant malignant disease

Price			Brand or
(ex man. excl. GST)			Generic
\$	Per		Manufacturer

Antiallergy Preparations

Allergic Emergencies

ICATIBANT – **Restricted** see terms below

⚡ Inj 10 mg per ml, 3 ml prefilled syringe2,668.00 1 Firazyr

➔**Restricted**

Clinical immunologist or relevant specialist

Initiation

Clinical immunologist or relevant specialist

Re-assessment required after 12 months

- Both:
- 1 Supply for anticipated emergency treatment of laryngeal/oro-pharyngeal or severe abdominal attacks of acute hereditary angioedema (HAE) for patients with confirmed diagnosis of C1-esterase inhibitor deficiency; and
 - 2 The patient has undergone product training and has agreed upon an action plan for self-administration.

Continuation

Re-assessment required after 12 months

Allergy Desensitisation

BEE VENOM – **Restricted** see terms below

⚡ Inj 550 mcg vial with diluent

➔**Restricted**

- Both:
- 1 RAST or skin test positive; and
 - 2 Patient has had severe generalised reaction to the sensitising agent.

PAPER WASP VENOM – **Restricted** see terms below

⚡ Inj 550 mcg vial with diluent

➔**Restricted**

- Both:
- 1 RAST or skin test positive; and
 - 2 Patient has had severe generalised reaction to the sensitising agent.

YELLOW JACKET WASP VENOM – **Restricted** see terms below

⚡ Inj 550 mcg vial with diluent

➔**Restricted**

- Both:
- 1 RAST or skin test positive; and
 - 2 Patient has had severe generalised reaction to the sensitising agent.

Allergy Prophylactics

BECLOMETHASONE DIPROPIONATE

Nasal spray 50 mcg per dose4.85 200 dose Alanase

Nasal spray 100 mcg per dose5.75 200 dose Alanase

BUDESONIDE

Nasal spray 50 mcg per dose4.85 200 dose Butacort Aqueous

Nasal spray 100 mcg per dose5.75 200 dose Butacort Aqueous

FLUTICASONE PROPIONATE

Nasal spray 50 mcg per dose – **1% DV Sep-15 to 2018**.....2.18 120 dose **Flixonase Hayfever & Allergy**

RESPIRATORY SYSTEM AND ALLERGIES

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
IPRATROPIUM BROMIDE			
Aqueous nasal spray 0.03% – 1% DV Jan-15 to 2017	3.95	15 ml	Univent
SODIUM CROMOGLYCATE			
Nasal spray 4%			
Antihistamines			
CETIRIZINE HYDROCHLORIDE			
Tab 10 mg	1.59	100	Zetop
Oral liq 1 mg per ml – 1% DV Feb-15 to 2017	2.99	200 ml	Histaclear
CHLORPHENIRAMINE MALEATE			
Oral liq 0.4 mg per ml			
Inj 10 mg per ml, 1 ml ampoule			
CYPROHEPTADINE HYDROCHLORIDE			
Tab 4 mg			
FEXOFENADINE HYDROCHLORIDE			
Tab 60 mg			
Tab 120 mg			
Tab 180 mg			
LORATADINE			
Tab 10 mg – 1% DV Dec-13 to 2016	1.30	100	Lorafix
Oral liq 1 mg per ml – 1% DV Nov-14 to 2016	4.25	200 ml	LoraPaed
PROMETHAZINE HYDROCHLORIDE			
Tab 10 mg – 1% DV Sep-15 to 2018	1.78	50	Allersoothe
Tab 25 mg – 1% DV Sep-15 to 2018	1.99	50	Allersoothe
Oral liq 1 mg per ml – 1% DV Sep-15 to 2018	2.59	100 ml	Allersoothe
Inj 25 mg per ml, 2 ml ampoule	11.99	5	Hospira
TRIMEPRAZINE TARTRATE			
Oral liq 6 mg per ml			
Anticholinergic Agents			
IPRATROPIUM BROMIDE			
Aerosol inhaler 20 mcg per dose			
Nebuliser soln 250 mcg per ml, 1 ml ampoule – 1% DV Sep-13 to 2016	3.26	20	Univent
Nebuliser soln 250 mcg per ml, 2 ml ampoule – 1% DV Sep-13 to 2016	3.37	20	Univent
Anticholinergic Agents with Beta-Adrenoceptor Agonists			
SALBUTAMOL WITH IPRATROPIUM BROMIDE			
Aerosol inhaler 100 mcg with ipratropium bromide 20 mcg per dose			
Nebuliser soln 2.5 mg with ipratropium bromide 0.5 mg per 2.5 ml ampoule – 1% DV Sep-15 to 2018	3.59	20	Duolin

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Long-Acting Muscarinic Agents

➔ Restricted

Initiation

All of the following:

- 1 To be used for the long-term maintenance treatment of bronchospasm and dyspnoea associated with COPD; and
- 2 In addition to standard treatment, the patient has trialed a short acting bronchodilator dose of at least 40 µg ipratropium q.i.d for one month; and
- 3 Either the patient's breathlessness according to the Medical Research Council (UK) dyspnoea scale is:
 - 3.1 Grade 4 (stops for breath after walking about 100 meters or after a few minutes on the level); or
 - 3.2 Grade 5 (too breathless to leave the house, or breathless when dressing or undressing); and
- 4 Actual FEV₁ as a % of predicted, must be below 60%.
- 5 Either:
 - 5.1 Patient is not a smoker (for reporting purposes only); or
 - 5.2 Patient is a smoker and has been offered smoking cessation counselling; and
- 6 The patient has been offered annual influenza immunization.

GLYCOPYRRONIUM – **Restricted** see terms above

Note: glycopyrronium treatment must not be used if the patient is also receiving treatment with subsidised tiotropium.

⬆ Powder for inhalation 50 mcg per dose 61.00 30 dose Seebri Breezhaler

TIOTROPIUM BROMIDE – **Restricted** see terms above

Note: tiotropium treatment must not be used if the patient is also receiving treatment with subsidised glycopyrronium.

⬆ Powder for inhalation 18 mcg per dose 70.00 30 dose Spiriva

Beta-Adrenoceptor Agonists

SALBUTAMOL

Oral liq 400 mcg per ml – 1% DV Jan-14 to 2016 2.06 150 ml **Ventolin**

Inj 500 mcg per ml, 1 ml ampoule

Inj 1 mg per ml, 5 ml ampoule

Aerosol inhaler, 100 mcg per dose 3.80 200 dose SalAir

4.00 Salamol

6.00 Ventolin

Nebuliser soln 1 mg per ml, 2.5 ml ampoule – 1% DV Sep-15 to 2018 3.19 20 **Asthalin**

Nebuliser soln 2 mg per ml, 2.5 ml ampoule – 1% DV Sep-15 to 2018 3.29 20 **Asthalin**

TERBUTALINE SULPHATE

Powder for inhalation 250 mcg per dose

Inj 0.5 mg per ml, 1 ml ampoule

Cough Suppressants

PHOLCODINE

Oral liq 1 mg per ml

Decongestants

OXYMETAZOLINE HYDROCHLORIDE

Aqueous nasal spray 0.25 mg per ml

Aqueous nasal spray 0.5 mg per ml

PSEUDOEPHEDRINE HYDROCHLORIDE

Tab 60 mg

SODIUM CHLORIDE

Aqueous nasal spray isotonic

RESPIRATORY SYSTEM AND ALLERGIES

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
SODIUM CHLORIDE WITH SODIUM BICARBONATE			
Soln for nasal irrigation			
XYLOMETAZOLINE HYDROCHLORIDE			
Aqueous nasal spray 0.05%			
Aqueous nasal spray 0.1%			
Nasal drops 0.05%			
Nasal drops 0.1%			

Inhaled Corticosteroids

BECLOMETHASONE DIPROPIONATE			
Aerosol inhaler 50 mcg per dose	8.54	200 dose	Beclazone 50
	9.30		Qvar
Aerosol inhaler 100 mcg per dose	12.50	200 dose	Beclazone 100
	15.50		Qvar
Aerosol inhaler 250 mcg per dose	22.67	200 dose	Beclazone 250
BUDESONIDE			
Nebuliser soln 250 mcg per ml, 2 ml ampoule			
Nebuliser soln 500 mcg per ml, 2 ml ampoule			
Powder for inhalation 100 mcg per dose			
Powder for inhalation 200 mcg per dose			
Powder for inhalation 400 mcg per dose			
FLUTICASONE			
Aerosol inhaler 50 mcg per dose	7.50	120 dose	Flixotide
			Floair
Powder for inhalation 50 mcg per dose	8.67	60 dose	Flixotide Accuhaler
Powder for inhalation 100 mcg per dose	13.87	60 dose	Flixotide Accuhaler
Aerosol inhaler 125 mcg per dose	13.60	120 dose	Flixotide
			Floair
Aerosol inhaler 250 mcg per dose	27.20	120 dose	Flixotide
			Floair
Powder for inhalation 250 mcg per dose	24.51	60 dose	Flixotide Accuhaler

Leukotriene Receptor Antagonists

MONTELUKAST – Restricted see terms below			
⚡ Tab 4 mg	18.48	28	Singulair
⚡ Tab 5 mg	18.48	28	Singulair
⚡ Tab 10 mg	18.48	28	Singulair

↪ Restricted

Pre-school wheeze

Both:

- To be used for the treatment of intermittent severe wheezing (possibly viral); and
- The patient has had at least three episodes in the previous 12 months of acute wheeze severe enough to seek medical attention.

Exercise-induced asthma

All of the following:

- Patient has been trialed with maximal asthma therapy, including inhaled corticosteroids and long-acting beta-adrenoceptor agonists; and
- Patient continues to receive optimal inhaled corticosteroid therapy; and

continued...

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

continued. . .

- 3 Patient continues to experience frequent episodes of exercise-induced bronchoconstriction.

Aspirin desensitisation

Clinical immunologist or allergist

All of the following:

- 1 Patient is undergoing aspirin desensitisation therapy under the supervision of a clinical immunologist or allergist; and
- 2 Patient has moderate to severe aspirin-exacerbated respiratory disease or Samter's triad; and
- 3 Nasal polyposis, confirmed radiologically or surgically; and
- 4 Documented aspirin or NSAID allergy confirmed by aspirin challenge or a clinical history of severe reaction to aspirin or NSAID where challenge would be considered dangerous.

Long-Acting Beta-Adrenoceptor Agonists

EFORMOTEROL FUMARATE

- Powder for inhalation 6 mcg per dose
- Powder for inhalation 12 mcg per dose

INDACATEROL

- Powder for inhalation 150 mcg per dose61.00 30 dose Onbrez Breezhaler
- Powder for inhalation 300 mcg per dose61.00 30 dose Onbrez Breezhaler

SALMETEROL

- Aerosol inhaler 25 mcg per dose26.46 120 dose Meterol Serevent
- Powder for inhalation 50 mcg per dose26.46 60 dose Serevent Accuhaler

Inhaled Corticosteroids with Long-Acting Beta-Adrenoceptor Agonists

BUDESONIDE WITH EFORMOTEROL – Restricted see terms below

- ⚡ Powder for inhalation 100 mcg with eformoterol fumarate 6 mcg
- ⚡ Powder for inhalation 200 mcg with eformoterol fumarate 6 mcg
- ⚡ Powder for inhalation 400 mcg with eformoterol fumarate 12 mcg
- ⚡ Aerosol inhaler 100 mcg with eformoterol fumarate 6 mcg
- ⚡ Aerosol inhaler 200 mcg with eformoterol fumarate 6 mcg

➡Restricted

Either:

- 1 All of the following:
 - 1.1 Patient is a child under the age of 12; and
 - 1.2 Has been treated with inhaled corticosteroids of at least 400 mcg per day beclomethasone or budesonide, or 200 mcg per day fluticasone; and
 - 1.3 The prescriber considers that the patient would receive additional clinical benefit from switching to a combination product; or
- 2 All of the following:
 - 2.1 Patient is over the age of 12; and
 - 2.2 Has been treated with inhaled corticosteroids of at least 800 mcg per day beclomethasone or budesonide, or 500 mcg per day fluticasone; and
 - 2.3 The prescriber considers that the patient would receive additional clinical benefit from switching to a combination product.

RESPIRATORY SYSTEM AND ALLERGIES

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
FLUTICASONE WITH SALMETEROL			
Aerosol inhaler 50 mcg with salmeterol 25 mcg	37.48	120 dose	RexAir Seretide
Powder for inhalation 100 mcg with salmeterol 50 mcg	37.48	60 dose	Seretide Accuhaler
Aerosol inhaler 125 mcg with salmeterol 25 mcg	49.69	120 dose	RexAir Seretide
Powder for inhalation 250 mcg with salmeterol 50 mcg	49.69	60 dose	Seretide Accuhaler

Mast Cell Stabilisers

NEDOCROMIL

Aerosol inhaler 2 mg per dose

SODIUM CROMOGLYCAT

Powder for inhalation 20 mg per dose

Aerosol inhaler 5 mg per dose

Methylxanthines

AMINOPHYLLINE

Inj 25 mg per ml, 10 ml ampoule – 1% DV Oct-14 to 2017 118.25 5 **DBL Aminophylline**

CAFFEINE CITRATE

Oral liq 20 mg per ml (caffeine 10 mg per ml) 14.85 25 ml Biomed

Inj 20 mg per ml (caffeine 10 mg per ml), 2.5 ml ampoule 55.75 5 Biomed

THEOPHYLLINE

Tab long-acting 250 mg

Oral liq 80 mg per 15 ml

Mucolytics and Expectorants

DORNASE ALFA – **Restricted** see terms below

☠ Nebuliser soln 2.5 mg per 2.5 ml ampoule 250.00 6 Pulmozyme

☛ **Restricted**

Any of the following:

- 1 Cystic fibrosis and the patient has been approved by the Cystic Fibrosis Panel; and/or
- 2 Significant mucus production and meets the following criteria
- 3 Treatment for up to four weeks for patients meeting the following:
 - 3.1 Patient is an in-patient; and
 - 3.2 The mucus production cannot be cleared by first line chest techniques; or
- 4 Treatment for up to three days for patients diagnosed with empyema.

SODIUM CHLORIDE

Nebuliser soln 7%, 90 ml bottle 23.50 90 ml Biomed

Pulmonary Surfactants

BERACTANT

Soln 200 mg per 8 ml vial 550.00 1 Survanta

PORACTANT ALFA

Soln 120 mg per 1.5 ml vial 425.00 1 Curosurf

Soln 240 mg per 3 ml vial 695.00 1 Curosurf

↑ Item restricted (see ☛ above); ☠ Item restricted (see ☛ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

Price (ex man. excl. GST)	Brand or Generic
\$	Per Manufacturer

Respiratory Stimulants

DOXAPRAM

Inj 20 mg per ml, 5 ml vial

Sclerosing Agents

TALC

Powder

Soln (slurry) 100 mg per ml, 50 ml

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Anti-Infective Preparations			
Antibacterials			
CHLORAMPHENICOL			
Eye oint 1%	3.19	4 g	Chlorsig
Ear drops 0.5%			
Eye drops 0.5% – 1% DV Sep-15 to 2018	0.98	10 ml	Chlorafast
Eye drops 0.5%, single dose			
CIPROFLOXACIN			
Eye drops 0.3%			
FRAMYCETIN SULPHATE			
Ear/eye drops 0.5%			
FUSIDIC ACID			
Eye drops 1%	4.50	5 g	Fucithalmic
GENTAMICIN SULPHATE			
Eye drops 0.3%	11.40	5 ml	Genoptoc
PROPAMIDINE ISETHIONATE			
Eye drops 0.1%			
SULPHACETAMIDE SODIUM			
Eye drops 10%			
TOBRAMYCIN			
Eye oint 0.3% – 1% DV Sep-14 to 2017	10.45	3.5 g	Tobrex
Eye drops 0.3% – 1% DV Sep-14 to 2017	11.48	5 ml	Tobrex
Antifungals			
NATAMYCIN			
Eye drops 5%			
Antivirals			
ACICLOVIR			
Eye oint 3%			
GANCICLOVIR			
Eye gel 0.15%			<i>e.g. Virgan</i>
Combination Preparations			
CIPROFLOXACIN WITH HYDROCORTISONE			
Ear drops ciprofloxacin 0.2% with 1% hydrocortisone – 1% DV Mar-15 to 2017	16.30	10 ml	Ciproxin HC Otic
DEXAMETHASONE WITH FRAMYCETIN AND GRAMICIDIN			
Ear/eye drops 500 mcg with framycetin sulphate 5 mg and gramicidin 50 mcg per ml			

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

e.g. Brand indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
DEXAMETHASONE WITH NEOMYCIN SULPHATE AND POLYMYXIN B SULPHATE			
Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin b sulphate 6,000 u per g – 1% DV Sep-14 to 2017	5.39	3.5 g	Maxitrol
Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin b sulphate 6,000 u per ml – 1% DV Sep-14 to 2017	4.50	5 ml	Maxitrol
DEXAMETHASONE WITH TOBRAMYCIN			
Eye drops 0.1% with tobramycin 0.3% – 1% DV Mar-15 to 2017	12.64	5 ml	Tobradex
FLUMETASONE PIVALATE WITH CLIOQUINOL			
Ear drops 0.02% with clioquinol 1%			
TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN AND NYSTATIN			
Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g	5.16	7.5 ml	Kenacomb

Anti-Inflammatory Preparations

Corticosteroids

DEXAMETHASONE			
Eye oint 0.1% – 1% DV Oct-14 to 2017	5.86	3.5 g	Maxidex
Eye drops 0.1% – 1% DV Oct-14 to 2017	4.50	5 ml	Maxidex
FLUOROMETHOLONE			
Eye drops 0.1% – 1% DV Sep-15 to 2018	3.09	5 ml	FML
PREDNISOLONE ACETATE			
Eye drops 0.12%			
Eye drops 1%			
PREDNISOLONE SODIUM PHOSPHATE			
Eye drops 0.5%, single dose (preservative free)	38.50	20 dose	Minims Prednisolone

Non-Steroidal Anti-Inflammatory Drugs

DICLOFENAC SODIUM			
Eye drops 0.1% – 1% DV Sep-14 to 2017	13.80	5 ml	Voltaren Ophtha
KETOROLAC TROMETAMOL			
Eye drops 0.5%			

Decongestants and Antiallergics

Antiallergic Preparations

LEVOCABASTINE			
Eye drops 0.05%			
LODOXAMIDE			
Eye drops 0.1% – 1% DV Sep-14 to 2017	8.71	10 ml	Lomide
OLOPATADINE			
Eye drops 0.1%			
SODIUM CROMOGLYCATE			
Eye drops 2%			

SENSORY ORGANS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Decongestants			
NAPHAZOLINE HYDROCHLORIDE			
Eye drops 0.1% – 1% DV Sep-14 to 2017	4.15	15 ml	Naphcon Forte
Diagnostic and Surgical Preparations			
Diagnostic Dyes			
FLUORESCEIN SODIUM			
Eye drops 2%, single dose			
Inj 10%, 5 ml vial	125.00	12	Fluorescite
Ophthalmic strips 1 mg			
FLUORESCEIN SODIUM WITH LIGNOCAINE HYDROCHLORIDE			
Eye drops 0.25% with lignocaine hydrochloride 4%, single dose			
LISSAMINE GREEN			
Ophthalmic strips 1.5 mg			
ROSE BENGAL SODIUM			
Ophthalmic strips 1%			
Irrigation Solutions			
MIXED SALT SOLUTION FOR EYE IRRIGATION			
Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium citrate 0.17%, 15 ml dropper bottle – 1% DV Jan-16 to 2018	5.00	15 ml	Balanced Salt Solution
Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium citrate 0.17%, 250 ml			<i>e.g. Balanced Salt Solution</i>
Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium citrate 0.17%, 500 ml bottle – 1% DV Jan-16 to 2018	10.50	500 ml	Balanced Salt Solution
Ocular Anaesthetics			
OXYBUPROCAINE HYDROCHLORIDE			
Eye drops 0.4%, single dose			
PROXYMETACAINE HYDROCHLORIDE			
Eye drops 0.5%			
TETRACAINE [AMETHOCAINE] HYDROCHLORIDE			
Eye drops 0.5%, single dose			
Eye drops 1%, single dose			
Viscoelastic Substances			
HYPROMELLOSE			
Inj 2%, 1 ml syringe			
Inj 2%, 2 ml syringe			

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
SODIUM HYALURONATE [HYALURONIC ACID]			
Inj 14 mg per ml, 0.85 ml syringe	50.00	1	Healon GV
Inj 14 mg per ml, 0.55 ml syringe	50.00	1	Healon GV
Inj 23 mg per ml, 0.6 ml syringe			
Inj 10 mg per ml, 0.85 ml syringe	30.00	1	Provisc
SODIUM HYALURONATE [HYALURONIC ACID] WITH CHONDROITIN SULPHATE			
Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.35 ml syringe and inj 10 mg sodium hyaluronate [hyaluronic acid] per ml, 0.4 ml syringe	64.00	1	Duovisc
Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.5 ml syringe and inj 10 mg sodium hyaluronate [hyaluronic acid] per ml, 0.55 ml syringe	74.00	1	Duovisc
Inj 30 mg with chondroitin sulphate 40 mg per ml, 0.75 ml syringe			

Other

DISODIUM EDETATE
 Inj 150 mg per ml, 20 ml ampoule
 Inj 150 mg per ml, 20 ml vial
 Inj 150 mg per ml, 100 ml vial

RIBOFLAVIN 5-PHOSPHATE
 Soln trans epithelial riboflavin
 Inj 0.1%
 Inj 0.1% plus 20% dextran T500

Glaucoma Preparations

Beta Blockers

BETAXOLOL
 Eye drops 0.25% – 1% **DV Sep-14 to 2017** 11.80 5 ml **Betoptic S**
 Eye drops 0.5% – 1% **DV Sep-14 to 2017** 7.50 5 ml **Betoptic**

LEVOBUNOLOL HYDROCHLORIDE
 Eye drops 0.5% 7.00 5 ml Betagan

TIMOLOL
 Eye drops 0.25% – 1% **DV Sep-14 to 2017** 1.45 5 ml **Arrow-Timolol**
 Eye drops 0.25%, gel forming – 1% **DV Mar-14 to 2016** 3.30 2.5 ml **Timoptol XE**
 Eye drops 0.5% – 1% **DV Sep-14 to 2017** 1.45 5 ml **Arrow-Timolol**
 Eye drops 0.5%, gel forming – 1% **DV Mar-14 to 2016** 3.78 2.5 ml **Timoptol XE**

Carbonic Anhydrase Inhibitors

ACETAZOLAMIDE
 Tab 250 mg – 1% **DV Sep-14 to 2017** 17.03 100 **Diamox**
 Inj 500 mg

BRINZOLAMIDE
 Eye drops 1%

DORZOLAMIDE
 Eye drops 2%

DORZOLAMIDE WITH TIMOLOL
 Eye drops 2% with timolol 0.5% – 1% **DV Dec-15 to 2018** 3.45 5 ml **Arrow-Dortim**

SENSORY ORGANS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Miotics			
ACETYLCHOLINE CHLORIDE Inj 20 mg vial with diluent			
PILOCARPINE HYDROCHLORIDE			
Eye drops 1% – 1% DV Sep-14 to 2017	4.26	15 ml	Isopto Carpine
Eye drops 2% – 1% DV Sep-14 to 2017	5.35	15 ml	Isopto Carpine
Eye drops 2%, single dose			
Eye drops 4% – 1% DV Sep-14 to 2017	7.99	15 ml	Isopto Carpine
Prostaglandin Analogues			
BIMATOPROST Eye drops 0.03%			
LATANOPROST Eye drops 0.005% – 1% DV Sep-15 to 2018			
	1.50	2.5 ml	Hysite
TRAVOPROST Eye drops 0.004%			
Sympathomimetics			
APRACLONIDINE Eye drops 0.5% – 1% DV Mar-15 to 2017			
	19.77	5 ml	lopidine
BRIMONIDINE TARTRATE Eye drops 0.2% – 1% DV Sep-14 to 2017			
	4.32	5 ml	Arrow-Brimonidine
BRIMONIDINE TARTRATE WITH TIMOLOL Eye drops 0.2% with timolol 0.5%			
Mydriatics and Cycloplegics			
Anticholinergic Agents			
ATROPINE SULPHATE Eye drops 0.5% Eye drops 1%, single dose Eye drops 1% – 1% DV Jul-14 to 2017			
	17.36	15 ml	Atropt
CYCLOPENTOLATE HYDROCHLORIDE Eye drops 0.5%, single dose Eye drops 1% – 1% DV Sep-14 to 2017			
	8.76	15 ml	Cyclogyl
TROPICAMIDE Eye drops 0.5% – 1% DV Oct-14 to 2017			
	7.15	15 ml	Mydriacyl
Eye drops 0.5%, single dose			
Eye drops 1% – 1% DV Oct-14 to 2017	8.66	15 ml	Mydriacyl
Eye drops 1%, single dose			
Sympathomimetics			
PHENYLEPHRINE HYDROCHLORIDE Eye drops 2.5%, single dose Eye drops 10%, single dose			

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Ocular Lubricants			
CARBOMER			
Ophthalmic gel 0.3%, single dose	8.25	30	Poly Gel
Ophthalmic gel 0.2%			
CARMELLOSE SODIUM			
Eye drops 0.5%			
Eye drops 0.5%, single dose			
Eye drops 1%			
Eye drops 1%, single dose			
HYPROMELLOSE			
Eye drops 0.5%	3.92	15 ml	Methopt
HYPROMELLOSE WITH DEXTRAN			
Eye drops 0.3% with dextran 0.1%	2.30	15 ml	Poly-Tears
Eye drops 0.3% with dextran 0.1%, single dose			
MACROGOL 400 AND PROPYLENE GLYCOL			
Eye drops 0.4% with propylene glycol 0.3% preservative free, single dose	4.30	24	Systane Unit Dose
PARAFFIN LIQUID WITH SOFT WHITE PARAFFIN			
Eye oint 42.5% with soft white paraffin 57.3%			
PARAFFIN LIQUID WITH WOOL FAT			
Eye oint 3% with wool fat 3% – 1% DV Jul-14 to 2017	3.63	3.5 g	Poly-Visc
POLYVINYL ALCOHOL			
Eye drops 1.4%	2.95	15 ml	Vistil
	3.62		Liquifilm Tears
Eye drops 3%	3.80	15 ml	Vistil Forte
	3.88		Liquifilm Forte
POLYVINYL ALCOHOL WITH POVIDONE			
Eye drops 1.4% with povidone 0.6%, single dose			
RETINOL PALMITATE			
Oint 138 mcg per g	3.80	5 g	VitA-POS
SODIUM HYALURONATE [HYALURONIC ACID]			
Eye drops 1 mg per ml	22.00	10 ml	Hyo-Fresh

Other Otological Preparations

ACETIC ACID WITH PROPYLENE GLYCOL			
Ear drops 2.3% with propylene glycol 2.8%			
DOCUSATE SODIUM			
Ear drops 0.5%			

Price
(ex man. excl. GST)
\$ Per Brand or
Generic
Manufacturer

Agents Used in the Treatment of Poisonings

Antidotes

ACETYL CYSTEINE			
Tab eff 200 mg			
Inj 200 mg per ml, 10 ml ampoule – 1% DV Sep-15 to 2018.....	78.34	10	DBL Acetylcysteine
DIGOXIN IMMUNE FAB			
Inj 38 mg vial			
Inj 40 mg vial			
ETHANOL			
Liq 96%			
ETHANOL WITH GLUCOSE			
Inj 10% with glucose 5%, 500 ml bottle			
ETHANOL, DEHYDRATED			
Inj 100%, 5 ml ampoule			
Inj 96%			
FLUMAZENIL			
Inj 0.1 mg per ml, 5 ml ampoule – 1% DV Sep-15 to 2018.....	85.05	5	Anexate
HYDROXOCOBALAMIN			
Inj 5 g vial			
Inj 2.5 g vial			
NALOXONE HYDROCHLORIDE			
Inj 400 mcg per ml, 1 ml ampoule	48.84	5	Hospira
PRALIDOXIME IODIDE			
Inj 25 mg per ml, 20 ml ampoule			
SODIUM NITRITE			
Inj 30 mg per ml, 10 ml ampoule			
SODIUM THIOSULFATE			
Inj 500 mg per ml, 20 ml ampoule			
Inj 250 mg per ml, 10 ml vial			
Inj 500 mg per ml, 10 ml vial			
SOYA OIL			
Inj 20%, 500 ml bag			
Inj 20%, 500 ml bottle			

Antitoxins

BOTULISM ANTITOXIN			
Inj 250 ml vial			
DIPHThERIA ANTITOXIN			
Inj 10,000 iu vial			

Antivenoms

RED BACK SPIDER ANTIVENOM			
Inj 500 u vial			

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)
e.g. *Brand* indicates brand example only. It is not a contracted product.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
SNAKE ANTIVENOM			
Inj 50 ml vial			

Removal and Elimination

CHARCOAL

Oral liq 200 mg per ml	43.50	250 ml	Carbasorb-X
------------------------------	-------	--------	-------------

DEFERASIROX – **Restricted** see terms below

⚡ Tab 125 mg dispersible	276.00	28	Exjade
⚡ Tab 250 mg dispersible	552.00	28	Exjade
⚡ Tab 500 mg dispersible	1,105.00	28	Exjade

➔ **Restricted**

Initiation

Haematologist

Re-assessment required after 2 years

All of the following:

- 1 The patient has been diagnosed with chronic iron overload due to congenital inherited anaemia; and
- 2 Deferasirox is to be given at a daily dose not exceeding 40 mg/kg/day; and
- 3 Any of the following:
 - 3.1 Treatment with maximum tolerated doses of deferiprone monotherapy or deferiprone and desferrioxamine combination therapy have proven ineffective as measured by serum ferritin levels, liver or cardiac MRI T2*; or
 - 3.2 Treatment with deferiprone has resulted in severe persistent vomiting or diarrhoea; or
 - 3.3 Treatment with deferiprone has resulted in arthritis; or
 - 3.4 Treatment with deferiprone is contraindicated due to a history of agranulocytosis (defined as an absolute neutrophil count (ANC) of < 0.5 cells per μL) or recurrent episodes (greater than 2 episodes) of moderate neutropenia (ANC 0.5 - 1.0 cells per μL)

Continuation

Haematologist

Re-assessment required after 2 years

Either:

- 1 For the first renewal following 2 years of therapy, the treatment has been tolerated and has resulted in clinical improvement in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels; or
- 2 For subsequent renewals, the treatment has been tolerated and has resulted in clinical stability or continued improvement in all three parameters namely serum ferritin, cardiac MRI T2* and liver MRI T2* levels.

DEFERIPRONE – **Restricted** see terms below

⚡ Tab 500 mg	533.17	100	Ferriprox
⚡ Oral liq 100 mg per ml	266.59	250 ml	Ferriprox

➔ **Restricted**

Patient has been diagnosed with chronic iron overload due to congenital inherited anaemia or acquired red cell aplasia.

DESFERRIOXAMINE MESILATE

Inj 500 mg vial – 1% DV Feb-16 to 2018	51.52	10	Desferal
	109.89		Hospira

(Hospira Inj 500 mg vial to be delisted 1 February 2016)

DICOBALT EDETATE

Inj 15 mg per ml, 20 ml ampoule

DIMERCAPROL

Inj 50 mg per ml, 2 ml ampoule

DIMERCAPTOSUCCINIC ACID

Cap 100 mg

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

SODIUM CALCIUM EDETATE
 Inj 200 mg per ml, 2.5 ml ampoule
 Inj 200 mg per ml, 5 ml ampoule

Antiseptics and Disinfectants

CHLORHEXIDINE

Soln 4%	1.86	50 ml	healthE
Soln 5%	15.50	500 ml	healthE

CHLORHEXIDINE WITH CETRIMIDE

Crm 0.1% with cetrimide 0.5%
 Foaming soln 0.5% with cetrimide 0.5%

CHLORHEXIDINE WITH ETHANOL

Soln 0.5% with ethanol 70%, non-staining (pink) 100 ml	2.65	1	healthE
Soln 2% with ethanol 70%, non-staining (pink) 100 ml	3.54	1	healthE
Soln 0.5% with ethanol 70%, non-staining (pink) 25 ml	1.55	1	healthE
Soln 0.5% with ethanol 70%, staining (red) 100 ml	2.90	1	healthE
Soln 2% with ethanol 70%, staining (red) 100 ml	3.86	1	healthE
Soln 0.5% with ethanol 70%, non-staining (pink) 500 ml	5.45	1	healthE
Soln 0.5% with ethanol 70%, staining (red) 500 ml	5.90	1	healthE
Soln 2% with ethanol 70%, staining (red) 500 ml	9.56	1	healthE

IODINE WITH ETHANOL

Soln 1% with ethanol 70%, 100 ml	9.30	1	healthE
--	------	---	---------

ISOPROPYL ALCOHOL

Soln 70%, 500 ml	5.00	1	PSM
	5.65		healthE

POVIDONE-IODINE

¶ Vaginal tab 200 mg

➔**Restricted**

Rectal administration pre-prostate biopsy.

Oint 10%	3.27	25 g	Betadine
Soln 10%	2.95	100 ml	Riodine
	6.20	500 ml	Riodine
			Betadine

Soln 5%
 Soln 7.5%
 Pad 10%
 Swab set 10%

POVIDONE-IODINE WITH ETHANOL

Soln 10% with ethanol 30%	10.00	500 ml	Betadine Skin Prep
Soln 10% with ethanol 70%			

SODIUM HYPOCHLORITE

Soln

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Contrast Media			
Iodinated X-ray Contrast Media			
DIATRIZOATE MEGGLUMINE WITH SODIUM AMIDOTRIZOATE			
Oral liq 660 mg per ml with sodium amidotrizoate 100 mg per ml, 100 ml bottle	22.50	100 ml	Gastrografin
Inj 260 mg with sodium amidotrizoate 40 mg per ml, 250 ml bottle	80.00	1	Urografin
DIATRIZOATE SODIUM			
Oral liq 370 mg per ml, 10 ml sachet	156.12	50	Ioscan
IODISED OIL			
Inj 38% w/w (480 mg per ml), 10 ml ampoule	143.00	1	Lipiodol Ultra Fluid
IODIXANOL			
Inj 270 mg per ml (iodine equivalent), 50 ml bottle – 5% DV Sep-14 to 2017	220.00	10	Visipaque
Inj 270 mg per ml (iodine equivalent), 100 ml bottle – 5% DV Sep-14 to 2017	430.00	10	Visipaque
Inj 320 mg per ml (iodine equivalent), 50 ml bottle – 5% DV Sep-14 to 2017	220.00	10	Visipaque
Inj 320 mg per ml (iodine equivalent), 100 ml bottle – 5% DV Sep-14 to 2017	430.00	10	Visipaque
Inj 320 mg per ml (iodine equivalent), 200 ml bottle – 5% DV Sep-14 to 2017	850.00	10	Visipaque
IOHEXOL			
Inj 240 mg per ml (iodine equivalent), 50 ml bottle – 5% DV Sep-14 to 2017	75.00	10	Omnipaque
Inj 300 mg per ml (iodine equivalent), 20 ml bottle – 5% DV Sep-14 to 2017	57.00	10	Omnipaque
Inj 300 mg per ml (iodine equivalent), 50 ml bottle – 5% DV Sep-14 to 2017	75.00	10	Omnipaque
Inj 300 mg per ml (iodine equivalent), 100 ml bottle – 5% DV Sep-14 to 2017	150.00	10	Omnipaque
Inj 350 mg per ml (iodine equivalent), 20 ml bottle – 5% DV Sep-14 to 2017	59.00	10	Omnipaque
Inj 350 mg per ml (iodine equivalent), 50 ml bottle – 5% DV Sep-14 to 2017	75.00	10	Omnipaque
Inj 350 mg per ml (iodine equivalent), 75 ml bottle – 5% DV Sep-14 to 2017	114.00	10	Omnipaque
Inj 350 mg per ml (iodine equivalent), 100 ml bottle – 5% DV Sep-14 to 2017	150.00	10	Omnipaque
Inj 350 mg per ml (iodine equivalent), 200 ml bottle – 5% DV Sep-14 to 2017	290.00	10	Omnipaque

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Non-iodinated X-ray Contrast Media			
BARIUM SULPHATE			
Powder for oral liq 20 mg per g (2% w/w), 22.1 g sachet	507.50	50	E-Z-Cat Dry
Oral liq 400 mg per ml (40% w/v, 30% w/w), bottle	17.39	148 g	Varibar - Thin Liquid
Oral liq 600 mg per g (60% w/w), tube	36.51	454 g	E-Z-Paste
Oral liq 400 mg per ml (40% w/v), bottle	38.40	240 ml	Varibar - Nectar
	145.04	230 ml	Varibar - Pudding
	155.35	250 ml	Varibar - Honey
Enema 1,250 mg per ml (125% w/v), 500 ml bag	282.30	12	Liquibar
Oral liq 22 mg per g (2.2% w/w), 250 ml bottle	175.00	24	CT Plus+
Oral liq 22 mg per g (2.2% w/w), 450 ml bottle	220.00	24	CT Plus+
Oral liq 1 mg per ml (0.1% w/v, 0.1% w/w), 450 ml bottle	441.12	24	Volumen
Oral liq 20.9 mg per ml (2.1% w/v, 2% w/w), 250 ml bottle	140.94	24	Readi-CAT 2
Powder for oral soln 97.65% w/w, 300 g bottle	237.76	24	X-Opaque-HD
Oral liq 400 mg per ml (40% w/v, 30% w/w), 20 ml bottle	52.35	3	Tagitol V
Oral liq 1,250 mg per ml (125% w/v), 2,000 ml bottle	91.77	1	Liquibar
BARIUM SULPHATE WITH SODIUM BICARBONATE			
Grans eff 382.2 mg per g with sodium bicarbonate 551.3 mg per g, 4 g sachet	102.93	50	E-Z-Gas II
CITRIC ACID WITH SODIUM BICARBONATE			
Powder 382.2 mg per g with sodium bicarbonate 551.3 mg per g, 4 g sachet			<i>e.g. E-Z-GAS II</i>
Paramagnetic Contrast Media			
GADOBENIC ACID			
Inj 334 mg per ml, 10 ml vial	324.74	10	Multihance
Inj 334 mg per ml, 20 ml vial	636.28	10	Multihance
GADOBUTROL			
Inj 1 mmol per ml, 15 ml vial			
Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 7.5 ml prefilled syringe	180.00	5	Gadovist
Inj 604.72 mg per ml (equivalent to 1 mmol per ml), 15 ml prefilled syringe	700.00	10	Gadovist
GADODIAMIDE			
Inj 287 mg per ml, 10 ml prefilled syringe	200.00	10	Omniscan
Inj 287 mg per ml, 10 ml vial	170.00	10	Omniscan
Inj 287 mg per ml, 5 ml vial	120.00	10	Omniscan
Inj 287 mg per ml, 15 ml prefilled syringe	320.00	10	Omniscan
GADOTERIC ACID			
Inj 279.32 mg per ml (0.5 mmol per ml), 10 ml prefilled syringe	24.50	1	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 15 ml bottle	34.50	1	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 15 ml prefilled syringe	41.00	1	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 20 ml prefilled syringe	55.00	1	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 10 ml bottle	23.20	1	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 20 ml bottle	46.30	1	Dotarem
Inj 279.32 mg per ml (0.5 mmol per ml), 5 ml bottle	12.30	1	Dotarem

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
GADOXETATE DISODIUM			
Inj 181.43 mg per ml (equivalent to 0.25 mmol per ml), 10 ml prefilled syringe	300.00	1	Primovist
MEGLUMINE GADOPENTETATE			
Inj 469 mg per ml, 10 ml prefilled syringe	95.00	5	Magnevist
Inj 469 mg per ml, 10 ml vial	185.00	10	Magnevist
MEGLUMINE IOTROXATE			
Inj 105 mg per ml, 100 ml bottle	150.00	100 ml	Biliscopin

Ultrasound Contrast Media

PERFLUTREN			
Inj 1.1 mg per ml, 1.5 ml vial – 5% DV Sep-14 to 2017	180.00	1	Definity
	720.00	4	Definity

Diagnostic Agents

ARGININE			
Inj 50 mg per ml, 500 ml bottle			
Inj 100 mg per ml, 300 ml bottle			
HISTAMINE ACID PHOSPHATE			
Nebuliser soln 0.6%, 10 ml vial			
Nebuliser soln 2.5%, 10 ml vial			
Nebuliser soln 5%, 10 ml vial			
MANNITOL			
Powder for inhalation			<i>e.g. Aridol</i>
METHACHOLINE CHLORIDE			
Powder 100 mg			
SECRETIN PENTAHYDROCHLORIDE			
Inj 100 u ampoule			
SINCALIDE			
Inj 5 mcg per vial			
TUBERCULIN, PURIFIED PROTEIN DERIVATIVE			
Inj 5 TU per 0.1 ml, 1 ml vial			

Diagnostic Dyes

BONNEY'S BLUE DYE			
Soln			
INDIGO CARMINE			
Inj 4 mg per ml, 5 ml ampoule			
Inj 8 mg per ml, 5 ml ampoule			
INDOCYANINE GREEN			
Inj 25 mg vial			
METHYLTHIONIUM CHLORIDE [METHYLENE BLUE]			
Inj 10 mg per ml, 10 ml ampoule			
Inj 10 mg per ml, 5 ml ampoule			
PATENT BLUE V			
Inj 2.5%, 2 ml ampoule	440.00	5	Obex Medical

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Irrigation Solutions			
CHLORHEXIDINE			
Irrigation soln 0.02%, bottle	2.92	100 ml	Baxter
Irrigation soln 0.05%, bottle	3.02	100 ml	Baxter
	3.63	500 ml	Baxter
Irrigation soln 0.1%, bottle	3.10	100 ml	Baxter
Irrigation soln 0.5%, bottle	4.69	500 ml	Baxter
Irrigation soln 0.02%, 500 ml bottle			
Irrigation soln 0.1%, 30 ml ampoule			
CHLORHEXIDINE WITH CETRIMIDE			
Irrigation soln 0.015% with cetrimide 0.15%, 30 ml ampoule			
Irrigation soln 0.015% with cetrimide 0.15%, bottle	3.21	100 ml	Baxter
	3.47	500 ml	Baxter
	4.17	1,000 ml	Baxter
Irrigation soln 0.05% with cetrimide 0.5%, bottle	4.20	100 ml	Baxter
	3.87	500 ml	Baxter
Irrigation soln 0.1% with cetrimide 1%, bottle	4.38	100 ml	Baxter
	5.81	500 ml	Baxter
GLYCINE			
Irrigation soln 1.5%, bottle	11.38	2,000 ml	Baxter
	14.44	3,000 ml	Baxter
SODIUM CHLORIDE			
Irrigation soln 0.9%, 30 ml ampoule	19.50	30 ml	Pfizer
Irrigation soln 0.9%, bottle	2.49	100 ml	Baxter
	2.88	500 ml	Baxter
	2.96	1,000 ml	Baxter
	10.00	2,000 ml	Baxter
	12.67	3,000 ml	Baxter
WATER			
Irrigation soln, bottle	2.68	100 ml	Baxter
	2.61	500 ml	Baxter
	2.75	1,000 ml	Baxter
	9.71	2,000 ml	Baxter
	15.80	3,000 ml	Baxter

Surgical Preparations

BISMUTH SUBNITRATE AND IODOFORM PARAFFIN

Paste

DIMETHYL SULFOXIDE

Soln 50%

Soln 99%

PHENOL

Inj 6%, 10 ml ampoule

PHENOL WITH IOXAGLIC ACID

Inj 12%, 10 ml ampoule

TROMETAMOL

Inj 36 mg per ml, 500 ml bottle

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
Cardioplegia Solutions			
ELECTROLYTES			
Inj 15 mmol/l sodium chloride, 9 mmol/l potassium chloride, 1 mmol/l potassium hydrogen 2-ketoglutarate, 4 mmol/l magnesium chloride, 18 mmol/l histidine hydrochloride, 180 mmol/l histidine, 2 mmol/l tryptophan, 30 mmol/l mannitol, 0.015 mmol/l calcium chloride, 1,000 ml bag			<i>e.g. Custodiol-HTK</i>
Inj aspartic acid 10.43 mg per ml, citric acid 0.22476 mg per ml, glutamic acid 11.53 mg per ml, sodium phosphate 0.1725 mg per ml, potassium chloride 2.15211 mg per ml, sodium citrate 1.80768 mg per ml, sodium hydroxide 6.31 mg per ml and trometamol 11.2369 mg per ml, 364 ml bag			<i>e.g. Cardioplegia Enriched Paed. Soln.</i>
Inj aspartic acid 8.481 mg per ml, citric acid 0.8188 mg per ml, glutamic acid 9.375 mg per ml, sodium phosphate 0.6285 mg per ml, potassium chloride 2.5 mg per ml, sodium citrate 6.585 mg per ml, sodium hydroxide 5.133 mg per ml and trometamol 9.097 mg per ml, 527 ml bag			<i>e.g. Cardioplegia Enriched Solution</i>
Inj citric acid 0.07973 mg per ml, sodium phosphate 0.06119 mg per ml, potassium chloride 2.181 mg per ml, sodium chloride 1.788 mg ml, sodium citrate 0.6412 mg per ml and trometamol 5.9 mg per ml, 523 ml bag			<i>e.g. Cardioplegia Base Solution</i>
Inj 110 mmol/l sodium, 16 mmol/l potassium, 1.2 mmol/l calcium, 16 mmol/l magnesium and 160 mmol/l chloride, 1,000 ml bag			<i>e.g. Cardioplegia Solution AHB7832</i>
Inj 143 mmol/l sodium, 16 mmol/l potassium, 16 mmol/l magnesium and 1.2 mmol/l calcium, 1,000 ml bag			<i>e.g. Cardioplegia Electrolyte Solution</i>

MONOSODIUM GLUTAMATE WITH SODIUM ASPARTATE

Inj 42.68 mg with sodium aspartate 39.48 mg per ml, 250 ml bottle

MONOSODIUM L-ASPARTATE

Inj 14 mmol per 10 ml, 10 ml

Cold Storage Solutions**SODIUM WITH POTASSIUM**

Inj 29 mmol/l with potassium 125 mmol/l, 1,000 ml bag

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Extemporaneously Compounded Preparations

ACETIC ACID

Liq

ALUM

Powder BP

ARACHIS OIL [PEANUT OIL]

Liq

ASCORBIC ACID

Powder

BENZOIN

Tincture compound BP

BISMUTH SUBGALLATE

Powder

BORIC ACID

Powder

CARBOXYMETHYLCELLULOSE

Soln 1.5%

CETRIMIDE

Soln 40%

CHLORHEXIDINE GLUCONATE

Soln 20 %

CHLOROFORM

Liq BP

CITRIC ACID

Powder BP

CLOVE OIL

Liq

COAL TAR

Soln BP

CODEINE PHOSPHATE

Powder

COLLODION FLEXIBLE

Liq

COMPOUND HYDROXYBENZOATE

Soln

CYSTEAMINE HYDROCHLORIDE

Powder

DISODIUM HYDROGEN PHOSPHATE WITH SODIUM DIHYDROGEN PHOSPHATE

Inj 37.46 mg with sodium dihydrogen phosphate 47.7 mg in 1.5 ml
ampoule

DITHRANOL

Powder

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
GLUCOSE [DEXTROSE] Powder			
GLYCERIN WITH SODIUM SACCHARIN Suspension	32.50	473 ml	Ora-Sweet SF
GLYCERIN WITH SUCROSE Suspension	32.50	473 ml	Ora-Sweet
GLYCEROL Liq	19.80	2,000 ml	ABM
HYDROCORTISONE Powder – 1% DV Dec-14 to 2017	59.50	25 g	ABM
LACTOSE Powder			
MAGNESIUM HYDROXIDE Paste			
MENTHOL Crystals			
METHADONE HYDROCHLORIDE Powder			
METHYL HYDROXYBENZOATE Powder			
METHYLCELLULOSE Powder			
Suspension	32.50	473 ml	Ora-Plus
METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCHARIN Suspension	32.50	473 ml	Ora-Blend SF
METHYLCELLULOSE WITH GLYCERIN AND SUCROSE Suspension	32.50	473 ml	Ora-Blend
OLIVE OIL Liq			
PARAFFIN Liq			
PHENOBARBITONE SODIUM Powder			
PHENOL Liq			
PILOCARPINE NITRATE Powder			
POLYHEXAMETHYLENE BIGUANIDE Liq			
POVIDONE K30 Powder			
PROPYLENE GLYCOL Liq	12.00	500 ml	ABM

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
SALICYLIC ACID Powder			
SILVER NITRATE Crystals			
SODIUM BICARBONATE Powder BP			
SODIUM CITRATE Powder			
SODIUM METABISULFITE Powder			
STARCH Powder			
SULPHUR Precipitated Sublimed			
SYRUP Liq (pharmaceutical grade)	21.75	2,000 ml	Midwest
THEOBROMA OIL Oint			
TRI-SODIUM CITRATE Crystals			
TRICHLORACETIC ACID Grans			
UREA Powder BP			
WOOL FAT Oint, anhydrous			
XANTHAN Gum 1%			
ZINC OXIDE Powder			

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

e.g. *Brand* indicates brand example only. It is not a contracted product.

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Food Modules

Carbohydrate

➔ Restricted

Use as an additive

Any of the following:

- 1 Cystic fibrosis; or
- 2 Chronic kidney disease; or
- 3 Cancer in children; or
- 4 Cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or
- 5 Faltering growth in an infant/child; or
- 6 Bronchopulmonary dysplasia; or
- 7 Premature and post premature infant; or
- 8 Inborn errors of metabolism.

Use as a module

For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Notes: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

CARBOHYDRATE SUPPLEMENT – **Restricted** see terms above

- ⬆ Powder 95 g carbohydrate per 100 g, 368 g can
- ⬆ Powder 96 g carbohydrate per 100 g, 400 g can

e.g. Polycal

Fat

➔ Restricted

Use as an additive

Any of the following:

- 1 Patient has inborn errors of metabolism; or
- 2 Faltering growth in an infant/child; or
- 3 Bronchopulmonary dysplasia; or
- 4 Fat malabsorption; or
- 5 Lymphangiectasia; or
- 6 Short bowel syndrome; or
- 7 Infants with necrotising enterocolitis; or
- 8 Biliary atresia; or
- 9 For use in a ketogenic diet; or
- 10 Chyle leak; or
- 11 Ascites; or
- 12 Patient has increased energy requirements, and for whom dietary measures have not been successful.

Use as a module

For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Notes: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

LONG-CHAIN TRIGLYCERIDE SUPPLEMENT – **Restricted** see terms above

- ⬆ Liquid 50 g fat per 100 ml, 200 ml bottle
- ⬆ Liquid 50 g fat per 100 ml, 500 ml bottle

e.g. Calogen

e.g. Calogen

MEDIUM-CHAIN TRIGLYCERIDE SUPPLEMENT – **Restricted** see terms above

- ⬆ Liquid 50 g fat per 100 ml, 250 ml bottle
- ⬆ Liquid 95 g fat per 100 ml, 500 ml bottle

e.g. Liquigen

e.g. MCT Oil

WALNUT OIL – **Restricted** see terms above

- ⬆ Liq

Price
(ex man. excl. GST)
\$ Per Brand or
Generic
Manufacturer

Protein

↔ **Restricted**

Use as an additive

Either:

- 1 Protein losing enteropathy; or
- 2 High protein needs.

Use as a module

For use as a component in a modular formula made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule or breast milk.

Notes: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

PROTEIN SUPPLEMENT – **Restricted** see terms above

↑ Powder 5 g protein, 0.67 g carbohydrate and 0.6 g fat per 6.6 g, 275 g can			<i>e.g. Promod</i>
↑ Powder 6 g protein per 7 g, can	8.95	227 g	Resource Beneprotein
↑ Powder 89 g protein, <1.5 g carbohydrate and 2 g fat per 100 g, 225 g can			<i>e.g. Protifar</i>

Other Supplements

BREAST MILK FORTIFIER

Powder 0.2 g protein, 0.7 g carbohydrate and 0.02 g fat per 1 g sachet	<i>e.g. FM 85</i>
Powder 0.5 g protein, 1.2 g carbohydrate and 0.08 g fat per 2 g sachet	<i>e.g. S26 Human Milk Fortifier</i>
Powder 0.6 g protein and 1.4 g carbohydrate per 2.2 g sachet	<i>e.g. Nutricia Breast Milk Fortifier</i>

CARBOHYDRATE AND FAT SUPPLEMENT – Restricted see terms below

↓ Powder 72.7 g carbohydrate and 22.3 g fat per 100 g, 400 g can	<i>e.g. Super Soluble Duocal</i>
--	----------------------------------

↔ **Restricted**

Both:

- 1 Infant or child aged four years or under; and
- 2 Any of the following:
 - 2.1 Cystic fibrosis; or
 - 2.2 Cancer in children; or
 - 2.3 Faltering growth; or
 - 2.4 Bronchopulmonary dysplasia; or
 - 2.5 Premature and post premature infants.

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Food/Fluid Thickeners

NOTE:

While pre-thickened drinks and supplements have not been included in Section H, DHB hospitals may continue to use such products for patients with dysphagia, provided that:

- use was established prior to 1 July 2013; and
- the product has not been specifically considered and excluded by PHARMAC; and
- use of the product conforms to any applicable indication restrictions for similar products that are listed in Section H (for example, use of thickened high protein products should be in line with the restriction for high protein oral feed in Section H).

PHARMAC intends to make a further decision in relation to pre-thickened drinks and supplements in the future, and will notify of any change to this situation.

CAROB BEAN GUM WITH MAIZE STARCH AND MALTODEXTRIN

Powder

*e.g. Feed Thickener
Karicare Aptamil*

GUAR GUM

Powder

e.g. Guarcol

MAIZE STARCH

Powder

*e.g. Resource Thicken
Up; Nuttilis*

MALTODEXTRIN WITH XANTHAN GUM

Powder

e.g. Instant Thick

MALTODEXTRIN WITH XANTHAN GUM AND ASCORBIC ACID

Powder

e.g. Easy Thick

Metabolic Products

➔ Restricted

Any of the following:

- 1 For the dietary management of homocystinuria, maple syrup urine disease, phenylketonuria (PKU), glutaric aciduria, isovaleric acidemia, propionic acidemia, methylmalonic acidemia, tyrosinaemia or urea cycle disorders; or
- 2 Patient has adrenoleukodystrophy; or
- 3 For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

Glutaric Aciduria Type 1 Products

AMINO ACID FORMULA (WITHOUT LYSINE AND LOW TRYPTOPHAN) – **Restricted** see terms above

⬆ Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre
per 100 g, 400 g can

e.g. GA1 Anamix Infant

⬆ Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can

*e.g. XLYS Low TRY
Maxamaid*

Homocystinuria Products

AMINO ACID FORMULA (WITHOUT METHIONINE) – **Restricted** see terms above

⬆ Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre
per 100 g, 400 g can

e.g. HCU Anamix Infant

⬆ Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can

e.g. XMET Maxamaid

⬆ Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can

e.g. XMET Maxamum

⬆ Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per
100 ml, 125 ml bottle

*e.g. HCU Anamix Junior
LQ*

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

Price
(ex man. excl. GST)
\$ Per Brand or
Generic
Manufacturer

Isovaleric Acidaemia Products

AMINO ACID FORMULA (WITHOUT LEUCINE) – **Restricted** see terms on the preceding page

- ⚡ Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can *e.g. IVA Anamix Infant*
- ⚡ Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can *e.g. XLEU Maxamaid*
- ⚡ Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can *e.g. XLEU Maxamum*

Maple Syrup Urine Disease Products

AMINO ACID FORMULA (WITHOUT ISOLEUCINE, LEUCINE AND VALINE) – **Restricted** see terms on the preceding page

- ⚡ Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can *e.g. MSUD Anamix Infant*
- ⚡ Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can *e.g. MSUD Maxamaid*
- ⚡ Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can *e.g. MSUD Maxamum*
- ⚡ Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle *e.g. MSUD Anamix Junior LQ*

Phenylketonuria Products

AMINO ACID FORMULA (WITHOUT PHENYLALANINE) – **Restricted** see terms on the preceding page

- ⚡ Tab 8.33 mg *e.g. Phlexy-10*
- ⚡ Powder 36 g protein, 32 g carbohydrate and 12.5 g fat per 100 g, 36 g sachet *e.g. PKU Anamix Junior*
- ⚡ Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can *e.g. PKU Anamix Infant*
- ⚡ Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can *e.g. XP Maxamaid*
- ⚡ Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can *e.g. XP Maxamum*
- ⚡ Powder 8.33 g protein and 8.8 g carbohydrate per 20 g sachet *e.g. Phlexy-10*
- ⚡ Liquid 10 g protein, 4.4 g carbohydrate and 0.25 g fibre per 100 ml, 62.5 ml bottle *e.g. PKU Lophlex LQ 10*
- ⚡ Liquid 20 g protein, 8.8 g carbohydrate and 0.34 g fibre per 100 ml, 125 ml bottle *e.g. PKU Lophlex LQ 20*
- ⚡ Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, bottle 13.10 125 ml PKU Anamix Junior LQ (Berry)
PKU Anamix Junior LQ (Orange)
PKU Anamix Junior LQ (Unflavoured)
- ⚡ Liquid 16 g protein, 7 g carbohydrate and 0.27 g fibre per 100 ml, 125 ml bottle *e.g. PKU Lophlex LQ 20*
- ⚡ Liquid 16 g protein, 7 g carbohydrate and 0.27 g fibre per 100 ml, 62.5 ml bottle *e.g. PKU Lophlex LQ 10*
- ⚡ Liquid 16 g protein, 7 g carbohydrate and 0.4 g fibre per 100 ml, 125 ml bottle *e.g. PKU Lophlex LQ 20*
- ⚡ Liquid 16 g protein, 7 g carbohydrate and 0.4 g fibre per 100 ml, 62.5 ml bottle *e.g. PKU Lophlex LQ 10*
- ⚡ Liquid 6.7 g protein, 5.1 g carbohydrate and 2 g fat per 100 ml, 250 ml carton *e.g. Easiphen*

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Propionic Acidaemia and Methylmalonic Acidaemia Products

AMINO ACID FORMULA (WITHOUT ISOLEUCINE, METHIONINE, THREONINE AND VALINE) – **Restricted** see terms on page 199

⬆ Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can	<i>e.g. MMA/PA Anamix Infant</i>
⬆ Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can	<i>e.g. XMTVI Maxamaid</i>
⬆ Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can	<i>e.g. XMTVI Maxamum</i>

Protein Free Supplements

PROTEIN FREE SUPPLEMENT – **Restricted** see terms on page 199

⬆ Powder nil added protein and 67 g carbohydrate per 100 g, 400 g can	<i>e.g. Energivit</i>
---	-----------------------

Tyrosinaemia Products

AMINO ACID FORMULA (WITHOUT PHENYLALANINE AND TYROSINE) – **Restricted** see terms on page 199

⬆ Powder 36 g protein, 32 g carbohydrate and 12.5 g fat per 100 g, 36 g sachet	<i>e.g. TYR Anamix Junior</i>
⬆ Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can	<i>e.g. TYR Anamix Infant</i>
⬆ Powder 25 g protein and 51 g carbohydrate per 100 g, 400 g can	<i>e.g. XPHEN, TYR Maxamaid</i>
⬆ Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle	<i>e.g. TYR Anamix Junior LQ</i>

Urea Cycle Disorders Products

AMINO ACID SUPPLEMENT – **Restricted** see terms on page 199

⬆ Powder 25 g protein and 65 g carbohydrate per 100 g, 200 g can	<i>e.g. Dialamine</i>
⬆ Powder 79 g protein per 100 g, 200 g can	<i>e.g. Essential Amino Acid Mix</i>

X-Linked Adrenoleukodystrophy Products

GLYCEROL TRIERUCATE – **Restricted** see terms on page 199

⬆ Liquid, 1,000 ml bottle

GLYCEROL TRIOLEATE – **Restricted** see terms on page 199

⬆ Liquid, 500 ml bottle

Specialised Formulas

Diabetic Products

➔ **Restricted**

Any of the following:

- 1 For patients with type I or type II diabetes suffering weight loss and malnutrition that requires nutritional support; or
- 2 For patients with pancreatic insufficiency; or
- 3 For patients who have, or are expected to, eat little or nothing for 5 days;
- 4 For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism; or

continued...

SPECIAL FOODS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

continued...

- 5 For use pre- and post-surgery; or
- 6 For patients being tube-fed; or
- 7 For tube-feeding as a transition from intravenous nutrition.

LOW-GI ENTERAL FEED 1 KCAL/ML – **Restricted** see terms on the preceding page

☛ Liquid 5 g protein, 9.6 g carbohydrate and 5.4 g fat per 100 ml, 1,000 ml bottle	7.50	1,000 ml	Glucerna Select RTH (Vanilla)
☛ Liquid 4.3 g protein, 11.3 g carbohydrate and 4.2 g fat per 100 ml, 1,000 ml bag			<i>e.g. Nutrison Advanced Diason</i>

LOW-GI ORAL FEED 1 KCAL/ML – **Restricted** see terms on the preceding page

☛ Liquid 4.5 g protein, 9.8 g carbohydrate, 4.4 g fat and 1.9 g fibre per 100 ml, can	2.10	237 ml	Sustagen Diabetic (Vanilla)
☛ Liquid 5 g protein, 9.6 g carbohydrate and 5.4 g fat per 100 ml, 250 ml bottle	1.88	250 ml	Glucerna Select (Vanilla)
☛ Liquid 6 g protein, 9.5 g carbohydrate, 4.7 g fat and 2.6 g fibre per 100 ml, can	2.10	237 ml	Resource Diabetic (Vanilla)
☛ Liquid 4.9 g protein, 11.7 g carbohydrate, 3.8 g fat and 2 g fibre per 100 ml, 200 ml bottle			<i>e.g. Diasip</i>

Elemental and Semi-Elemental Products

☛ **Restricted**

Any of the following:

- 1 Malabsorption; or
- 2 Short bowel syndrome; or
- 3 Enterocutaneous fistulas; or
- 4 Eosinophilic enteritis (including oesophagitis); or
- 5 Inflammatory bowel disease; or
- 6 Acute pancreatitis where standard feeds are not tolerated; or
- 7 Patients with multiple food allergies requiring enteral feeding.

AMINO ACID ORAL FEED – **Restricted** see terms above

☛ Powder 11.5 g protein, 61.7 g carbohydrate and 0.8 g fat per sachet	4.50	80.4 g	Vivonex TEN
---	------	--------	-------------

AMINO ACID ORAL FEED 0.8 KCAL/ML – **Restricted** see terms above

☛ Liquid 2.5 g protein, 11 g carbohydrate and 3.5 g fat per 100 ml, 250 ml carton			<i>e.g. Elemental 028 Extra</i>
---	--	--	---------------------------------

PEPTIDE-BASED ENTERAL FEED 1 KCAL/ML – **Restricted** see terms above

☛ Liquid 4 g protein, 17.6 g carbohydrate and 1.7 g fat per 100 ml, 1,000 ml bag			<i>e.g. Nutrison Advanced Peptisorb</i>
--	--	--	---

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
PEPTIDE-BASED ORAL FEED – Restricted see terms on the preceding page			
⬆ Powder 12.5 g protein, 55.4 g carbohydrate and 3.25 g fat per sachet	4.40	79 g	Vital HN
⬆ Powder 13.7 g protein, 62.9 g carbohydrate and 17.5 g fat per 100 g, 400 g can			<i>e.g. Peptamen Junior</i>
⬆ Powder 13.8 g protein, 59 g carbohydrate and 18 g fat per 100 g, 400 g can			<i>e.g. MCT Peptide; MCT Peptide 1+</i>
⬆ Powder 15.8 g protein, 49.5 g carbohydrate and 4.65 g fat per 76 g sachet	7.50	76 g	Alitraq
⬆ Liquid 6.75 g protein, 18.4 g carbohydrate and 5.5 g fat per 100 ml, bottle	18.06	1,000 ml	Vital
<i>(Vital HN Powder 12.5 g protein, 55.4 g carbohydrate and 3.25 g fat per sachet to be delisted 1 February 2016)</i>			

PEPTIDE-BASED ORAL FEED 1 KCAL/ML – Restricted see terms on the preceding page			
⬆ Liquid 5 g protein, 16 g carbohydrate and 1.69 g fat per 100 ml, carton	4.95	237 ml	Peptamen OS 1.0 (Vanilla)

Fat Modified Products

FAT-MODIFIED FEED – **Restricted** see terms below

⬆ Powder 11.4 g protein, 68 g carbohydrate and 11.8 g fat per 100 g, 400 g can			<i>e.g. Monogen</i>
--	--	--	---------------------

↔ Restricted

Any of the following:

- 1 Patient has metabolic disorders of fat metabolism; or
- 2 Patient has a chyle leak; or
- 3 Modified as a modular feed, made from at least one nutrient module and at least one further product listed in Section D of the Pharmaceutical Schedule, for adults.

Notes: Patients are required to meet any Special Authority criteria associated with all of the products used in the modular formula.

Hepatic Products

↔ Restricted

For children (up to 18 years) who require a liver transplant

HEPATIC ORAL FEED – **Restricted** see terms above

⬆ Powder 11 g protein, 64 g carbohydrate and 20 g fat per 100 g, can	78.97	400 g	Heparon Junior
--	-------	-------	----------------

High Calorie Products

↔ Restricted

Any of the following:

- 1 Patient is fluid volume or rate restricted; or
- 2 Patient requires low electrolyte; or
- 3 Both:
 - 3.1 Any of the following:
 - 3.1.1 Cystic fibrosis; or
 - 3.1.2 Any condition causing malabsorption; or
 - 3.1.3 Faltering growth in an infant/child; or
 - 3.1.4 Increased nutritional requirements; and
 - 3.2 Patient has substantially increased metabolic requirements.

ENTERAL FEED 2 KCAL/ML – **Restricted** see terms above

⬆ Liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, bottle	5.50	500 ml	Nutrison Concentrated
⬆ Liquid 8.4 g protein, 21.9 g carbohydrate, 9.1 g fat and 0.5 g fibre per 100 ml, bottle	11.00	1,000 ml	TwoCal HN RTH (Vanilla)

Products with Hospital Supply Status (HSS) are in **bold**

Expiry date of HSS period is 30 June of the year indicated unless otherwise stated.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

ORAL FEED 2 KCAL/ML – **Restricted** see terms on the preceding page

† Liquid 8.4 g protein, 22.4 g carbohydrate, 8.9 g fat and 0.8 g fibre per 100 ml, bottle	1.90	200 ml	Two Cal HN
---	------	--------	------------

High Protein Products

HIGH PROTEIN ENTERAL FEED 1.25 KCAL/ML – **Restricted** see terms below

‡ Liquid 6.3 g protein, 14.2 g carbohydrate and 4.9 g fat per 100 ml, 1,000 ml bag			<i>e.g. Nutrison Protein Plus</i>
--	--	--	-----------------------------------

➔ Restricted

Both:

- 1 The patient has a high protein requirement; and
- 2 Any of the following:
 - 2.1 Patient has liver disease; or
 - 2.2 Patient is obese (BMI > 30) and is undergoing surgery; or
 - 2.3 Patient is fluid restricted; or
 - 2.4 Patient's needs cannot be more appropriately met using high calorie product.

HIGH PROTEIN ENTERAL FEED 1.28 KCAL/ML – **Restricted** see terms below

‡ Liquid 6.3 g protein, 14.1 g carbohydrate, 4.9 g fat and 1.5 g fibre per 100 ml, 1,000 ml bag			<i>e.g. Nutrison Protein Plus Multi Fibre</i>
---	--	--	---

➔ Restricted

Both:

- 1 The patient has a high protein requirement; and
- 2 Any of the following:
 - 2.1 Patient has liver disease; or
 - 2.2 Patient is obese (BMI > 30) and is undergoing surgery; or
 - 2.3 Patient is fluid restricted; or
 - 2.4 Patient's needs cannot be more appropriately met using high calorie product.

Infant Formulas

AMINO ACID FORMULA – **Restricted** see terms on the next page

‡ Powder 1.95 g protein, 8.1 g carbohydrate and 3.5 g fat per 100 ml, 400 g can			<i>e.g. Neocate</i>
‡ Powder 13 g protein, 52.5 g carbohydrate and 24.5 g fat per 100 g, 400 g can			<i>e.g. Neocate LCP</i>
‡ Powder 13.5 g protein, 52 g carbohydrate and 24.5 g fat per 100 g, can	53.00	400 g	Neocate Gold (Unflavoured)
‡ Powder 14 g protein, 50 g carbohydrate and 24.3 g fat per 100 g, 400 g can			<i>e.g. Neocate Advance</i>
‡ Powder 16 g protein, 51.4 g carbohydrate and 21 g fat per 100 g, can	53.00	400 g	Neocate Advance (Vanilla)
‡ Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, can	53.00	400 g	Elecare LCP (Unflavoured)
‡ Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, can	53.00	400 g	Elecare (Unflavoured) Elecare (Vanilla)
‡ Powder 6 g protein, 31.5 g carbohydrate and 5.88 g fat per sachet	6.00	48.5 g	Vivonex Paediatric

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

➔ Restricted

Initiation

Any of the following:

- 1 Extensively hydrolysed formula has been reasonably trialled and is inappropriate due to documented severe intolerance or allergy or malabsorption; or
- 2 History of anaphylaxis to cows' milk protein formula or dairy products; or
- 3 Eosinophilic oesophagitis.

Note: A reasonable trial is defined as a 2-4 week trial.

Continuation

Both:

- 1 An assessment as to whether the infant can be transitioned to a cows' milk protein, soy, or extensively hydrolysed infant formula has been undertaken; and
- 2 The outcome of the assessment is that the infant continues to require an amino acid infant formula.

EXTENSIVELY HYDROLYSED FORMULA – **Restricted** see terms below

- ⚡ Powder 14 g protein, 53.4 g carbohydrate and 27.3 g fat per 100 g,
450 g can

*e.g. Aptamil Gold+ Pepti
Junior*

➔ Restricted

Initiation

Any of the following:

- 1 Both:
 - 1.1 Cows' milk formula is inappropriate due to severe intolerance or allergy to its protein content; and
 - 1.2 Either:
 - 1.2.1 Soy milk formula has been reasonably trialled without resolution of symptoms; or
 - 1.2.2 Soy milk formula is considered clinically inappropriate or contraindicated; or
- 2 Severe malabsorption; or
- 3 Short bowel syndrome; or
- 4 Intractable diarrhoea; or
- 5 Biliary atresia; or
- 6 Cholestatic liver diseases causing malabsorption; or
- 7 Cystic fibrosis; or
- 8 Proven fat malabsorption; or
- 9 Severe intestinal motility disorders causing significant malabsorption; or
- 10 Intestinal failure; or
- 11 For step down from Amino Acid Formula.

Note: A reasonable trial is defined as a 2-4 week trial, or signs of an immediate IgE mediated allergic reaction.

Continuation

Both:

- 1 An assessment as to whether the infant can be transitioned to a cows' milk protein or soy infant formula has been undertaken; and
- 2 The outcome of the assessment is that the infant continues to require an extensively hydrolysed infant formula.

FRUCTOSE-BASED FORMULA

- Powder 14.6 g protein, 49.7 g carbohydrate and 30.8 g fat per 100 g,
400 g can

e.g. Galactomin 19

LACTOSE-FREE FORMULA

- Powder 1.3 g protein, 7.3 g carbohydrate and 3.5 g fat per 100 ml,
900 g can

*e.g. Karicare Aptamil
Gold De-Lact*

- Powder 1.5 g protein, 7.2 g carbohydrate and 3.6 g fat per 100 ml,
900 g can

e.g. S26 Lactose Free

SPECIAL FOODS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
LOW-CALCIUM FORMULA			
Powder 14.6 g protein, 53.7 g carbohydrate and 26.1 g fat per 100 g, 400 g can			<i>e.g. Locasol</i>
PAEDIATRIC ORAL FEED 1 KCAL/ML – Restricted see terms below			
☒ Liquid 2.6 g protein, 10.3 g carbohydrate, 5.4 g fat and 0.6 g fibre per 100 ml, 100 ml bottle			<i>e.g. Infatrin</i>
➔ Restricted			
Both:			
1 Either:			
1.1 The patient is fluid restricted; or			
1.2 The patient has increased nutritional requirements due to faltering growth; and			
2 Patient is under 18 months old and weighs less than 8kg.			
PRETERM FORMULA – Restricted see terms below			
☒ Powder 1.9 g protein, 7.5 g carbohydrate and 3.9 g fat per 14 g, can	15.25	400 g	S-26 Gold Premgro
☒ Liquid 2.2 g protein, 8.4 g carbohydrate and 4.4 g fat per 100 ml, bottle	0.75	100 ml	S26 LBW Gold RTF
☒ Liquid 2.3 g protein, 8.6 g carbohydrate and 4.2 g fat per 100 ml, 90 ml bottle			<i>e.g. Pre Nan Gold RTF</i>
☒ Liquid 2.6 g protein, 8.4 g carbohydrate and 3.9 g fat per 100 ml, 70 ml bottle			<i>e.g. Karicare Aptamil Gold+Preterm</i>
➔ Restricted			
For infants born before 33 weeks' gestation or weighing less than 1.5 kg at birth.			
THICKENED FORMULA			
Powder 1.8 g protein, 8.1 g carbohydrate and 3.3 g fat per 100 ml, 900 g can			<i>e.g. Karicare Aptamil Thickened AR</i>

Ketogenic Diet Products

HIGH FAT FORMULA – Restricted see terms below			
☒ Powder 15.25 g protein, 3 g carbohydrate and 73 g fat per 100 g, can	35.50	300 g	Ketocal 4:1 (Unflavoured) Ketocal 4:1 (Vanilla)
☒ Powder 15.3 g protein, 7.2 g carbohydrate and 67.7 g fat per 100 g, can	35.50	300 g	Ketocal 3:1 (Unflavoured)
➔ Restricted			
For patients with intractable epilepsy, pyruvate dehydrogenase deficiency or glucose transported type-1 deficiency and other conditions requiring a ketogenic diet.			

Paediatric Products

➔**Restricted**

Both:

- 1 Child is aged one to ten years; and
- 2 Any of the following:
 - 2.1 The child is being fed via a tube or a tube is to be inserted for the purposes of feeding; or
 - 2.2 Any condition causing malabsorption; or
 - 2.3 Faltering growth in an infant/child; or
 - 2.4 Increased nutritional requirements; or
 - 2.5 The child is being transitioned from TPN or tube feeding to oral feeding; or
 - 2.6 The child has eaten, or is expected to eat, little or nothing for 3 days.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
PAEDIATRIC ORAL FEED – Restricted see terms on the preceding page			
☒ Powder 14.9 g protein, 54.3 g carbohydrate and 24.7 g fat per 100 g, can	20.00	850 g	Pediasure (Vanilla)
PAEDIATRIC ENTERAL FEED 0.76 KCAL/ML – Restricted see terms on the preceding page			
☒ Liquid 2.5 g protein, 12.5 g carbohydrate, 3.3 g fat and 0.7 g fibre per 100 ml, bag	4.00	500 ml	Nutrini Low Energy Multifibre RTH
PAEDIATRIC ENTERAL FEED 1 KCAL/ML – Restricted see terms on the preceding page			
☒ Liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, bag	2.68	500 ml	Pediasure RTH
☒ Liquid 2.8 g protein, 12.3 g carbohydrate and 4.4 g fat per 100 ml, 500 ml bag			<i>e.g. Nutrini RTH</i>
PAEDIATRIC ENTERAL FEED 1.5 KCAL/ML – Restricted see terms on the preceding page			
☒ Liquid 4.1 g protein, 18.5 g carbohydrate, 6.7 g fat and 0.8 g fibre per 100 ml, bag	6.00	500 ml	Nutrini Energy Multi Fibre
☒ Liquid 4.1 g protein, 18.5 g carbohydrate and 6.7 g fat per 100 ml, 500 ml bag			<i>e.g. Nutrini Energy RTH</i>
PAEDIATRIC ORAL FEED 1 KCAL/ML – Restricted see terms on the preceding page			
☒ Liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml, bottle	1.07	200 ml	Pediasure (Chocolate) Pediasure (Strawberry) Pediasure (Vanilla)
☒ Liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml, can	1.34	250 ml	Pediasure (Vanilla)
PAEDIATRIC ORAL FEED 1.5 KCAL/ML – Restricted see terms on the preceding page			
☒ Liquid 3.4 g protein, 18.8 g carbohydrate and 6.8 g fat per 100 ml, 200 ml bottle			<i>e.g. Fortini</i>
☒ Liquid 4.0 g protein, 18.8 g carbohydrate, 6.8 g fat and 1.5 g fibre per 100 ml, 200 ml bottle			<i>e.g. Fortini Multifibre</i>

Renal Products

LOW ELECTROLYTE ENTERAL FEED 1.8 KCAL/ML – Restricted see terms below			
☒ Liquid 8.1 g protein, 14.74 g carbohydrate, 9.77 g fat and 1.26 g fibre per 100 ml, bottle	6.08	500 ml	Nepro HP RTH
☛ Restricted For patients with acute or chronic kidney disease.			
LOW ELECTROLYTE ORAL FEED – Restricted see terms below			
☒ Powder 7.5 g protein, 59 g carbohydrate and 26.3 g fat per 100 g, 400 g can			<i>e.g. Kindergen</i>
☛ Restricted For children (up to 18 years) with acute or chronic kidney disease			
LOW ELECTROLYTE ORAL FEED 1.8 KCAL/ML			
☒ Liquid 8 g protein, 14.74 g carbohydrate, 9.77 g fat and 1.26 g fibre per 100 ml, carton	2.67	220 ml	Nepro HP (Strawberry) Nepro HP (Vanilla)
☛ Restricted For patients with acute or chronic kidney disease.			

SPECIAL FOODS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
LOW ELECTROLYTE ORAL FEED 2 KCAL/ML – Restricted see terms below			
☞ Liquid 9.1 g protein, 19 g carbohydrate and 10 g fat per 100 ml, carton	3.31	237 ml	Novasource Renal (Vanilla)
☞ Liquid 3 g protein, 25.5 g carbohydrate and 9.6 g fat per 100 ml, 237 ml bottle			
☞ Liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, 125 ml carton			<i>e.g. Renilon 7.5</i>

➔Restricted

For patients with acute or chronic kidney disease.

Respiratory Products

LOW CARBOHYDRATE ORAL FEED 1.5 KCAL/ML – Restricted see terms below

☞ Liquid 6.2 g protein, 10.5 g carbohydrate and 9.32 g fat per 100 ml, bottle	1.66	237 ml	Pulmocare (Vanilla)
---	------	--------	---------------------

➔Restricted

For patients with CORD and hypercapnia, defined as a CO2 value exceeding 55 mmHg

Surgical Products

HIGH ARGININE ORAL FEED 1.4 KCAL/ML – Restricted see terms below

☞ Liquid 7.6 g protein, 18.9 g carbohydrate, 3.9 g fat and 1.4 g fibre per 100 ml, carton	4.00	237 ml	Impact Advanced Recovery (Chocolate) Impact Advanced Recovery (Vanilla)
---	------	--------	---

➔Restricted

Three packs per day for 5 to 7 days prior to major gastrointestinal, head or neck surgery

PREOPERATIVE CARBOHYDRATE FEED 0.5 KCAL/ML – Restricted see terms below

☞ Oral liq 0 g protein, 12.6 g carbohydrate and 0 g fat per 100 ml, 200 ml bottle	6.80	4	preOp
---	------	---	-------

➔Restricted

Maximum of 400 ml as part of an Enhanced Recovery After Surgery (ERAS) protocol 2 to 3 hours before major abdominal surgery.

Standard Feeds

➔Restricted

Any of the following:

- 1 For patients with malnutrition, defined as any of the following:
 - 1.1 BMI < 18.5; or
 - 1.2 Greater than 10% weight loss in the last 3-6 months; or
 - 1.3 BMI < 20 with greater than 5% weight loss in the last 3-6 months; or
- 2 For patients who have, or are expected to, eat little or nothing for 5 days; or
- 3 For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism; or
- 4 For use pre- and post-surgery; or
- 5 For patients being tube-fed; or
- 6 For tube-feeding as a transition from intravenous nutrition; or
- 7 For any other condition that meets the community Special Authority criteria.

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
ENTERAL FEED 1.5 KCAL/ML – Restricted see terms on the preceding page			
⬆ Liquid 5.4 g protein, 13.6 g carbohydrate and 3.3 g fat per 100 ml, 1,000 ml bottle			<i>e.g. Isosource Standard RTH</i>
⬆ Liquid 6 g protein, 18.3 g carbohydrate and 5.8 g fat per 100 ml, bag	7.00	1,000 ml	Nutrison Energy
⬆ Liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 1.5 g fibre per 100 ml, 1,000 ml bag			<i>e.g. Nutrison Energy Multi Fibre</i>
⬆ Liquid 6.25 g protein, 20 g carbohydrate and 5 g fat per 100 ml, can	1.75	250 ml	Ensure Plus HN
⬆ Liquid 6.27 g protein, 20.4 g carbohydrate and 4.9 g fat per 100 ml, bag	7.00	1,000 ml	Ensure Plus HN RTH
⬆ Liquid 6.38 g protein, 21.1 g carbohydrate, 4.9 g fat and 1.2 g fibre per 100 ml, bag	7.00	1,000 ml	Jevity HiCal RTH
ENTERAL FEED 1 KCAL/ML – Restricted see terms on the preceding page			
⬆ Liquid 4 g protein, 13.6 g carbohydrate and 3.4 g fat per 100 ml, bottle	2.65	500 ml	Osmolite RTH
	5.29	1,000 ml	Osmolite RTH
⬆ Liquid 4 g protein, 13.6 g carbohydrate and 3.4 g fat per 100 ml, can	1.24	250 ml	Osmolite
⬆ Liquid 4 g protein, 14.1 g carbohydrate, 3.47 g fat and 1.76 g fibre per 100 ml, bottle	2.65	500 ml	Jevity RTH
	5.29	1,000 ml	Jevity RTH
⬆ Liquid 4 g protein, 14.1 g carbohydrate, 3.47 g fat and 1.76 g fibre per 100 ml, can	1.32	237 ml	Jevity
⬆ Liquid 4 g protein, 12.3 g carbohydrate and 3.9 g fat per 100 ml, 1,000 ml bag			<i>e.g. NutrisonStdRTH; NutrisonLowSodium</i>
⬆ Liquid 4 g protein, 12.3 g carbohydrate, 3.9 g fat and 1.5 g fibre per 100 ml, 1000 ml bag			<i>e.g. Nutrison Multi Fibre</i>
ENTERAL FEED 1.2 KCAL/ML – Restricted see terms on the preceding page			
⬆ Liquid 5.55 g protein, 15.1 g carbohydrate, 3.93 g fat and 2 g fibre per 100 ml, 1,000 ml bag			<i>e.g. Jevity Plus RTH</i>
ORAL FEED – Restricted see terms on the preceding page			
⬆ Powder 16 g protein, 59.8 g carbohydrate and 14 g fat per 100 g, can	13.00	850 g	Ensure (Chocolate) Ensure (Vanilla)
⬆ Powder 21.9 g protein, 53.5 g carbohydrate and 14.5 g fat per 100 g, can	3.67	350 g	Fortisip (Vanilla)
⬆ Powder 23 g protein, 65 g carbohydrate and 2.5 g fat per 100 g, can	14.90	840 g	Sustagen Hospital Formula (Chocolate) Sustagen Hospital Formula (Vanilla)
Note: Community subsidy of Sustagen Hospital Formula is subject to both Special Authority criteria and a manufacturer's surcharge. Higher subsidy by endorsement is available for patients meeting the following endorsement criteria; fat malabsorption, fat intolerance or chyle leak.			
ORAL FEED 1 KCAL/ML – Restricted see terms on the preceding page			
⬆ Liquid 3.8 g protein, 23 g carbohydrate and 12.7 g fibre per 100 ml, 237 ml carton			<i>e.g. Resource Fruit Beverage</i>

SPECIAL FOODS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
ORAL FEED 1.5 KCAL/ML – Restricted see terms on page 208			
↑ Liquid 5.5 g protein, 21.1 g carbohydrate and 4.81 g fat per 100 ml, can	1.33	237 ml	Ensure Plus (Chocolate) Ensure Plus (Vanilla)
↑ Liquid 6.25 g protein, 20.2 g carbohydrate and 4.92 g fat per 100 ml, carton	1.26	200 ml	Ensure Plus (Banana) Ensure Plus (Chocolate) Ensure Plus (Fruit of the Forest) Ensure Plus (Vanilla)
↑ Liquid 4 g protein and 33.5 g carbohydrate per 100 ml, 200 ml bottle			<i>e.g. Fortijuce</i>
↑ Liquid 6 g protein, 18.4 g carbohydrate and 5.8 g fat per 100 ml, 200 ml bottle			<i>e.g. Fortisip</i>
↑ Liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 2.3 g fibre per 100 ml, 200 ml bottle			<i>e.g. Fortisip Multi Fibre</i>

↑ Item restricted (see ➡ above); ↓ Item restricted (see ➡ below)

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Bacterial and Viral Vaccines

DIPHTHERIA, TETANUS, PERTUSSIS AND POLIO VACCINE – **Restricted** see terms below

<p>¶ Inj 30 IU diphtheria toxoid with 30IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin and 80 D-antigen units poliomyelitis virus in 0.5 ml syringe – 1% DV Jul-14 to 2017</p>	0.00	10	Infanrix IPV
--	------	----	---------------------

➔ **Restricted**

Funded for any of the following:

- 1 A single dose for children up to the age of 7 who have completed primary immunisation; or
- 2 A course of up to four vaccines is funded for catch up programmes for children (to the age of 10 years) to complete full primary immunisation; or
- 3 An additional four doses (as appropriate) are funded for (re-)immunisation for patients post HSCT, or chemotherapy; pre- or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or
- 4 Five doses will be funded for children requiring solid organ transplantation.

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes

DIPHTHERIA, TETANUS, PERTUSSIS, POLIO, HEPATITIS B AND HAEMOPHILUS INFLUENZAE TYPE B VACCINE – **Restricted** see terms below

<p>¶ Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin, 80 D-antigen units poliomyelitis virus, 10 mcg hepatitis B surface antigen in 0.5 ml syringe (1) and inj 10 mcg haemophilus influenzae type B vaccine vial – 1% DV Jul-14 to 2017</p>	0.00	10	Infanrix-hexa
--	------	----	----------------------

➔ **Restricted**

Funded for patients meeting any of the following criteria:

- 1 Up to four doses for children up to and under the age of 10 for primary immunisation; or
- 2 An additional four doses (as appropriate) are funded for (re-)immunisation for children up to and under the age of 10 who are patients post haematopoietic stem cell transplantation, or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or
- 3 Up to five doses for children up to and under the age of 10 receiving solid organ transplantation.

Note: A course of up-to four vaccines is funded for catch up programmes for children (up to and under the age of 10 years) to complete full primary immunisation. Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

Bacterial Vaccines

ADULT DIPHTHERIA AND TETANUS VACCINE

<p>¶ Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid in 0.5 ml syringe – 1% DV Jul-14 to 2017</p>	0.00	5	ADT Booster
--	------	---	--------------------

➔ **Restricted**

Any of the following:

- 1 For vaccination of patients aged 45 and 65 years old; or
- 2 For vaccination of previously unimmunised or partially immunised patients; or
- 3 For revaccination following immunosuppression; or
- 4 For boosting of patients with tetanus-prone wounds; or
- 5 For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

VACCINES

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
BACILLUS CALMETTE-GUERIN VACCINE – Restricted see terms below			
† Inj Mycobacterium bovis BCG (Bacillus Calmette-Guerin), Danish strain 1331, live attenuated, vial Danish strain 1331, live attenuated, vial with diluent – 1% DV Oct-14 to 2017	0.00	10	BCG Vaccine
➔ Restricted For infants at increased risk of tuberculosis Note: increased risk is defined as: <ol style="list-style-type: none"> 1 Living in a house or family with a person with current or past history of TB; or 2 Having one or more household members or carers who within the last 5 years lived in a country with a rate of TB > or equal to 40 per 100,000 for 6 months or longer; or 3 During their first 5 years will be living 3 months or longer in a country with a rate of TB > or equal to 40 per 100,000. Note: A list of countries with high rates of TB are available at http://www.health.govt.nz/tuberculosis (Search for Downloads) or www.bcgatlas.org/index.php			
DIPHTHERIA, TETANUS AND PERTUSSIS VACCINE – Restricted see terms below			
† Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid, 8 mcg pertussis toxoid, 8 mcg pertussis filamentous haemagglutinin and 2.5 mcg pertactin in 0.5 ml syringe – 1% DV Jul-14 to 2017.....	0.00	1 10	Boostrix Boostrix
➔ Restricted Funded for any of the following: <ol style="list-style-type: none"> 1 A single vaccine for pregnant woman between gestational weeks 28 and 38; or 2 A course of up to four vaccines is funded for children from age 7 up the age of 18 years inclusive to complete full primary immunisation; or 3 An additional four doses (as appropriate) are funded for (re-)immunisation for patients post haematopoietic stem cell transplantation or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens Note: Tdap is not registered for patients aged less than 10 years. Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.			
HAEMOPHILUS INFLUENZAE TYPE B VACCINE – Restricted see terms below			
† Inj 10 mcg vial with diluent syringe – 1% DV Jul-14 to 2017	0.00	1	Act-HIB
➔ Restricted One dose for patients meeting any of the following: <ol style="list-style-type: none"> 1 For primary vaccination in children; or 2 An additional dose (as appropriate) is funded for (re-)immunisation for patients post haematopoietic stem cell transplantation, or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, pre- or post cochlear implants, renal dialysis and other severely immunosuppressive regimens; or 3 For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician. 			
MENINGOCOCCAL (A, C, Y AND W-135) CONJUGATE VACCINE – Restricted see terms on the next page			
† Inj 4 mcg or each meningococcal polysaccharide conjugated to a total of approximately 48 mcg of diphtheria toxoid carrier per 0.5 ml vial – 1% DV Jul-14 to 2017	0.00	1	Menactra

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➔ **Restricted**

Any of the following:

- 1 Up to three doses and a booster every five years for patients pre- and post splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre or post solid organ transplant; or
- 2 One dose for close contacts of meningococcal cases; or
- 3 A maximum of two doses for bone marrow transplant patients; or
- 4 A maximum of two doses for patients following immunosuppression*.

Note: children under seven years of age require two doses 8 weeks apart, a booster dose three years after the primary series and then five yearly.

*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

MENINGOCOCCAL C CONJUGATE VACCINE – Restricted see terms below

⚡ Inj 10 mcg in 0.5 ml syringe – 1% DV Jul-14 to 2017	0.00	1	Neisvac-C
		10	Neisvac-C

➔ **Restricted**

Any of the following:

- 1 Up to three doses and a booster every five years for patients pre- and post splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre or post solid organ transplant; or
- 2 One dose for close contacts of meningococcal cases; or
- 3 A maximum of two doses for bone marrow transplant patients; or
- 4 A maximum of two doses for patients following immunosuppression*.

Note: children under seven years of age require two doses 8 weeks apart, a booster dose three years after the primary series and then five yearly.

*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.

PNEUMOCOCCAL (PCV13) CONJUGATE VACCINE – Restricted see terms below

⚡ Inj 30.8 mcg in 0.5 ml syringe – 1% DV Oct-14 to 2017	0.00	1	Prevenar 13
		10	Prevenar 13

➔ **Restricted**

Any of the following:

- 1 A primary course of up to four doses for previously unvaccinated individuals up to the age of 59 months inclusive; or
- 2 Up to three doses as appropriate to complete the primary course of immunisation for individuals under the age of 59 months who have received one to three doses of PCV10; or
- 3 One dose is funded for high risk children (over the age of 17 months and up to the age of 18) who have previously received four doses of PCV10; or
- 4 Up to an additional four doses (as appropriate) are funded for (re-)immunisation of patients with HIV, for patients post haematopoietic stem cell transplantation HSCT, or chemotherapy; pre- or post splenectomy; functional asplenia, pre- or post- solid organ transplant, renal dialysis, complement deficiency (acquired or inherited), cochlear implants, or primary immunodeficiency; or
- 5 For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

Note: Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes

PNEUMOCOCCAL (PPV23) POLYSACCHARIDE VACCINE – Restricted see terms below

⚡ Inj 575 mcg in 0.5 ml prefilled syringe (25 mcg of each 23 pneumococcal serotype) – 1% DV Jun-15 to 2017	0.00	1	Pneumovax 23
--	------	---	---------------------

➔ **Restricted**

Any of the following:

- 1 Up to three doses for patients pre- or post-splenectomy or with functional asplenia; or
- 2 Up to two doses are funded for high risk children to the age of 18; or
- 3 For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.

SALMONELLA TYPHI VACCINE – Restricted see terms on the next page

⚡ Inj 25 mcg in 0.5 ml syringe			
--------------------------------	--	--	--

VACCINES

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➔ **Restricted**

For use during typhoid fever outbreaks

Viral Vaccines

HEPATITIS A VACCINE – **Restricted** see terms below

⚡ Inj 720 ELISA units in 0.5 ml syringe – 1% DV Jul-14 to 2017	0.00	1	Havrix Junior
⚡ Inj 1440 ELISA units in 1 ml syringe – 1% DV Jul-14 to 2017	0.00	1	Havrix

➔ **Restricted**

Funded for patients meeting any of the following criteria:

- 1 Two vaccinations for use in transplant patients; or
- 2 Two vaccinations for use in children with chronic liver disease; or
- 3 One dose of vaccine for close contacts of known hepatitis A cases.

HEPATITIS B RECOMBINANT VACCINE

⚡ Inj 5 mcg in 0.5 ml vial – 1% DV Jul-14 to 2017	0.00	1	HBvaxPRO
---	------	---	----------

➔ **Restricted**

Funded for patients meeting any of the following criteria:

- 1 For household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or
- 2 For children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or
- 3 For children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination; or
- 4 For HIV positive patients; or
- 5 For hepatitis C positive patients; or
- 6 For patients following non-consensual sexual intercourse; or
- 7 For patients following immunosuppression; or
- 8 For transplant patients; or
- 9 Following needle stick injury.

⚡ Inj 10 mcg in 1 ml vial – 1% DV Jul-14 to 2017	0.00	1	HBvaxPRO
--	------	---	----------

➔ **Restricted**

Funded for patients meeting any of the following criteria:

- 1 For household or sexual contacts of known acute hepatitis B patients or hepatitis B carriers; or
- 2 For children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or
- 3 For children up to and under the age of 18 years inclusive who are considered not to have achieved a positive serology and require additional vaccination; or
- 4 For HIV positive patients; or
- 5 For hepatitis C positive patients; or
- 6 For patients following non-consensual sexual intercourse; or
- 7 For patients following immunosuppression; or
- 8 For transplant patients; or
- 9 Following needle stick injury.

⚡ Inj 40 mcg per 1 ml vial – 1% DV Jul-14 to 2017	0.00	1	HBvaxPRO
---	------	---	----------

➔ **Restricted**

Funded for any of the following criteria:

- 1 For dialysis patients; or
- 2 For liver or kidney transplant patient.

HUMAN PAPILLOMAVIRUS (6, 11, 16 AND 18) VACCINE [HPV] – **Restricted** see terms on the next page

⚡ Inj 120 mcg in 0.5 ml syringe – 1% DV Jul-14 to 2017	0.00	10	Gardasil
--	------	----	----------

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➔ **Restricted**

Maximum of three doses for patient meeting any of the following criteria:

- 1 Females aged under 20 years old; or
- 2 Patients aged under 26 years old with confirmed HIV infection; or
- 3 For use in transplant (including stem cell) patients; or
- 4 An additional dose for patients under 26 years of age post chemotherapy.

INFLUENZA VACCINE – **Restricted** see terms below

¶ Inj 45 mcg in 0.5 ml syringe	90.00	10	Fluarix Influvac
--------------------------------------	-------	----	---------------------

➔ **Restricted**

Any of the following:

- 1 All people 65 years of age and over; or
- 2 People under 65 years of age who:
 - 2.1 Have any of the following cardiovascular diseases:
 - 2.1.1 Ischaemic heart disease; or
 - 2.1.2 Congestive heart failure; or
 - 2.1.3 Rheumatic heart disease; or
 - 2.1.4 Congenital heart disease; or
 - 2.1.5 Cerebro-vascular disease; or
 - 2.2 Have any of the following chronic respiratory diseases:
 - 2.2.1 Asthma, if on a regular preventative therapy; or
 - 2.2.2 Other chronic respiratory disease with impaired lung function; or
 - 2.3 Have diabetes; or
 - 2.4 Have chronic renal disease; or
 - 2.5 Have any cancer, excluding basal and squamous skin cancers if not invasive; or
 - 2.6 Have any of the following other conditions:
 - 2.6.1 Autoimmune disease; or
 - 2.6.2 Immune suppression or immune deficiency; or
 - 2.6.3 HIV; or
 - 2.6.4 Transplant recipients; or
 - 2.6.5 Neuromuscular and CNS diseases/ disorders; or
 - 2.6.6 Haemoglobinopathies; or
 - 2.6.7 Are children on long term aspirin; or
 - 2.6.8 Have a cochlear implant; or
 - 2.6.9 Errors of metabolism at risk of major metabolic decompensation; or
 - 2.6.10 Pre and post splenectomy; or
 - 2.6.11 Down syndrome; or
 - 2.7 Are pregnant; or
 - 2.8 Are children aged four and under who have been hospitalised for respiratory illness or have a history of significant respiratory illness; or
- 3 Patients who are compulsorily detained long-term in a forensic unit within a DHB hospital in the 2015 season.

Note: The following conditions are excluded from funding:

- asthma not requiring regular preventative therapy; and
- hypertension and/or dyslipidaemia without evidence of end-organ disease.

MEASLES, MUMPS AND RUBELLA VACCINE – **Restricted** see terms on the next page

¶ Inj 1000 TCID50 measles, 12500 TCID50 mumps and 1000 TCID50 rubella vial with diluent – 1% DV Jul-14 to 2017	0.00	10	M-M-R-II
---	------	----	----------

VACCINES

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

➔ **Restricted**

A maximum of two doses for any patient meeting the following criteria:

- 1 For primary vaccination in children; or
- 2 For revaccination following immunosuppression; or
- 3 For any individual susceptible to measles, mumps or rubella; or
- 4 A maximum of three doses for children who have had their first dose prior to 12 months.

Note: Please refer to the Immunisation Handbook for appropriate schedule for catch up programmes.

POLIOMYELITIS VACCINE – **Restricted** see terms below

⚡ Inj 80 D-antigen units in 0.5 ml syringe – 1% DV Jul-14 to 2017	0.00	1	IPOL
---	------	---	-------------

➔ **Restricted**

Up to three doses for patients meeting either of the following:

- 1 For partially vaccinated or previously unvaccinated individuals; or
- 2 For revaccination following immunosuppression.

Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

RABIES VACCINE

Inj 2.5 IU vial with diluent

ROTAVIRUS LIVE REASSORTANT ORAL VACCINE – **Restricted** see terms below

⚡ Oral susp G1, G2, G3, G4, P1(8) 11.5 million CCID50 units per 2 ml, tube – 1% DV Jul-14 to 2017	0.00	10	RotaTeq
--	------	----	----------------

➔ **Restricted**

Maximum of three doses for patients meeting the following:

- 1 First dose to be administered in infants aged under 15 weeks of age; and
- 2 No vaccination being administered to children aged 8 months or over.

VARICELLA VACCINE [CHICKEN POX VACCINE] – **Restricted** see terms below

⚡ Inj 2,000 PFU vial with diluent – 1% DV Jul-14 to 2017	0.00	1	Varilrix
--	------	---	-----------------

➔ **Restricted**

Maximum of two doses for any of the following:

- 1 For non-immune patients:
 - 1.1 With chronic liver disease who may in future be candidates for transplantation; or
 - 1.2 With deteriorating renal function before transplantation; or
 - 1.3 Prior to solid organ transplant; or
 - 1.4 Prior to any elective immunosuppression*.
- 2 For patients at least 2 years after bone marrow transplantation, on advice of their specialist.
- 3 For patients at least 6 months after completion of chemotherapy, on advice of their specialist.
- 4 For HIV positive non immune to varicella with mild or moderate immunosuppression on advice of HIV specialist.
- 5 For patients with inborn errors of metabolism at risk of major metabolic decompensation, with no clinical history of varicella.
- 6 For household contacts of paediatric patients who are immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella.
- 7 For household contacts of adult patients who have no clinical history of varicella and who are severely immunocompromised, or undergoing a procedure leading to immune compromise where the household contact has no clinical history of varicella

* immunosuppression due to steroid or other immunosuppressive therapy must be for a treatment period of greater than 28 days

Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Optional Pharmaceuticals

NOTE:

In addition to the products expressly listed here in Part III: Optional Pharmaceuticals, a number of additional Optional Pharmaceuticals, including some wound care products and disposable laparoscopic equipment, are listed in an addendum to Part III which is available at www.pharmac.govt.nz. The Optional Pharmaceuticals listed in the addendum are deemed to be listed in Part III, and the Rules of the Pharmaceutical Schedule applying to products listed in Part III apply to them.

BLOOD GLUCOSE DIAGNOSTIC TEST METER

1 meter with 50 lancets, a lancing device, and 10 diagnostic test strips	20.00	1	Caresens II Caresens N Caresens N POP
Meter	9.00	1	FreeStyle Lite On Call Advanced Accu-Chek Performa
	19.00		

BLOOD GLUCOSE DIAGNOSTIC TEST STRIP

Blood glucose test strips	10.56	50 test	CareSens CareSens N FreeStyle Lite
	21.65		Accu-Chek Performa Freestyle Optium
	28.75		
Blood glucose test strips × 50 and lancets × 5	19.10	50 test	On Call Advanced

BLOOD KETONE DIAGNOSTIC TEST METER

Meter	40.00	1	Freestyle Optium Freestyle Optium Neo
-------------	-------	---	--

(Freestyle Optium Meter to be delisted 1 May 2016)

INSULIN PEN NEEDLES

29 g × 12.7 mm	10.50	100	B-D Micro-Fine
31 g × 5 mm	11.75	100	B-D Micro-Fine
31 g × 6 mm	10.50	100	ABM
31 g × 8 mm	10.50	100	B-D Micro-Fine
32 g × 4 mm	10.50	100	B-D Micro-Fine

INSULIN SYRINGES, DISPOSABLE WITH ATTACHED NEEDLE

Syringe 0.3 ml with 29 g × 12.7 mm needle	13.00	100	B-D Ultra Fine
Syringe 0.3 ml with 31 g × 8 mm needle	13.00	100	B-D Ultra Fine II
Syringe 0.5 ml with 29 g × 12.7 mm needle	13.00	100	B-D Ultra Fine
Syringe 0.5 ml with 31 g × 8 mm needle	13.00	100	B-D Ultra Fine II
Syringe 1 ml with 29 g × 12.7 mm needle	13.00	100	B-D Ultra Fine
Syringe 1 ml with 31 g × 8 mm needle	13.00	100	B-D Ultra Fine II

KETONE BLOOD BETA-KETONE ELECTRODES

Test strips	15.50	10 strip	Freestyle Optium Ketone
-------------------	-------	----------	-------------------------

MASK FOR SPACER DEVICE

Small	2.20	1	e-chamber Mask
Size 2	2.99	1	EZ-fit Paediatric Mask

(EZ-fit Paediatric Mask Size 2 to be delisted 1 February 2016)

PART III - OPTIONAL PHARMACEUTICALS

	Price (ex man. excl. GST) \$	Per	Brand or Generic Manufacturer
PEAK FLOW METER			
Low Range	9.54	1	Mini-Wright AFS Low Range
	11.44		Breath-Alert
Normal Range	9.54	1	Mini-Wright Standard Breath-Alert
	11.44		
<i>(Breath-Alert Low Range to be delisted 1 February 2016)</i>			
<i>(Breath-Alert Normal Range to be delisted 1 February 2016)</i>			
PREGNANCY TEST - HCG URINE			
Cassette – 1% DV Sep-15 to 2017	17.60	40 test	EasyCheck
SODIUM NITROPRUSSIDE			
Test strip	6.00	50 strip	Accu-Chek Ketur-Test
SPACER DEVICE			
220 ml (single patient)	2.95	1	e-chamber Turbo
230 ml (single patient)	4.72	1	Space Chamber Plus
510 ml (single patient)	5.12	1	e-chamber La Grande
800 ml	8.50	1	Volumatic
<i>(Space Chamber Plus 230 ml (single patient) to be delisted 1 February 2016)</i>			

- Symbols -

8-methoxypsoralen54

- A -

A-Scabies50
 Abacavir sulphate84
 Abacavir sulphate with lamivudine 84
 Abciximab148
 Abilify118
 Abiraterone acetate140
 Acarbose16
 Accu-Chek Ketur-Test218
 Accu-Chek Performa217
 Accuretic 1037
 Accuretic 2037
 Acetazolamide183
 Acetic acid
 Extemporaneously Compounded Preparations194
 Genito-Urinary56
 Acetic acid with hydroxyquinoline, glycerol and ricinoleic acid56
 Acetic acid with propylene glycol185
 Acetylcholine chloride184
 Acetylcysteine186
 Aciclovir
 Infections89
 Sensory180
 Aciclovir-Claris89
 Acid Citrate Dextrose A31
 Acidex13
 Acipimox44
 Acitretin53
 Aclasta95
 Act-HIB212
 Actavis120
 Actemra167
 Actinomycin D129
 Adalimumab148
 Adapalene50
 Adefin XL41
 Adefovir dipivoxil86
 Adenosine38-39
 Adenuric99
 Adrenaline45
 ADT Booster211
 Adult diphtheria and tetanus vaccine211
 Advantan53
 Advate30

Aerrane104
 Afinitor171
 AFT SLS-free51
 Agents Affecting the Renin-Angiotensin System37
 Agents for Parkinsonism and Related Disorders103
 Agents Used in the Treatment of Poisonings186
 Air Flow Products112
 Ajmaline39
 Alanase173
 Albendazole80
 Alendronate sodium93-94
 Alendronate sodium with cholecalciferol94
 Alfacalcidol25
 Alfentanil108
 Alinia81
 Alitraq203
 Allersoothe174
 Allopurinol98
 Alpha tocopheryl acetate26
 Alpha-Adrenoceptor Blockers38
 Alprazolam123
 Alprostadil hydrochloride46
 Alteplase33
 Alum194
 Aluminium chloride28
 Aluminium hydroxide13
 Aluminium hydroxide with magnesium hydroxide and simethicone13
 Amantadine hydrochloride103
 AmBisome77
 Ambrisentan47
 Amethocaine107, 182
 Nervous107
 Sensory182
 Amikacin70
 Amiloride hydrochloride43
 Amiloride hydrochloride with furosemide42
 Amiloride hydrochloride with hydrochlorothiazide42
 Aminophylline178
 Amiodarone hydrochloride39
 Amisulpride118
 Amitriptyline111
 Amlodipine41
 Amorolfine49
 Amoxicillin73

Amoxicillin Actavis73
 Amoxicillin with clavulanic acid73
 Amphotericin B
 Alimentary23
 Infections77
 Amsacrine131
 Amyl nitrite46
 Anabolic Agents60
 Anaesthetics104
 Anagrelide hydrochloride131
 Analgesics107
 Anastrozole141
 Andriol Testocaps60
 Androderm60
 Androgen Agonists and Antagonists60
 Anexate186
 Antabuse127
 Antacids and Antiflatulents13
 Anti-Infective Agents56
 Anti-Infective Preparations
 Dermatological49
 Sensory180
 Anti-Inflammatory Preparations181
 Antiacne Preparations50
 Antiallergy Preparations173
 Antianaemics27
 Antiarrhythmics38
 Antibacterials70
 Anticholinergic Agents174
 Anticholinesterases93
 Antidepressants111
 Antidiarrhoeals and Intestinal Anti-Inflammatory Agents13
 Antiepilepsy Drugs113
 Antifibrinolytics, Haemostatics and Local Sclerosants28
 Antifungals76
 Antihypotensives39
 Antimigraine Preparations117
 Antimycobacterials79
 Antinaus118
 Antinausea and Vertigo Agents117
 Antiparasitics80
 Antipruritic Preparations50
 Antipsychotic Agents118
 Antiretrovirals82
 Antirheumatoid Agents93
 Antiseptics and

Disinfectants	188	Arginine		Blood	32
Antispasmodics and Other		Alimentary	20	Nervous	107
Agents Altering Gut		Various	191	Asthalin	175
Motility	15	Argipressin [Vasopressin]	68	Atazanavir sulphate	85
Antithrombotics	30	Aripiprazole	118	Atenolol	39
Antithymocyte globulin		Aristocort	53	Atenolol-AFT	39
(equine)	170	Aromasin	142	ATGAM	170
Antithymocyte globulin		Arrow - Clopid	32	Ativan	123
(rabbit)	171	Arrow-Amitriptyline	111	Atomoxetine	125
Antiulcerants	15	Arrow-Bendrofluzide	43	Atorvastatin	43
Antivirals	86	Arrow-Brimonidine	184	Atovaquone with proguanil	
Anxiolytics	123	Arrow-Calcium	21	hydrochloride	80
Apidra	17	Arrow-Diazepam	123	Atracurium besylate	99
Apidra Solostar	17	Arrow-Dortim	183	Atripa	84
Apo-Allopurinol	98	Arrow-Doxorubicin	129	Atropine sulphate	
Apo-Amiloride	43	Arrow-Etidronate	95	Cardiovascular	39
Apo-Amlodipine	41	Arrow-Fluoxetine	112	Sensory	184
Apo-Amoxi	73	Arrow-Gabapentin	113	Atropt	184
Apo-Azithromycin	72	Arrow-Iloprost	48	Augmentin	73
Apo-Ciclopirox	49	Arrow-Lamotrigine	115	Auranofin	93
Apo-Cilazapril/		Arrow-Losartan &		Ava 20 ED	56
Hydrochlorothiazide	37	Hydrochlorothiazide	38	Ava 30 ED	56
Apo-Clarithromycin	72	Arrow-Morphine LA	109	Avelox	74
Apo-Clomipramine	111	Arrow-Norfloxacin	74	Avelox IV 400	74
Apo-Diclo SR	101	Arrow-Ornidazole	81	Avonex	123
Apo-Diltiazem CD	41	Arrow-Quinapril 10	37	Avonex Pen	123
Apo-Doxazosin	38	Arrow-Quinapril 20	37	Azacidine	130
Apo-Folic Acid	28	Arrow-Quinapril 5	37	Azactam	75
Apo-Imiquimod Cream 5%	54	Arrow-Roxithromycin	72	Azamun	171
Apo-Megestrol	140	Arrow-Sertraline	112	Azathioprine	171
Apo-Mirtazapine	112	Arrow-Simva	44	Azithromycin	72
Apo-Moclobemide	112	Arrow-Sumatriptan	117	Azol	63
Apo-Nadolol	40	Arrow-Timolol	183	AZT	84
Apo-Nicotinic Acid	44	Arrow-Tolterodine	59	Aztreonam	75
Apo-Oxybutynin	59	Arrow-Topiramate	116		
Apo-Perindopril	37	Arrow-Tramadol	111	- B -	
Apo-Pindolol	40	Arrow-Venlafaxine XR	112	B-D Micro-Fine	217
Apo-Prazosin	38	Arsenic trioxide	131	B-D Ultra Fine	217
Apo-Prednisone	61	Artemether with lumefantrine	80	B-D Ultra Fine II	217
Apo-Prednisone S29	61	Artesunate	80	Bacillus calmette-guerin	
Apo-Propranolol	40	Articaine hydrochloride	105	(BCG)	171
Apo-Pyridoxine	25	Articaine hydrochloride with		Bacillus calmette-guerin	
Apo-Ropinirole	104	adrenaline	105	vaccine	212
Apomine	103	Asacol	14	Baclofen	99
Apomorphine hydrochloride	103	Asamax	14	Bacterial and Viral Vaccines	211
Apraclonidine	184	Ascorbic acid		Bacterial Vaccines	211
Aprepitant	117	Alimentary	25	Balanced Salt Solution	182
Apresoline	46	Extemporaneously		Baraclude	86
Aprotinin	28	Compounded		Barium sulphate	190
Aqueous cream	51	Preparations	194	Barium sulphate with sodium	
Arachis oil [Peanut oil]	194	Aspen Adrenaline	45	bicarbonate	190
Arava	93	Aspen Ciprofloxacin	74	Barrier Creams and	
Aremed	141	Aspirin		Emollients	50
				Basiliximab	155

BCG Vaccine	212	Bezalip	43	Bupivacaine hydrochloride with	
BD PosiFlush	35	Bezalip Retard	43	adrenaline	105
Beclazone 100	176	Bicalaccord	140	Bupivacaine hydrochloride with	
Beclazone 250	176	Bicalutamide	140	fentanyl	106
Beclazone 50	176	Bicillin LA	73	Bupivacaine hydrochloride with	
Beclomethasone		BiCNU	129	glucose	106
dipropionate	173, 176	Bile and Liver Therapy	16	Buprenorphine with	
Bee venom	173	Biisocopin	191	naloxone	127
Bendrofluzide	43	Bimatoprost	184	Bupropion hydrochloride	127
Bendroflumethiazide		Biodone	109	Burinex	42
[Bendrofluzide]	43	Biodone Extra Forte	109	Buscopan	15
BeneFIX	29	Biodone Forte	109	Buserelin	63
Benzathine benzylpenicillin	73	Biotin	20	Buspirone hydrochloride	123
Benzbromaron AL 100	98	Bisacodyl	20	Busulfan	129
Benzbromarone	98	Bismuth subgallate	194	Butacort Aqueous	173
Benzocaine	105	Bismuth subnitrate and iodoform			
Benzoin	194	paraffin	192	- C -	
Benzoyl peroxide	50	Bismuth trioxide	16	Cabergoline	62
Benztrop	103	Bisoprolol fumarate	40	Caffeine	125
Benztropine mesylate	103	Bivalirudin	30	Caffeine citrate	178
Benzydamine hydrochloride	23	Bleomycin sulphate	129	Cal-d-Forte	25
Benzydamine hydrochloride with		Blood glucose diagnostic test		Calamine	50
cetylpyridinium chloride	23	meter	217	Calcipotriol	53
Benzylpenicillin sodium [Penicillin		Blood glucose diagnostic test		Calcitonin	60
G]	73	strip	217	Calcitriol	25
Beractant	178	Blood ketone diagnostic test		Calcitriol-AFT	25
Beta Cream	52	meter	217	Calcium carbonate	13, 21
Beta Ointment	52	Boceprevir	89	Calcium Channel Blockers	41
Beta Scalp	54	Bonney's blue dye	191	Calcium chloride	33
Beta-Adrenoceptor Agonists	175	Boostrix	212	Calcium folinate	139
Beta-Adrenoceptor Blockers	39	Boric acid	194	Calcium Folate Ebewe	139
Betadine	188	Bortezomib	131	Calcium gluconate	
Betadine Skin Prep	188	Bosentan	47	Blood	33
Betagan	183	Bosvate	40	Dermatological	55
Betahistine dihydrochloride	117	Botox	100	Calcium Homeostasis	60
Betaine	20	Botulism antitoxin	186	Calcium polystyrene	
Betamethasone	60	Breath-Alert	218	sulphonate	36
Betamethasone dipropionate	52	Bridion	100	Calcium Resonium	36
Betamethasone dipropionate		Brilinta	32	Calsource	21
with calcipotriol	53	Brimonidine tartrate	184	Cancidas	78
Betamethasone sodium		Brimonidine tartrate with		Candesartan cilexetil	38
phosphate with		timolol	184	Candestar	38
betamethasone acetate	60	Brinzolamide	183	Capecitabine	130
Betamethasone valerate	52, 54	Bromocriptine	103	Capecitabine Winthrop	130
Betamethasone valerate with		Brufen SR	101	Capoten	37
clicloquinol	53	Budesonide		Capsaicin	
Betamethasone valerate with		Alimentary	13	Musculoskeletal System	102
fusidic acid	53	Respiratory	173, 176	Nervous	107
Betaxolol	183	Budesonide with		Captopril	37
Betoptic	183	efomedoterol	177	Carbamazepine	113
Betoptic S	183	Bumetanide	42	Carbasorb-X	187
Bevacizumab	155	Bupafan	106	Carbimazole	68
Bezafibrate	43	Bupivacaine hydrochloride	105	Carbomer	185

Carboplatin	134	Chloral hydrate	124	Citanest	107
Carboprost trometamol	57	Chlorambucil	129	Citric acid	194
Carboxymethylcellulose		Chloramphenicol		Citric acid with magnesium oxide	
Alimentary	23	Infections	75	and sodium picosulfate	19
Extemporaneously		Sensory	180	Citric acid with sodium	
Compounded		Chlorhexidine	188, 192	bicarbonate	190
Preparations	194	Chlorhexidine gluconate		Cladribine	130
Cardinol LA	40	Alimentary	23	Clarithromycin	72
Cardizem CD	41	Extemporaneously		Clexane	31
CareSens	217	Compounded		Clindamycin	75
Caresens II	217	Preparations	194	Clindamycin ABM	75
CareSens N	217	Genito-Urinary	56	Clinicians Multivit & Mineral	
Caresens N	217	Chlorhexidine with		Boost	24
Caresens N POP	217	cetrimide	188, 192	Clinicians Renal Vit	24
Carmellose sodium	185	Chlorhexidine with ethanol	188	Clobazam	113
Carmustine	129	Chloroform	194	Clobetasol BNM	52
Carvedilol	40	Chloroquine phosphate	80	Clobetasol propionate	52, 54
Caspofungin	78	Chlorothiazide	43	Clobetasone butyrate	52
Catapres	42	Chlorpheniramine maleate	174	Clofazimine	79
Catapres-TTS-1	42	Chlorpromazine		Clomazol	49, 56
Catapres-TTS-2	42	hydrochloride	119	Clomiphene citrate	62
Catapres-TTS-3	42	Chlorsig	180	Clomipramine hydrochloride	111
Ceenu	129	Chlortalidone		Clonazepam	113, 123
Cefaclor	71	[Chlortalidone]	43	Clonidine	42
Cefalexin	71	Chlorthalidone	43	Clonidine BNM	42
Cefalexin Sandoz	71	Choice TT380 Short	56	Clonidine hydrochloride	42
Cefazolin	71	Choice TT380 Standard	56	Clopidogrel	32
Cefepime	71	Cholecalciferol	25	Clopine	119
Cefepime-AFT	71	Cholestyramine	44	Clopixol	121, 122
Cefotaxime	71	Choline salicylate with		Clostridium botulinum type A	
Cefotaxime Sandoz	71	cetalkonium chloride	23	toxin	100
Cefoxitin	71	Cholvastin	43	Clotrimazole	
Cefoxitin Actavis	71	Choriogonadotropin alfa	64	Dermatological	49
Ceftaroline fosamil	71	Ciclopirox olamine	49	Genito-Urinary	56
Ceftazidime	71	Ciclosporin	142	Clove oil	194
Ceftriaxone	71	Cidofovir	89	Clozapine	119
Ceftriaxone-AFT	71	Cilazapril	37	Clozaril	119
Cefuroxime	71	Cilazapril with		Co-trimoxazole	76
Celecoxib	100	hydrochlorothiazide	37	Coal tar	194
Celiprolol	40	Cilicaine	73	Coal tar with salicylic acid and	
CellCept	171	Cilicaine VK	73	sulphur	53
Celol	40	Cimetidine	15	Coal tar with triethanolamine	
Centrally-Acting Agents	42	Cinchocaine hydrochloride with		lauryl sulphate and	
Cephalexin ABM	71	hydrocortisone	14	fluorescein	54
Cetirizine hydrochloride	174	Cipflox	74	Cocaine hydrochloride	106
Cetomacrogol	51	Ciprofloxacin		Cocaine hydrochloride with	
Cetomacrogol with glycerol	51	Infections	74	adrenaline	106
Cetrimide	194	Sensory	180	Codeine phosphate	
Champix	128	Ciprofloxacin with		Extemporaneously	
Charcoal	187	hydrocortisone	180	Compounded	
Chemotherapeutic Agents	129	Ciproxin HC Otic	180	Preparations	194
Chicken pox vaccine	216	Cisplatin	134	Nervous	108
Chlorafast	180	Citalopram hydrobromide	112	Cogentin	103

Colaspase [L-asparaginase]	132	Cyproterone acetate	60	Deferasirox	187	
Colchicine	99	Cyproterone acetate with ethinyloestradiol	56	Deferiprone	187	
Colestimethate	75	Cysteamine hydrochloride	194	Defibrotide	30	
Colestipol hydrochloride	44	Cytarabine	131	Definity	191	
Colgout	99	- D -			Demeclocycline hydrochloride	74
Colifoam	14	D-Penamine	93	Deoxycoformycin	133	
Colistin sulphomethate [Colestimethate]	75	Dabigatran	30	Depo-Medrol	61	
Colistin-Link	75	Dacarbazine	132	Depo-Medrol with Lidocaine	61	
Collodion flexible	194	Dactinomycin [Actinomycin D]	129	Depo-Provera	57	
Colofac	15	Daivobet	53	Depo-Testosterone	60	
Colony-Stimulating Factors	33	Daivonex	53	Deprim	76	
Coloxyl	19	Dalacin C	75	Dermol	54	
Compound electrolytes	33, 36	Dalteparin	30	Desferal	187	
Compound electrolytes with glucose	34, 36	Danaparoid	30	Desferrioxamine mesilate	187	
Compound hydroxybenzoate	194	Danazol	63	Desflurane	104	
Compound sodium lactate [Hartmann's solution]	34	Dantrium	100	Desmopressin acetate	68	
Compound sodium lactate with glucose	34	Dantrium IV	100	Desmopressin-PH&T	68	
Concerta	126	Dantrolene	100	Dexamethasone Hormone Preparations	61	
Condyline	54	Dapa-Tabs	43	Sensory	181	
Contraceptives	56	Dapsone Contracted	79	Dexamethasone phosphate	61	
Contrast Media	189	Infections	79	Dexamethasone with framycetin and gramicidin	180	
Cordarone-X	39	Daptomycin	75	Dexamethasone with neomycin sulphate and polymyxin B sulphate	181	
Corticosteroids Dermatological	52	Darunavir	85	Dexamethasone with tobramycin	181	
Hormone Preparations	60	Dasatinib	135	Dexamethasone-hameln	61	
Corticotrorelin (ovine)	63	Daunorubicin	129	Dexamfetamine sulfate	125	
Cosmegen	129	DBL Acetylcysteine	186	Dexmedetomidine	104	
Cough Suppressants	175	DBL Amikacin	70	Dexmethsone	61	
Creon 10000	18	DBL Aminophylline	178	Dextrose	16, 34, 194	
Creon 25000	18	DBL Bleomycin Sulfate	129	Alimentary	16	
Crotamiton	50	DBL Carboplatin	134	Blood	34	
Crystaderm	49	DBL Cefotaxime	71	Extemporaneously Compounded Preparations	194	
CT Plus+	190	DBL Cisplatin	134	Dextrose with sodium citrate and citric acid [Acid Citrate Dextrose A]	31	
Cubicin	75	DBL Docetaxel	139	DHC Continus	108	
Curam Duo	73	DBL Ergometrine	58	Diabetes	16	
Curosurf	178	DBL Leucovorin Calcium	139	Diacomit	115	
Cvite	25	DBL Meropenem	70	Diagnostic Agents	191	
Cyclizine hydrochloride	117	DBL Morphine Sulphate	109	Diagnostic and Surgical Preparations	182	
Cyclizine lactate	117	DBL Pethidine Hydrochloride	110	Diamide Relief	13	
Cyclogyl	184	DBL Rocuronium Bromide	100	Diamox	183	
Cyclopentolate hydrochloride	184	DBL Sterile Dopamine Concentrate	45	Diatrizoate meglumine with sodium amidotrizoate	189	
Cyclophosphamide	129	DBL Tobramycin	70	Diatrizoate sodium	189	
Cycloserine	79	DDI	84			
Cyklokapron	29	De-Nol	16			
Cymevene	89	De-Worm	80			
Cyproheptadine hydrochloride	174	Decongestants	175			
		Decongestants and Antiallergics	181			
		Decozol	23			

Diazepam	113, 123	Dobutamine-Claris	45	tenofovir disoproxil fumarate	84
Diazoxide		Docetaxel	139	Efexor XR	112
Alimentary	16	Docusate sodium		Effient	32
Cardiovascular	46	Alimentary	19	Eformoterol fumarate	177
Dicarz	40	Sensory	185	Efudix	54
Dichlorobenzyl alcohol with amylmetacresol	23	Docusate sodium with sennosides	19	Elecare (Unflavoured)	204
Diclofenac Sandoz	101	Domperidone	117	Elecare (Vanilla)	204
Diclofenac sodium		Donepezil hydrochloride	127	Elecare LCP (Unflavoured)	204
Musculoskeletal System	101	Donepezil-Rex	127	Electrolytes	193
Sensory	181	Dopamine hydrochloride	45	Eligard	64
Dicobalt edetate	187	Dopergin	104	Elocon	53
Didanosine [DDI]	84	Dopress	111	Elocon Alcohol Free	53
Diflucan	77	Dornase alfa	178	Eltrombopag	28
Diflucortolone valerate	52	Dorzolamide	183	Emend Tri-Pack	117
Digestives Including		Dorzolamide with timolol	183	EMLA	107
Enzymes	18	Dostinex	62	Emtricitabine	84
Digoxin	39	Dotarem	190	Emtricitabine with tenofovir disoproxil fumarate	84
Digoxin immune Fab	186	Dothiepin hydrochloride	111	Emtriva	84
Dihydrocodeine tartrate	108	Doxapram	179	Emulsifying ointment	51
Dihydroergotamine		Doxazosin	38	Enalapril maleate	37
mesylate	117	Doxepin hydrochloride	111	Enalapril maleate with hydrochlorothiazide	37
Diltiazem hydrochloride	41	Doxine	75	Enbrel	142
Dilzem	41	Doxorubicin Ebewe	129	Endocrine Therapy	140
Dimercaprol	187	Doxorubicin hydrochloride	129	Endoxan	129
Dimercaptosuccinic acid	187	Doxycycline	75	Enfuvirtide	82
Dimethicone	50	DP Fusidic Acid Cream	49	Enoxaparin	31
Dimethyl sulfoxide	192	DP Lotn HC	52	Ensure (Chocolate)	209
Dinoprostone	58	DP-Anastrozole	141	Ensure (Vanilla)	209
Diphemanil metilsulfate	54	Dr Reddy's Omeprazole	15	Ensure Plus (Banana)	210
Diphenoxylate hydrochloride with atropine sulphate	13	Dr Reddy's Ondansetron	118	Ensure Plus (Chocolate)	210
Diphtheria antitoxin	186	Dr Reddy's Terbinafine	78	Ensure Plus (Fruit of the Forest)	210
Diphtheria, tetanus and pertussis vaccine	212	Droperidol	117	Ensure Plus (Vanilla)	210
Diphtheria, tetanus, pertussis and polio vaccine	211	Drugs Affecting Bone Metabolism	93	Ensure Plus HN	209
Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine	211	Duolin	174	Ensure Plus HN RTH	209
Diprivan	105	Duride	45	Entacapone	104
Dipyridamole	32	Dynastat	102	Entapone	104
Disodium edetate	183	Dysport	100	Entecavir	86
Disodium hydrogen phosphate with sodium dihydrogen phosphate	194	- E -		Enzymes	98
Disopyramide phosphate	39	e-chamber La Grande	218	Ephedrine	45
Disulfiram	127	e-chamber Mask	217	Epilim IV	115
Dithranol	194	e-chamber Turbo	218	Epirubicin Ebewe	130
Diuretics	42	E-Mycin	72	Epirubicin hydrochloride	130
Diurin 40	42	E-Z-Cat Dry	190	Epoetin alfa [Erythropoietin alfa]	27
Dobutamine hydrochloride	45	E-Z-Gas II	190	Epoprostenol	47
		E-Z-Paste	190	Eprex	27
		EasyCheck	218	Eptacog alfa [Recombinant factor VIIa]	29
		Econazole nitrate	49	Eptifibatide	32
		Edrophonium chloride	93		
		Efavirenz	83		
		Efavirenz with emtricitabine and			

Ergometrine maleate	58	FEIBA NF	29	Flumazenil	186
Ergotamine tartrate with caffeine	117	Felodipine	41	Flumetasone pivalate with clicloquinol	181
Erlotinib	135	Fenpaed	101	Fluocortolone caproate with fluocortolone pivalate and cinchocaine	14
Ertapenem	70	Fentanyl	108	Fluorescein sodium	182
Erythrocin IV	72	Fentanyl Sandoz	108	Fluorescein sodium with lignocaine hydrochloride	182
Erythromycin (as ethylsuccinate)	72	Ferinject	22	Fluorescite	182
Erythromycin (as lactobionate)	72	Ferodan	22	Fluorometholone	181
Erythromycin (as stearate)	72	Ferric carboxymaltose	22	Fluorouracil	131
Erythropoietin alfa	27	Ferric subsulfate	28	Fluorouracil sodium	54
Escitalopram	112	Ferriprox	187	Fluoxetine hydrochloride	112
Esmolol hydrochloride	40	Ferro-F-Tabs	22	Flupenthixol decanoate	121
Etanercept	142	Ferro-tab	22	Fluphenazine decanoate	121
Ethambutol hydrochloride	79	Ferrograd	22	Flutamide	140
Ethanol	186	Ferrous fumarate	22	Flutamin	140
Ethanol with glucose	186	Ferrous fumarate with folic acid	22	Fluticasone	176
Ethanol, dehydrated	186	Ferrous gluconate with ascorbic acid	22	Fluticasone propionate	173
Ethics Aspirin EC	32	Ferrous sulphate	22	Fluticasone with salmeterol	178
Ethics Enalapril	37	Ferrous sulphate with ascorbic acid	22	FML	181
Ethics Lisinopril	37	Ferrous sulphate with folic acid	22	Foban	49
Ethinylloestradiol	63	Ferrum H	22	Folic acid	28
Ethinylloestradiol with desogestrel	56	Fexofenadine hydrochloride	174	Fondaparinux sodium	31
Ethinylloestradiol with levonorgestrel	56	Filgrastim	33	Food Modules	197
Ethinylloestradiol with norethisterone	56	Finasteride	58	Food/Fluid Thickeners	199
Ethosuximide	113	Fingolimod	123	Forteo	98
Ethyl chloride	106	Finpro	58	Fortisp (Vanilla)	209
Etidronate disodium	95	Firazyr	173	Fortum	71
Etomidate	104	Flagyl	81	Fosamax	93
Etopophos	132	Flagyl-S	81	Fosamax Plus	94
Etoposide	132	Flamazine	49	Foscarnet sodium	89
Etoposide (as phosphate)	132	Flecainide acetate	39	Fosfomycin	75
Etoricoxib	101	Fleet Phosphate Enema	20	Fragmin	30
Etravirine	83	Flionase Hayfever & Allergy	173	Framycetin sulphate	180
Everolimus	171	Flixotide	176	Freeflex	35
Evista	97	Flixotide Accuhaler	176	FreeStyle Lite	217
Exelon	127	Floair	176	Freestyle Optium	217
Exemestane	142	Florinef	61	Freestyle Optium Ketone	217
Exjade	187	Fluanxol	121	Freestyle Optium Neo	217
Extemporaneously Compounded Preparations	194	Fluarix	215	Fresofol 1%	105
EZ-fit Paediatric Mask	217	Flucloxacillin	73	Frusemide-Claris	42
Ezemibe	44	Flucloxin	73	Fucidin	75
Ezetimibe	44	Fluconazole	77	Fucithalamic	180
Ezetimibe with simvastatin	44	Fluconazole-Claris	77	Fungilin	23
- F -		Flucytosine	78	Furosemide (frusemide)	42
Factor eight inhibitor bypassing fraction	29	Fludara Oral	131	Fusidic acid Dermatological	49
Febuxostat	99	Fludarabine Ebewe	131	Infections	75
		Fludarabine phosphate	131	Sensory	180
		Fludrocortisone acetate	61	Fuzeon	82
		Fluids and Electrolytes	33		

- G -

Gabapentin	113
Gacet	108
Gadobenic acid	190
Gadobutrol	190
Gadodiamide	190
Gadoteric acid	190
Gadovist	190
Gadoxetate disodium	191
Ganciclovir	
Infections	89
Sensory	180
Gardasil	214
Gastrografin	189
Gastrosoothe	15
Gefitinib	135
Gelatine, succinylated	36
Gelofusine	36
Gemcitabine	131
Gemcitabine Ebewe	131
Gemfibrozil	43
Genoptic	180
Genox	141
Gentamicin sulphate	
Infections	70
Sensory	180
Gestrinone	63
Gilenya	123
Ginet	36
Glatiramer acetate	123
Glaucoma Preparations	183
Glibenclamide	18
Gliclazide	18
Glipizide	18
Glivec	136
Glizide	18
Glucagen Hypokit	16
Glucagon hydrochloride	16
Glucerna Select (Vanilla)	202
Glucerna Select RTH (Vanilla)	202
Glucobay	16
Glucose [Dextrose]	
Alimentary	16
Blood	34
Extemporaneously Compounded Preparations	195
Glucose with potassium chloride	34
Glucose with potassium chloride and sodium chloride	34

Glucose with sodium chloride	34
Glucose with sucrose and fructose	16
Glycerin with sodium saccharin	195
Glycerin with sucrose	195
Glycerol	
Alimentary	20
Extemporaneously Compounded Preparations	195
Glycerol with paraffin	51
Glyceryl trinitrate	
Alimentary	15
Cardiovascular	45
Glycine	192
Glycopyrronium	175
Glycopyrronium bromide	15
Glypressin	69
Glytrin	45
Gonadorelin	63
Goserelin	63
Granirex	117
Granisetron	117

- H -

Habitrol	128
Habitrol (Classic)	128
Habitrol (Fruit)	128
Habitrol (Mint)	128
Haem arginate	21
Haemophilus influenzae type B vaccine	212
Haldol	121
Haldol Concentrate	121
Haloperidol	119
Haloperidol decanoate	121
Hameln	108
Hartmann's solution	34
Havrix	214
Havrix Junior	214
HBvaxPRO	214
Healon GV	183
healthE Dimethicone 10%	50
healthE Dimethicone 5%	50
healthE Fatty Cream	51
Heparin sodium	31
Heparinised saline	31
Heparon Junior	203
Hepatitis A vaccine	214
Hepatitis B recombinant vaccine	214
Hepsera	86
Herceptin	169

Hexamine hippurate	76
Histaclear	174
Histamine acid phosphate	191
Holoxan	129
Hormone Replacement Therapy	62
HPV	214
Humalog Mix 25	17
Humalog Mix 50	17
Human papillomavirus (6, 11, 16 and 18) vaccine [HPV]	214
Humatin	70
Humira	148
HumiraPen	148
Hyaluronic acid	23, 182, 183, 185
Alimentary	23
Sensory	182, 183, 185
Hyaluronidase	98
Hybloc	40
Hydralazine hydrochloride	46
Hydrea	132
Hydrocortisone	
Dermatological	52
Extemporaneously Compounded Preparations	195
Hormone Preparations	61
Hydrocortisone acetate	
Alimentary	14
Dermatological	52
Hydrocortisone and paraffin liquid and lanolin	52
Hydrocortisone butyrate	52, 54
Hydrocortisone with miconazole	53
Hydrocortisone with natamycin and neomycin	53
Hydrocortisone with paraffin and wool fat	52
Hydrogen peroxide	49
Hydroxocobalamin	
Alimentary	25
Various	186
Hydroxychloroquine	93
Hydroxyethyl starch 130/0.4 with magnesium chloride, potassium chloride, sodium acetate and sodium chloride	36
Hydroxyethyl starch 130/0.4 with sodium chloride	36
Hydroxyurea	132

Hygroton	43	protamine	17	- J -	Jadelle	57
Hylo-Fresh	185	Insulin neutral	17	Jevity	209	
Hyoscine butylbromide	15	Insulin neutral with insulin isophane	17	Jevity HiCal RTH	209	
Hyoscine hydrobromide	117-118	Insulin pen needles	217	Jevity RTH	209	
Hyperuricaemia and Antigout	98	Insulin syringes, disposable with attached needle	217	- K -	Kaletra	85
Hypnovel	124	Integrilin	32	Kenacomb	181	
Hypromellose	182, 185	Intelence	83	Kenacort-A 10	61	
Hypromellose with dextran	185	Interferon alfa-2a	91	Kenacort-A 40	61	
Hysite	184	Interferon alfa-2b	91	Kenalog in Orabase	23	
- I -		Interferon beta-1-alfa	123	Ketamine	104	
Ibiamox	73	Interferon beta-1-beta	124	Ketocal 3:1 (Unflavoured)	206	
Ibuprofen	101	Interferon gamma	91	Ketocal 4:1 (Unflavoured)	206	
Icatibant	173	Intra-uterine device	56	Ketocal 4:1 (Vanilla)	206	
Idarubicin hydrochloride	130	Invanz	70	Ketoconazole Dermatological	49	
Ifosfamide	129	Invega Sustenna	122	Infections	76	
Ikorel	46	Iodine	68	Ketone blood beta-ketone electrodes	217	
Iloprost	48	Iodine with ethanol	188	Ketoprofen	101	
Imatinib mesilate	136	Iodised oil	189	Ketorolac trometamol	181	
Imatinib-AFT	136	Iodixanol	189	Kivexa	84	
Imiglucerase	21	Iohexol	189	Klacid	72	
Imipenem with cilastatin	70	Iopidine	184	Klean Prep	19	
Imipenem+Cilastatin RBX	70	Ioscan	189	Kogenate FS	30	
Imipramine hydrochloride	111	IPOL	216	Konakion MM	30	
Imiquimod	54	Ipratropium bromide	174	Konsyl-D	19	
Immune Modulators	91	Iressa	135	- L -	L-asparaginase	132
Immunosuppressants	142	Irinotecan Actavis 100	132	L-ornithine L-aspartate	16	
Impact Advanced Recovery (Chocolate)	208	Irinotecan Actavis 40	132	Labetalol	40	
Impact Advanced Recovery (Vanilla)	208	Irinotecan hydrochloride	132	Lacosamide	114	
Imuran	171	Iron polymaltose	22	Lactose	195	
Indacaterol	177	Iron sucrose	22	Lactulose	20	
Indapamide	43	Irrigation Solutions	192	Laevolac	20	
Indigo carmine	191	ISENTRESS	86	Lamictal	115	
Indinavir	85	Ismo 40 Retard	45	Lamivudine	84, 87	
Indocyanine green	191	Ismo-20	45	Lamotrigine	115	
Indomethacin	101	Isoflurane	104	Lansoprazole	15	
Infanrix IPV	211	Isoniazid	79	Lantus	17	
Infanrix-hexa	211	Isoniazid with rifampicin	79	Lantus SoloStar	17	
Infliximab	155	Isoprenaline	45	Lanzol Relief	15	
Influenza vaccine	215	Isopropyl alcohol	188	Lapatinib	136	
Influvac	215	Isoptin	42	Lariam	81	
Inhaled Corticosteroids	176	Isopto Carpine	184	Latanoprost	184	
Insulin aspart	17	Isosorbide mononitrate	45	Lax-Sachets	20	
Insulin aspart with insulin aspart protamine	17	Isotane 10	50	Lax-Suppositories	20	
Insulin glargine	17	Isotane 20	50	Lax-Tabs	20	
Insulin glulisine	17	Isotretinoin	50	Laxatives	19	
Insulin isophane	17	Ispaghula (psyllium) husk	19	Laxsol	19	
Insulin lispro	17	Isradipine	41	Leflunomide	93	
Insulin lispro with insulin lispro protamine	17	Itch-Soothe	50			
		Itraconazole	77			
		Itrazole	77			
		Ivermectin	80			

Lenalidomide	132	Lisinopril	37	glycol	185	
Letrole	142	Lissamine green	182	Madopar 125	104	
Letrozole	142	Lisuride hydrogen maleate	104	Madopar 250	104	
Leukotriene Receptor Antagonists	176	Lithicarb FC	120	Madopar 62.5	104	
Leunase	132	Lithium carbonate	120	Madopar HBS	104	
Leuprorelin acetate	64	LMX4	107	Madopar Rapid	104	
Leustatin	130	Local Preparations for Anal and Rectal Disorders	14	Mafenide acetate	49	
Levetiracetam	115	Locoid	52, 54	Magnesium hydroxide Alimentary	22	
Levetiracetam-Rex	115	Locoid Crelo	52	Extemporaneously Compounded Preparations	195	
Levobunolol hydrochloride	183	Locoid Lipocream	52	Magnesium oxide	22	
Levocabastine	181	Lodoxamide	181	Magnesium sulphate	22	
Levocarnitine	21	Logem	115	Magnevist	191	
Levodopa with benserazide	104	Lomide	181	Malarone	80	
Levodopa with carbidopa	104	Lomustine	129	Malarone Junior	80	
Levomepromazine	119	Long-Acting Beta-Adrenoceptor Agonists	177	Malathion [Maldison]	50	
Levonorgestrel	57	Loniten	46	Malathion with permethrin and piperonyl butoxide	50	
Levosimendan	45	Loperamide hydrochloride	13	Maldison	50	
Levothyroxine	68	Lopinavir with ritonavir	85	Mannitol Cardiovascular	42	
Lidocaine [lignocaine]	107	Lopresor	40	Various	191	
Lidocaine [Lignocaine] hydrochloride	106	Lorafix	174	Maprotiline hydrochloride	111	
Lidocaine [Lignocaine] hydrochloride with adrenaline	106	LoraPaed	174	Marcain	105	
Lidocaine [Lignocaine] hydrochloride with adrenaline and tetracaine hydrochloride	106	Loratadine	174	Marcain Heavy	106	
Lidocaine [Lignocaine] hydrochloride with chlorhexidine	106	Lorazepam	113, 123	Marcain Isobaric	105	
Lidocaine [Lignocaine] hydrochloride with phenylephrine hydrochloride	106	Lormetazepam	124	Marcain with Adrenaline	105	
Lidocaine [Lignocaine] with prilocaine	107	Losartan Actavis	38	Marevan	32	
Lidocaine-Claris	106	Losartan potassium	38	Marine Blue Lotion SPF 50+	54	
Lignocaine	106	Losartan potassium with hydrochlorothiazide	38	Mask for spacer device	217	
lignocaine	61, 107	Lovir	89	Mast Cell Stabilisers	178	
Hormone Preparations	61	Loxamine	112	Maxidex	181	
Nervous	107	Lucrin Depot PDS	64	Maxitrol	181	
Lincomycin	76	Lycinate	45	Measles, mumps and rubella vaccine	215	
Linezolid	76	Lyderm	50	Mebendazole	80	
Lioresal Intrathecal	99	- M -			Mebeverine hydrochloride	15
Liothyronine sodium	68	m-Amoxiclav	73	Medrol	61	
Lipazil	43	m-Eslon	109	Medroxyprogesterone	63	
Lipid-Modifying Agents	43	M-M-R-II	215	Medroxyprogesterone acetate Genito-Urinary	57	
Lipiodol Ultra Fluid	189	m-Nystatin	23	Hormone Preparations	62	
Liquibar	190	Mabthera	161	Mefenamic acid	101	
Liquifilm Forte	185	Macrogl 3350 with ascorbic acid, potassium chloride and sodium chloride	19	Mefloquine	81	
Liquifilm Tears	185	Macrogl 3350 with potassium chloride, sodium bicarbonate and sodium chloride	20	Megestrol acetate	140	
		Macrogl 3350 with potassium chloride, sodium bicarbonate, sodium chloride and sodium sulphate	19	Meglumine gadopentetate	191	
		Macrogl 400 and propylene glycol	185	Meglumine iotroxate	191	
				Melatonin	124	
				Meloxicam	101	
				Melphalan	129	
				Menactra	212	

Meningococcal (A, C, Y and W-135) conjugate vaccine	212	lidocaine [lignocaine]	61	Monosodium glutamate with sodium aspartate	193
Meningococcal C conjugate vaccine	213	Methylthionium chloride [Methylene blue]	191	Monosodium l-aspartate	193
Menthol	195	Methylxanthines	178	Montelukast	176
Mepivacaine hydrochloride	107	Metoclopramide hydrochloride	118	Morotocog alfa [Recombinant factor VIII]	29
Mercaptopurine	131	Metoclopramide hydrochloride with paracetamol	117	Morphine hydrochloride	109
Meropenem	70	Metolazone	43	Morphine sulphate	109
Mesalazine	14	Metoprolol - AFT CR	40	Morphine tartrate	109
Mesna	139	Metoprolol succinate	40	Motetis	103
Mestinin	93	Metoprolol tartrate	40	Mouth and Throat	23
Metabolic Disorder Agents	20	Metronidazole Dermatological	49	Moxifloxacin	74
Metabolic Products	199	Infections	81	Mucolytics and Expectorants	178
Metamide	118	Metyrapone	63	Multihance	190
Metaraminol	46	Mexiletine hydrochloride	39	Multiple Sclerosis Treatments	123
Metchek	18	Mexiletine Hydrochloride USP	39	Multivitamin and mineral supplement	24
Metferol	177	Miacalcic	60	Multivitamin renal	24
Metformin hydrochloride	18	Mianserin hydrochloride	111	Multivitamins	24-25
Metformin Mylan	18	Micolette	20	Mupirocin	49
Methacholine chloride	191	Miconazole	23	Muscle Relaxants and Related Agents	99
Methadone hydrochloride Extemporaneously Compounded Preparations	195	Miconazole nitrate Dermatological	49	Myambutol	79
Nervous	109	Genito-Urinary	56	Mycobutin	79
Methatabs	109	Micreme	56	Mycosyl	49
Methohexital sodium	104	Micreme H	53	Mycophenolate mofetil	171
Methopt	185	Microgynon 50 ED	56	Mydriacyl	184
Methotrexate	131	Midazolam	124	Mydriatics and Cycloplegics	184
Methotrexate Ebewe	131	Midodrine	39	Mylan Atenolol	39
Methotrexate Sandoz	131	Mifepristone	57	Mylan-Bosentan	47
Methoxsalen [8-methoxypsoralen]	54	Milrinone	46	Myleran	129
Methoxyflurane	107	Minerals	21		
Methyl aminolevulinate hydrochloride	54	Mini-Wright AFS Low Range	218	- N -	
Methyl hydroxybenzoate	195	Mini-Wright Standard	218	Nadolol	40
Methylcellulose	195	Minidiab	18	Naloxone hydrochloride	186
Methylcellulose with glycerin and sodium saccharin	195	Minirin	68	Naltraccord	127
Methylcellulose with glycerin and sucrose	195	Minocycline	75	Naltrexone hydrochloride	127
Methylidopa	42	Minoxidil	46	Naphazoline hydrochloride	182
Methylene blue	191	Mirtazapine	112	Naphcon Forte	182
Methylphenidate hydrochloride	126	Misoprostol	15	Naprosyn SR 1000	102
Methylprednisolone (as sodium succinate)	61	Mitomycin C	130	Naprosyn SR 750	102
Methylprednisolone aceponate	53	Mitozantrone	130	Naproxen	102
Methylprednisolone acetate	61	Mitozantrone Ebewe	130	Naropin	107
Methylprednisolone acetate with		Mivacron	100	Natalizumab	123
		Mivacurium chloride	100	Natamycin	180
		Mixed salt solution for eye irrigation	182	Natulan	133
		Moclobemide	112	Nausicalm	117
		Modafinil	126	Nauzene	117
		Moderate	121	Navelbine	140
		Mometasone furoate	53	Nedocromil	178
				Nefopam hydrochloride	108
				Neisvac-C	213

Neo-B12	25	Novatrelin	53	Ondanaccord	118
Neocate Advance (Vanilla)	204	NovoMix 30 FlexPen	17	Ondansetron	118
Neocate Gold (Unflavoured)	204	NovoRapid FlexPen	17	Ondansetron ODT-DRLA	118
Neoral	142	NovoSeven RT	29	One-Alpha	25
Neostigmine metilsulfate	93	Noxafil	77	Onrex	118
Neostigmine metilsulfate with glycopyrronium bromide	93	Nupentin	113	Optional Pharmaceuticals	217
Neosynephrine HCL	46	Nutrini Energy Multi Fibre	207	Ora-Blend	195
Nepro HP (Strawberry)	207	Nutrini Low Energy Multifibre RTH	207	Ora-Blend SF	195
Nepro HP (Vanilla)	207	Nutrison Concentrated	203	Ora-Plus	195
Nepro HP RTH	207	Nutrison Energy	209	Ora-Sweet	195
Neulastim	33	Nyefax Retard	41	Ora-Sweet SF	195
Neupogen	33	Nystatin Alimentary	23	Oratane	50
Neurontin	113	Dermatological	49	Ornidazole	81
NeuroTabs	21	Genito-Urinary	56	Orphenadrine citrate	100
Nevirapine	83	Infections	77	Orphenadrine hydrochloride	103
Nevirapine Alphapharm	83	NZ Medical & Scientific	63	Oruvail SR	101
Nicardipine hydrochloride	41	- O -		Oseltamivir	90
Nicorandil	46	Obstetric Preparations	57	Osmolite	209
Nicotine	128	Octocog alfa [Recombinant factor VIII]	30	Osmolite RTH	209
Nicotinic acid	44	Octreotide	140	Ospamox	73
Nifedipine	41	Ocular Lubricants	185	Other Cardiac Agents	45
Nilotinib	137	Oestradiol	62-63	Other Endocrine Agents	62
Nilstat	23, 77	Oestradiol valerate	62	Other Oestrogen Preparations	63
Nimodipine	41	Oestradiol with norethisterone acetate	62	Other Otolological Preparations	185
Nitazoxanide	81	Oestriol Genito-Urinary	58	Other Progestogen Preparations	63
Nitrados	124	Hormone Preparations	63	Other Skin Preparations	54
Nitrates	45	Oestrogens	58	Ox-Pam	123
Nitrazepam	124	Oestrogens (conjugated equine)	62	Oxaliccord	134
Nitroderm TTS 10	45	Oestrogens with medroxyprogesterone acetate	62	Oxaliplatin	134
Nitroderm TTS 5	45	Oil in water emulsion	51	Oxaliplatin Actavis 100	134
Nitrofurantoin	76	Oily phenol [Phenol oily]	15	Oxaliplatin Actavis 50	134
Nitrolingual Pump Spray	45	Olanzapine	120-121	Oxandrolone	60
Nitronal	45	Olive oil	195	Oxazepam	123
Noflam 250	102	Olopatadine	181	Oxpentifylline	46
Noflam 500	102	Olisalazine	14	Oxybuprocaine hydrochloride	182
Non-Steroidal Anti-Inflammatory Drugs	100	Omalizumab	160	Oxybutynin	59
Nonacog alfa [Recombinant factor IX]	29	Omeprazole	15	Oxycodone Controlled Release Tablets (BNM)	110
Noradrenaline	46	Omezol Relief	15	Oxycodone hydrochloride	110
Norethisterone Genito-Urinary	57	Omnipaque	189	Oxycodone Orion	110
Hormone Preparations	63	Omniscan	190	OxyContin	110
Norethisterone with mestranol	56	Omnitrope	64	Oxymetazoline hydrochloride	175
Norfloxacin	74	On Call Advanced	217	OxyNorm	110
Noriday 28	57	Onbrez Breezhaler	177	Oxytocin	58
Normison	124	Oncaspar	133	Oxytocin BNM	58
Norpress	111	OncoTICE	171	Oxytocin with ergometrine maleate	58
Nortriptyline hydrochloride	111			Ozole	77
Norvir	85				
Novasource Renal (Vanilla)	208				

- P -	
Pacifen	99
Pacific Bupirone	123
Paclitaxel	139
Paclitaxel Ebewe	139
Paliperidone	122
Pamidronate disodium	95
Pamisol	95
Pancreatic enzyme	18
Pancuronium bromide	100
Pantoprazole	16
Pantoprazole Actavis 20	16
Pantoprazole Actavis 40	16
Papaverine hydrochloride	46
Paper wasp venom	173
Para-aminosalicylic Acid	79
Paracare	108
Paracare Double Strength	108
Paracetamol	108
Paracetamol + Codeine (Relieve)	110
Paracetamol with codeine	110
Paraffin	
Alimentary	19
Dermatological	52
Extemporaneously Compounded	195
Preparations	195
Paraffin liquid with soft white paraffin	185
Paraffin liquid with wool fat	185
Paraffin with wool fat	52
Paragesic Soluble	108
Paraldehyde	113
Parecoxib	102
Paromomycin	70
Paroxetine hydrochloride	112
Paser	79
Patent blue V	191
Paxam	123
Pazopanib	137
Peak flow meter	218
Peanut oil	194
Pediasure (Chocolate)	207
Pediasure (Strawberry)	207
Pediasure (Vanilla)	207
Pediasure RTH	207
Pegaspargase	133
Pegasys	91
Pegasys RBV Combination Pack	91
Pegfilgrastim	33
Pegylated interferon alfa-2a	91
Penicillamine	93
Penicillin G	73
Penicillin V	73
Pentacarinat	81
Pentagastrin	63
Pentamidine isethionate	81
Pentasa	14
Pentostatin [Deoxycofomycin]	133
Pentoxifylline [Oxpentifylline]	46
Peptamen OS 1.0 (Vanilla)	203
Peptisoothe	15
Perfalgan	108
Perflutren	191
Perhexiline maleate	42
Pericyazine	120
Perindopril	37
Permethrin	50
Peteha	79
Pethidine hydrochloride	110
Pexsig	42
Phenelzine sulphate	111
Phenindione	31
Phenobarbitone	115, 124
Phenobarbitone sodium	195
Phenol	
Extemporaneously Compounded	195
Preparations	195
Various	192
Phenol oily	15
Phenol with ioxaglic acid	192
Phenoxybenzamine hydrochloride	38
Phenoxyethylpenicillin [Penicillin V]	73
Phentolamine mesylate	38
Phenylephrine hydrochloride	
Cardiovascular	46
Sensory	184
Phenytoln	115
Phenytoln sodium	113, 115
Pholcodine	175
Phosphorus	36
Phytomenadione	30
Picibanil	171
Pilocarpine hydrochloride	184
Pilocarpine nitrate	195
Pimafucort	53
Pindolol	40
Pinetarsol	54
Pioglitazone	18
Piperacillin with tazobactam	73
Pipothiazine palmitate	122
Pituitary and Hypothalamic Hormones and Analogues	63
Pivmecillinam	76
Pizotifen	117
PKU Anamix Junior LQ (Berry)	200
PKU Anamix Junior LQ (Orange)	200
PKU Anamix Junior LQ (Unflavoured)	200
Plaquenil	93
Plendil ER	41
Pneumococcal (PCV13) conjugate vaccine	213
Pneumococcal (PPV23) polysaccharide vaccine	213
Pneumovax 23	213
Podophyllotoxin	54
Polidocanol	28
Poliomyelitis vaccine	216
Poloxamer	19
Poly Gel	185
Poly-Tears	185
Poly-Visc	185
Polyhexamethylene biguanide	195
Polyvinyl alcohol	185
Polyvinyl alcohol with povidone	185
Poractant alfa	178
Posaconazole	77
Postinor-1	57
Potassium chloride	34, 36
Potassium chloride with sodium chloride	35
Potassium citrate	59
Potassium dihydrogen phosphate	35
Potassium iodate	
Alimentary	21
Hormone Preparations	68
Potassium iodate with iodine	21
Potassium perchlorate	68
Potassium permanganate	54
Povidone K30	195
Povidone-iodine	188
Povidone-iodine with ethanol	188
Pradaxa	30
Pralidoxime iodide	186
Pramipexole hydrochloride	104

INDEX**Generic Chemicals and Brands**

Prasugrel	32	Pseudoephedrine		Respiratory Stimulants	179
Pravastatin	43	hydrochloride	175	Retinol	25
Praziquantel	80	Psoriasis and Eczema		Retinol Palmitate	185
Prazosin	38	Preparations	53	Retrovir	84
Precedex	104	PTU	68	Retrovir IV	84
Prednisolone	61	Pulmocare (Vanilla)	208	Reutenox	102
Prednisolone acetate	181	Pulmonary Surfactants	178	Revlimid	132
Prednisolone sodium		Pulmozyme	178	Revolade	28
phosphate	181	Puri-nethol	131	RexAir	178
Prednisone	61	Pyrazinamide	79	Reyataz	85
Pregnancy test - hCG urine	218	Pyridostigmine bromide	93	Riboflavin 5-phosphate	183
preOp	208	Pyridoxal-5-phosphate	21	Rifabutin	79
Prevenar 13	213	Pyridoxine hydrochloride	25	Rifadin	80
Prezista	85	Pyrimethamine	81	Rifampicin	80
Prilocaine hydrochloride	107	Pytazen SR	32	Rifaximin	16
Prilocaine hydrochloride with				Rifinah	79
felypressin	107	- Q -		Rilutek	103
Primaquine phosphate	81	Q 300	81	Riluzole	103
Primidone	115	Quetapel	120	Ringer's solution	35
Primolut N	63	Quetiapine	120	Riodine	188
Primovist	191	Quinapril	37	Risedronate Sandoz	95
Probenecid	99	Quinapril with		Risedronate sodium	95
Procaine penicillin	73	hydrochlorothiazide	37	Risperdal Consta	122
Procarbazine hydrochloride	133	Quinine dihydrochloride	81	Risperdal Quicklet	120
Prochlorperazine	118	Quinine sulphate	81	Risperidone	120, 122
Proctosedyl	14	Qvar	176	Risperon	120
Procur	60			Ritalin	126
Procyclidine hydrochloride	103	- R -		Ritalin LA	126
Procytox	129	RA-Morph	109	Ritalin SR	126
Prodopa	42	Rabies vaccine	216	Ritonavir	85
Progesterone	58	Raloxifene	97	Rituximab	161
Proglucem	16	Raltegravir potassium	86	Rivaroxaban	31
Proglycem	16	Ramipex	104	Rivastigmine	127
Progynova	62	Ranbaxy-Cefaclor	71	Rivotril	113
Prokinex	117	Ranibizumab	161	Rizamelt	117
Promethazine hydrochloride	174	Ranitidine	15	Rizatriptan	117
Promethazine theoclate	118	Ranitidine Relief	15	Rocuronium bromide	100
Propafenone hydrochloride	39	Rapamune	171	Ropinirole hydrochloride	104
Propamidine isethionate	180	Rasburicase	99	Ropivacaine hydrochloride	107
Propofol	105	Readi-CAT 2	190	Ropivacaine hydrochloride with	
Propranolol	40	Reandron 1000	60	fentanyl	107
Propylene glycol	195	Recombinant factor IX	29	Ropivacaine Kabi	107
Propylthiouracil	68	Recombinant factor VIIa	29	Rose bengal sodium	182
Prostin E2	58	Recombinant factor VIII	29	RotaTeq	216
Prostin VR	46	Rectogesic	15	Rotavirus live reassortant oral	
Protamine sulphate	31	Red back spider antivenom	186	vaccine	216
Protionamide	79	Redipred	61	Roxane	13
Protirelin	68	Relenza Rotadisk	90	Roxithromycin	72
Provera	62, 63	Remicade	155	Rubifen	126
Provisc	183	Remifentanyl hydrochloride	110	Rubifen SR	126
Provine MCT-LCT 1%	105	ReoPro	148		
Proxymetacaine		Resonium A	36	- S -	
hydrochloride	182	Resource Beneprotein	198	S-26 Gold Premgro	206
		Resource Diabetic (Vanilla)	202	S26 LBW Gold RTF	206

SalAir	175	alginate	13	phosphoric acid	20
Salamol	175	Sodium alginate with sodium		Sodium polystyrene	
Salazopyrin	14	bicarbonate and calcium		sulphonate	36
Salazopyrin EN	14	carbonate	13	Sodium stibogluconate	81
Salbutamol	175	Sodium aurothiomalate	93	Sodium tetradecyl sulphate	29
Salbutamol with ipratropium		Sodium benzoate	21	Sodium thiosulfate	186
bromide	174	Sodium bicarbonate		Sodium valproate	115
Salicylic acid	196	Blood	35-36	Sodium with potassium	193
Salmeterol	177	Extemporaneously		Solian	118
Salmonella typhi vaccine	213	Compounded		Solifenacin succinate	59
Sandimmun	142	Preparations	196	Solu-Cortef	61
Sandomigran	117	Sodium calcium edetate	188	Solu-Medrol	61
Sandostatin LAR	140	Sodium carboxymethylcellulose		Somatropin	64
Scalp Preparations	54	with pectin and gelatine	23	Sotacor	40
Scandonest 3%	107	Sodium chloride		Sotalol	40
Sclerosing Agents	179	Blood	35-36	Soya oil	186
Scopoderm TTS	117	Respiratory	175, 178	Space Chamber Plus	218
Sebizole	49	Various	192	Spacer device	218
Secretin pentahydrochloride	191	Sodium chloride with sodium		Span-K	36
Sedatives and Hypnotics	124	bicarbonate	176	Specialised Formulas	201
Seebri Breezhaler	175	Sodium citrate		Spiractin	43
Selegiline hydrochloride	104	Alimentary	13	Spiramycin	81
Sennosides	20	Extemporaneously		Spiriva	175
Serenace	119	Compounded		Spirolactone	43
Seretide	178	Preparations	196	Sprycel	135
Seretide Accuhaler	178	Sodium citrate with sodium		Standard Feeds	208
Serevent	177	chloride and potassium		Staphlex	73
Serevent Accuhaler	177	chloride	31	Starch	196
Serophene	62	Sodium citrate with sodium lauryl		Stavudine	84
Sertraline	112	sulphoacetate	20	Sterculia with frangula	19
Sevoflurane	105	Sodium citro-tartrate	59	Stesolid	113
Sevredol	109	Sodium cromoglycate		Stimulants / ADHD	
SII-Onco-BCG	171	Alimentary	14	Treatments	125
Sildenafil	47	Respiratory	174, 178	Stiripentol	115
Silver nitrate		Sensory	181	Stocrin	83
Dermatological	54	Sodium dihydrogen phosphate		Strattera	125
Extemporaneously		[Sodium acid phosphate]	35	Streptomycin sulphate	70
Compounded		Sodium fluoride	21	Stromectol	80
Preparations	196	Sodium hyaluronate [Hyaluronic acid]		Suboxone	127
Simethicone	13	Alimentary	23	Sucralfate	16
Simulect	155	Sensory	183, 185	Sucrose	108
Simvastatin	44	Sodium hyaluronate [Hyaluronic		Sugammadex	100
Sincalide	191	acid] with chondroitin		Sulindac	102
Sinemet	104	sulphate	183	Sulphacetamide sodium	180
Sinemet CR	104	Sodium hypochlorite	188	Sulphadiazine	76
Singulair	176	Sodium metabisulfite	196	Sulphadiazine silver	49
Sirolimus	171	Sodium nitrite	186	Sulphasalazine	14
Slow-Lopresor	40	Sodium nitroprusside		Sulphur	196
Snake antivenom	187	Cardiovascular	47	Sumatriptan	117
Sodibic	36	Part III - OPTIONAL		Sunitinib	138
Sodium acetate	35	PHARMACEUTICALS	218	Sunscreen, proprietary	54
Sodium acid phosphate	35	Sodium phenylbutyrate	21	Suprane	104
Sodium alginate with magnesium		Sodium phosphate with		Surgical Preparations	192

Survanta	178	[Tetracosactrin]	63	Tranylcyproline sulphate	111
Sustagen Diabetic (Vanilla)	202	Tetracosactrin	63	Trastuzumab	169
Sustagen Hospital Formula (Chocolate)	209	Tetracyclin Wolff	75	Travoprost	184
Sustagen Hospital Formula (Vanilla)	209	Tetracycline	75	Treatments for Dementia	127
Sutent	138	Thalidomide	134	Treatments for Substance Dependence	127
Suxamethonium chloride	100	Thalomid	134	Tretinoin	
Symmetrel	103	Theobroma oil	196	Dermatological	50
Sympathomimetics	45	Theophylline	178	Oncology	134
Synacthen	63	Thiamine hydrochloride	25	Trexate	131
Synacthen Depot	63	Thioguanine	131	Tri-sodium citrate	196
Syntometrine	58	Thiopental [Thiopentone] sodium	105	Triamcinolone acetoneide	
Syrup	196	Thiopentone	105	Alimentary	23
Systane Unit Dose	185	Thiotepa	129	Dermatological	53
		Thrombin	29	Hormone Preparations	61
		Thymol glycerin	23	Triamcinolone acetoneide with gramicidin, neomycin and nystatin	181
- T -		Thyroid and Antithyroid Preparations	68	Triamcinolone acetoneide with neomycin sulphate, gramicidin and nystatin	53
Tacrolimus	142	Thyrotropin alfa	63	Triamcinolone hexacetoneide	61
Tacrolimus Sandoz	142	Ticagrelor	32	Triazolam	124
Tagitol V	190	Ticarcillin with clavulanic acid	73	Trichloroacetic acid	196
Talc	179	Ticlopidine	33	Trichozole	81
Tambocor	39	Tigecycline	75	Trientine dihydrochloride	21
Tambocor CR	39	Timolol	183	Trifluoperazine	
Tamoxifen citrate	141	Timolol maleate	40	hydrochloride	120
Tamsulosin	59	Timoptol XE	183	Trimeprazine tartrate	174
Tamsulosin-Rex	59	Tiotropium bromide	175	Trimethoprim	76
Tarceva	135	TMP	76	Trimethoprim with sulphamethoxazole [Co-trimoxazole]	76
Tasigna	137	TOBI	70	Trisodium citrate	32
Tasmar	104	Tobradex	181	Trometamol	192
Tegretol	113	Tobramycin		Tropicamide	184
Tegretol CR	113	Infections	70	Tropisetron	118
Teicoplanin	76	Sensory	180	Tropisetron-AFT	118
Temaccord	133	Tobrex	180	Truvada	84
Temazepam	124	Tocilizumab	167	Tuberculin, purified protein derivative	191
Temozolomide	133	Tofranil	111	Two Cal HN	204
Tenecteplase	33	Tolcapone	104	TwoCal HN RTH (Vanilla)	203
Tenofovir disoproxil fumarate	88	Tolterodine tartrate	59	Tykerb	136
Tenoxicam	102	Topamax	116	Tysabri	123
Terazosin	38	Topical Products for Joint and Muscular Pain	102		
Terbinafine	78	Topiramate	116	- U -	
Terbutaline	58	Topiramate Actavis	116	Ultiva	110
Terbutaline sulphate	175	Tracrium	99	Ultraproct	114
Teriparatide	98	Tramadol hydrochloride	111	Univent	174
Terlipressin	69	Tramal 100	111	Ural	59
Testosterone	60	Tramal 50	111	Urea	
Testosterone cypionate	60	Tramal SR 100	111	Dermatological	52
Testosterone esters	60	Tramal SR 150	111		
Testosterone undecanoate	60	Tramal SR 200	111		
Tetrabenazine	103	Trandolapril	37		
Tetracaine [Amethocaine] hydrochloride		Tranexamic acid	29		
Nervous	107				
Sensory	182				
Tetracosactide					

Extemporaneously Compounded Preparations	196	Vinorelbine	140	- Y -	
Urex Forte	42	Viral Vaccines	214	Yellow jacket wasp venom	173
Urografin	189	Viramune Suspension	83	- Z -	
Urokinase	33	Viread	88	Zanamivir	90–91
Urologicals	58	Visipaque	189	Zantac	15
Uromitexan	139	Vistil	185	Zapril	37
Ursodeoxycholic acid	18	Vistil Forte	185	Zarator	43
Ursosan	18	VitA-POS	185	Zarzio	33
Utrogestan	58	Vital	203	Zavedos	130
- V -		Vital HN	203	Zeffix	87
Vaclovir	90	Vitamin A with vitamins D and C	25	Zetop	174
Valaciclovir	90	Vitamin B complex	25	Ziagen	84
Valcyte	90	Vitamin B6 25	25	Zidovudine [AZT]	84
Valganciclovir	90	Vitamins	24	Zidovudine [AZT] with lamivudine	84
Valtrex	90	Vivonex Paediatric	204	Zimybe	44
Vancomycin	76	Vivonex TEN	202	Zinacef	71
Varenicline	128	Volibris	47	Zinc	
Varibar - Honey	190	Voltaren	101	Alimentary	22
Varibar - Nectar	190	Voltaren D	101	Dermatological	51
Varibar - Pudding	190	Voltaren Ophtha	181	Zinc and castor oil	51
Varibar - Thin Liquid	190	Volumatic	36	Zinc chloride	22
Varicella vaccine [Chicken pox vaccine]	216	Volulyte 6%	218	Zinc oxide	196
Varelix	216	Volumatic	218	Zinc sulphate	22
Vasodilators	46	VoLumen	190	Zinc with wool fat	51
Vasopressin	68	Voluven	36	Zincaps	22
Vasopressin Agents	68	Voriconazole	78	Zinforo	71
Vecuronium bromide	100	Votrient	137	Zinnat	71
Vedafil	47	Vttack	78	Ziprasidone	121
Velcade	131	- W -		Zithromax	72
Veletri	47	Warfarin sodium	32	Zoladex	63
Venlafaxine	112	Wart Preparations	54	Zoledronic acid	
Venofer	22	Water		Hormone Preparations	60
Ventavis	48	Blood	36	Musculoskeletal	
Ventolin	175	Various	192	System	95–97
Vepesid	132	Wool fat		Zometa	60
Verapamil hydrochloride	42	Dermatological	52	Zopiclone	124
Vergo 16	117	Extemporaneously Compounded Preparations	196	Zopiclone Actavis	124
Verpamil SR	42	- X -		Zostrix	102
Vesanoid	134	X-Opaque-HD	190	Zostrix HP	107
Vesicare	59	Xanthan	196	Zuclopenthixol acetate	121
Vexazone	18	Xarelto	31	Zuclopenthixol decanoate	122
Vfend	78	Xifaxan	16	Zuclopenthixol hydrochloride	121
Victrelis	89	Xolair	160	Zusdone	121
Vidaza	130	Xylocaine	106	Zyban	127
Vigabatrin	116	Xylocaine Viscous	106	Zypine	120
Vimpat	114	Xylometazoline hydrochloride	176	Zypine ODT	120
Vinblastine sulphate	139	Xyntha	29	Zyprexa Relprev	121
Vincristine sulphate	140			Zytiga	140
				Zyvox	76

